Node1	Edge_Type	Node2	Weight	Score	Paper_List	Original_Text
of the	anatomy	scale	3	0	9136504|26258842|27752075	PMID:9136504; Original text:On the basis of the global improvement item of the Clinical Global Impression Scale, 12 of 18 subjects were considered responders.|PMID:26258842; Original text:Total scores of the the Autism Behavior Checklist, the Childhood Autism Rating Scale, and disease were decreased in both groups after 3 months (p<0.05) compared with the scores prior to treatment.|PMID:27752075; Original text:Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group.
spectrum disorders	disease_to_anatomy	lymphocyte	1	0	34641964	PMID:34641964; Original text:A significant decrease in the CD4+ lymphocyte was found in spectrum disorders patients compared to controls [- 1.51 (95% CI - 2.99; - 0.04)
depression	disease	rumination	1	0	22964266	PMID:22964266; Original text:Results showed a significant reduction in depression, anxiety and rumination in the intervention group, as opposed to the control group.
anxiety	disease	depression	5	0	22964266|9934941|33381856|32090389|31947912	PMID:22964266; Original text:Results showed a significant reduction in depression, anxiety and rumination in the intervention group, as opposed to the control group.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:33381856; Original text:Self-reported anxiety was found to be significantly higher in youth with a lower Intelligence quotient, while depression was positively associated with Intelligence quotient.|PMID:32090389; Original text:Only the mindfulness-based stress reduction group demonstrated significant reductions in depression, and neither group significantly changed in anxiety.|PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
anxiety	disease	rumination	1	0	22964266	PMID:22964266; Original text:Results showed a significant reduction in depression, anxiety and rumination in the intervention group, as opposed to the control group.
depression	disease_to_anatomy	group	1	0	22964266	PMID:22964266; Original text:Results showed a significant reduction in depression, anxiety and rumination in the intervention group, as opposed to the control group.
rumination	disease_to_anatomy	group	1	0	22964266	PMID:22964266; Original text:Results showed a significant reduction in depression, anxiety and rumination in the intervention group, as opposed to the control group.
anxiety	disease_to_anatomy	group	2	0	22964266|20001837	PMID:22964266; Original text:Results showed a significant reduction in depression, anxiety and rumination in the intervention group, as opposed to the control group.|PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.
adaptive	disease	adaptive disability	1	0	11893094	PMID:11893094; Original text:A significant discrepancy between intelligence and daily adaptive functioning, or adaptive disability (adaptive disability), has been previously found to be a associated with significant psychological morbidity in preschool children with disruptive behavior (disruptive behavior).
adaptive	disease	disruptive behavior	1	0	11893094	PMID:11893094; Original text:A significant discrepancy between intelligence and daily adaptive functioning, or adaptive disability (adaptive disability), has been previously found to be a associated with significant psychological morbidity in preschool children with disruptive behavior (disruptive behavior).
adaptive disability	disease	disruptive behavior	2	0	11893094|11893094	PMID:11893094; Original text:A significant discrepancy between intelligence and daily adaptive functioning, or adaptive disability (adaptive disability), has been previously found to be a associated with significant psychological morbidity in preschool children with disruptive behavior (disruptive behavior).|PMID:11893094; Original text:A significant contribution of adaptive disability to adverse outcomes in the disruptive behavior group remained on some measures even after controlling for initial severity of disruptive behavior.
adaptive disability	disease	cd	1	0	11893094	PMID:11893094; Original text:adaptive disability also contributed significantly to CD symptoms at follow-up after controlling for initial disruptive behavior severity and initial CD symptoms.
naltrexone	chemical_to_disease	autistic symptomatology	1	0	9028057	"PMID:9028057; Original text:The behavioural evaluation was conducted using the specific BSE and CARS rating scales naltrexone treatment produced a significant reduction of the autistic symptomatology in seven (""responders"") out of 12 children."
naltrexone	chemical_to_anatomy	of the	2	0	9028057|7654128	"PMID:9028057; Original text:The behavioural evaluation was conducted using the specific BSE and CARS rating scales naltrexone treatment produced a significant reduction of the autistic symptomatology in seven (""responders"") out of 12 children.|PMID:7654128; Original text:On the contrary, naltrexone increased the incidence of stereotypic behavior on the Aberrant Behavior Checklist, and the care staff evaluated the effect of the 50-mg/d treatment as being significantly worse than that of the placebo treatment as measured by the Clinical Global Impression Scale."
autistic symptomatology	disease_to_anatomy	of the	1	0	9028057	"PMID:9028057; Original text:The behavioural evaluation was conducted using the specific BSE and CARS rating scales naltrexone treatment produced a significant reduction of the autistic symptomatology in seven (""responders"") out of 12 children."
lymphocyte	anatomy	of the	1	0	9028057	PMID:9028057; Original text:The behavioural improvement was accompanied by alterations in the distribution of the major lymphocyte subsets, with a significant increase of the T-helper-inducers (CD4+CD8-) and a significant reduction of the T-cytotoxic-suppressor (CD4-CD8+) resulting in a normalization of the CD4/CD8 ratio.
lymphocyte	anatomy	subsets	1	0	9028057	PMID:9028057; Original text:The behavioural improvement was accompanied by alterations in the distribution of the major lymphocyte subsets, with a significant increase of the T-helper-inducers (CD4+CD8-) and a significant reduction of the T-cytotoxic-suppressor (CD4-CD8+) resulting in a normalization of the CD4/CD8 ratio.
lymphocyte	anatomy	lymphocyte subsets	1	0	9028057	PMID:9028057; Original text:The behavioural improvement was accompanied by alterations in the distribution of the major lymphocyte subsets, with a significant increase of the T-helper-inducers (CD4+CD8-) and a significant reduction of the T-cytotoxic-suppressor (CD4-CD8+) resulting in a normalization of the CD4/CD8 ratio.
of the	anatomy	subsets	1	0	9028057	PMID:9028057; Original text:The behavioural improvement was accompanied by alterations in the distribution of the major lymphocyte subsets, with a significant increase of the T-helper-inducers (CD4+CD8-) and a significant reduction of the T-cytotoxic-suppressor (CD4-CD8+) resulting in a normalization of the CD4/CD8 ratio.
lymphocyte subsets	anatomy	of the	1	0	9028057	PMID:9028057; Original text:The behavioural improvement was accompanied by alterations in the distribution of the major lymphocyte subsets, with a significant increase of the T-helper-inducers (CD4+CD8-) and a significant reduction of the T-cytotoxic-suppressor (CD4-CD8+) resulting in a normalization of the CD4/CD8 ratio.
lymphocyte subsets	anatomy	subsets	1	0	9028057	PMID:9028057; Original text:The behavioural improvement was accompanied by alterations in the distribution of the major lymphocyte subsets, with a significant increase of the T-helper-inducers (CD4+CD8-) and a significant reduction of the T-cytotoxic-suppressor (CD4-CD8+) resulting in a normalization of the CD4/CD8 ratio.
3 of	anatomy	group (	1	0	25643864	PMID:25643864; Original text:Primary analyses indicated significantly better posttest performance for the treatment group (compared to controls) on 3 of the 4 measures of emotion decoding and encoding and these were maintained at 5-week follow-up.
3 of	anatomy	of the	2	0	25643864|11466160	PMID:25643864; Original text:Primary analyses indicated significantly better posttest performance for the treatment group (compared to controls) on 3 of the 4 measures of emotion decoding and encoding and these were maintained at 5-week follow-up.|PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.
group (	anatomy	of the	7	0	25643864|34510916|24214165|18080171|28138381|8986845|33383952	PMID:25643864; Original text:Primary analyses indicated significantly better posttest performance for the treatment group (compared to controls) on 3 of the 4 measures of emotion decoding and encoding and these were maintained at 5-week follow-up.|PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).|PMID:24214165; Original text:Results show that the children in the treatment group (n = 17) who received 30 sessions of the occupational therapy intervention scored significantly higher (p = 0.003, d = 1.2) on Goal Attainment Scales (primary outcome), and also scored significantly better on measures of caregiver assistance in self-care (p = 0.008 d = 0.9) and socialization (p = 0.04, d = 0.7) than the Usual Care control group (n = 15).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:28138381; Original text:Analysis of the the parent-rated social responsiveness scale total raw score demonstrated significant decrease for the DCS group compared to the placebo group (p = 0.042) indicating greater maintenance of treatment effect in the DCS group.|PMID:8986845; Original text:13 (76%) of the Asperger syndrome patients were rated as pedantic compared to 4 (31%) of the high-functioning autism group (chi 2 = 6.3; p = .01).|PMID:33383952; Original text:Meta-analysis of 24 case-control studies demonstrated that children and adolescents with disorder had significantly lower vitamin D concentration than that of the control group (mean difference (MD): -7.46 ng/mL, 95% confidence interval (95% confidence interval): -10.26; -4.66 ng/mL, p < 0.0001, I = 98%).
autistic	disease	epilepsy	3	0	34510916|18565495|18565495	PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).|PMID:18565495; Original text:There was a strong discrepancy in relative risk (relative risk) according to IQ, with more autistic patients with intellectual disability having epilepsy (relative risk = .555; 95% confidence interval [CI]: .42-.73; p < .001).|PMID:18565495; Original text:There was a strong discrepancy in relative risk according to sex, favoring comorbidity of epilepsy in autistic girls (relative risk = .549; 95% CI: .45-.66; p < .001).
, and	anatomy	group (	5	0	34510916|12151468|24214165|22265360|30196397	PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).|PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).|PMID:24214165; Original text:Results show that the children in the treatment group (n = 17) who received 30 sessions of the occupational therapy intervention scored significantly higher (p = 0.003, d = 1.2) on Goal Attainment Scales (primary outcome), and also scored significantly better on measures of caregiver assistance in self-care (p = 0.008 d = 0.9) and socialization (p = 0.04, d = 0.7) than the Usual Care control group (n = 15).|PMID:22265360; Original text:Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively).|PMID:30196397; Original text:Improvement in LSAS scores from baseline to the primary endpoint was significantly greater for 3,4-methylenedioxymethamphetamine group compared to the placebo group (P = 0.037), and placebo-subtracted Cohen's d effect size was very large (d = 1.4, CI - 0.074, 2.874).
, and	anatomy	of the	43	0	34510916|24518398|29443933|29498298|25876214|33942547|29427532|24214165|24352377|22784311|29966749|26258842|7654128|17574799|16160627|31549310|27807755|9690938|15863467|32112261|14561452|15673999|24061784|32563542|28242040|32168067|30980177|24408892|30305689|16919132|27183106|19823139|22508080|26551748|24828014|30979038|12804129|32840005|32947424|34018333|28036350|28036350|15492353	"PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).|PMID:24518398; Original text:Notably, many of the reviewed studies had significant limitations, including lack of replication, limited sample sizes, retrospective design, recall and publication biases, inadequate matching of cases and controls, and the use of nonstandard tools to diagnose ASD.|PMID:29443933; Original text:Unmet parent carer mental health needs pose a significant risk to the psychological, physical, and social well-being of the parents of the child affected by Autism Spectrum Disorder and jeopardize the adaptive functioning of the family as well as the potential of the child affected by Autism Spectrum Disorder.|PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.|PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.|PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.|PMID:29427532; Original text:Significant improvements from baseline to study endpoint were observed in several subscales of the CCC-2, SRS, CGI-I, CGI-S, and ADOS, including Associated Maladaptive Behaviors (P ≤ .043), Reciprocal Social Interaction (P = .015), Communication (P < .001), and Stereotyped Behaviors and Repetitive Interests (P ≤ .013).|PMID:24214165; Original text:Results show that the children in the treatment group (n = 17) who received 30 sessions of the occupational therapy intervention scored significantly higher (p = 0.003, d = 1.2) on Goal Attainment Scales (primary outcome), and also scored significantly better on measures of caregiver assistance in self-care (p = 0.008 d = 0.9) and socialization (p = 0.04, d = 0.7) than the Usual Care control group (n = 15).|PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).|PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:29966749; Original text:Additionally, we discuss the clinical significance of the The blood-brain barrier in diagnosis (genetic markers, dynamic contrast-enhanced-magnetic resonance imaging, and blood biomarkers) and in treatment (drug delivery).|PMID:26258842; Original text:Total scores of the the Autism Behavior Checklist, the Childhood Autism Rating Scale, and disease were decreased in both groups after 3 months (p<0.05) compared with the scores prior to treatment.|PMID:7654128; Original text:On the contrary, naltrexone increased the incidence of stereotypic behavior on the Aberrant Behavior Checklist, and the care staff evaluated the effect of the 50-mg/d treatment as being significantly worse than that of the placebo treatment as measured by the Clinical Global Impression Scale.|PMID:17574799; Original text:Comparisons of abused and nonabused women revealed significant differences in childhood, adolescent, and adult functioning, indicative of the pervasive detrimental effects of early abuse.|PMID:16160627; Original text:Post hoc analysis looking at the 3 core symptoms of autism, that is, social interaction, communication, and stereotyped behaviors, revealed a significant improvement of the social interaction score after 6 months of active treatment.|PMID:31549310; Original text:Results documented that cooperative parent-mediated therapy showed an additional benefit on the same low-intensity psychosocial intervention with significant improvements of the primary blinded outcome, socio-communication skills, and of some secondary outcomes such as disorder symptom severity, emotional problems and parental stress related to parent-child dysfunctional interaction.|PMID:27807755; Original text:Results of the study demonstrated that participants made significant improvements with their social behavior (p < .001) following intervention, and the results were maintained up to 32 weeks after intervention had concluded.|PMID:9690938; Original text:The autistic group's performance on the false belief, belief term comprehension, and belief term expression tasks was significantly poorer than that of the Asperger, language impaired, and normal groups.|PMID:15863467; Original text:Diagnostic criteria, age of the sample, and urban or rural location were associated with estimated prevalence of all all autism spectrum disorders.|PMID:32112261; Original text:Regarding the treatment, a meta-analysis of behavioral interventions, including only three randomized controlled trials, found significant effects in terms of increase in total sleep time (24.41 min, 95% CI 5.71-43.11, P = 0.01), decrease in sleep-onset latency (- 18.31 min, 95% CI - 30.84 to - 5.77, P = 0.004), and a significant effect on sleep efficiency (5.59, 95% CI 0.87-10.31, P = 0.02), albeit the risk of bias of the included studies was rated ""high"" in relation to issues with the blinding.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:15673999; Original text:Vitamin C levels were measured at the end of the study, and the placebo group had levels that were significantly below average for typical children, whereas the supplement group had near-average levels.|PMID:24061784; Original text:Specifically, participants in the placebo group were significantly less likely than participants in the citalopram group to respond at week 12 if they entered the study more symptomatic on each of the 3 composite measures, and they were at least 2 times less likely to be responders.|PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.|PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).|PMID:30305689; Original text:Of the included studies, half (n = 6) demonstrated significant weight loss; including comprehensive (n = 3), pharmaceutical (n = 2), and exercise (n = 1) interventions.|PMID:16919132; Original text:Significant effects were found in these studies even with extremely small samples, and the findings are important because they demonstrate the potential of the medium of music for autistic children.|PMID:27183106; Original text:However, the lack of significant results was associated with high methodological heterogeneity, low quality of the studies, small sample size, and scarce reliability of the methods used in previous studies, which need to be validated and standardized.|PMID:19823139; Original text:There have been significant advances in our knowledge of the early signs of ASD through the use of retrospective videotape analysis, parental report, screening studies, and more recently, studies on high-risk infant siblings.|PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.|PMID:26551748; Original text:We found significant differences between before and after the therapy in the length of the gait cycle that became more stable in the sagital plane and concluded that our results proved that horse therapy may be successfully used as an additional therapy for children with autism, and it may be a form of rehabilitation in cases when other therapies are not successful.|PMID:24828014; Original text:Six of the 48 subjects met two criteria for responders to risperidone, and the median values of interleukin (interleukin)-5 were significantly higher (p=0.005) in the overall responder group than in nonresponders.|PMID:30979038; Original text:The results showed that PS128 ameliorated opposition/defiance behaviors, and that the total score of The Swanson, Nolan, and Pelham-IV-Taiwan version for younger children (aged 712) improved significantly compared with the placebo group.|PMID:12804129; Original text:Despite the short duration of the treatment, behavioral measures also displayed a significant improvement, and most of the effect disappeared after the discontinuation of the melatonin (p = 0.001).|PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).|PMID:34018333; Original text:Our results show that activation of the the ventromedial prefrontal cortex with anodal Transcranial direct current stimulation significantly improved mind in children with disorder compared with both, r-temporoparietal junction Transcranial direct current stimulation, and sham stimulation.|PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.|PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.|PMID:15492353; Original text:Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the the Aberrant Behavior Checklist; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom."
epilepsy	disease_to_anatomy	group (	1	0	34510916	PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).
epilepsy	disease_to_anatomy	of the	2	0	34510916|19454962	PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).|PMID:19454962; Original text:However, critical review of the literature reveals that the rate in idiopathic cases with normal lower intelligence quotient is still significantly above the population risk suggesting that autism itself is associated with an increased risk of epilepsy.
epilepsy	disease_to_anatomy	, and	4	0	34510916|20087181|19319661|24123946	PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).|PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.|PMID:19319661; Original text:The most significant clinical features were mental retardation, epilepsy and autistic behaviour, and these symptoms did not worsen, in contrast to other reports.|PMID:24123946; Original text:The del15q11.2 was found to be significantly associated with intellectual disability, schizophrenia, epilepsy, and disorder.
autistic	disease_to_anatomy	group (	3	0	34510916|2977280|30399531	PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).|PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.|PMID:30399531; Original text:There was also a higher prevalence of alexithymia in the disorder group (49.93% compared to 4.89%), with a significantly increased risk of alexithymia in autistic participants.
autistic	disease_to_anatomy	of the	15	0	34510916|12816888|9895151|7854533|7854533|21826280|22688012|9690938|14561452|16919132|18425890|11408327|30517284|25817280|34563942	PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).|PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:9895151; Original text:In contrast, there is a lack of significant difference in the cross-sectional size of the posterior hippocampal formation between autistic and normal subjects, which is discrepant with predictions based on some autopsy studies.|PMID:7854533; Original text:By contrast, measures of vermian lobules VI and VII and the posterior portion of the corpus callosum in these same autistic and normal volunteers differed significantly, by more than 9.9%.|PMID:7854533; Original text:The lack of a significant difference in the cross-sectional size of the posterior hippocampal formation between autistic and normal 6- to 42-year-olds is discrepant with predictions based on some, but not all, autopsy studies.|PMID:21826280; Original text:We propose that alteration of the expression and/or timing of critical period circuit refinement in primary sensory brain areas may significantly contribute to autistic phenotypes, including cognitive and behavioral impairments.|PMID:22688012; Original text:The majority of the data are based on molecular, cytogenetic, linkage and association studies of autistic subjects, but newer methods, including whole-exome sequencing, are also beginning to make significant contributions to our understanding of autism.|PMID:9690938; Original text:The autistic group's performance on the false belief, belief term comprehension, and belief term expression tasks was significantly poorer than that of the Asperger, language impaired, and normal groups.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:16919132; Original text:Significant effects were found in these studies even with extremely small samples, and the findings are important because they demonstrate the potential of the medium of music for autistic children.|PMID:18425890; Original text:There were only three significant treatment effects in favour of the diet intervention: overall autistic traits, mean difference (mean difference) =|PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.|PMID:30517284; Original text:The results of the identified studies confirm the significant importance of these instruments in improving the communicative process of autistic children.|PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.|PMID:34563942; Original text:While significant variation was noted across individual study findings, much of the existing literature supported three preliminary findings about the nature of autistic camouflaging: (1) adults with more self-reported autistic traits report greater engagement in camouflaging; (2) sex and gender differences exist in camouflaging; and (3) higher self-reported camouflaging is associated with worse mental health outcomes.
autistic	disease_to_anatomy	, and	7	0	34510916|25729218|21299356|9690938|14561452|16919132|15730889	"PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).|PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.|PMID:21299356; Original text:Covering the literature from 1943 to the present in the PubMed and Ovid Medline databases, this review summarizes evidence of hormones, metabolites, amino acids, and other biomarkers present in significantly different quantities in autistic subjects compared to age- and sex-matched controls.|PMID:9690938; Original text:The autistic group's performance on the false belief, belief term comprehension, and belief term expression tasks was significantly poorer than that of the Asperger, language impaired, and normal groups.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:16919132; Original text:Significant effects were found in these studies even with extremely small samples, and the findings are important because they demonstrate the potential of the medium of music for autistic children.|PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
(ci	anatomy	(ci)	1	0	27109830	PMID:27109830; Original text:In disorder, there were significant differences between the clinical group and healthy controls, with the disorder group making significantly more perseverative errors, indicating greater difficulty in set-shifting [pooled effect size of d = 0.67, 95% confidence interval (CI) 0.53-0.81, p ⩽ 0.001].
(ci)	anatomy	ci)	1	0	27109830	PMID:27109830; Original text:In disorder, there were significant differences between the clinical group and healthy controls, with the disorder group making significantly more perseverative errors, indicating greater difficulty in set-shifting [pooled effect size of d = 0.67, 95% confidence interval (CI) 0.53-0.81, p ⩽ 0.001].
(ci	anatomy	ci)	1	0	27109830	PMID:27109830; Original text:In disorder, there were significant differences between the clinical group and healthy controls, with the disorder group making significantly more perseverative errors, indicating greater difficulty in set-shifting [pooled effect size of d = 0.67, 95% confidence interval (CI) 0.53-0.81, p ⩽ 0.001].
, 2	anatomy	2	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
, 2	anatomy	facial expression	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
, 2	anatomy	4	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
, 2	anatomy	, and	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
(p	anatomy	, 2	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
, 2	anatomy	6	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
2	anatomy	facial expression	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
2	anatomy	4	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
, and	anatomy	2	2	0	31096266|26361994	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
(p	anatomy	2	2	0	31096266|24391123	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:24391123; Original text:Between visits 1 and 2, mean anxiety and behavior scores decreased significantly by 0.8 points (P = .03) for subjects within groups C and D. Significant changes were not observed within groups A and B. Mean anxiety and behavior scores did not differ significantly between groups over time, although group A versus C pairwise comparisons showed a trend toward significance (P = .06).
2	anatomy	6	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
4	anatomy	facial expression	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
, and	anatomy	facial expression	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
(p	anatomy	facial expression	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
6	anatomy	facial expression	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
, and	anatomy	4	2	0	31096266|23821414	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:23821414; Original text:Forty-nine patients were enrolled in the study, and forty children completed the trial (dropouts: placebo = 4, riluzole = 5).
(p	anatomy	4	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
4	anatomy	6	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
(p	anatomy	, and	36	0	31096266|25302490|26890560|26313946|16190799|29427532|24214165|24352377|8911222|32173844|25313065|32149480|20973712|8498878|27807755|26792761|22265360|22265360|22151477|24408892|8911223|19968048|21208598|25149412|28342168|32347624|19284641|19284641|19284641|12804129|30196397|23101743|28036350|19736351|27126856|33376247	"PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:25302490; Original text:Statistically significant differences (p < 0.05) were shown on ATEC/ABC scores for the domains of speech, sociability, sensory, and overall health, as well as reductions in the total scores when compared to pretreatment values.|PMID:26890560; Original text:Groups with early support were more successful in scheduling or completing appointments for recommended services overall including medical, educational, therapeutic, and parent resource appointments (p = .031).|PMID:26313946; Original text:Two-way ANOVA showed a significant sex-by-diagnosis interaction in total correct score (F(1,711) = 5.090, p = 0.024, ηp2 = 0.007) arising from a significant sex difference between control males and females (p < 0.001, Cohen's d = 0.47), and an absence of a sex difference between males and females with autism (p = 0.907, d = 0.01); significant case-control differences were observed across sexes, with effect sizes of d = 0.35 in males and d = 0.69 in females.|PMID:16190799; Original text:Irritability subscale was the primary outcome measure (p = 0.65), and CGI--Improvement (p = 0.16) and OAS (p = 0.96) were secondary outcome measures.|PMID:29427532; Original text:Significant improvements from baseline to study endpoint were observed in several subscales of the CCC-2, SRS, CGI-I, CGI-S, and ADOS, including Associated Maladaptive Behaviors (P ≤ .043), Reciprocal Social Interaction (P = .015), Communication (P < .001), and Stereotyped Behaviors and Repetitive Interests (P ≤ .013).|PMID:24214165; Original text:Results show that the children in the treatment group (n = 17) who received 30 sessions of the occupational therapy intervention scored significantly higher (p = 0.003, d = 1.2) on Goal Attainment Scales (primary outcome), and also scored significantly better on measures of caregiver assistance in self-care (p = 0.008 d = 0.9) and socialization (p = 0.04, d = 0.7) than the Usual Care control group (n = 15).|PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).|PMID:8911222; Original text:Tryptophan depletion led to a significant increase in behaviors such as whirling, flapping, pacing, banging and hitting self, rocking, and toe walking (P < .05).|PMID:32173844; Original text:Measuring the effectiveness of diuretic, by studying correlations in the CARS showed an efficacy of this treatment at 3 months (p˂10-3), 6 months (p˂10-3), at 9 months (p = 0.010) and 12 months (p = 0.04), and this compared to the initial assessment.|PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).|PMID:32149480; Original text:There were significant decreases in total autism treatment evaluation checklist scores (P = 0.014), sociability sub-scores (P = 0.021), and behavioral, health, and physical condition sub-scores (P = 0.011) in the Transcranial direct current stimulation treatment group.|PMID:20973712; Original text:Statistically significantly greater improvement was seen with aripiprazole versus placebo (p < 0.05) for all arms in both trials on the the Aberrant Behavior Checklist-Irritability total subscale score and on the following individual the Aberrant Behavior Checklist-Irritability items: Mood changes quickly, cries/screams inappropriately, and stamps feet/bangs objects.|PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.|PMID:27807755; Original text:Results of the study demonstrated that participants made significant improvements with their social behavior (p < .001) following intervention, and the results were maintained up to 32 weeks after intervention had concluded.|PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)|PMID:22265360; Original text:Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively).|PMID:22265360; Original text:On Age Equivalent scores, Socialization and Communication domains showed greater improvement in COMB versus MED (p = .03 and 0.05, and effect sizes = 0.33 and 0.14, respectively).|PMID:22151477; Original text:The supplement group had significantly greater improvements than the placebo group on the Parental Global Impressions-Revised (PGI-R, Average Change, p = 0.008), and on the subscores for Hyperactivity (p = 0.003), Tantrumming (p = 0.009), Overall (p = 0.02), and Receptive Language (p = 0.03).|PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).|PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).|PMID:19968048; Original text:The conclusions from a nonparametric repeated-measures technique indicate that mean night sleep duration was longer on melatonin than placebo by 21 minutes (p = .02), mean sleep-onset latency was shorter by 28 minutes (p = .0001), and mean sleep-onset time was earlier by 42 minutes (p = .02).|PMID:21208598; Original text:Two randomized clinical trials reported a significant benefit of massage for sensory profile (P < .01), adaptive behavior (P < .05), and language and social abilities (P < .01) as compared with a special education program.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).|PMID:28342168; Original text:After adjusting for potential covariates, having autism spectrum disorders was associated with significantly lower trabecular bone mineral density and bone strength at the radius, and with marginally lower total body less head bone mineral content (p < 0.09).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:19284641; Original text:After 40 sessions, mean physician Clinical Global Impression scores significantly improved in the tre1.3 atmosphereent group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the tre1.3 atmosphereent group were rated as ""very much improved"" or ""much improved"" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the tre1.3 atmosphereent group improved compared to 10/26 (38%) of controls (p = 0.0024).|PMID:19284641; Original text:Mean parental Clinical Global Impression scores significantly improved in the tre1.3 atmosphereent group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).|PMID:12804129; Original text:Despite the short duration of the treatment, behavioral measures also displayed a significant improvement, and most of the effect disappeared after the discontinuation of the melatonin (p = 0.001).|PMID:30196397; Original text:Improvement in LSAS scores from baseline to the primary endpoint was significantly greater for 3,4-methylenedioxymethamphetamine group compared to the placebo group (P = 0.037), and placebo-subtracted Cohen's d effect size was very large (d = 1.4, CI - 0.074, 2.874).|PMID:23101743; Original text:The the behavior management treatment had shown a significant advantage for child behavioral noncompliance (p = .006, d = 0.34), irritability (p = .01, d = 0.48), and hyperactivity/noncompliance (p = .04, d = 0.55) with a lower medication dose.|PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.|PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).|PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).|PMID:33376247; Original text:When combining the presence of magnetic resonance imaging findings, facial morphological variants, and genetic copy number variants, statistically significant relationships were found with disorder and attention-deficit hyperactivity disorder diagnoses (p = 0.0006 and p = 0.002, respectively)."
, and	anatomy	6	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
(p	anatomy	6	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	chemical_to_mechanism	oxytocin	33	0	31096266|31096266|26503762|28864977|33622389|33622389|33622389|27071789|32398642|32398642|34062986|24352377|24352377|25070538|12496956|22278094|25416642|28696286|26394796|26394796|26336909|26336909|26336909|31229634|34593045|32161366|25149412|27651096|28534875|26094200|8759044|28467893|30262887	"PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:31096266; Original text:Quantitative facial expression analyses successfully verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and demonstrated a time-course change in efficacy.|PMID:26503762; Original text:Compared with placebo, oxytocin led to significant improvements on the primary outcome of caregiver-rated social responsiveness.|PMID:28864977; Original text:In the last decade, there has been a significant interest in using oxytocin to treat social behavior deficits in disorder.|PMID:33622389; Original text:Among the 35 metabolites measured, a significant increase in N,N-dimethylglycine was detected in the subjects administered oxytocin compared with those given placebo at a medium effect size (false discovery rate (false discovery rate) corrected P = 0.043, d = 0.74, N = 83).|PMID:33622389; Original text:Furthermore, subgroup analyses of the participants displaying a prominent time-course change in oxytocin efficacy revealed a significant effect of oxytocin on N,N-dimethylglycine levels with a large effect size (Pfalse discovery rate = 0.004, d = 1.13, N = 60).|PMID:33622389; Original text:The increase in N,N-dimethylglycine was significantly correlated with oxytocin-induced clinical changes, assessed as changes in quantifiable characteristics of autistic facial expression, including both of improvements between baseline and 2 weeks (Pfalse discovery rate = 0.006, r = - 0.485, N = 43) and deteriorations between 2 and 4 weeks|PMID:27071789; Original text:Some studies have reported significant improvement of the core symptoms of disorder by long-term oxytocin administration, while other studies showed no such improvement.|PMID:32398642; Original text:Results showed that the time spent viewing both dynamic and static social vs. non-social stimuli was negatively associated with trait autism and significantly increased following intranasal oxytocin.|PMID:32398642; Original text:Overall, our findings demonstrate that oxytocin significantly shifts gaze preference towards social vs. non-social stimuli and to the eyes of fearful faces.|PMID:34062986; Original text:We observed improvements in Aberrant Behavior Checklist and the Social Responsiveness Scale scores and significant improvements in the Clinical Global Impression-improvement between those receiving probiotics and oxytocin combination therapy compared to those receiving placebo (p < 0.05).|PMID:24352377; Original text:Intranasal oxytocin enabled the participants to make the nonverbal information-based judgments more frequently (P = .03) with shorter response time (P = .02).|PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:25070538; Original text:The oxytocin-induced increases in the functional magnetic resonance imaging signal could be predicted by the NAA differences between the oxytocin and placebo sessions (P=0.002), an effect that remained after controlling for variability in the time between the functional magnetic resonance imaging and (1)H-MRS scans (P=0.006) and the order of administration of oxytocin and placebo (P=0.001).|PMID:12496956; Original text:Patients with autism spectrum disorders showed a significant reduction in repetitive behaviors following oxytocin infusion in comparison to placebo infusion.|PMID:22278094; Original text:Under oxytocin activation differences between genotypes were more evident (though not statistically significantly increased) and slower reaction times were accelerated in homozygotic risk allele carriers.|PMID:25416642; Original text:Here we extend our previous work by significantly increasing the number of participants to enable the use of more stringent statistical thresholds that permit more precise localization of oxytocin and vasopressin effects in the brain.|PMID:28696286; Original text:When pretreatment neuropeptide measures were included in the statistical model, the neuropeptide oxytocin compared with placebo treatment significantly enhanced social abilities in children with disorder [as measured by the trial's primary outcome measure, the Social Responsiveness Scale (SRS)].|PMID:26394796; Original text:Previous clinical trials of a single dose of oxytocin have consistently reported significantly positive effects on various experimental measures associated with the core symptoms of disorder.|PMID:26394796; Original text:However, to date, randomized clinical trials of continual administration of oxytocin have failed to reveal significant positive effects on clinically meaningful endpoints, such as how those with disorder interact during interpersonal interactions.|PMID:26336909; Original text:Data obtained from 18 participants who completed the trial showed that 6-week intranasal administration of oxytocin significantly reduced autism core symptoms specific to social reciprocity, which was clinically evaluated by Autism Diagnostic Observation Scale (P = 0.034, PFDR < 0.05, Cohen's d = 0.78).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).|PMID:31229634; Original text:Results revealed a marginal significant interaction effect between treatment, condition and task (p = 0.054), with Bonferroni-corrected post-hoc tests indicating that The neuropeptide oxytocin specifically increased antisaccade errors for social stimuli (ps < 0.04, effect sizes 0.46-0.88), but not non-social stimuli.|PMID:34593045; Original text:There was no statistically significant improvement with oxytocin as compared to placebo on the the Aberrant Behavior Checklist-Social Withdrawal (Mann-Whitney U = 50,|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:25149412; Original text:Behaviourally, oxytocin significantly increased the correct rate in inferring others' social emotions (P = 0.043, one-tail).|PMID:27651096; Original text:Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with disorder.|PMID:28534875; Original text:To our knowledge, this is the first trial to assess the dose-dependent effects of a single oxytocin administration in autism, with results indicating that a low dose of oxytocin can significantly modulate overt emotion salience despite minimal systemic exposure.|PMID:26094200; Original text:

It was brought to the authors' attention that there were several significant data analytic errors linked to the data entry and the software program that was used in the published meta-analysis comparing the effect of intranasal oxytocin versus placebo administration on psychiatric symptoms.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations.|PMID:28467893; Original text:A single dose of intranasal oxytocin significantly improved the recognition of basic emotions, particularly fear, and increased the expression of positive emotions among the healthy individuals.|PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin."
oxytocin	chemical_to_anatomy	, 2	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	chemical_to_anatomy	2	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	chemical_to_anatomy	facial expression	3	0	31096266|31096266|33622389	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:31096266; Original text:Quantitative facial expression analyses successfully verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and demonstrated a time-course change in efficacy.|PMID:33622389; Original text:The increase in N,N-dimethylglycine was significantly correlated with oxytocin-induced clinical changes, assessed as changes in quantifiable characteristics of autistic facial expression, including both of improvements between baseline and 2 weeks (Pfalse discovery rate = 0.006, r = - 0.485, N = 43) and deteriorations between 2 and 4 weeks
oxytocin	chemical_to_anatomy	4	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	chemical_to_anatomy	, and	4	0	31096266|24352377|25092245|28467893	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).|PMID:25092245; Original text:Thus, a meta-analytic review of extant studies is needed to determine whether The oxytocin receptor gene shows association with disorder, and to elucidate which specific single-nucleotide polymorphisms have a significant effect on disorder.|PMID:28467893; Original text:A single dose of intranasal oxytocin significantly improved the recognition of basic emotions, particularly fear, and increased the expression of positive emotions among the healthy individuals.
oxytocin	chemical_to_anatomy	(p	8	0	31096266|34062986|24352377|24352377|24352377|26336909|31229634|25149412	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:34062986; Original text:We observed improvements in Aberrant Behavior Checklist and the Social Responsiveness Scale scores and significant improvements in the Clinical Global Impression-improvement between those receiving probiotics and oxytocin combination therapy compared to those receiving placebo (p < 0.05).|PMID:24352377; Original text:Intranasal oxytocin enabled the participants to make the nonverbal information-based judgments more frequently (P = .03) with shorter response time (P = .02).|PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).|PMID:26336909; Original text:Data obtained from 18 participants who completed the trial showed that 6-week intranasal administration of oxytocin significantly reduced autism core symptoms specific to social reciprocity, which was clinically evaluated by Autism Diagnostic Observation Scale (P = 0.034, PFDR < 0.05, Cohen's d = 0.78).|PMID:31229634; Original text:Results revealed a marginal significant interaction effect between treatment, condition and task (p = 0.054), with Bonferroni-corrected post-hoc tests indicating that The neuropeptide oxytocin specifically increased antisaccade errors for social stimuli (ps < 0.04, effect sizes 0.46-0.88), but not non-social stimuli.|PMID:25149412; Original text:Behaviourally, oxytocin significantly increased the correct rate in inferring others' social emotions (P = 0.043, one-tail).
oxytocin	chemical_to_anatomy	6	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	mechanism_to_anatomy	, 2	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	mechanism_to_anatomy	2	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	mechanism_to_anatomy	facial expression	3	0	31096266|31096266|33622389	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:31096266; Original text:Quantitative facial expression analyses successfully verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and demonstrated a time-course change in efficacy.|PMID:33622389; Original text:The increase in N,N-dimethylglycine was significantly correlated with oxytocin-induced clinical changes, assessed as changes in quantifiable characteristics of autistic facial expression, including both of improvements between baseline and 2 weeks (Pfalse discovery rate = 0.006, r = - 0.485, N = 43) and deteriorations between 2 and 4 weeks
oxytocin	mechanism_to_anatomy	4	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	mechanism_to_anatomy	, and	2	0	31096266|28467893	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:28467893; Original text:A single dose of intranasal oxytocin significantly improved the recognition of basic emotions, particularly fear, and increased the expression of positive emotions among the healthy individuals.
oxytocin	mechanism_to_anatomy	(p	7	0	31096266|34062986|24352377|24352377|26336909|31229634|25149412	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:34062986; Original text:We observed improvements in Aberrant Behavior Checklist and the Social Responsiveness Scale scores and significant improvements in the Clinical Global Impression-improvement between those receiving probiotics and oxytocin combination therapy compared to those receiving placebo (p < 0.05).|PMID:24352377; Original text:Intranasal oxytocin enabled the participants to make the nonverbal information-based judgments more frequently (P = .03) with shorter response time (P = .02).|PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Data obtained from 18 participants who completed the trial showed that 6-week intranasal administration of oxytocin significantly reduced autism core symptoms specific to social reciprocity, which was clinically evaluated by Autism Diagnostic Observation Scale (P = 0.034, PFDR < 0.05, Cohen's d = 0.78).|PMID:31229634; Original text:Results revealed a marginal significant interaction effect between treatment, condition and task (p = 0.054), with Bonferroni-corrected post-hoc tests indicating that The neuropeptide oxytocin specifically increased antisaccade errors for social stimuli (ps < 0.04, effect sizes 0.46-0.88), but not non-social stimuli.|PMID:25149412; Original text:Behaviourally, oxytocin significantly increased the correct rate in inferring others' social emotions (P = 0.043, one-tail).
oxytocin	mechanism_to_anatomy	6	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	chemical_to_disease	autistic	2	0	31096266|26336909	PMID:31096266; Original text:Quantitative facial expression analyses successfully verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and demonstrated a time-course change in efficacy.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).
autistic	disease_to_mechanism	oxytocin	2	0	31096266|26336909	PMID:31096266; Original text:Quantitative facial expression analyses successfully verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and demonstrated a time-course change in efficacy.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).
autistic	disease_to_anatomy	facial expression	1	0	31096266	PMID:31096266; Original text:Quantitative facial expression analyses successfully verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and demonstrated a time-course change in efficacy.
autism	disease	catatonia	1	0	18427869	PMID:18427869; Original text:Catatonia should be assessed in people with autism when there is an obvious and marked deterioration in movement, vocalizations, pattern of activities, self-care, and practical skills.
autism	disease_to_anatomy	, and	43	0	18427869|23455605|31994188|27105825|9672054|29498298|28378499|26313946|16083327|18626481|9809262|15749246|32149480|16160627|10425586|9934941|21690083|29286586|26359749|31665947|34627165|24061784|32563542|32168067|23782128|11573335|22070180|21629200|15090875|21863344|27721995|17367287|23766737|26551748|11525418|19284641|9442997|19736351|23471985|19948568|22457638|20969835|25861158	PMID:18427869; Original text:Catatonia should be assessed in people with autism when there is an obvious and marked deterioration in movement, vocalizations, pattern of activities, self-care, and practical skills.|PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.|PMID:31994188; Original text:The concept of autism is a significant contribution from child psychiatry that has entered wider culture and public consciousness, and has evolved significantly over the last four decades.|PMID:27105825; Original text:Functional enrichment analysis detected significant over-representation of target gene clusters related to transcriptional activation, neuronal development, and the Simons Foundation Autism Database genes.|PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.|PMID:28378499; Original text:Significant improvements in children's behavior were observed on parent-report measures of social communication skills and autism symptoms, clinician ratings of overall autism symptom severity and degree of improvement, standardized measures of expressive vocabulary, and objective eye-tracking measures of children's attention to social stimuli, indicating that these measures may be useful endpoints in future studies.|PMID:26313946; Original text:Two-way ANOVA showed a significant sex-by-diagnosis interaction in total correct score (F(1,711) = 5.090, p = 0.024, ηp2 = 0.007) arising from a significant sex difference between control males and females (p < 0.001, Cohen's d = 0.47), and an absence of a sex difference between males and females with autism (p = 0.907, d = 0.01); significant case-control differences were observed across sexes, with effect sizes of d = 0.35 in males and d = 0.69 in females.|PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.|PMID:18626481; Original text:The current results from seven studies suggested a significant association of minor physical anomalies in autism with a robust pooled effect size (d=0.84), and thereby provide the strongest evidence to date about the close association between minor physical anomalies and autism.|PMID:9809262; Original text:In the experimental group, there were greater gains in language abilities, significant increases in caregivers' knowledge about autism, greater perception of control on the part of mothers, and greater parent satisfaction.|PMID:15749246; Original text:Autism is a complex developmental disorder without an established single etiology but with significant contributions from genetic studies, functional research, and neuropsychiatric and neuroradiologic investigations.|PMID:32149480; Original text:There were significant decreases in total autism treatment evaluation checklist scores (P = 0.014), sociability sub-scores (P = 0.021), and behavioral, health, and physical condition sub-scores (P = 0.011) in the Transcranial direct current stimulation treatment group.|PMID:16160627; Original text:Post hoc analysis looking at the 3 core symptoms of autism, that is, social interaction, communication, and stereotyped behaviors, revealed a significant improvement of the social interaction score after 6 months of active treatment.|PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:21690083; Original text:It was found that after the parents added home-based DIR/Floortime™ intervention at an average of 15.2 hours/week for three months, the intervention group made significantly greater gains in all three measures employed in the study: Functional Emotional Assessment Scale (Functional Emotional Assessment Scale) (F = 5.1, p = .031), Childhood Autism Rating Scale (F = 2.1, p = .002), and the Functional Emotional Questionnaires (F = 6.8, p = .006).|PMID:29286586; Original text:Cognitive enhancement therapy (Cognitive enhancement therapy), an 18-month cognitive remediation intervention designed to improve thinking and social understanding, was found to be more effective than supportive therapy at improving mental quickness, attention, and employment in adults living with autism.|PMID:26359749; Original text:For secondary outcomes, the intervention reduced autism-risk behaviours (0.50, CI -0.15 to 1.08), increased parental non-directiveness (0.81, 0.28 to 1.52), improved attention disengagement (0.48, -0.01 to 1.02), and improved parent-rated infant adaptive function (χ(2)[2] 15.39, p=0.0005).|PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:34627165; Original text:Among the biological processes that were examined, genes involved in synaptic integrity, neurotransmitter metabolism, and cell adhesion molecules were significantly involved in the development of autism.|PMID:24061784; Original text:Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12.|PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:23782128; Original text:(DSM-IV-TR) criteria for an autism spectrum disorder (disorder) on the Autism Diagnostic Interview-Revised (-Revised) and the Autism Diagnostic Observation Schedule (the Autism Diagnostic Observation Schedule), and had significant symptoms of attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder).|PMID:11573335; Original text:Autism is a behaviorally defined disorder that comprises a controversial diagnostic category due to heterogeneity in symptomatology, causation, and etiology and significant variance in response to intervention.|PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).|PMID:21629200; Original text:Significant correlations between changes in serum free-carnitine levels and positive clinical changes were observed for hand muscle strength (R2=0.23, P=0.046), cognitive scores (R2=0.27, P=0.019), and Childhood Autism Rating Scale scores (R2=0.20, P=0.047).|PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.|PMID:21863344; Original text:Empathy, for instance, is a rather elaborated human ability, and several recent studies point to significant impairments in patients suffering from psychiatric disorders, such as schizophrenia or autism.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.|PMID:17367287; Original text:A number of endogenous biomarkers associated with autism risk have been investigated, and these may help identify significant biologic pathways that, in turn, will aid in the discovery of specific genes and exposures.|PMID:23766737; Original text:It was observed by the parents, coaches, and study investigators that the children who were less than 3 years of age showed improvements in autism symptoms; however, the group was too small to reach statistical significance.|PMID:26551748; Original text:We found significant differences between before and after the therapy in the length of the gait cycle that became more stable in the sagital plane and concluded that our results proved that horse therapy may be successfully used as an additional therapy for children with autism, and it may be a form of rehabilitation in cases when other therapies are not successful.|PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.|PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.|PMID:9442997; Original text:A significant effect of informant was found for the PDD group, and this effect was particularly pronounced when children with autism were considered separately.|PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).|PMID:23471985; Original text:As a posthoc analysis, we conducted genome-wide association scans on several organizational and topological network measures derived from the matrices to discover variants in and around genes associated with autism (autism), development (NEDD4), and mental retardation (UBE2A) significantly associated with connectivity.|PMID:19948568; Original text:Compared with children who received community-intervention, children who received the Early Start Denver Model showed significant improvements in IQ, adaptive behavior, and autism diagnosis.|PMID:22457638; Original text:Genes regulating cell cycle also exhibited autism-specific number variations in DNA derived from prefrontal cortex, and these genes were significantly associated with autism in genome-wide association study datasets.|PMID:20969835; Original text:We present initial evidence offering proof of concept that brain anatomy can be used to accurately distinguish adults with autism from healthy controls, and from some other neurodevelopmental disorders (some other neurodevelopmental disorders).|PMID:25861158; Original text:tDCS also significantly increased at the stimulation site, and an increase in tDCS was significantly associated with improvements in the two domains of autism treatment evaluation checklist impacted by tDCS.
catatonia	disease_to_anatomy	, and	2	0	18427869|16697303	PMID:18427869; Original text:Catatonia should be assessed in people with autism when there is an obvious and marked deterioration in movement, vocalizations, pattern of activities, self-care, and practical skills.|PMID:16697303; Original text:Catatonia should be assessed in any patient with spectrum disorders when there is an obvious and marked deterioration in movement, pattern of activities, self-care, and practical skills, compared with previous levels, through a comprehensive diagnostic evaluation of medical and psychiatric symptoms.
autism spectrum disorders	disease	rheumatoid arthritis	1	0	28319657	PMID:28319657; Original text:Another case-control study showed a statistically significant 8-fold increase in autoimmune disorders, including rheumatoid arthritis, in mothers of offspring with autism spectrum disorders compared to controls.
autoimmune disorders	disease	rheumatoid arthritis	1	0	28319657	PMID:28319657; Original text:Another case-control study showed a statistically significant 8-fold increase in autoimmune disorders, including rheumatoid arthritis, in mothers of offspring with autism spectrum disorders compared to controls.
autism spectrum disorders	disease	autoimmune disorders	1	0	28319657	PMID:28319657; Original text:Another case-control study showed a statistically significant 8-fold increase in autoimmune disorders, including rheumatoid arthritis, in mothers of offspring with autism spectrum disorders compared to controls.
n-acetylcysteine	chemical_to_disease	irritability	1	0	22342106	PMID:22342106; Original text:Compared with placebo, oral N-acetylcysteine resulted in significant improvements on ABC irritability subscale (F = 6.80; p < .001; d = .96).
n-acetylcysteine	chemical_to_anatomy	, oral	1	0	22342106	PMID:22342106; Original text:Compared with placebo, oral N-acetylcysteine resulted in significant improvements on ABC irritability subscale (F = 6.80; p < .001; d = .96).
irritability	disease_to_anatomy	, oral	1	0	22342106	PMID:22342106; Original text:Compared with placebo, oral N-acetylcysteine resulted in significant improvements on ABC irritability subscale (F = 6.80; p < .001; d = .96).
cortisol	chemical_to_anatomy	salivary	1	0	31657508	PMID:31657508; Original text:After the training sessions, the participants' self-confidence had improved and salivary cortisol levels were significantly decreased in the Simple Virtual Audiences group as compared to those in the independent study group.
asd	disease_to_anatomy	of the	10	0	24518398|29498298|22638012|28314733|23893101|19823139|28036350|26559825|28000020|27746319	PMID:24518398; Original text:Notably, many of the reviewed studies had significant limitations, including lack of replication, limited sample sizes, retrospective design, recall and publication biases, inadequate matching of cases and controls, and the use of nonstandard tools to diagnose ASD.|PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.|PMID:22638012; Original text:Modulation of the processing of facial expressions of emotion by serotonin significantly differs in people with ASD compared with control subjects.|PMID:28314733; Original text:The poor understanding of the genetics of ASD and SCHZ is a significant hurdle to developing effective treatments for these costly conditions.|PMID:23893101; Original text:This study provides the first independent replication and extension of the empirically-supported PEERS social skills intervention for adolescents with ASD.|PMID:19823139; Original text:There have been significant advances in our knowledge of the early signs of ASD through the use of retrospective videotape analysis, parental report, screening studies, and more recently, studies on high-risk infant siblings.|PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.|PMID:26559825; Original text:A significant association for the carriers of the T-allele of the rs7794745 with high functioning ASD was found in the case-control sample [OR = 1.547; (95 % CI 1.056-2.266); p = 0.025].|PMID:28000020; Original text:The aim of the present narrative review was to explore if structural brain imaging studies may shed light on key brain areas that are linked to both ASD and ADHD symptoms and undergo significant changes during development.|PMID:27746319; Original text:We highlight new avenues for the analysis of cortical oscillation patterns in ASD which are sensitive to trial-to-trial variability within the participant, in order to validate the significance of increased response variability as possible endophenotype of the disorder.
asd	disease_to_anatomy	, and	14	0	24518398|29498298|33456050|22546059|34499230|31665947|21263444|32305492|20694583|19823139|21692142|28036350|30446273|26559825	PMID:24518398; Original text:Notably, many of the reviewed studies had significant limitations, including lack of replication, limited sample sizes, retrospective design, recall and publication biases, inadequate matching of cases and controls, and the use of nonstandard tools to diagnose ASD.|PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.|PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.|PMID:22546059; Original text:The findings indicate that, as adults, many people with ASD, including those of normal IQ, are significantly disadvantaged regarding employment, social relationships, physical and mental health, and quality of life.|PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.|PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.|PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:20694583; Original text:Individuals with co-occurring ASD and attention-deficit/hyperactivity disorder symptoms are more severely impaired, with significant deficits seen in social processing, adaptive functioning, and executive control.|PMID:19823139; Original text:There have been significant advances in our knowledge of the early signs of ASD through the use of retrospective videotape analysis, parental report, screening studies, and more recently, studies on high-risk infant siblings.|PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.|PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.|PMID:30446273; Original text:Assessing the occurrence of ASD and Attention-Deficit/Hyperactivity Disorder would improve the significant cost of healthcare, therapies, and overall daily living for families with children affected by Cerebral Palsy.|PMID:26559825; Original text:Overall, including case-control, sibs, and meta-analysis, we could not detect any significant association with the CNTNAP2 gene and high functioning ASD.
adhd	disease	anxiety	2	0	23455605|27043118	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.|PMID:27043118; Original text:In addition, memantine treatment was associated with significant improvement in ADHD and anxiety symptom severity.
adhd	disease	autism	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
adhd	disease	social	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
adhd	disease	emotional disorders	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
anxiety	disease	autism	6	0	23455605|22502839|9934941|23357440|27721995|11466160	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.|PMID:22502839; Original text:The Transcutaneous electrical acupoint stimulation group showed a significant improvement over the control in their emotional response, fear or anxiety, level/consistency of intellective relations and general impressions on the Childhood Autism Rating Scale (the Childhood Autism Rating Scale) as well as improvements in the sensory and related factors in the Autism Behavior Checklist (the Autism Behavior Checklist).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:23357440; Original text:To examine the efficacy of a modular cognitive-behavioral therapy (a modular cognitive-behavioral therapy) protocol relative to treatment as usual (TAU) among children with high-functioning autism spectrum disorders (spectrum disorders) and clinically significant anxiety.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.|PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.
anxiety	disease	social	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
anxiety	disease	emotional disorders	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
autism	disease	social	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
autism	disease	emotional disorders	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
emotional disorders	disease	social	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
adhd	disease_to_anatomy	, and	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
anxiety	disease_to_anatomy	, and	7	0	23455605|28477505|9934941|32090389|27721995|23965288|19365716	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.|PMID:28477505; Original text:At post- assessment, compared to children in the a waitlist control condition, children in the either the BRAVE-ONLINE condition condition demonstrated a significantly greater reduction in number of anxiety diagnoses, clinical severity of diagnosis, and self and parent reported anxiety symptoms, as well as significantly greater increases in overall functioning.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:32090389; Original text:Only the mindfulness-based stress reduction group demonstrated significant reductions in depression, and neither group significantly changed in anxiety.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.|PMID:23965288; Original text:Pretreatment Developmental Disability-Child Global Assessment Scale scores correlated with severity of autism spectrum disorders core symptoms (r = -.388, p = .034), pragmatic communication (r = .407, p = .032), and verbal ability (r = .449, p = .013) and did not correlate with severity of anxiety symptoms or with parent-reported adaptive behavior.|PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.
social	disease_to_anatomy	, and	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
emotional disorders	disease_to_anatomy	, and	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
, and	anatomy	areas of	3	0	29248909|28296862|19365716	PMID:29248909; Original text:Significantly different performances were observed in the areas of occupation of communication space, proportion of communicative interactivity, and social-cognitive performance.|PMID:28296862; Original text:It is characterized by persistent deficits in social communication and social interaction, restricted and repetitive patterns of behavior, interests, or activities, and causes clinically significant impairment in social, occupational, or other important areas of functioning.|PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.
areas of	anatomy	space	1	0	29248909	PMID:29248909; Original text:Significantly different performances were observed in the areas of occupation of communication space, proportion of communicative interactivity, and social-cognitive performance.
, and	anatomy	space	1	0	29248909	PMID:29248909; Original text:Significantly different performances were observed in the areas of occupation of communication space, proportion of communicative interactivity, and social-cognitive performance.
the serotonin transporter gene gene	mechanism	the serotonin transporter gene loci	1	0	15882779	PMID:15882779; Original text:Our findings suggest that it is unlikely that DNA variations in the The serotonin transporter gene gene play a significant role in the genetic predisposition to autism in the Chinese Han population or that allelic heterogeneity at the The serotonin transporter gene loci dilutes potential disease-allele association.
serotonin	chemical_to_disease	autism	3	0	15882779|15292671|18286633	PMID:15882779; Original text:Our findings suggest that it is unlikely that DNA variations in the The serotonin transporter gene gene play a significant role in the genetic predisposition to autism in the Chinese Han population or that allelic heterogeneity at the The serotonin transporter gene loci dilutes potential disease-allele association.|PMID:15292671; Original text:In addition, platelet-poor plasma serotonin levels were inversely correlated with the Overt Aggression Scale scores among subjects with autism (r = -0.64, p < 0.05).|PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
serotonin	chemical_to_mechanism	the serotonin transporter gene gene	1	0	15882779	PMID:15882779; Original text:Our findings suggest that it is unlikely that DNA variations in the The serotonin transporter gene gene play a significant role in the genetic predisposition to autism in the Chinese Han population or that allelic heterogeneity at the The serotonin transporter gene loci dilutes potential disease-allele association.
serotonin	chemical_to_mechanism	the serotonin transporter gene loci	1	0	15882779	PMID:15882779; Original text:Our findings suggest that it is unlikely that DNA variations in the The serotonin transporter gene gene play a significant role in the genetic predisposition to autism in the Chinese Han population or that allelic heterogeneity at the The serotonin transporter gene loci dilutes potential disease-allele association.
autism	disease_to_mechanism	the serotonin transporter gene gene	1	0	15882779	PMID:15882779; Original text:Our findings suggest that it is unlikely that DNA variations in the The serotonin transporter gene gene play a significant role in the genetic predisposition to autism in the Chinese Han population or that allelic heterogeneity at the The serotonin transporter gene loci dilutes potential disease-allele association.
autism	disease_to_mechanism	the serotonin transporter gene loci	1	0	15882779	PMID:15882779; Original text:Our findings suggest that it is unlikely that DNA variations in the The serotonin transporter gene gene play a significant role in the genetic predisposition to autism in the Chinese Han population or that allelic heterogeneity at the The serotonin transporter gene loci dilutes potential disease-allele association.
(clinical	anatomy	group	1	0	27552585	PMID:27552585; Original text:However, in male participants, Clinical Global Impression-Improvement (Clinical Global Impression-Improvement) scores in the high-dose group, but not the low-dose group, were significantly higher than in the placebo group.
autism spectrum	disease_to_anatomy	, and	5	0	33734889|34387753|24757919|29587698|23530174	PMID:33734889; Original text:For direct stakeholders such as individuals with autism spectrum disorder (disorder), social validation has mostly included participants who do not experience significant speech, language, and communication limitations while frequently omitting individuals with disorder who have complex communication needs (complex communication needs).|PMID:34387753; Original text:This review synthesizes recent, clinically relevant findings on the scope, significance, and centrality of motor skill differences in autism spectrum disorder (disorder).|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.|PMID:29587698; Original text:Significant racial, ethnic, and socioeconomic disparities exist in access to evidence-based treatment services for children with autism spectrum disorder (disorder).|PMID:23530174; Original text:Results indicated that 54% of children who screened positive on the Toddlers and Toddlers/F presented with an autism spectrum disorder (disorder), and 98% presented with clinically significant developmental concerns warranting intervention.
hyperactivity	disease	irritability	18	0	26088658|26208985|19858761|24201232|9934941|19772883|23782127|18685284|22782459|22419332|32168067|30980177|32347624|19284641|32947424|23101743|25580916|22999292	PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:19858761; Original text:Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, combined treatment showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04).|PMID:24201232; Original text:Among ABC-C subscales, Hyperactivity and Irritability showed significantly greater reduction in the amantadine group than the placebo group.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:19772883; Original text:The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in the Aberrant Behavior Checklist-Community subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech.|PMID:23782127; Original text:The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:22782459; Original text:Primary outcome measure was the change in irritability subscale of ABC-C. Significant time × treatment interaction was observed for Irritability (F (1.658, 63.0χ1) = 13.580, P < 0.001), Lethargy/Social Withdrawal (F (1.948, 74.03χ) = 16.811, P < 0.001), and Stereotypic Behavior (F(1.74χ, 66.198) = 1χ.104, P < 0.001), but not for Hyperactivity/Noncompliance (F (χ.564, 97.4χ4) = 1.469, P = 0.χ3χ), and Inappropriate Speech subscales (F (1.607, 61.075) = 0.173, P = 0.794).|PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).|PMID:23101743; Original text:The the behavior management treatment had shown a significant advantage for child behavioral noncompliance (p = .006, d = 0.34), irritability (p = .01, d = 0.48), and hyperactivity/noncompliance (p = .04, d = 0.55) with a lower medication dose.|PMID:25580916; Original text:Repeated-measures analysis showed significant effect for time × treatment interaction in irritability (P = 0.01) and hyperactivity/noncompliance (P = 0.02) subscales.|PMID:22999292; Original text:Difference between the two treatment arms was significant as the group that received memantine had greater reduction in Aberrant Behavior Checklist-Community subscale scores for irritability, stereotypic behaviour and hyperactivity.
(p	anatomy	of the	21	0	26088658|12816888|31685286|26890560|29427532|24214165|24352377|8911222|20973712|29146048|27807755|22987458|32635367|25804268|24408892|18080171|21631313|33170378|28138381|12804129|28036350	"PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).|PMID:26890560; Original text:In comparison with the non-Medicaid groups, the Medicaid groups more often endorsed the 9 questions on the usefulness of the assessment as being ""A Great Deal"" useful (p = .022).|PMID:29427532; Original text:Significant improvements from baseline to study endpoint were observed in several subscales of the CCC-2, SRS, CGI-I, CGI-S, and ADOS, including Associated Maladaptive Behaviors (P ≤ .043), Reciprocal Social Interaction (P = .015), Communication (P < .001), and Stereotyped Behaviors and Repetitive Interests (P ≤ .013).|PMID:24214165; Original text:Results show that the children in the treatment group (n = 17) who received 30 sessions of the occupational therapy intervention scored significantly higher (p = 0.003, d = 1.2) on Goal Attainment Scales (primary outcome), and also scored significantly better on measures of caregiver assistance in self-care (p = 0.008 d = 0.9) and socialization (p = 0.04, d = 0.7) than the Usual Care control group (n = 15).|PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).|PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).|PMID:20973712; Original text:Several additional items measuring tantrum-like behaviors improved in the flexibly dosed trial and at least one arm of the fixed-dose trial (p < 0.05).|PMID:29146048; Original text:The meta-analysis of the literature suggested a weak but significant association between autism spectrum disorder diagnosis and increased cerebellar volume (p = .049, uncorrected), but the analysis of ABIDE did not show any relationship.|PMID:27807755; Original text:Results of the study demonstrated that participants made significant improvements with their social behavior (p < .001) following intervention, and the results were maintained up to 32 weeks after intervention had concluded.|PMID:22987458; Original text:The mean total the Autism Treatment Evaluation Checklist score scores by both parents and clinicians were significantly improved after intervention in both arms of the study compared to the score before intervention (P < 0.001 in both groups by parents, P = 0.015 in hyperbaric oxygen therapy group and P = 0.004 in sham group by clinician).|PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.|PMID:25804268; Original text:At post-treatment, participants showed significant improvements on all subscales of the Social Responsiveness Scale (P < 0.01) and the Social and Attention Problems syndrome scales of the Child Behavior Checklist (P < 0.05).|PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:21631313; Original text:Results demonstrated a large effect size of the difference between pre-/post-that transcranial direct current stimulation groups (p < 0.0005, d = 2.78), indicating syntax acquisition.|PMID:33170378; Original text:No statistically significant difference (p > 0.05) was observed for any of the outcome measures assessed.|PMID:28138381; Original text:Analysis of the the parent-rated social responsiveness scale total raw score demonstrated significant decrease for the DCS group compared to the placebo group (p = 0.042) indicating greater maintenance of treatment effect in the DCS group.|PMID:12804129; Original text:Despite the short duration of the treatment, behavioral measures also displayed a significant improvement, and most of the effect disappeared after the discontinuation of the melatonin (p = 0.001).|PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome."
(primary	anatomy	of the	3	0	26088658|24214165|15492353	PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:24214165; Original text:Results show that the children in the treatment group (n = 17) who received 30 sessions of the occupational therapy intervention scored significantly higher (p = 0.003, d = 1.2) on Goal Attainment Scales (primary outcome), and also scored significantly better on measures of caregiver assistance in self-care (p = 0.008 d = 0.9) and socialization (p = 0.04, d = 0.7) than the Usual Care control group (n = 15).|PMID:15492353; Original text:Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the the Aberrant Behavior Checklist (primary endpoint) compared with those who were taking placebo.
(p	anatomy	(primary	3	0	26088658|24214165|32347624	PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:24214165; Original text:Results show that the children in the treatment group (n = 17) who received 30 sessions of the occupational therapy intervention scored significantly higher (p = 0.003, d = 1.2) on Goal Attainment Scales (primary outcome), and also scored significantly better on measures of caregiver assistance in self-care (p = 0.008 d = 0.9) and socialization (p = 0.04, d = 0.7) than the Usual Care control group (n = 15).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
irritability	disease_to_anatomy	of the	7	0	26088658|26262902|32168067|30980177|28719227|32947424|15492353	PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:26262902; Original text:Insistence on sameness and irritability symptoms significantly improved over the course of the 6 week treatment period (p<0.0001) in this open-label trial.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:28719227; Original text:Significant differences in change of the ABC-C scale irritability (mean difference [95% confidence interval (95% confidence interval)] = -3.45|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).|PMID:15492353; Original text:Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the the Aberrant Behavior Checklist (primary endpoint) compared with those who were taking placebo.
irritability	disease_to_anatomy	(p	11	0	26088658|16190799|20973712|18685284|32347624|19284641|19284641|23821414|23101743|25580916|26361994	PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:16190799; Original text:Irritability subscale was the primary outcome measure (p = 0.65), and CGI--Improvement (p = 0.16) and OAS (p = 0.96) were secondary outcome measures.|PMID:20973712; Original text:Statistically significantly greater improvement was seen with aripiprazole versus placebo (p < 0.05) for all arms in both trials on the the Aberrant Behavior Checklist-Irritability total subscale score and on the following individual the Aberrant Behavior Checklist-Irritability items: Mood changes quickly, cries/screams inappropriately, and stamps feet/bangs objects.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:19284641; Original text:In the tre1.3 atmosphereent group compared to the control group, mean changes on the Aberrant Behavior Checklist total score and subscales were similar except a greater number of children improved in irritability (p = 0.0311).|PMID:23821414; Original text:A significantly greater improvement in the study primary outcome (the ABC-C irritability subscale score) was achieved by the riluzole-treated children compared with the placebo group (P = 0.03).|PMID:23101743; Original text:The the behavior management treatment had shown a significant advantage for child behavioral noncompliance (p = .006, d = 0.34), irritability (p = .01, d = 0.48), and hyperactivity/noncompliance (p = .04, d = 0.55) with a lower medication dose.|PMID:25580916; Original text:Repeated-measures analysis showed significant effect for time × treatment interaction in irritability (P = 0.01) and hyperactivity/noncompliance (P = 0.02) subscales.|PMID:26361994; Original text:Univariate analyses showed that the symptom of irritability improved in the entire sample (p = 0.023 after 2 weeks, p = 0.061 at study endpoint), although no difference was observed between the venlafaxine and placebo groups.
irritability	disease_to_anatomy	(primary	4	0	26088658|23212807|32347624|15492353	PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:23212807; Original text:Mean baseline (range 27-29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose-(-12.4 [6.5]; p < 0.001), but not low-dose (-7.4 [8.1]; p = 0.164) group, versus placebo (-3.5 [10.7]).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:15492353; Original text:Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the the Aberrant Behavior Checklist (primary endpoint) compared with those who were taking placebo.
hyperactivity	disease_to_anatomy	of the	6	0	26088658|18552703|32168067|30980177|29159857|32947424	PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:18552703; Original text:Significant benefits were observed on the Hyperactivity subscale of the parent and teacher Aberrant Behavior Checklist (Aberrant Behavior Checklist) and Global Improvement Ratings.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:29159857; Original text:-1.13 to -0.43; 4 studies, 73 participants; P < 0.001; low-quality evidence) and parents (mean difference (mean difference) -6.61 points, 95% 95% confidence interval -12.19 to -1.03, rated on the hyperactivity subscale of the Aberrant Behviour Checklist, range 0 to 48; 2 studies, 71 participants; P = 0.02; low-quality evidence).|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
hyperactivity	disease_to_anatomy	(p	8	0	26088658|20166790|18685284|22151477|32347624|19284641|23101743|25580916	PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:20166790; Original text:Subjects with either C/T or C/C (n = 16) genotypes showed a three-fold greater improvement than T/T MDR1 C3435T genotype (n = 6) (mean decrease of 15.1 +/- 12.6, or 50.7% from baseline, versus 4.5 +/- 5.1, or 15.6% from baseline) in parent-rated ABC Hyperactivity scores over 8 weeks (p = 0.03).|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:22151477; Original text:The supplement group had significantly greater improvements than the placebo group on the Parental Global Impressions-Revised (PGI-R, Average Change, p = 0.008), and on the subscores for Hyperactivity (p = 0.003), Tantrumming (p = 0.009), Overall (p = 0.02), and Receptive Language (p = 0.03).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:23101743; Original text:The the behavior management treatment had shown a significant advantage for child behavioral noncompliance (p = .006, d = 0.34), irritability (p = .01, d = 0.48), and hyperactivity/noncompliance (p = .04, d = 0.55) with a lower medication dose.|PMID:25580916; Original text:Repeated-measures analysis showed significant effect for time × treatment interaction in irritability (P = 0.01) and hyperactivity/noncompliance (P = 0.02) subscales.
hyperactivity	disease_to_anatomy	(primary	2	0	26088658|32347624	PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
autism	disease	sleep	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
autism	disease	parasomnias	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
autism	disease	sleep disorders	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
parasomnias	disease	sleep	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
sleep	disease	sleep disorders	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
parasomnias	disease	sleep disorders	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
carnosine	chemical_to_disease	autism	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
carnosine	chemical_to_disease	sleep	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
carnosine	chemical_to_disease	parasomnias	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
carnosine	chemical_to_disease	sleep disorders	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
carnosine	chemical_to_anatomy	(p	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
autism	disease_to_anatomy	(p	13	0	29430839|26313946|32149480|29763417|22987458|26336909|29211740|26746121|20440023|16948927|32966919|19736351|19736351	"PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.|PMID:26313946; Original text:Two-way ANOVA showed a significant sex-by-diagnosis interaction in total correct score (F(1,711) = 5.090, p = 0.024, ηp2 = 0.007) arising from a significant sex difference between control males and females (p < 0.001, Cohen's d = 0.47), and an absence of a sex difference between males and females with autism (p = 0.907, d = 0.01); significant case-control differences were observed across sexes, with effect sizes of d = 0.35 in males and d = 0.69 in females.|PMID:32149480; Original text:There were significant decreases in total autism treatment evaluation checklist scores (P = 0.014), sociability sub-scores (P = 0.021), and behavioral, health, and physical condition sub-scores (P = 0.011) in the Transcranial direct current stimulation treatment group.|PMID:29763417; Original text:Our results showed no significant differences between individual and group interventions in effects on ""autism general symptoms"" (no study available for group intervention), ""developmental quotient"" (no study available for group intervention), ""expressive language"" (p = 0.56), ""receptive language"" (p = 0.29), ""reciprocity of social interaction towards others"" (p = 0.62), or ""adaptive behaviour"" (p = 0.43).|PMID:22987458; Original text:The mean total the Autism Treatment Evaluation Checklist score scores by both parents and clinicians were significantly improved after intervention in both arms of the study compared to the score before intervention (P < 0.001 in both groups by parents, P = 0.015 in hyperbaric oxygen therapy group and P = 0.004 in sham group by clinician).|PMID:26336909; Original text:Data obtained from 18 participants who completed the trial showed that 6-week intranasal administration of oxytocin significantly reduced autism core symptoms specific to social reciprocity, which was clinically evaluated by Autism Diagnostic Observation Scale (P = 0.034, PFDR < 0.05, Cohen's d = 0.78).|PMID:29211740; Original text:There was no statistically significant difference in the effects on autism general symptoms between the social-communication-focused model and the multimodal developmental model (p = 0.83).|PMID:26746121; Original text:There was no difference in the the Autism Diagnostic Observation Schedule Composite Total Score between baseline and 24 weeks among the 3 treatment groups (P = .400); however, the the Autism Diagnostic Observation Schedule Restricted and Repetitive Behavior score showed a time-by-treatment effect (P = .006); the 2.5-mg buspirone group showed significant improvement (P = .003), whereas placebo and 5.0-mg buspirone groups showed no change.|PMID:20440023; Original text:Children with autism in this study showed improved motor proficiency and sensory integrative functions after 20-week Simulated Developmental Horse-Riding Program (p < .01).|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).|PMID:32966919; Original text:The clinical symptoms of autism measured by CARS and the Autism Treatment Assessment Checklist scales were alleviated significantly (P = 0.021 and P |PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).|PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes."
sleep	disease_to_anatomy	(p	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
parasomnias	disease_to_anatomy	(p	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
sleep disorders	disease_to_anatomy	(p	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
levels of	anatomy	of all	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
levels of	anatomy	peripheral blood	2	0	27654278|33420109	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
levels of	anatomy	of brain	3	0	27654278|27654278|33420109	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).|PMID:27654278; Original text:Subgroup analyses in 4 studies revealed that neonates diagnosed with disorder later in life had no association with blood levels of brain-derived neurotrophic factor (Hedges g, 0.384; 95% CI, -0.244 to 1.011; P = .23), whereas children in the nonneonate disorder group (15 studies) demonstrated significantly increased brain-derived neurotrophic factor levels compared with healthy controls (Hedges g, 0.524; 95% CI, 0.206 to 0.842; P = .001).|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
of all	anatomy	peripheral blood	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
of all	anatomy	of brain	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
of brain	anatomy	peripheral blood	2	0	27654278|33420109	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain	mechanism_to_anatomy	levels of	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
brain	mechanism_to_anatomy	of all	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
brain	mechanism_to_anatomy	peripheral blood	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
brain	mechanism_to_anatomy	of brain	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
group (	anatomy	levels of	3	0	27654278|24375082|32966919	PMID:27654278; Original text:Subgroup analyses in 4 studies revealed that neonates diagnosed with disorder later in life had no association with blood levels of brain-derived neurotrophic factor (Hedges g, 0.384; 95% CI, -0.244 to 1.011; P = .23), whereas children in the nonneonate disorder group (15 studies) demonstrated significantly increased brain-derived neurotrophic factor levels compared with healthy controls (Hedges g, 0.524; 95% CI, 0.206 to 0.842; P = .001).|PMID:24375082; Original text:The serum levels of activation-regulated chemokine decreased significantly (P = 0.004) in boiled camel milk and in raw camel milk group (P = 0.01) too, but no effect was observed (P = 0.68) in placebo group.|PMID:32966919; Original text:Serum levels of 25(25-hydroxyvitamin)D increased significantly in the vitamin D group (P = 0.001).
group (	anatomy	of brain	1	0	27654278	PMID:27654278; Original text:Subgroup analyses in 4 studies revealed that neonates diagnosed with disorder later in life had no association with blood levels of brain-derived neurotrophic factor (Hedges g, 0.384; 95% CI, -0.244 to 1.011; P = .23), whereas children in the nonneonate disorder group (15 studies) demonstrated significantly increased brain-derived neurotrophic factor levels compared with healthy controls (Hedges g, 0.524; 95% CI, 0.206 to 0.842; P = .001).
brain-derived neurotrophic factor	mechanism_to_anatomy	levels of	2	0	27654278|33420109	PMID:27654278; Original text:Subgroup analyses in 4 studies revealed that neonates diagnosed with disorder later in life had no association with blood levels of brain-derived neurotrophic factor (Hedges g, 0.384; 95% CI, -0.244 to 1.011; P = .23), whereas children in the nonneonate disorder group (15 studies) demonstrated significantly increased brain-derived neurotrophic factor levels compared with healthy controls (Hedges g, 0.524; 95% CI, 0.206 to 0.842; P = .001).|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism_to_anatomy	group (	1	0	27654278	PMID:27654278; Original text:Subgroup analyses in 4 studies revealed that neonates diagnosed with disorder later in life had no association with blood levels of brain-derived neurotrophic factor (Hedges g, 0.384; 95% CI, -0.244 to 1.011; P = .23), whereas children in the nonneonate disorder group (15 studies) demonstrated significantly increased brain-derived neurotrophic factor levels compared with healthy controls (Hedges g, 0.524; 95% CI, 0.206 to 0.842; P = .001).
brain-derived neurotrophic factor	mechanism_to_anatomy	of brain	2	0	27654278|33420109	PMID:27654278; Original text:Subgroup analyses in 4 studies revealed that neonates diagnosed with disorder later in life had no association with blood levels of brain-derived neurotrophic factor (Hedges g, 0.384; 95% CI, -0.244 to 1.011; P = .23), whereas children in the nonneonate disorder group (15 studies) demonstrated significantly increased brain-derived neurotrophic factor levels compared with healthy controls (Hedges g, 0.524; 95% CI, 0.206 to 0.842; P = .001).|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
, anterior	anatomy	superior frontal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
of the	anatomy	superior frontal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
superior frontal	anatomy	superior temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
superior frontal	anatomy	the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
(p	anatomy	superior frontal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
of the superior	anatomy	superior frontal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
superior frontal	anatomy	temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
inferior frontal	anatomy	superior frontal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
superior frontal	anatomy	temporal sulcus	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
frontal sulcus	anatomy	superior frontal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
, anterior	anatomy	of the	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
, anterior	anatomy	superior temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
, anterior	anatomy	the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
(p	anatomy	, anterior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
, anterior	anatomy	of the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
, anterior	anatomy	temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
, anterior	anatomy	inferior frontal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
, anterior	anatomy	temporal sulcus	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
, anterior	anatomy	frontal sulcus	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
of the	anatomy	superior temporal	2	0	12816888|32161366	"PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
of the	anatomy	the superior	2	0	12816888|14561452	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
of the	anatomy	of the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
of the	anatomy	temporal	4	0	12816888|22395004|32161366|8759044	"PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
inferior frontal	anatomy	of the	3	0	12816888|26994483|25817280	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
of the	anatomy	temporal sulcus	2	0	12816888|32161366	"PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
frontal sulcus	anatomy	of the	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
superior temporal	anatomy	the superior	2	0	12816888|17706781	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.
(p	anatomy	superior temporal	2	0	12816888|25149412	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
of the superior	anatomy	superior temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
superior temporal	anatomy	temporal	7	0	12816888|32714385|17706781|23452684|32161366|26769980|25149412	"PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.|PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels)."
inferior frontal	anatomy	superior temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
superior temporal	anatomy	temporal sulcus	5	0	12816888|32714385|17706781|32161366|25149412	"PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels)."
frontal sulcus	anatomy	superior temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
(p	anatomy	the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
of the superior	anatomy	the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
temporal	anatomy	the superior	3	0	12816888|17706781|14561452	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
inferior frontal	anatomy	the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
temporal sulcus	anatomy	the superior	2	0	12816888|17706781	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.
frontal sulcus	anatomy	the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
(p	anatomy	of the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
(p	anatomy	temporal	2	0	12816888|25149412	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
(p	anatomy	inferior frontal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
(p	anatomy	temporal sulcus	2	0	12816888|25149412	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
(p	anatomy	frontal sulcus	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
of the superior	anatomy	temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
inferior frontal	anatomy	of the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
of the superior	anatomy	temporal sulcus	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
frontal sulcus	anatomy	of the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
inferior frontal	anatomy	temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
temporal	anatomy	temporal sulcus	5	0	12816888|32714385|17706781|32161366|25149412	"PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels)."
frontal sulcus	anatomy	temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
inferior frontal	anatomy	temporal sulcus	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
frontal sulcus	anatomy	inferior frontal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
frontal sulcus	anatomy	temporal sulcus	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
autistic	disease_to_anatomy	superior frontal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
autistic	disease_to_anatomy	, anterior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
autistic	disease_to_anatomy	superior temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
autistic	disease_to_anatomy	the superior	2	0	12816888|14561452	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
autistic	disease_to_anatomy	(p	7	0	12816888|15292671|32745763|20623006|2977280|12858328|10382134	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:15292671; Original text:Significantly lower platelet-poor plasma serotonin levels were observed in the autistic group as compared to the controls (p = 0.03).|PMID:32745763; Original text:Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma reduced glutathione and oxidized glutathione levels as well as reduced glutathione:oxidized glutathione ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively).|PMID:20623006; Original text:Out of total of 48 acupuncture points present on ten fingertips of both hands and associated to organs/organ systems, autistic children differed significantly from controls (p < 0.05) in 36 (images without filter) and 12 (images with filter), siblings differed significantly from controls (p < 0.05) in 12 (images without filter) and seven (images with filter), autistic children differed significantly (p < 0.05) from siblings in eight (images without filter) and one (images with filter), fathers of autistic children differed significantly (p < 0.05) from controls in 14 (images without filter) and three (images with filter) and mothers of autistic children differed significantly (p < 0.05) from controls in five (images without filter) and nine (images with filter|PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.|PMID:12858328; Original text:A significant elevation in platelet-poor plasma 5-HT levels in adult autistic patients was reached 60 min after meal administration (p < 0.03 vs control and p = 0.05 vs baseline) and a significant decrease was noted after 120 min (p < 0.01 vs baseline).|PMID:10382134; Original text:While the employment of questionnaires disclosed that autistic children had an earlier morning awakening time and multiple and early night arousals, actigraphic monitoring showed that with the exception of an earlier morning arousal time (p = .045), sleep patterns of autistic children were similar to that of normal children.
autistic	disease_to_anatomy	of the superior	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
autistic	disease_to_anatomy	temporal	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
autistic	disease_to_anatomy	inferior frontal	2	0	12816888|25817280	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.|PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
autistic	disease_to_anatomy	temporal sulcus	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
autistic	disease_to_anatomy	frontal sulcus	1	0	12816888	PMID:12816888; Original text:Specifically, we found anterior and superior shifting of the superior frontal sulci bilaterally (P < or = 0.0003), anterior shifting of the right Sylvian fissure (P = 0.0002), the superior temporal sulcus (P = 0.0006 right, P = 0.02 left) and the left inferior frontal sulcus (P < or = 0.002) in the autistic group relative to the normal group.
, and	anatomy	, t	1	0	31714621	PMID:31714621; Original text:In contrast, patients in the resveratrol group showed greater decline in hyperactivity/non-compliance score as a secondary outcome measure (mean difference [CI = 95%] = 4.51 [0.10-8.92], t = 2.04; P = .04), and repeated measures analysis showed significant effect for time × treatment effect on this subscale score (F = 3.81; df = 1.30; P = .043).
resveratrol	chemical_to_disease	hyperactivity	1	0	31714621	PMID:31714621; Original text:In contrast, patients in the resveratrol group showed greater decline in hyperactivity/non-compliance score as a secondary outcome measure (mean difference [CI = 95%] = 4.51 [0.10-8.92], t = 2.04; P = .04), and repeated measures analysis showed significant effect for time × treatment effect on this subscale score (F = 3.81; df = 1.30; P = .043).
resveratrol	chemical_to_anatomy	, and	1	0	31714621	PMID:31714621; Original text:In contrast, patients in the resveratrol group showed greater decline in hyperactivity/non-compliance score as a secondary outcome measure (mean difference [CI = 95%] = 4.51 [0.10-8.92], t = 2.04; P = .04), and repeated measures analysis showed significant effect for time × treatment effect on this subscale score (F = 3.81; df = 1.30; P = .043).
resveratrol	chemical_to_anatomy	, t	1	0	31714621	PMID:31714621; Original text:In contrast, patients in the resveratrol group showed greater decline in hyperactivity/non-compliance score as a secondary outcome measure (mean difference [CI = 95%] = 4.51 [0.10-8.92], t = 2.04; P = .04), and repeated measures analysis showed significant effect for time × treatment effect on this subscale score (F = 3.81; df = 1.30; P = .043).
hyperactivity	disease_to_anatomy	, and	15	0	31714621|19858761|9934941|23782127|22782459|27278054|22151477|32168067|8282676|30980177|32347624|19284641|32947424|23101743|33029705	PMID:31714621; Original text:In contrast, patients in the resveratrol group showed greater decline in hyperactivity/non-compliance score as a secondary outcome measure (mean difference [CI = 95%] = 4.51 [0.10-8.92], t = 2.04; P = .04), and repeated measures analysis showed significant effect for time × treatment effect on this subscale score (F = 3.81; df = 1.30; P = .043).|PMID:19858761; Original text:Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, combined treatment showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:23782127; Original text:The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks.|PMID:22782459; Original text:Primary outcome measure was the change in irritability subscale of ABC-C. Significant time × treatment interaction was observed for Irritability (F (1.658, 63.0χ1) = 13.580, P < 0.001), Lethargy/Social Withdrawal (F (1.948, 74.03χ) = 16.811, P < 0.001), and Stereotypic Behavior (F(1.74χ, 66.198) = 1χ.104, P < 0.001), but not for Hyperactivity/Noncompliance (F (χ.564, 97.4χ4) = 1.469, P = 0.χ3χ), and Inappropriate Speech subscales (F (1.607, 61.075) = 0.173, P = 0.794).|PMID:27278054; Original text:Both groups showed a significant improvement in attention-deficit/hyperactivity disorder symptoms after 24 weeks of treatment (attention-deficit/hyperactivity disorder Rating Scale, Conners Parent Rating Scale-Hyperactivity, and Clinical Global Improvement-Severity Scale).|PMID:22151477; Original text:The supplement group had significantly greater improvements than the placebo group on the Parental Global Impressions-Revised (PGI-R, Average Change, p = 0.008), and on the subscores for Hyperactivity (p = 0.003), Tantrumming (p = 0.009), Overall (p = 0.02), and Receptive Language (p = 0.03).|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:8282676; Original text:In the present study, naltrexone significantly reduced only hyperactivity, and no serious untoward effects were observed.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).|PMID:23101743; Original text:The the behavior management treatment had shown a significant advantage for child behavioral noncompliance (p = .006, d = 0.34), irritability (p = .01, d = 0.48), and hyperactivity/noncompliance (p = .04, d = 0.55) with a lower medication dose.|PMID:33029705; Original text:The repeated measures analysis showed significant effect for time × treatment interaction on inappropriate speech (F = 3.51; df = 1.61; P = 0.044), stereotypic behavior (F = 4.02; df = 1.37; P = 0.036), and hyperactivity/noncompliance (F = 6.79; df = 1.66; P = 0.003) subscale scores.
hyperactivity	disease_to_anatomy	, t	1	0	31714621	PMID:31714621; Original text:In contrast, patients in the resveratrol group showed greater decline in hyperactivity/non-compliance score as a secondary outcome measure (mean difference [CI = 95%] = 4.51 [0.10-8.92], t = 2.04; P = .04), and repeated measures analysis showed significant effect for time × treatment effect on this subscale score (F = 3.81; df = 1.30; P = .043).
loneliness	disease_to_anatomy	, and	1	0	21915740	PMID:21915740; Original text:Results revealed that treated young adults reported significantly less loneliness and improved social skills knowledge, while caregivers reported significant improvements in young adults' overall social skills, social responsiveness, empathy, and frequency of get-togethers.
, a	anatomy	, and	12	0	16182672|25729218|26052790|25313065|25092245|31665947|32112261|14561452|32892962|28036350|22426803|29939056	"PMID:16182672; Original text:Taking into account scores at recruitment, child's level of ability, diagnostic grouping, and the interval between assessments, a significant advantage was found for the intervention group in parents' observed use of facilitative strategies and in children's vocabulary size.|PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.|PMID:26052790; Original text:After 6 months, enriched children showed statistically significant gains in their IQ scores, a decline in their atypical sensory responses, and an improvement in their receptive language performance, compared to controls.|PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).|PMID:25092245; Original text:Thus, a meta-analytic review of extant studies is needed to determine whether The oxytocin receptor gene shows association with disorder, and to elucidate which specific single-nucleotide polymorphisms have a significant effect on disorder.|PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:32112261; Original text:Regarding the treatment, a meta-analysis of behavioral interventions, including only three randomized controlled trials, found significant effects in terms of increase in total sleep time (24.41 min, 95% CI 5.71-43.11, P = 0.01), decrease in sleep-onset latency (- 18.31 min, 95% CI - 30.84 to - 5.77, P = 0.004), and a significant effect on sleep efficiency (5.59, 95% CI 0.87-10.31, P = 0.02), albeit the risk of bias of the included studies was rated ""high"" in relation to issues with the blinding.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.|PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.|PMID:29939056; Original text:These findings support the preliminary efficacy of Intervention, a classroom-based, teacher-implemented intervention for improving active engagement, adaptive communication, social skills, executive functioning, and problem behavior within a heterogeneous sample of students with disorder."
, a	anatomy	level of	1	0	16182672	PMID:16182672; Original text:Taking into account scores at recruitment, child's level of ability, diagnostic grouping, and the interval between assessments, a significant advantage was found for the intervention group in parents' observed use of facilitative strategies and in children's vocabulary size.
, and	anatomy	level of	1	0	16182672	PMID:16182672; Original text:Taking into account scores at recruitment, child's level of ability, diagnostic grouping, and the interval between assessments, a significant advantage was found for the intervention group in parents' observed use of facilitative strategies and in children's vocabulary size.
autism	disease_to_anatomy	of the	34	0	26068453|16460701|29498298|11699803|11241879|26448791|33720503|14959806|26258842|27752075|28393350|16160627|8879465|20804367|18286633|19454962|22688012|22987458|15590241|12693778|15358868|30563709|32563542|32168067|31744938|26769980|11408327|11466160|26551748|27868194|9232480|2047330|8986845|8759044	"PMID:26068453; Original text:On the basis of this review, suggestions are offered for further research and its significance for our understanding of the genetic determinants of autism.|PMID:16460701; Original text:Traditional morphometric methods detected a significant reduction in the total callosal area and in the anterior third of the the corpus callosum in patients with autism; however, 3D maps revealed significant reductions in both the splenium and genu of the the corpus callosum in patients.|PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.|PMID:11699803; Original text:For the primary efficacy analysis, change of the Autism Diagnostic Observation Schedule social-communication total score from week 0 to week 4, no statistically significant difference was obtained between placebo (-0.8 +/- 2.9) and secretin groups (-0.6 +/- 1.4; t54 = 0.346, p < .73).|PMID:11241879; Original text:Although we are far from having a complete understanding of the causes and deficits that define autism, significant progress has been made over the past few years.|PMID:26448791; Original text:However, by 12 and 24 months post-implementation there was a significant difference between intervention and control clinics in terms of the intervention clinics consistently screening eligible patients with a validated autism tool.|PMID:33720503; Original text:This study is a meta-analysis of the association of maternal infection during pregnancy and subsequent autism in offspring.|PMID:14959806; Original text:Psychological research has helped to develop new developmental models for the disorder and there have also been significant advances in the molecular genetics of autism and understanding of the underlying neurobiological processes.|PMID:26258842; Original text:The total scores of the the Autism Behavior Checklist and the Cglobal improvement were significantly (p<0.05) lower in the combined treatment group than in the single treatment group.|PMID:27752075; Original text:Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group.|PMID:28393350; Original text:Effect estimates in favour of intervention on autism prodromal symptoms, maximal at 27 months, had confidence intervals (confidence intervals) at each separate time point including the null, but showed a significant overall effect over the course of the intervention and follow-up period (effect size [ES]|PMID:16160627; Original text:Post hoc analysis looking at the 3 core symptoms of autism, that is, social interaction, communication, and stereotyped behaviors, revealed a significant improvement of the social interaction score after 6 months of active treatment.|PMID:8879465; Original text:These preliminary results encourage our research on this chromosome, which could be considered as a significant genetic component of the multifactorial etiology of autism.|PMID:20804367; Original text:Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism.|PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.|PMID:19454962; Original text:However, critical review of the literature reveals that the rate in idiopathic cases with normal lower intelligence quotient is still significantly above the population risk suggesting that autism itself is associated with an increased risk of epilepsy.|PMID:22688012; Original text:The majority of the data are based on molecular, cytogenetic, linkage and association studies of autistic subjects, but newer methods, including whole-exome sequencing, are also beginning to make significant contributions to our understanding of autism.|PMID:22987458; Original text:The mean total the Autism Treatment Evaluation Checklist score scores by both parents and clinicians were significantly improved after intervention in both arms of the study compared to the score before intervention (P < 0.001 in both groups by parents, P = 0.015 in hyperbaric oxygen therapy group and P = 0.004 in sham group by clinician).|PMID:15590241; Original text:Journal of the Association of the Academy of Minority Physicians, 9, 9-15] reported an uncontrolled trial of secretin with three participants with autism, which apparently resulted in significant behavioral improvement.|PMID:12693778; Original text:Significant improvement (> 12 units of the Childhood Autism Rating Scale) was recorded in two patients (pre-Scale: 35.00 +/- 1.41[mean +/- SD]), average improvement (> 8-12 units) in eight patients (pre-Scale: 41.88 +/-|PMID:15358868; Original text:Experiment 3 showed that increases in target-distractor similarity slowed the visual search performance of the control group significantly more than that of the autism group, suggesting that the adults with autism have a superior visual discrimination ability.|PMID:30563709; Original text:Advances in sequencing technology have significantly expanded our understanding of the genetics of autism and neurodevelopmental disorders (neurodevelopmental disorders).|PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:31744938; Original text:The considerable significance of the genetics associated with autism has led to the identification of many risk genes for disorder used for the probing of disorder specificity and shared cognitive features over the past few decades.|PMID:26769980; Original text:Variations in gray matter volume were significantly associated with the mean age and mean total IQ score of the patients, as well as with the percentage of male patients with autism.|PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.|PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.|PMID:26551748; Original text:We found significant differences between before and after the therapy in the length of the gait cycle that became more stable in the sagital plane and concluded that our results proved that horse therapy may be successfully used as an additional therapy for children with autism, and it may be a form of rehabilitation in cases when other therapies are not successful.|PMID:27868194; Original text:The autism symptoms of the children improved significantly, following 4-month vitamin D3 supplementation, but not in the placebo group.|PMID:9232480; Original text:Both the clinical significance of the immune changes and the causal connection between immune changes and psychopathological phenomena in autism remain to be elucidated.|PMID:2047330; Original text:This is the human significance of the term autism.|PMID:8986845; Original text:13 (76%) of the Asperger syndrome patients were rated as pedantic compared to 4 (31%) of the high-functioning autism group (chi 2 = 6.3; p = .01).|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease	sensory impairment	1	0	18826014	PMID:18826014; Original text:Sensory impairment is a common and significant feature of children on the autism spectrum.
tcf4 gene	mechanism	tcf4 gene product	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
nervous system	anatomy	of the	2	0	23640545|28562301	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.|PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
gene product	anatomy	nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
central nervous	anatomy	nervous system	3	0	23640545|27180342|28562301	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.|PMID:27180342; Original text:These developments underline the significance of microRNAs as potential biomarkers for diagnosing and prognosing central nervous system diseases.|PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
central nervous system	anatomy	nervous system	3	0	23640545|27180342|28562301	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.|PMID:27180342; Original text:These developments underline the significance of microRNAs as potential biomarkers for diagnosing and prognosing central nervous system diseases.|PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
gene product	anatomy	of the	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
central nervous	anatomy	of the	2	0	23640545|28562301	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.|PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
central nervous system	anatomy	of the	2	0	23640545|28562301	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.|PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
central nervous	anatomy	gene product	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
central nervous system	anatomy	gene product	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
central nervous	anatomy	central nervous system	3	0	23640545|27180342|28562301	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.|PMID:27180342; Original text:These developments underline the significance of microRNAs as potential biomarkers for diagnosing and prognosing central nervous system diseases.|PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
schizophrenia	disease_to_mechanism	tcf4 gene	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
schizophrenia	disease_to_mechanism	tcf4 gene product	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
schizophrenia	disease_to_anatomy	nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
schizophrenia	disease_to_anatomy	of the	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
schizophrenia	disease_to_anatomy	gene product	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
schizophrenia	disease_to_anatomy	central nervous	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
schizophrenia	disease_to_anatomy	central nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene	mechanism_to_anatomy	nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene	mechanism_to_anatomy	of the	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene	mechanism_to_anatomy	gene product	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene	mechanism_to_anatomy	central nervous	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene	mechanism_to_anatomy	central nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene product	mechanism_to_anatomy	nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene product	mechanism_to_anatomy	of the	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene product	mechanism_to_anatomy	gene product	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene product	mechanism_to_anatomy	central nervous	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene product	mechanism_to_anatomy	central nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
casein	mechanism	gluten	2	0	26418822|26148018	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.|PMID:26148018; Original text:The mean approach withdrawal problem composite score was significantly higher before supplementation than after, both in the placebo and in the gluten-casein group.
autism spectrum disorder	disease_to_mechanism	gluten	1	0	26418822	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.
autism spectrum disorder	disease_to_mechanism	casein	1	0	26418822	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.
autism spectrum disorder	disease_to_anatomy	of the	8	0	26418822|29443933|27056845|29146048|32294031|23965928|27501063|19538990	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.|PMID:29443933; Original text:Unmet parent carer mental health needs pose a significant risk to the psychological, physical, and social well-being of the parents of the child affected by Autism Spectrum Disorder and jeopardize the adaptive functioning of the family as well as the potential of the child affected by Autism Spectrum Disorder.|PMID:27056845; Original text:The main findings were that both groups of children with autism spectrum disorder significantly exhibited improvements in motor skill proficiency (the total motor composite and two motor-area composites) and executive function (three indices of the Wisconsin Card Sorting Test) after 12 weeks of physical activity intervention.|PMID:29146048; Original text:The meta-analysis of the literature suggested a weak but significant association between autism spectrum disorder diagnosis and increased cerebellar volume (p = .049, uncorrected), but the analysis of ABIDE did not show any relationship.|PMID:32294031; Original text:Significant vitamin D deficiency is described within children affected by Autism Spectrum Disorder and in pregnant mothers whose offspring will later develop Autism Spectrum Disorder, suggesting a possible role of the hormone as a contributing risk factor in the etiopathogenesis of Autism Spectrum Disorder.|PMID:23965928; Original text:Autism spectrum disorder (disorder) is a neurological disorder in which a significant number of the children experience a developmental regression characterized by a loss of previously acquired skills and abilities.|PMID:27501063; Original text:We performed meta-analyses of the univariate studies, identifying significant differences in mean pitch and pitch range between individuals with Autism Spectrum Disorder and comparison participants (Cohen's d of 0.4-0.5 and discriminatory accuracy of about 61-64%).|PMID:19538990; Original text:An atypical pattern of eye contact behaviour is one of the most significant symptoms of Autism Spectrum Disorder (Autism Spectrum Disorder).
gluten	mechanism_to_anatomy	of the	1	0	26418822	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.
casein	mechanism_to_anatomy	of the	1	0	26418822	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.
autism	disease_to_mechanism	httlpr	1	0	16103890	PMID:16103890; Original text:Allele transmissions to individuals diagnosed with autism were biased only for HTTLPR, both for the narrow diagnosis of autism (P=0.035) and for the broader diagnosis of autism spectrum (P=0.007).
httlpr alleles	mechanism_to_anatomy	, a	1	0	16103890	PMID:16103890; Original text:With respect to this locus, there are now seven of 12 studies reporting significant transmission bias of HTTLPR alleles, a noteworthy result in itself.
, and	anatomy	, neuronal	1	0	27105825	PMID:27105825; Original text:Functional enrichment analysis detected significant over-representation of target gene clusters related to transcriptional activation, neuronal development, and the Simons Foundation Autism Database genes.
, neuronal	anatomy	neuronal	1	0	27105825	PMID:27105825; Original text:Functional enrichment analysis detected significant over-representation of target gene clusters related to transcriptional activation, neuronal development, and the Simons Foundation Autism Database genes.
, and	anatomy	neuronal	2	0	27105825|31744938	PMID:27105825; Original text:Functional enrichment analysis detected significant over-representation of target gene clusters related to transcriptional activation, neuronal development, and the Simons Foundation Autism Database genes.|PMID:31744938; Original text:This review highlights the role of disorder risk genes in gene transcription and translation regulation processes, as well as neuronal activity modulation, synaptic plasticity, disrupted key biological signaling pathways, and the novel candidate genes that play a significant role in the pathophysiology of disorder.
autism	disease_to_anatomy	, neuronal	1	0	27105825	PMID:27105825; Original text:Functional enrichment analysis detected significant over-representation of target gene clusters related to transcriptional activation, neuronal development, and the Simons Foundation Autism Database genes.
autism	disease_to_anatomy	neuronal	2	0	27105825|8759044	"PMID:27105825; Original text:Functional enrichment analysis detected significant over-representation of target gene clusters related to transcriptional activation, neuronal development, and the Simons Foundation Autism Database genes.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
schizophrenia	disease_to_anatomy	levels of	1	0	22987847	PMID:22987847; Original text:From the perspective of those of us working on the genetics of schizophrenia, recent progress in identifying specific genetic risk factors at highly robust levels of statistical significance has been striking.
, and	anatomy	length	1	0	29164435	PMID:29164435; Original text:Findings indicate significant differences in the following components of written expression; length, legibility, handwriting size, speed, spelling, and overall structure, highlighting the need for future research to determine if the characteristics of written expression in individuals with disorder are similar to other struggling writers.
length	anatomy	structure	1	0	29164435	PMID:29164435; Original text:Findings indicate significant differences in the following components of written expression; length, legibility, handwriting size, speed, spelling, and overall structure, highlighting the need for future research to determine if the characteristics of written expression in individuals with disorder are similar to other struggling writers.
, and	anatomy	structure	1	0	29164435	PMID:29164435; Original text:Findings indicate significant differences in the following components of written expression; length, legibility, handwriting size, speed, spelling, and overall structure, highlighting the need for future research to determine if the characteristics of written expression in individuals with disorder are similar to other struggling writers.
anxiety	disease	autism spectrum disorder	1	0	32511015	PMID:32511015; Original text:Results indicated that clinician-rated anxiety severity and parent-rated externalizing behaviors and autism spectrum disorder severity significantly predicted pre-treatment accommodation.
neuro	disease	social	1	0	2487481	PMID:2487481; Original text:On the basis of the examinations of visual perception (retinal pathology, tunnel vision) perceptual processing (recognition of feelings, sex and age) and the disintegration of multimodal stimuli it can be presumed that social and emotional deficits are to be seen in connection with a deviant perceptive interpretation of the world and irregular processing on the basis of a neuro-biological handicap (the absence of a genetic determined reference-system for emotionally significant stimuli), which can have various causes (comp.
, sex	anatomy	of the	1	0	2487481	PMID:2487481; Original text:On the basis of the examinations of visual perception (retinal pathology, tunnel vision) perceptual processing (recognition of feelings, sex and age) and the disintegration of multimodal stimuli it can be presumed that social and emotional deficits are to be seen in connection with a deviant perceptive interpretation of the world and irregular processing on the basis of a neuro-biological handicap (the absence of a genetic determined reference-system for emotionally significant stimuli), which can have various causes (comp.
neuro	disease_to_anatomy	, sex	1	0	2487481	PMID:2487481; Original text:On the basis of the examinations of visual perception (retinal pathology, tunnel vision) perceptual processing (recognition of feelings, sex and age) and the disintegration of multimodal stimuli it can be presumed that social and emotional deficits are to be seen in connection with a deviant perceptive interpretation of the world and irregular processing on the basis of a neuro-biological handicap (the absence of a genetic determined reference-system for emotionally significant stimuli), which can have various causes (comp.
neuro	disease_to_anatomy	of the	1	0	2487481	PMID:2487481; Original text:On the basis of the examinations of visual perception (retinal pathology, tunnel vision) perceptual processing (recognition of feelings, sex and age) and the disintegration of multimodal stimuli it can be presumed that social and emotional deficits are to be seen in connection with a deviant perceptive interpretation of the world and irregular processing on the basis of a neuro-biological handicap (the absence of a genetic determined reference-system for emotionally significant stimuli), which can have various causes (comp.
social	disease_to_anatomy	, sex	1	0	2487481	PMID:2487481; Original text:On the basis of the examinations of visual perception (retinal pathology, tunnel vision) perceptual processing (recognition of feelings, sex and age) and the disintegration of multimodal stimuli it can be presumed that social and emotional deficits are to be seen in connection with a deviant perceptive interpretation of the world and irregular processing on the basis of a neuro-biological handicap (the absence of a genetic determined reference-system for emotionally significant stimuli), which can have various causes (comp.
social	disease_to_anatomy	of the	2	0	2487481|25804268	PMID:2487481; Original text:On the basis of the examinations of visual perception (retinal pathology, tunnel vision) perceptual processing (recognition of feelings, sex and age) and the disintegration of multimodal stimuli it can be presumed that social and emotional deficits are to be seen in connection with a deviant perceptive interpretation of the world and irregular processing on the basis of a neuro-biological handicap (the absence of a genetic determined reference-system for emotionally significant stimuli), which can have various causes (comp.|PMID:25804268; Original text:At post-treatment, participants showed significant improvements on all subscales of the Social Responsiveness Scale (P < 0.01) and the Social and Attention Problems syndrome scales of the Child Behavior Checklist (P < 0.05).
developmental disabilities	disease	disorders	2	0	23823984|24757919	PMID:23823984; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication and behavioral challenges.|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
autism spectrum	disease	developmental disabilities	2	0	23823984|24757919	PMID:23823984; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication and behavioral challenges.|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
autism spectrum	disease	disorders	2	0	23823984|24757919	PMID:23823984; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication and behavioral challenges.|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
developmental disabilities	disease_to_anatomy	group of	2	0	23823984|24757919	PMID:23823984; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication and behavioral challenges.|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
disorders	disease_to_anatomy	group of	2	0	23823984|24757919	PMID:23823984; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication and behavioral challenges.|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
autism spectrum	disease_to_anatomy	group of	2	0	23823984|24757919	PMID:23823984; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication and behavioral challenges.|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
corpus callosum	anatomy	of the	2	0	16460701|7854533	PMID:16460701; Original text:Traditional morphometric methods detected a significant reduction in the total callosal area and in the anterior third of the the corpus callosum in patients with autism; however, 3D maps revealed significant reductions in both the splenium and genu of the the corpus callosum in patients.|PMID:7854533; Original text:By contrast, measures of vermian lobules VI and VII and the posterior portion of the corpus callosum in these same autistic and normal volunteers differed significantly, by more than 9.9%.
autism	disease_to_anatomy	corpus callosum	2	0	16460701|19748080	PMID:16460701; Original text:Traditional morphometric methods detected a significant reduction in the total callosal area and in the anterior third of the the corpus callosum in patients with autism; however, 3D maps revealed significant reductions in both the splenium and genu of the the corpus callosum in patients.|PMID:19748080; Original text:The present study determined the significance and magnitude of reductions in corpus callosum total and regional area measures in autism.
autistic	disease	necrosis	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease	tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease	tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism	interleukin-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism	interleukin-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism	interleukin-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism	interferon-γ	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism	interferon-γ	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism	il-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, brain	anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
blood	anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, and	anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, a	anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
blood	anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, tumor	anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, brain	anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, and	anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, a	anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, brain	anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, brain	anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, and	anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, a	anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
brain	anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, tumor	anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, and	anatomy	brain	3	0	25729218|32222129|31237191	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.|PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.|PMID:31237191; Original text:The 'fractional amplitude of low-frequency fluctuations' (fALFF) was measured across the whole brain, and, where its major non-intoxicating component cannabidiol significantly altered fALFF, we tested if functional connectivity (functional connectivity) of those regions was also affected by its major non-intoxicating component cannabidiol.
, and	anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, a	anatomy	brain	2	0	25729218|29704525	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.|PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, a	anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
, tumor	anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	interleukin-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	interferon-γ	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	il-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	ifn-γ	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	interleukin-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	interferon-γ	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	il-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	ifn-γ	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	tumor necrosis factor-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	interleukin-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	interferon-γ	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	il-6	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	ifn-γ	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	tnf-α	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_anatomy	, a	3	0	25729218|28217829|14561452	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.|PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
autistic	disease_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
neurocognitive decline	disease	neuronopathic mucopolysaccharidoses ii	1	0	30442188	PMID:30442188; Original text:Patients with neuronopathic Mucopolysaccharidoses II have a plateau of cognitive and adaptive development on average by 4 to 4.5 years of age, although there is significant variability, followed by progressive neurocognitive decline.
alzheimer's disease	disease	parkinson's disease	1	0	30577116	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.
parkinson's disease	disease	stroke	1	0	30577116	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.
dementia	disease	parkinson's disease	1	0	30577116	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.
alzheimer's disease	disease	stroke	1	0	30577116	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.
alzheimer's disease	disease	dementia	2	0	30577116|23471985	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.|PMID:23471985; Original text:Older people who carried the connectivity variant had significantly milder clinical dementia scores and lower risk of Alzheimer's disease.
dementia	disease	stroke	1	0	30577116	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.
of the	anatomy	of the eye	1	0	19428496	PMID:19428496; Original text:We start with behavioral data demonstrating the importance of the eye region and the impact of gaze on the most significant aspects of face processing.
of the eye	anatomy	the eye	1	0	19428496	PMID:19428496; Original text:We start with behavioral data demonstrating the importance of the eye region and the impact of gaze on the most significant aspects of face processing.
of face	anatomy	of the eye	1	0	19428496	PMID:19428496; Original text:We start with behavioral data demonstrating the importance of the eye region and the impact of gaze on the most significant aspects of face processing.
of the	anatomy	the eye	1	0	19428496	PMID:19428496; Original text:We start with behavioral data demonstrating the importance of the eye region and the impact of gaze on the most significant aspects of face processing.
of face	anatomy	of the	1	0	19428496	PMID:19428496; Original text:We start with behavioral data demonstrating the importance of the eye region and the impact of gaze on the most significant aspects of face processing.
of face	anatomy	the eye	1	0	19428496	PMID:19428496; Original text:We start with behavioral data demonstrating the importance of the eye region and the impact of gaze on the most significant aspects of face processing.
endocytosis	disease	viral myocarditis	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
attention-deficit/hyperactivity disorder	disease	viral myocarditis	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
attention-deficit/hyperactivity disorder	disease	endocytosis	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
, viral	anatomy	of the	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
(p	anatomy	, viral	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
viral myocarditis	disease_to_anatomy	of the	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
viral myocarditis	disease_to_anatomy	(p	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
viral myocarditis	disease_to_anatomy	, viral	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
endocytosis	disease_to_anatomy	of the	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
endocytosis	disease_to_anatomy	(p	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
endocytosis	disease_to_anatomy	, viral	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
attention-deficit/hyperactivity disorder	disease_to_anatomy	of the	2	0	31685286|23503544	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).|PMID:23503544; Original text:A significant positive correlation was found between the changes in the total scores of the depression and the attention-deficit/hyperactivity disorder severity (Spearman correlation r = 0.65
attention-deficit/hyperactivity disorder	disease_to_anatomy	(p	2	0	31685286|20166790	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).|PMID:20166790; Original text:Parent-rated attention-deficit/hyperactivity disorder Pelham scores also differed by genotype (p = 0.05).
attention-deficit/hyperactivity disorder	disease_to_anatomy	, viral	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
kiaa0319l	mechanism	tdo2	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
chd1l	mechanism	kiaa0319l	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
chd1l	mechanism	tdo2	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
, tissue	anatomy	tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
kiaa0319l	mechanism_to_anatomy	tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
kiaa0319l	mechanism_to_anatomy	, tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
tdo2	mechanism_to_anatomy	tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
tdo2	mechanism_to_anatomy	, tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
chd1l	mechanism_to_anatomy	tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
chd1l	mechanism_to_anatomy	, tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
autism spectrum disorder	disease_to_anatomy	, and	10	0	29443933|32222129|30230414|28929285|24231171|28218722|23782128|26769980|33434711|26975670	PMID:29443933; Original text:Unmet parent carer mental health needs pose a significant risk to the psychological, physical, and social well-being of the parents of the child affected by Autism Spectrum Disorder and jeopardize the adaptive functioning of the family as well as the potential of the child affected by Autism Spectrum Disorder.|PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.|PMID:30230414; Original text:Autism spectrum disorder is associated with significant healthcare costs, and early diagnosis can substantially reduce these.|PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.|PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).|PMID:23782128; Original text:(DSM-IV-TR) criteria for an autism spectrum disorder (disorder) on the Autism Diagnostic Interview-Revised (-Revised) and the Autism Diagnostic Observation Schedule (the Autism Diagnostic Observation Schedule), and had significant symptoms of attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder).|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:26975670; Original text:Nevertheless, significant progress has been made in characterizing the neuroanatomical underpinnings of autism spectrum disorder across the human life span, and in identifying the molecular pathways that may be affected in autism spectrum disorder.
erythrocyte membrane	anatomy	membrane	1	0	28935269	PMID:28935269; Original text:Treatment with ω3 improved the erythrocyte membrane ω6/ω3 ratio (treatment effect p<0.008, d=0.66; within subjects effect p<0.007, d=0.5) without changing plasma antioxidant status.
erythrocyte	anatomy	membrane	1	0	28935269	PMID:28935269; Original text:Treatment with ω3 improved the erythrocyte membrane ω6/ω3 ratio (treatment effect p<0.008, d=0.66; within subjects effect p<0.007, d=0.5) without changing plasma antioxidant status.
erythrocyte	anatomy	erythrocyte membrane	1	0	28935269	PMID:28935269; Original text:Treatment with ω3 improved the erythrocyte membrane ω6/ω3 ratio (treatment effect p<0.008, d=0.66; within subjects effect p<0.007, d=0.5) without changing plasma antioxidant status.
obsessive-compulsive disorder	disease	psychiatric disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
personality disorders	disease	psychiatric disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
primary	disease	psychiatric disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	psychiatric disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
psychiatric disorders	disease	schizophrenia	3	0	32129844|27748930|21863344	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.|PMID:21863344; Original text:Empathy, for instance, is a rather elaborated human ability, and several recent studies point to significant impairments in patients suffering from psychiatric disorders, such as schizophrenia or autism.
bipolar disorder	disease	psychiatric disorders	2	0	32129844|27748930	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bvftd	disease	psychiatric disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	psychiatric disorders	2	0	32129844|27748930	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
psychiatric disorders	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
obsessive-compulsive disorder	disease	personality disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
obsessive-compulsive disorder	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	obsessive-compulsive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
obsessive-compulsive disorder	disease	schizophrenia	2	0	32129844|32503201	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:32503201; Original text:(Obsessive-Compulsive Disorder), one on Schizophrenia (Schizophrenia) and one on Eating Disorders (Eating Disorders).
bipolar disorder	disease	obsessive-compulsive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bvftd	disease	obsessive-compulsive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	obsessive-compulsive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
obsessive-compulsive disorder	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
personality disorders	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	personality disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
personality disorders	disease	schizophrenia	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bipolar disorder	disease	personality disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bvftd	disease	personality disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	personality disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
personality disorders	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
primary	disease	schizophrenia	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bipolar disorder	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bvftd	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
primary	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	schizophrenia	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bipolar disorder	disease	major depressive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bvftd	disease	major depressive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	major depressive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bipolar disorder	disease	schizophrenia	4	0	32129844|27748930|29045744|31780770	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.|PMID:29045744; Original text:The predictive risk of each isolated developmental marker is low, but a significant percentage of subjects with schizophrenia and a minority of adults with bipolar disorder showed signs of premorbid abnormalities in childhood.|PMID:31780770; Original text:In a direct comparison between schizophrenia and bipolar disorder, there were no significant differences.
bvftd	disease	schizophrenia	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	schizophrenia	3	0	32129844|27748930|28152400	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.|PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
schizophrenia	disease	symptomatic	2	0	32129844|28152400	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
bipolar disorder	disease	bvftd	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	bipolar disorder	2	0	32129844|27748930	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bipolar disorder	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	bvftd	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bvftd	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	symptomatic	2	0	32129844|28152400	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
autism spectrum disorder	disease	impairment in social skills	1	0	23055002	PMID:23055002; Original text:Children with an autism spectrum disorder have significant impairment in social skills.
6	chemical_to_disease	autism	1	0	15652871	PMID:15652871; Original text:Nocturnal 6-sulphatoxymelatonin excretion rate was significantly and substantially lower in patients with autism than in normal controls (mean +/-
asd	disease	infections	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
fetal stem cells	anatomy	stem cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
cells	anatomy	stem cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
fetal stem	anatomy	stem cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
cells	anatomy	fetal stem cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
fetal stem	anatomy	fetal stem cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
cells	anatomy	fetal stem	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
infections	disease_to_anatomy	stem cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
infections	disease_to_anatomy	fetal stem cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
infections	disease_to_anatomy	cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
infections	disease_to_anatomy	fetal stem	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
asd	disease_to_anatomy	stem cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
asd	disease_to_anatomy	fetal stem cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
asd	disease_to_anatomy	cells	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
asd	disease_to_anatomy	fetal stem	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
, and	anatomy	, sensory	4	0	25302490|9934941|15937041|27721995	PMID:25302490; Original text:Statistically significant differences (p < 0.05) were shown on ATEC/ABC scores for the domains of speech, sociability, sensory, and overall health, as well as reductions in the total scores when compared to pretreatment values.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:15937041; Original text:Overall, there were no statistically significant differences in speech, sociability, sensory, and health scores for treatment versus placebo periods.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
(p	anatomy	, sensory	3	0	25302490|18080171|19284641	PMID:25302490; Original text:Statistically significant differences (p < 0.05) were shown on ATEC/ABC scores for the domains of speech, sociability, sensory, and overall health, as well as reductions in the total scores when compared to pretreatment values.|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:19284641; Original text:On the Autism Treatment Evaluation Checklist, sensory/cognitive awareness significantly improved (p = 0.0367) in the tre1.3 atmosphereent group compared to the control group.
, and	anatomy	pathways	2	0	33924211|31744938	PMID:33924211; Original text:It summarizes the mechanism of signaling pathways, their significance, and implications for disorder.|PMID:31744938; Original text:This review highlights the role of disorder risk genes in gene transcription and translation regulation processes, as well as neuronal activity modulation, synaptic plasticity, disrupted key biological signaling pathways, and the novel candidate genes that play a significant role in the pathophysiology of disorder.
autism spectrum disorders	disease_to_anatomy	of sensory	1	0	18512135	PMID:18512135; Original text:Results from 14 studies indicated a significant high difference between autism spectrum disorders and typical groups in the presence/frequency of sensory symptoms, with the greatest difference in under-responsivity, followed by over-responsivity and sensation seeking.
palmitoylethanolamide	chemical	risperidone	1	0	29807317	PMID:29807317; Original text:Meanwhile, there was a trend toward significance for superior effect of risperidone plus Palmitoylethanolamide over risperidone plus placebo on inappropriate speech at trial endpoint (d = 0.51, p = 0.051).
palmitoylethanolamide	chemical_to_disease	inappropriate speech	1	0	29807317	PMID:29807317; Original text:Meanwhile, there was a trend toward significance for superior effect of risperidone plus Palmitoylethanolamide over risperidone plus placebo on inappropriate speech at trial endpoint (d = 0.51, p = 0.051).
risperidone	chemical_to_disease	inappropriate speech	1	0	29807317	PMID:29807317; Original text:Meanwhile, there was a trend toward significance for superior effect of risperidone plus Palmitoylethanolamide over risperidone plus placebo on inappropriate speech at trial endpoint (d = 0.51, p = 0.051).
autistic	disease	macrocephaly	1	0	26456415	PMID:26456415; Original text:Head circumference was significantly larger in autistic compared to control individuals, with 822/5225 (15.7%) autistic individuals displaying macrocephaly.
risperidone	chemical_to_anatomy	group (	7	0	9672054|12151468|12151468|12151468|18080171|18080171|16948927	PMID:9672054; Original text:For persons completing the study, 8 (57%) of 14 patients treated with risperidone were categorized as responders (daily dose [mean+/-SD], 2.9+/-1.4 mg) compared with none of 16 in the placebo group (P<.002).|PMID:12151468; Original text:Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001).|PMID:12151468; Original text:The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the the Clinical Global Impressions - Improvement scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of placebo, P<0.001).|PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
depression	disease	irritability	3	0	9672054|15529462|9934941	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
irritability	disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
irritability	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
autism	disease	irritability	4	0	9672054|9934941|31725473|32168067	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:31725473; Original text:Results from the general linear model repeated measures analysis demonstrated significant time-treatment interaction on irritability subscale (F1.55 = 3.45; P = 0.048) and Childhood Autism Rating Scale (F1.41 = 4.08; P = 0.034) scores.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
aggression	disease	irritability	6	0	9672054|9934941|15746480|19519261|22549762|20010551	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:15746480; Original text:Subjects' the Overt Aggression Scale aggression scores showed significant correlation with the already validated retrospectively rated Aberrant Behavior Checklist Community Scale irritability subscale.|PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.|PMID:20010551; Original text:Irritability/aggression is a significant comorbid symptom in this population, which greatly impacts burden of care.
anxiety or	disease	irritability	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
depression	disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
depression	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
autism	disease	depression	2	0	9672054|9934941	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
aggression	disease	depression	2	0	9672054|9934941	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anxiety or	disease	depression	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
nervousness	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
autism	disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
aggression	disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
anxiety or	disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
autism	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
aggression	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
anxiety or	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
aggression	disease	autism	3	0	9672054|18439113|9934941	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:18439113; Original text:Aggression and self-injury may be associated symptoms of autism and can result in significant harm to those affected as well as marked distress for their families.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anxiety or	disease	autism	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
aggression	disease	anxiety or	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
risperidone	chemical_to_disease	irritability	6	0	9672054|12151468|12151468|17019624|24132248|15492353	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:12151468; Original text:Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001).|PMID:12151468; Original text:The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the the Clinical Global Impressions - Improvement scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of placebo, P<0.001).|PMID:17019624; Original text:Risperidone [mean dose ( +/- SD): 1.37 mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in the Aberrant Behavior Checklist-Irritability versus placebo [mean change ( +/- SD): -13.4 (1.5) vs. -7.2 (1.4), P<0.05; ES=-0.7].|PMID:24132248; Original text:Irritability subscale were equally randomized to receive either galantamine (up to 24 mg/day) or placebo, in addition to risperidone (up to 2 mg/day), for 10 weeks.|PMID:15492353; Original text:Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the the Aberrant Behavior Checklist (primary endpoint) compared with those who were taking placebo.
risperidone	chemical_to_disease	depression	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
risperidone	chemical_to_disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
risperidone	chemical_to_disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
risperidone	chemical_to_disease	autism	4	0	9672054|17019624|17069546|16948927	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:17019624; Original text:Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism.|PMID:17069546; Original text:Significant differences between groups found at baseline complicated the analyses; however, controlling for some of these differences revealed that preschoolers on risperidone demonstrated greater improvements in autism severity.|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
risperidone	chemical_to_disease	aggression	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
risperidone	chemical_to_disease	anxiety or	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
risperidone	chemical_to_anatomy	, and	9	0	9672054|12151468|22784311|22784311|18439113|15930063|24828014|15492353|15492353	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).|PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.|PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.|PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).|PMID:24828014; Original text:Six of the 48 subjects met two criteria for responders to risperidone, and the median values of interleukin (interleukin)-5 were significantly higher (p=0.005) in the overall responder group than in nonresponders.|PMID:15492353; Original text:Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the the Aberrant Behavior Checklist; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom.|PMID:15492353; Original text:Risperidone-treated subjects experienced statistically significantly greater increases in weight (2.7 vs 1.0 kg), pulse rate, and systolic blood pressure.
irritability	disease_to_anatomy	, and	16	0	9672054|16190799|15529462|19858761|20973712|9934941|23782127|22782459|32168067|30980177|19519261|22549762|32347624|19284641|32947424|23101743	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:16190799; Original text:Irritability subscale was the primary outcome measure (p = 0.65), and CGI--Improvement (p = 0.16) and OAS (p = 0.96) were secondary outcome measures.|PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.|PMID:19858761; Original text:Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, combined treatment showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04).|PMID:20973712; Original text:Statistically significantly greater improvement was seen with aripiprazole versus placebo (p < 0.05) for all arms in both trials on the the Aberrant Behavior Checklist-Irritability total subscale score and on the following individual the Aberrant Behavior Checklist-Irritability items: Mood changes quickly, cries/screams inappropriately, and stamps feet/bangs objects.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:23782127; Original text:The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks.|PMID:22782459; Original text:Primary outcome measure was the change in irritability subscale of ABC-C. Significant time × treatment interaction was observed for Irritability (F (1.658, 63.0χ1) = 13.580, P < 0.001), Lethargy/Social Withdrawal (F (1.948, 74.03χ) = 16.811, P < 0.001), and Stereotypic Behavior (F(1.74χ, 66.198) = 1χ.104, P < 0.001), but not for Hyperactivity/Noncompliance (F (χ.564, 97.4χ4) = 1.469, P = 0.χ3χ), and Inappropriate Speech subscales (F (1.607, 61.075) = 0.173, P = 0.794).|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).|PMID:23101743; Original text:The the behavior management treatment had shown a significant advantage for child behavioral noncompliance (p = .006, d = 0.34), irritability (p = .01, d = 0.48), and hyperactivity/noncompliance (p = .04, d = 0.55) with a lower medication dose.
depression	disease_to_anatomy	, and	5	0	9672054|15529462|9934941|24408892|32090389	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).|PMID:32090389; Original text:Only the mindfulness-based stress reduction group demonstrated significant reductions in depression, and neither group significantly changed in anxiety.
nervousness	disease_to_anatomy	, and	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
repetitive behavior	disease_to_anatomy	, and	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
aggression	disease_to_anatomy	, and	5	0	9672054|9934941|8911223|19519261|22549762	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).|PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
anxiety or	disease_to_anatomy	, and	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
impairments	disease	learning impaired	1	0	7002017	PMID:7002017; Original text:The effects of preschool impairments in language development on subsequent school achievement are significant: 60% of these children are in special classes for the learning impaired at 9 years of age.
asd	disease	autism	4	0	29498298|30617550|31665947|25941080	PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.|PMID:30617550; Original text:Level 1 screening tools for ASD showed consistent statistically significant results and therefore are adequate to detect autism at 14-36 months.|PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
definition)	anatomy	of the	1	0	29498298	PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.
, and	anatomy	definition)	1	0	29498298	PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.
autism	disease_to_anatomy	definition)	1	0	29498298	PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.
asd	disease_to_anatomy	definition)	1	0	29498298	PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.
, and	anatomy	complex	2	0	32222129|32563542	PMID:32222129; Original text:Animal studies have demonstrated the benefit of using mTOR inhibitors for various symptoms of Tuberous sclerosis complex, and they have been successfully translated into clinical trials with significant improvement in symptom burden.|PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.
tuberous sclerosis	disease_to_mechanism	mtor	1	0	32222129	PMID:32222129; Original text:Animal studies have demonstrated the benefit of using mTOR inhibitors for various symptoms of Tuberous sclerosis complex, and they have been successfully translated into clinical trials with significant improvement in symptom burden.
tuberous sclerosis	disease_to_anatomy	, and	3	0	32222129|32222129|32563542	PMID:32222129; Original text:Animal studies have demonstrated the benefit of using mTOR inhibitors for various symptoms of Tuberous sclerosis complex, and they have been successfully translated into clinical trials with significant improvement in symptom burden.|PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.|PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.
tuberous sclerosis	disease_to_anatomy	complex	2	0	32222129|32563542	PMID:32222129; Original text:Animal studies have demonstrated the benefit of using mTOR inhibitors for various symptoms of Tuberous sclerosis complex, and they have been successfully translated into clinical trials with significant improvement in symptom burden.|PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.
mtor	mechanism_to_anatomy	, and	1	0	32222129	PMID:32222129; Original text:Animal studies have demonstrated the benefit of using mTOR inhibitors for various symptoms of Tuberous sclerosis complex, and they have been successfully translated into clinical trials with significant improvement in symptom burden.
mtor	mechanism_to_anatomy	complex	1	0	32222129	PMID:32222129; Original text:Animal studies have demonstrated the benefit of using mTOR inhibitors for various symptoms of Tuberous sclerosis complex, and they have been successfully translated into clinical trials with significant improvement in symptom burden.
neuropsychiatric disorders	disease	tuberous sclerosis	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
mood disorders	disease	tuberous sclerosis	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
autism spectrum disorder	disease	tuberous sclerosis	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
intellectual disability	disease	tuberous sclerosis	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
mood disorders	disease	neuropsychiatric disorders	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
autism spectrum disorder	disease	neuropsychiatric disorders	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
intellectual disability	disease	neuropsychiatric disorders	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
autism spectrum disorder	disease	mood disorders	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
intellectual disability	disease	mood disorders	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
autism spectrum disorder	disease	intellectual disability	4	0	32222129|28929285|24231171|33434711	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.|PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.|PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
neuropsychiatric disorders	disease_to_anatomy	, and	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
mood disorders	disease_to_anatomy	, and	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
intellectual disability	disease_to_anatomy	, and	8	0	32222129|28929285|24231171|31018221|33434711|24123946|28036350|24246273	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.|PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.|PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.|PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:24123946; Original text:The del15q11.2 was found to be significantly associated with intellectual disability, schizophrenia, epilepsy, and disorder.|PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.|PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
, heart	anatomy	the brain	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, skin	anatomy	the brain	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
heart	anatomy	the brain	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, and	anatomy	the brain	2	0	32222129|21692142	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.|PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
eyes	anatomy	the brain	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
brain	anatomy	the brain	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
kidneys	anatomy	the brain	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, heart	anatomy	, skin	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, heart	anatomy	heart	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, and	anatomy	, heart	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, heart	anatomy	eyes	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, heart	anatomy	brain	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, heart	anatomy	kidneys	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, skin	anatomy	heart	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, and	anatomy	, skin	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, skin	anatomy	eyes	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, skin	anatomy	brain	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, skin	anatomy	kidneys	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, and	anatomy	heart	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
eyes	anatomy	heart	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
brain	anatomy	heart	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
heart	anatomy	kidneys	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, and	anatomy	eyes	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
, and	anatomy	kidneys	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
brain	anatomy	eyes	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
eyes	anatomy	kidneys	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
brain	anatomy	kidneys	1	0	32222129	PMID:32222129; Original text:The brain, heart, skin, eyes, kidneys, and lungs are commonly involved in this syndrome, with neurologic symptoms comprising a significant source of morbidity and mortality.
sumatriptan	chemical_to_disease	autistic	1	0	10808042	PMID:10808042; Original text:This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects.
sumatriptan	chemical_to_mechanism	growth hormone	2	0	10808042|10649829	PMID:10808042; Original text:This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects.|PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
sumatriptan	chemical_to_anatomy	growth hormone	2	0	10808042|10649829	PMID:10808042; Original text:This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects.|PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
autistic	disease_to_mechanism	growth hormone	1	0	10808042	PMID:10808042; Original text:This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects.
autistic	disease_to_anatomy	growth hormone	1	0	10808042	PMID:10808042; Original text:This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects.
growth hormone	mechanism_to_anatomy	growth hormone	2	0	10808042|10649829	PMID:10808042; Original text:This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects.|PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
groups	anatomy	of the	1	0	26890560	"PMID:26890560; Original text:In comparison with the non-Medicaid groups, the Medicaid groups more often endorsed the 9 questions on the usefulness of the assessment as being ""A Great Deal"" useful (p = .022)."
(p	anatomy	groups	4	0	26890560|30933867|24824660|25534777	"PMID:26890560; Original text:In comparison with the non-Medicaid groups, the Medicaid groups more often endorsed the 9 questions on the usefulness of the assessment as being ""A Great Deal"" useful (p = .022).|PMID:30933867; Original text:Comparing the results of both experimental and control groups, a statistically significant difference was found on total CARS score (p < 0.0005).|PMID:24824660; Original text:When combining groups, a statistically significant decrease of 37% was found from baseline to week 8 when study drug was completed using a linear mixed effects model (P = 0.003).|PMID:25534777; Original text:When the data were combined across both groups, however, significant improvements in primary outcome measures were observed (P < 0.05)."
autism	disease	spectrum disorders	2	0	22228009|23357440	PMID:22228009; Original text:There now exist multiple lines of evidence pointing to a significant genetic component underlying the aetiology of autism spectrum disorders (spectrum disorders).|PMID:23357440; Original text:To examine the efficacy of a modular cognitive-behavioral therapy (a modular cognitive-behavioral therapy) protocol relative to treatment as usual (TAU) among children with high-functioning autism spectrum disorders (spectrum disorders) and clinically significant anxiety.
epilepsy and	disease	sleep disorders	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
autism spectrum disorders	disease	epilepsy and	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
behavioral and cognitive abnormalities	disease	epilepsy and	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
autism spectrum disorders	disease	sleep disorders	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
behavioral and cognitive abnormalities	disease	sleep disorders	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
autism spectrum disorders	disease	behavioral and cognitive abnormalities	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
oxytocin	chemical_to_disease	social behavior deficits	1	0	28864977	PMID:28864977; Original text:In the last decade, there has been a significant interest in using oxytocin to treat social behavior deficits in disorder.
social behavior deficits	disease_to_mechanism	oxytocin	1	0	28864977	PMID:28864977; Original text:In the last decade, there has been a significant interest in using oxytocin to treat social behavior deficits in disorder.
, and	anatomy	groups	1	0	17097142	PMID:17097142; Original text:The scores representing communication and social interaction were continuously distributed across the two fragile X groups, and they were significantly elevated compared with the non-fragile X controls.
fragile	disease_to_anatomy	groups	1	0	17097142	PMID:17097142; Original text:The scores representing communication and social interaction were continuously distributed across the two fragile X groups, and they were significantly elevated compared with the non-fragile X controls.
fragile	disease_to_anatomy	, and	1	0	17097142	PMID:17097142; Original text:The scores representing communication and social interaction were continuously distributed across the two fragile X groups, and they were significantly elevated compared with the non-fragile X controls.
oxytocin	chemical_to_anatomy	, a	2	0	33622389|25092245	PMID:33622389; Original text:Among the 35 metabolites measured, a significant increase in N,N-dimethylglycine was detected in the subjects administered oxytocin compared with those given placebo at a medium effect size (false discovery rate (false discovery rate) corrected P = 0.043, d = 0.74, N = 83).|PMID:25092245; Original text:Thus, a meta-analytic review of extant studies is needed to determine whether The oxytocin receptor gene shows association with disorder, and to elucidate which specific single-nucleotide polymorphisms have a significant effect on disorder.
oxytocin	mechanism_to_anatomy	, a	1	0	33622389	PMID:33622389; Original text:Among the 35 metabolites measured, a significant increase in N,N-dimethylglycine was detected in the subjects administered oxytocin compared with those given placebo at a medium effect size (false discovery rate (false discovery rate) corrected P = 0.043, d = 0.74, N = 83).
oxytocin	chemical_to_anatomy	of the	6	0	33622389|27071789|24352377|32161366|27651096|8759044	"PMID:33622389; Original text:Furthermore, subgroup analyses of the participants displaying a prominent time-course change in oxytocin efficacy revealed a significant effect of oxytocin on N,N-dimethylglycine levels with a large effect size (Pfalse discovery rate = 0.004, d = 1.13, N = 60).|PMID:27071789; Original text:Some studies have reported significant improvement of the core symptoms of disorder by long-term oxytocin administration, while other studies showed no such improvement.|PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:27651096; Original text:Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with disorder.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	of the	5	0	33622389|27071789|32161366|27651096|8759044	"PMID:33622389; Original text:Furthermore, subgroup analyses of the participants displaying a prominent time-course change in oxytocin efficacy revealed a significant effect of oxytocin on N,N-dimethylglycine levels with a large effect size (Pfalse discovery rate = 0.004, d = 1.13, N = 60).|PMID:27071789; Original text:Some studies have reported significant improvement of the core symptoms of disorder by long-term oxytocin administration, while other studies showed no such improvement.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:27651096; Original text:Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with disorder.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
and 2	anatomy	facial expression	1	0	33622389	PMID:33622389; Original text:The increase in N,N-dimethylglycine was significantly correlated with oxytocin-induced clinical changes, assessed as changes in quantifiable characteristics of autistic facial expression, including both of improvements between baseline and 2 weeks (Pfalse discovery rate = 0.006, r = - 0.485, N = 43) and deteriorations between 2 and 4 weeks
oxytocin	chemical_to_anatomy	and 2	1	0	33622389	PMID:33622389; Original text:The increase in N,N-dimethylglycine was significantly correlated with oxytocin-induced clinical changes, assessed as changes in quantifiable characteristics of autistic facial expression, including both of improvements between baseline and 2 weeks (Pfalse discovery rate = 0.006, r = - 0.485, N = 43) and deteriorations between 2 and 4 weeks
oxytocin	mechanism_to_anatomy	and 2	1	0	33622389	PMID:33622389; Original text:The increase in N,N-dimethylglycine was significantly correlated with oxytocin-induced clinical changes, assessed as changes in quantifiable characteristics of autistic facial expression, including both of improvements between baseline and 2 weeks (Pfalse discovery rate = 0.006, r = - 0.485, N = 43) and deteriorations between 2 and 4 weeks
, temporal	anatomy	parietal	1	0	34245768	PMID:34245768; Original text:Infants of very preterm birth with intrauterine growth restriction displayed a relative volumetric decrease in gray matter in limbic regions and a relative increase in frontoinsular, temporal-parietal, and frontal areas compared with peers of very preterm birth who were AGA.
, and	anatomy	, temporal	1	0	34245768	PMID:34245768; Original text:Infants of very preterm birth with intrauterine growth restriction displayed a relative volumetric decrease in gray matter in limbic regions and a relative increase in frontoinsular, temporal-parietal, and frontal areas compared with peers of very preterm birth who were AGA.
, temporal	anatomy	temporal	2	0	34245768|22395004	PMID:34245768; Original text:Infants of very preterm birth with intrauterine growth restriction displayed a relative volumetric decrease in gray matter in limbic regions and a relative increase in frontoinsular, temporal-parietal, and frontal areas compared with peers of very preterm birth who were AGA.|PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, temporal	anatomy	gray matter	1	0	34245768	PMID:34245768; Original text:Infants of very preterm birth with intrauterine growth restriction displayed a relative volumetric decrease in gray matter in limbic regions and a relative increase in frontoinsular, temporal-parietal, and frontal areas compared with peers of very preterm birth who were AGA.
, and	anatomy	parietal	5	0	34245768|14561452|14561452|21692142|22426803	PMID:34245768; Original text:Infants of very preterm birth with intrauterine growth restriction displayed a relative volumetric decrease in gray matter in limbic regions and a relative increase in frontoinsular, temporal-parietal, and frontal areas compared with peers of very preterm birth who were AGA.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
parietal	anatomy	temporal	4	0	34245768|14561452|21692142|8759044	"PMID:34245768; Original text:Infants of very preterm birth with intrauterine growth restriction displayed a relative volumetric decrease in gray matter in limbic regions and a relative increase in frontoinsular, temporal-parietal, and frontal areas compared with peers of very preterm birth who were AGA.|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
gray matter	anatomy	parietal	1	0	34245768	PMID:34245768; Original text:Infants of very preterm birth with intrauterine growth restriction displayed a relative volumetric decrease in gray matter in limbic regions and a relative increase in frontoinsular, temporal-parietal, and frontal areas compared with peers of very preterm birth who were AGA.
, and	anatomy	temporal	7	0	34245768|17706781|14561452|23452684|26769980|25149412|21692142	PMID:34245768; Original text:Infants of very preterm birth with intrauterine growth restriction displayed a relative volumetric decrease in gray matter in limbic regions and a relative increase in frontoinsular, temporal-parietal, and frontal areas compared with peers of very preterm birth who were AGA.|PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).|PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
, and	anatomy	gray matter	2	0	34245768|26769980	PMID:34245768; Original text:Infants of very preterm birth with intrauterine growth restriction displayed a relative volumetric decrease in gray matter in limbic regions and a relative increase in frontoinsular, temporal-parietal, and frontal areas compared with peers of very preterm birth who were AGA.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	temporal	2	0	34245768|26769980	PMID:34245768; Original text:Infants of very preterm birth with intrauterine growth restriction displayed a relative volumetric decrease in gray matter in limbic regions and a relative increase in frontoinsular, temporal-parietal, and frontal areas compared with peers of very preterm birth who were AGA.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism	disease	spectrum disorder	1	0	33573238	PMID:33573238; Original text:There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (spectrum disorder), including the significance of adopting a gluten-free and casein-free (GFCF) diet.
autism	disease_to_mechanism	casein	1	0	33573238	PMID:33573238; Original text:There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (spectrum disorder), including the significance of adopting a gluten-free and casein-free (GFCF) diet.
spectrum disorder	disease_to_mechanism	casein	1	0	33573238	PMID:33573238; Original text:There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (spectrum disorder), including the significance of adopting a gluten-free and casein-free (GFCF) diet.
autism	disease_to_anatomy	gastrointestinal system	1	0	33573238	PMID:33573238; Original text:There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (spectrum disorder), including the significance of adopting a gluten-free and casein-free (GFCF) diet.
spectrum disorder	disease_to_anatomy	gastrointestinal system	1	0	33573238	PMID:33573238; Original text:There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (spectrum disorder), including the significance of adopting a gluten-free and casein-free (GFCF) diet.
casein	mechanism_to_anatomy	gastrointestinal system	1	0	33573238	PMID:33573238; Original text:There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (spectrum disorder), including the significance of adopting a gluten-free and casein-free (GFCF) diet.
asperger syndrome	disease	attention deficit hyperactivity disorder	4	0	31965841|31965841|25760553|25760553	PMID:31965841; Original text:attention deficit hyperactivity disorder or Asperger syndrome was diagnosed at the age of 13 years in 17.1% children in the placebo and none in the probiotic group (P=0.008).|PMID:31965841; Original text:This study found significant differences in species composition and number of cells belonging to the genus Bifidobacterium between healthy children and children who later developed attention deficit hyperactivity disorder or Asperger syndrome at different time points.|PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).|PMID:25760553; Original text:The diagnoses of attention deficit hyperactivity disorder (attention deficit hyperactivity disorder) and Asperger syndrome (Asperger syndrome) by a child neurologist or psychiatrist were based on ICD-10 diagnostic criteria.
attention deficit hyperactivity disorder	disease_to_anatomy	group (	2	0	31965841|25760553	PMID:31965841; Original text:attention deficit hyperactivity disorder or Asperger syndrome was diagnosed at the age of 13 years in 17.1% children in the placebo and none in the probiotic group (P=0.008).|PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).
asperger syndrome	disease_to_anatomy	group (	3	0	31965841|25760553|8986845	PMID:31965841; Original text:attention deficit hyperactivity disorder or Asperger syndrome was diagnosed at the age of 13 years in 17.1% children in the placebo and none in the probiotic group (P=0.008).|PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).|PMID:8986845; Original text:13 (76%) of the Asperger syndrome patients were rated as pedantic compared to 4 (31%) of the high-functioning autism group (chi 2 = 6.3; p = .01).
autism spectrum disorders	disease_to_anatomy	(p	4	0	28918862|28918862|28342168|25944453	PMID:28918862; Original text:Overall, we found autism spectrum disorders patients exhibited an impaired Prepulse inhibition compared with healthy controls (p = 0.008).|PMID:28918862; Original text:Specifically, significant Prepulse inhibition deficits were observed among autism spectrum disorders children/adolescents, compared with their healthy counterparts (p = 0.019).|PMID:28342168; Original text:After adjusting for potential covariates, having autism spectrum disorders was associated with significantly lower trabecular bone mineral density and bone strength at the radius, and with marginally lower total body less head bone mineral content (p < 0.09).|PMID:25944453; Original text:Only patients with symptomatic Infantile spasms developed autism spectrum disorders (p = 0.003).
1	anatomy	of the	2	0	15055365|32168067	PMID:15055365; Original text:In Experiment 1, although the participants were instructed to disregard the cue and the target was correctly cued in only 50% of the trials, both groups of children responded significantly faster to cued targets than to uncued targets, regardless of the cue.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
glutamine	chemical	vitamin b6	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
clumsiness	disease	hypersensitivity to sound	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
vitamin b6	chemical_to_disease	hypersensitivity to sound	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
vitamin b6	chemical_to_disease	clumsiness	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
glutamine	chemical_to_disease	hypersensitivity to sound	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
glutamine	chemical_to_disease	clumsiness	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
vitamin b6	chemical_to_anatomy	, and	2	0	30287864|3886023	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.|PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
glutamine	chemical_to_anatomy	, and	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
hypersensitivity to sound	disease_to_anatomy	, and	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
clumsiness	disease_to_anatomy	, and	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
, and	anatomy	process of	1	0	30548710	PMID:30548710; Original text:This review illustrates the significant impact that positive experiences with first-line professionals have during the process of diagnosis, and how these experiences lay the foundation for all future relationships with other service providers.
autism	disease	developmental disorders	1	0	16083327	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.
asperger	disease	autism	1	0	16083327	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.
asperger	disease	developmental disorders	1	0	16083327	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.
, and	anatomy	group of	3	0	16083327|10384736|24757919	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.|PMID:10384736; Original text:Data from healthy elderly subjects, and a small group of left hemisphere patients (who received the tasks in modified form), suggest that this impairment on mental state tasks is not a function of task difficulty.|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
autism	disease_to_anatomy	group of	2	0	16083327|16115783	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.|PMID:16115783; Original text:10- to 15-year-old children with autism and a group of 12 age- and sex-matched healthy controls.
developmental disorders	disease_to_anatomy	, and	2	0	16083327|28036350	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.|PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.
developmental disorders	disease_to_anatomy	group of	1	0	16083327	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.
asperger	disease_to_anatomy	, and	2	0	16083327|9690938	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.|PMID:9690938; Original text:The autistic group's performance on the false belief, belief term comprehension, and belief term expression tasks was significantly poorer than that of the Asperger, language impaired, and normal groups.
asperger	disease_to_anatomy	group of	1	0	16083327	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.
neurotensin	chemical_to_disease	asd	2	0	23570274|25941080	PMID:23570274; Original text:neurotensin is significantly increased in serum of ASD children along with mitochondrial DNA (mitochondrial DNA).|PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
neurotensin	chemical_to_mechanism	neurotensin	2	0	23570274|25941080	PMID:23570274; Original text:neurotensin is significantly increased in serum of ASD children along with mitochondrial DNA (mitochondrial DNA).|PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
neurotensin	chemical_to_anatomy	mitochondrial	1	0	23570274	PMID:23570274; Original text:neurotensin is significantly increased in serum of ASD children along with mitochondrial DNA (mitochondrial DNA).
asd	disease_to_mechanism	neurotensin	3	0	23570274|23688533|25941080	PMID:23570274; Original text:neurotensin is significantly increased in serum of ASD children along with mitochondrial DNA (mitochondrial DNA).|PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.|PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
asd	disease_to_anatomy	mitochondrial	4	0	23570274|23688533|21263444|21263444	PMID:23570274; Original text:neurotensin is significantly increased in serum of ASD children along with mitochondrial DNA (mitochondrial DNA).|PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.|PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
neurotensin	mechanism_to_anatomy	mitochondrial	2	0	23570274|23688533	PMID:23570274; Original text:neurotensin is significantly increased in serum of ASD children along with mitochondrial DNA (mitochondrial DNA).|PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
luteolin	chemical	rapamycin	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
, mast	anatomy	mast cells	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
, mast	anatomy	microglia	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
mast cells	anatomy	microglia	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
luteolin	chemical_to_disease	asd	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
rapamycin	chemical_to_disease	asd	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
luteolin	chemical_to_anatomy	, mast	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
luteolin	chemical_to_anatomy	mast cells	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
luteolin	chemical_to_anatomy	microglia	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
rapamycin	chemical_to_anatomy	, mast	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
rapamycin	chemical_to_anatomy	mast cells	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
rapamycin	chemical_to_anatomy	microglia	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
asd	disease_to_anatomy	, mast	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
asd	disease_to_anatomy	mast cells	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
asd	disease_to_anatomy	microglia	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
autism	disease_to_anatomy	areas	1	0	23404617	PMID:23404617; Original text:For a significant proportion of children with autism, it appears early intensive behavioural intervention may be capable of promoting brain connectivity in specific cerebral areas, which is one of autism's underlying challenges.
irritability	disease_to_anatomy	group (	3	0	12151468|12151468|23821414	PMID:12151468; Original text:Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001).|PMID:12151468; Original text:The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the the Clinical Global Impressions - Improvement scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of placebo, P<0.001).|PMID:23821414; Original text:A significantly greater improvement in the study primary outcome (the ABC-C irritability subscale score) was achieved by the riluzole-treated children compared with the placebo group (P = 0.03).
group (	anatomy	scale	1	0	12151468	PMID:12151468; Original text:The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the the Clinical Global Impressions - Improvement scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of placebo, P<0.001).
risperidone	chemical_to_anatomy	scale	2	0	12151468|15930063	PMID:12151468; Original text:The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the the Clinical Global Impressions - Improvement scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of placebo, P<0.001).|PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).
irritability	disease_to_anatomy	scale	1	0	12151468	PMID:12151468; Original text:The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the the Clinical Global Impressions - Improvement scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of placebo, P<0.001).
risperidone	chemical_to_disease	weight gain	4	0	12151468|32469700|21186965|31063671	PMID:12151468; Original text:Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001).|PMID:32469700; Original text:There was a significant association between weight gain, waist circumference and risperidone.|PMID:21186965; Original text:Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
drooling	disease	fatigue	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drowsiness	disease	fatigue	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
dizziness	disease	fatigue	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
fatigue	disease	increased appetite	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drooling	disease	drowsiness	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
dizziness	disease	drooling	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drooling	disease	increased appetite	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
dizziness	disease	drowsiness	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drowsiness	disease	increased appetite	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
dizziness	disease	increased appetite	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
risperidone	chemical_to_disease	fatigue	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
risperidone	chemical_to_disease	drooling	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
risperidone	chemical_to_disease	drowsiness	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
risperidone	chemical_to_disease	dizziness	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
risperidone	chemical_to_disease	increased appetite	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
fatigue	disease_to_anatomy	group (	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
fatigue	disease_to_anatomy	, and	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drooling	disease_to_anatomy	group (	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drooling	disease_to_anatomy	, and	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drowsiness	disease_to_anatomy	group (	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drowsiness	disease_to_anatomy	, and	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
dizziness	disease_to_anatomy	group (	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
dizziness	disease_to_anatomy	, and	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
increased appetite	disease_to_anatomy	group (	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
increased appetite	disease_to_anatomy	, and	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
central nervous system diseases	disease_to_anatomy	nervous system	1	0	27180342	PMID:27180342; Original text:These developments underline the significance of microRNAs as potential biomarkers for diagnosing and prognosing central nervous system diseases.
central nervous system diseases	disease_to_anatomy	central nervous	1	0	27180342	PMID:27180342; Original text:These developments underline the significance of microRNAs as potential biomarkers for diagnosing and prognosing central nervous system diseases.
central nervous system diseases	disease_to_anatomy	central nervous system	1	0	27180342	PMID:27180342; Original text:These developments underline the significance of microRNAs as potential biomarkers for diagnosing and prognosing central nervous system diseases.
risperidone	chemical_to_anatomy	sensory motor	4	0	18026891|15930063|18080171|18080171	PMID:18026891; Original text:There was significant improvement on RF-RLRS sensory motor and language subscale and ABC scores in risperidone group.|PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
autism	disease_to_anatomy	levels of	2	0	11570630|22070180	PMID:11570630; Original text:Levels of I in the CSF were statistically significantly lower in the children with autism than in the control children (p=0.03).|PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
methylene tetrahydrofolate reductase	mechanism	mthfr	1	0	34440744	PMID:34440744; Original text:Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk.
methylene tetrahydrofolate	chemical_to_disease	asd	1	0	34440744	PMID:34440744; Original text:Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk.
methylene tetrahydrofolate	chemical_to_mechanism	methylene tetrahydrofolate reductase	1	0	34440744	PMID:34440744; Original text:Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk.
methylene tetrahydrofolate	chemical_to_mechanism	mthfr	1	0	34440744	PMID:34440744; Original text:Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk.
asd	disease_to_mechanism	methylene tetrahydrofolate reductase	1	0	34440744	PMID:34440744; Original text:Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk.
asd	disease_to_mechanism	mthfr	1	0	34440744	PMID:34440744; Original text:Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk.
of the	anatomy	pineal gland	1	0	21517957	PMID:21517957; Original text:Already, recent advances in understanding signalling dynamics in the human pineal gland have significantly helped to counteract chronobiological dysfunctions through a proper restoration of the nocturnal melatonin surge.
melatonin	chemical_to_anatomy	pineal gland	1	0	21517957	PMID:21517957; Original text:Already, recent advances in understanding signalling dynamics in the human pineal gland have significantly helped to counteract chronobiological dysfunctions through a proper restoration of the nocturnal melatonin surge.
melatonin	chemical_to_anatomy	of the	2	0	21517957|12804129	PMID:21517957; Original text:Already, recent advances in understanding signalling dynamics in the human pineal gland have significantly helped to counteract chronobiological dysfunctions through a proper restoration of the nocturnal melatonin surge.|PMID:12804129; Original text:Despite the short duration of the treatment, behavioral measures also displayed a significant improvement, and most of the effect disappeared after the discontinuation of the melatonin (p = 0.001).
creatine	chemical	gaba	1	0	23370056	PMID:23370056; Original text:The ratio of GABA to Creatine was significantly lower in the autism spectrum disorders group than the control subjects.
creatine	nutrient_to_chemical	gaba	1	0	23370056	PMID:23370056; Original text:The ratio of GABA to Creatine was significantly lower in the autism spectrum disorders group than the control subjects.
creatine	nutrient_to_chemical	creatine	2	0	23370056|22848344	PMID:23370056; Original text:The ratio of GABA to Creatine was significantly lower in the autism spectrum disorders group than the control subjects.|PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	nutrient_to_disease	autism spectrum disorders	1	0	23370056	PMID:23370056; Original text:The ratio of GABA to Creatine was significantly lower in the autism spectrum disorders group than the control subjects.
gaba	chemical_to_disease	autism spectrum disorders	1	0	23370056	PMID:23370056; Original text:The ratio of GABA to Creatine was significantly lower in the autism spectrum disorders group than the control subjects.
creatine	chemical_to_disease	autism spectrum disorders	1	0	23370056	PMID:23370056; Original text:The ratio of GABA to Creatine was significantly lower in the autism spectrum disorders group than the control subjects.
4	anatomy	of the	1	0	11699803	PMID:11699803; Original text:For the primary efficacy analysis, change of the Autism Diagnostic Observation Schedule social-communication total score from week 0 to week 4, no statistically significant difference was obtained between placebo (-0.8 +/- 2.9) and secretin groups (-0.6 +/- 1.4; t54 = 0.346, p < .73).
autism	disease_to_mechanism	secretin	2	0	11699803|15590241	PMID:11699803; Original text:For the primary efficacy analysis, change of the Autism Diagnostic Observation Schedule social-communication total score from week 0 to week 4, no statistically significant difference was obtained between placebo (-0.8 +/- 2.9) and secretin groups (-0.6 +/- 1.4; t54 = 0.346, p < .73).|PMID:15590241; Original text:Journal of the Association of the Academy of Minority Physicians, 9, 9-15] reported an uncontrolled trial of secretin with three participants with autism, which apparently resulted in significant behavioral improvement.
autism	disease_to_anatomy	4	1	0	11699803	PMID:11699803; Original text:For the primary efficacy analysis, change of the Autism Diagnostic Observation Schedule social-communication total score from week 0 to week 4, no statistically significant difference was obtained between placebo (-0.8 +/- 2.9) and secretin groups (-0.6 +/- 1.4; t54 = 0.346, p < .73).
secretin	mechanism_to_anatomy	of the	5	0	11699803|15590241|15590241|10588965|15937041	PMID:11699803; Original text:For the primary efficacy analysis, change of the Autism Diagnostic Observation Schedule social-communication total score from week 0 to week 4, no statistically significant difference was obtained between placebo (-0.8 +/- 2.9) and secretin groups (-0.6 +/- 1.4; t54 = 0.346, p < .73).|PMID:15590241; Original text:Journal of the Association of the Academy of Minority Physicians, 9, 9-15] reported an uncontrolled trial of secretin with three participants with autism, which apparently resulted in significant behavioral improvement.|PMID:15590241; Original text:Almost none of the studies reported any significant effects and none concluded that secretin was effective.|PMID:10588965; Original text:As compared with placebo, secretin treatment was not associated with significant improvements in any of the outcome measures.|PMID:15937041; Original text:Improvement in speech was found during the treatment phase of the trial (p=0.0479 for secretin versus placebo) only in children not using other medications.
secretin	mechanism_to_anatomy	4	1	0	11699803	PMID:11699803; Original text:For the primary efficacy analysis, change of the Autism Diagnostic Observation Schedule social-communication total score from week 0 to week 4, no statistically significant difference was obtained between placebo (-0.8 +/- 2.9) and secretin groups (-0.6 +/- 1.4; t54 = 0.346, p < .73).
oxytocin	chemical_to_disease	autism	4	0	32398642|26336909|28534875|8759044	"PMID:32398642; Original text:Results showed that the time spent viewing both dynamic and static social vs. non-social stimuli was negatively associated with trait autism and significantly increased following intranasal oxytocin.|PMID:26336909; Original text:Data obtained from 18 participants who completed the trial showed that 6-week intranasal administration of oxytocin significantly reduced autism core symptoms specific to social reciprocity, which was clinically evaluated by Autism Diagnostic Observation Scale (P = 0.034, PFDR < 0.05, Cohen's d = 0.78).|PMID:28534875; Original text:To our knowledge, this is the first trial to assess the dose-dependent effects of a single oxytocin administration in autism, with results indicating that a low dose of oxytocin can significantly modulate overt emotion salience despite minimal systemic exposure.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease_to_mechanism	oxytocin	4	0	32398642|26336909|28534875|8759044	"PMID:32398642; Original text:Results showed that the time spent viewing both dynamic and static social vs. non-social stimuli was negatively associated with trait autism and significantly increased following intranasal oxytocin.|PMID:26336909; Original text:Data obtained from 18 participants who completed the trial showed that 6-week intranasal administration of oxytocin significantly reduced autism core symptoms specific to social reciprocity, which was clinically evaluated by Autism Diagnostic Observation Scale (P = 0.034, PFDR < 0.05, Cohen's d = 0.78).|PMID:28534875; Original text:To our knowledge, this is the first trial to assess the dose-dependent effects of a single oxytocin administration in autism, with results indicating that a low dose of oxytocin can significantly modulate overt emotion salience despite minimal systemic exposure.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease	autistic disorder	3	0	22987897|32006372|16078860	PMID:22987897; Original text:We conclude that a 20-week parent education programme including skills training for parents of young children with autistic disorder provides significant improvements in child adaptive behaviour and symptoms of autism for low-functioning children.|PMID:32006372; Original text:This paper will discuss recent literature on the significance of metabolic aspects in autistic disorder and highlight the influence of nutrition intervention on the symptoms of autism.|PMID:16078860; Original text:Although there has been a significant increase in autism genetics research recently, validated susceptibility genes for the most common, sporadic forms of autistic disorder, as well as familial autism, have yet to be identified.
autism	disease	maladaptive	1	0	24439092	PMID:24439092; Original text:These findings suggest that NeuroModulation Technique is a promising intervention for autism that has the potential to produce a significant reduction in maladaptive behaviors and a significant increase in adaptive behaviors within a relatively short period of time.
avp	chemical_to_anatomy	scale	1	0	31043522	PMID:31043522; Original text:Intranasal AVP treatment compared to placebo enhanced social abilities as assessed by change from baseline in this phase 2 trial's primary outcome measure, the Social Responsiveness Scale, 2nd Edition total score (SRS-2 T score; F 1,20 = 9.853; P = 0.0052; ηp  = 33.0%; Cohen's d = 1.40).
baz1b	mechanism	gtf2ird1	1	0	30008175	PMID:30008175; Original text:However, we report on two nominally significant SNPs in two genes that have been implicated in the cognitive and social phenotypes of Williams syndrome, BAZ1B and GTF2IRD1.
williams syndrome	disease_to_mechanism	gtf2ird1	1	0	30008175	PMID:30008175; Original text:However, we report on two nominally significant SNPs in two genes that have been implicated in the cognitive and social phenotypes of Williams syndrome, BAZ1B and GTF2IRD1.
williams syndrome	disease_to_mechanism	baz1b	1	0	30008175	PMID:30008175; Original text:However, we report on two nominally significant SNPs in two genes that have been implicated in the cognitive and social phenotypes of Williams syndrome, BAZ1B and GTF2IRD1.
cerebellum	anatomy	posterior superior	1	0	32714385	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.
posterior superior	anatomy	posterior superior temporal	2	0	32714385|25149412	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
posterior superior	anatomy	superior temporal	2	0	32714385|25149412	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
posterior superior	anatomy	temporal	2	0	32714385|25149412	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
posterior superior	anatomy	temporal sulcus	2	0	32714385|25149412	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
cerebellum	anatomy	posterior superior temporal	1	0	32714385	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.
cerebellum	anatomy	superior temporal	2	0	32714385|26769980	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	temporal	2	0	32714385|26769980	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	temporal sulcus	1	0	32714385	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.
posterior superior temporal	anatomy	superior temporal	2	0	32714385|25149412	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
posterior superior temporal	anatomy	temporal	2	0	32714385|25149412	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
posterior superior temporal	anatomy	temporal sulcus	2	0	32714385|25149412	PMID:32714385; Original text:Resting-state functional connectivity (Resting-state functional connectivity) between the the right posterior superior temporal sulcus and the left cerebellum significantly decreased in the real group than the sham group after intermittent theta burst stimulation.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
autism	disease	autistic	6	0	24375082|3513570|22688012|28217829|17531541|11408327	PMID:24375082; Original text:camel milk administered for 2 wk significantly improved clinical measurements of autism severity and decreased serum level of activation-regulated chemokine in autistic children, but subsequent studies are recommended.|PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.|PMID:22688012; Original text:The majority of the data are based on molecular, cytogenetic, linkage and association studies of autistic subjects, but newer methods, including whole-exome sequencing, are also beginning to make significant contributions to our understanding of autism.|PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.|PMID:17531541; Original text:One final point is the initial overgrowth of white matter in the first 2 years of life in autistic children, followed later by arrested growth, resulting in aberrant connectivity; myelination of white matter will likely be significant in the etiology of autism.|PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.
autism	disease_to_anatomy	level of	2	0	24375082|16494569	PMID:24375082; Original text:camel milk administered for 2 wk significantly improved clinical measurements of autism severity and decreased serum level of activation-regulated chemokine in autistic children, but subsequent studies are recommended.|PMID:16494569; Original text:Children with autism had a 75% higher level of total vitamin B6 than the controls (medians of 56 versus 32 ng/mL, respectively, p = 0.00002).
autistic	disease_to_anatomy	level of	3	0	24375082|24676906|24676906	PMID:24375082; Original text:camel milk administered for 2 wk significantly improved clinical measurements of autism severity and decreased serum level of activation-regulated chemokine in autistic children, but subsequent studies are recommended.|PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.|PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
(p	anatomy	levels of	6	0	24375082|32635367|22151477|24515505|26746121|32966919	PMID:24375082; Original text:The serum levels of activation-regulated chemokine decreased significantly (P = 0.004) in boiled camel milk and in raw camel milk group (P = 0.01) too, but no effect was observed (P = 0.68) in placebo group.|PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.|PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.|PMID:24515505; Original text:Children with parent-reported disorder had higher levels of health care office visits and prescription drug use compared with children without disorder (P < .05).|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).|PMID:32966919; Original text:Serum levels of 25(25-hydroxyvitamin)D increased significantly in the vitamin D group (P = 0.001).
(p	anatomy	group (	18	0	24375082|24214165|25760553|2977280|22265360|8911223|18080171|18080171|27103982|23065117|28138381|16948927|23821414|30196397|32966919|28273822|32387472|28291262	PMID:24375082; Original text:The serum levels of activation-regulated chemokine decreased significantly (P = 0.004) in boiled camel milk and in raw camel milk group (P = 0.01) too, but no effect was observed (P = 0.68) in placebo group.|PMID:24214165; Original text:Results show that the children in the treatment group (n = 17) who received 30 sessions of the occupational therapy intervention scored significantly higher (p = 0.003, d = 1.2) on Goal Attainment Scales (primary outcome), and also scored significantly better on measures of caregiver assistance in self-care (p = 0.008 d = 0.9) and socialization (p = 0.04, d = 0.7) than the Usual Care control group (n = 15).|PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).|PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.|PMID:22265360; Original text:Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively).|PMID:8911223; Original text:Eight (53%) of 15 patients in the fluvoxamine-treated group were categorized as responders compared with none of 15 in the placebo group (P = .001).|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).|PMID:23065117; Original text:A significant number of new words were heard in the home environment for the melodic based communication therapy group (p = .04).|PMID:28138381; Original text:Analysis of the the parent-rated social responsiveness scale total raw score demonstrated significant decrease for the DCS group compared to the placebo group (p = 0.042) indicating greater maintenance of treatment effect in the DCS group.|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).|PMID:23821414; Original text:A significantly greater improvement in the study primary outcome (the ABC-C irritability subscale score) was achieved by the riluzole-treated children compared with the placebo group (P = 0.03).|PMID:30196397; Original text:Improvement in LSAS scores from baseline to the primary endpoint was significantly greater for 3,4-methylenedioxymethamphetamine group compared to the placebo group (P = 0.037), and placebo-subtracted Cohen's d effect size was very large (d = 1.4, CI - 0.074, 2.874).|PMID:32966919; Original text:Serum levels of 25(25-hydroxyvitamin)D increased significantly in the vitamin D group (P = 0.001).|PMID:28273822; Original text:Caregivers of 10-week therapeutic horseback riding group participants reported significant improvements in participants' caring actions with the family pet compared with the a no-horse barn activity group (p = 0.013; effect size = 0.74).|PMID:32387472; Original text:The global ADOS score and social interaction and communication sub scores were significantly improved at week 12 compared to baseline in the folinic acid group (P = 0.003, P = 0.004 and P = 0.022, respectively), but not in the placebo group (P = 0.574, P = 0.780, P = 0.269, respectively).|PMID:28291262; Original text:The mean CARS value was significantly improved in the completers group (P: 0.015).
valproate	chemical	vpa	1	0	16190799	PMID:16190799; Original text:In this prospective double-blind, placebo-controlled study, 30 subjects (20 boys, 10 girls) 6-20 years of age with pervasive developmental disorders and significant aggression were randomized and received treatment with valproate (VPA) or placebo (PBO) for 8 weeks as outpatients.
aggression	disease	pervasive developmental disorders	1	0	16190799	PMID:16190799; Original text:In this prospective double-blind, placebo-controlled study, 30 subjects (20 boys, 10 girls) 6-20 years of age with pervasive developmental disorders and significant aggression were randomized and received treatment with valproate (VPA) or placebo (PBO) for 8 weeks as outpatients.
valproate	chemical_to_disease	aggression	1	0	16190799	PMID:16190799; Original text:In this prospective double-blind, placebo-controlled study, 30 subjects (20 boys, 10 girls) 6-20 years of age with pervasive developmental disorders and significant aggression were randomized and received treatment with valproate (VPA) or placebo (PBO) for 8 weeks as outpatients.
valproate	chemical_to_disease	pervasive developmental disorders	1	0	16190799	PMID:16190799; Original text:In this prospective double-blind, placebo-controlled study, 30 subjects (20 boys, 10 girls) 6-20 years of age with pervasive developmental disorders and significant aggression were randomized and received treatment with valproate (VPA) or placebo (PBO) for 8 weeks as outpatients.
vpa	chemical_to_disease	aggression	1	0	16190799	PMID:16190799; Original text:In this prospective double-blind, placebo-controlled study, 30 subjects (20 boys, 10 girls) 6-20 years of age with pervasive developmental disorders and significant aggression were randomized and received treatment with valproate (VPA) or placebo (PBO) for 8 weeks as outpatients.
vpa	chemical_to_disease	pervasive developmental disorders	1	0	16190799	PMID:16190799; Original text:In this prospective double-blind, placebo-controlled study, 30 subjects (20 boys, 10 girls) 6-20 years of age with pervasive developmental disorders and significant aggression were randomized and received treatment with valproate (VPA) or placebo (PBO) for 8 weeks as outpatients.
ammonia	chemical	vpa	1	0	16190799	PMID:16190799; Original text:Two subjects receiving VPA developed increased serum ammonia levels, one with an associated parent report of slurred speech and mild cognitive slowing.
vpa	chemical_to_disease	cognitive slowing	1	0	16190799	PMID:16190799; Original text:Two subjects receiving VPA developed increased serum ammonia levels, one with an associated parent report of slurred speech and mild cognitive slowing.
ammonia	chemical_to_disease	cognitive slowing	1	0	16190799	PMID:16190799; Original text:Two subjects receiving VPA developed increased serum ammonia levels, one with an associated parent report of slurred speech and mild cognitive slowing.
autism	disease	physical anomalies	2	0	18626481|18626481	PMID:18626481; Original text:Using the cumulative data from seven studies on minor physical anomalies in autism, this meta-analysis seeks to examine whether the aggregate data provide evidence of a large mean effect size and statistical significance for minor physical anomalies in autism.|PMID:18626481; Original text:The current results from seven studies suggested a significant association of minor physical anomalies in autism with a robust pooled effect size (d=0.84), and thereby provide the strongest evidence to date about the close association between minor physical anomalies and autism.
physical anomalies	disease_to_anatomy	, and	1	0	18626481	PMID:18626481; Original text:The current results from seven studies suggested a significant association of minor physical anomalies in autism with a robust pooled effect size (d=0.84), and thereby provide the strongest evidence to date about the close association between minor physical anomalies and autism.
deficits in social communication	disease_to_anatomy	areas of	1	0	28296862	PMID:28296862; Original text:It is characterized by persistent deficits in social communication and social interaction, restricted and repetitive patterns of behavior, interests, or activities, and causes clinically significant impairment in social, occupational, or other important areas of functioning.
deficits in social communication	disease_to_anatomy	, and	1	0	28296862	PMID:28296862; Original text:It is characterized by persistent deficits in social communication and social interaction, restricted and repetitive patterns of behavior, interests, or activities, and causes clinically significant impairment in social, occupational, or other important areas of functioning.
autism	disease	vascular pathology	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
autism	disease	cerebral hypoperfusion	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
cerebral hypoperfusion	disease	vascular pathology	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
the brain	anatomy	the cerebral	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
autism	disease_to_anatomy	the brain	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
autism	disease_to_anatomy	the cerebral	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
vascular pathology	disease_to_anatomy	the brain	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
vascular pathology	disease_to_anatomy	the cerebral	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
cerebral hypoperfusion	disease_to_anatomy	the brain	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
cerebral hypoperfusion	disease_to_anatomy	the cerebral	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
autism	disease	developmental disabilities	1	0	17923388	PMID:17923388; Original text:IQ scores increased significantly more in the autism group than in the developmental disabilities group.
autism	disease	cognitive increments	1	0	17923388	PMID:17923388; Original text:Improvement of social-communicative behaviors and the intensive intervention are related to significant cognitive increments in autism.
areas of	anatomy	base	1	0	26874219	PMID:26874219; Original text:Despite this small base, Magnetoencephalography research has made a significant impact on several areas of translational neuroscience, largely through its unique capacity to quantify the oscillatory dynamics of activated brain circuits in humans.
brain growth abnormalities	disease_to_anatomy	is	1	0	17919128	PMID:17919128; Original text:The significance of future controlled studies should be judged based on their explanatory powers; that is, how well do they relate to brain growth abnormalities and/or provide useful clinicopathological correlates.
neurodevelopmental disorders	disease	neuroimaging	1	0	29608989	PMID:29608989; Original text:Significant advances have been made already, and future decades will continue to see innovative progress in neuroimaging research endeavors of neurodevelopmental disorders.
neurodevelopmental disorders	disease_to_anatomy	, and	3	0	29608989|15090875|20969835	PMID:29608989; Original text:Significant advances have been made already, and future decades will continue to see innovative progress in neuroimaging research endeavors of neurodevelopmental disorders.|PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.|PMID:20969835; Original text:We present initial evidence offering proof of concept that brain anatomy can be used to accurately distinguish adults with autism from healthy controls, and from some other neurodevelopmental disorders (some other neurodevelopmental disorders).
neuroimaging	disease_to_anatomy	, and	1	0	29608989	PMID:29608989; Original text:Significant advances have been made already, and future decades will continue to see innovative progress in neuroimaging research endeavors of neurodevelopmental disorders.
r-bh4	chemical_to_mechanism	r-bh4	1	0	9236697	PMID:9236697; Original text:R-BH4 levels in CSF increased significantly after treatment.
hippocampal formation	anatomy	of the	2	0	9895151|7854533	PMID:9895151; Original text:In contrast, there is a lack of significant difference in the cross-sectional size of the posterior hippocampal formation between autistic and normal subjects, which is discrepant with predictions based on some autopsy studies.|PMID:7854533; Original text:The lack of a significant difference in the cross-sectional size of the posterior hippocampal formation between autistic and normal 6- to 42-year-olds is discrepant with predictions based on some, but not all, autopsy studies.
autistic	disease_to_anatomy	hippocampal formation	2	0	9895151|7854533	PMID:9895151; Original text:In contrast, there is a lack of significant difference in the cross-sectional size of the posterior hippocampal formation between autistic and normal subjects, which is discrepant with predictions based on some autopsy studies.|PMID:7854533; Original text:The lack of a significant difference in the cross-sectional size of the posterior hippocampal formation between autistic and normal 6- to 42-year-olds is discrepant with predictions based on some, but not all, autopsy studies.
acrophobia	disease	obsessive-compulsive disorder	1	0	31166547	PMID:31166547; Original text:In the obsessive-compulsive disorder and acrophobia trials, rTMS significantly reduced symptoms compared to placebo.
asperger's syndrome	disease	autism	2	0	12818906|2047334	PMID:12818906; Original text:Discriminant functions analysis shows pathological demand avoidance syndrome to be significantly different on many counts from classic autism and Asperger's syndrome, both separately and together, including an equal sex ratio (150 cases).|PMID:2047334; Original text:Although some differences in etiology between autism and Asperger's syndrome have been identified, these are of uncertain clinical significance.
, and	anatomy	of joint	1	0	18752063	PMID:18752063; Original text:A significant positive effect of methylphenidate was seen on children's use of joint attention initiations, response to bids for joint attention, self-regulation, and regulated affective state.
methylphenidate	chemical_to_anatomy	of joint	1	0	18752063	PMID:18752063; Original text:A significant positive effect of methylphenidate was seen on children's use of joint attention initiations, response to bids for joint attention, self-regulation, and regulated affective state.
methylphenidate	chemical_to_anatomy	, and	2	0	18752063|18439113	PMID:18752063; Original text:A significant positive effect of methylphenidate was seen on children's use of joint attention initiations, response to bids for joint attention, self-regulation, and regulated affective state.|PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
homovanillic acid	chemical	hva	1	0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
b6-mg	chemical	homovanillic acid	1	0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
biochemical	chemical	homovanillic acid	1	0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
b6-mg	chemical	hva	1	0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
biochemical	chemical	hva	1	0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
b6-mg	chemical	biochemical	1	0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
b6-mg	chemical_to_anatomy	, middle	1	0	7124567	PMID:7124567; Original text:During B6-Mg treatment, middle latency evoked potentials exhibited a significant increase of amplitude.
fluvoxamine	chemical_to_disease	obsessive-compulsive disorder	2	0	11085201|11085201	PMID:11085201; Original text:fluvoxamine 100 to 300 mg/day for 6 to 10 weeks significantly reduced symptoms of obsessive-compulsive disorder (obsessive-compulsive disorder) compared with placebo.|PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
desipramine	chemical	fluvoxamine	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
desipramine	chemical	serotonin	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical	desipramine	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
desipramine	chemical	paroxetine	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
clomipramine	chemical	desipramine	2	0	11085201|8498878	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.|PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
fluvoxamine	chemical	serotonin	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical	fluvoxamine	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
fluvoxamine	chemical	paroxetine	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
clomipramine	chemical	fluvoxamine	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical	serotonin	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
paroxetine	chemical	serotonin	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
clomipramine	chemical	serotonin	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical	paroxetine	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical	clomipramine	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
clomipramine	chemical	paroxetine	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
desipramine	chemical_to_disease	obsessive-compulsive disorder	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
serotonin	chemical_to_disease	obsessive-compulsive disorder	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical_to_disease	obsessive-compulsive disorder	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
paroxetine	chemical_to_disease	obsessive-compulsive disorder	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
clomipramine	chemical_to_disease	obsessive-compulsive disorder	1	0	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
fluvoxamine	chemical	imipramine	1	0	11085201	PMID:11085201; Original text:Fluvoxamine < or = 300 mg/day for 6 to 8 weeks was as effective as imipramine in patients with panic disorder, and significantly more effective than placebo.
imipramine	chemical_to_disease	panic disorder	1	0	11085201	PMID:11085201; Original text:Fluvoxamine < or = 300 mg/day for 6 to 8 weeks was as effective as imipramine in patients with panic disorder, and significantly more effective than placebo.
fluvoxamine	chemical_to_disease	panic disorder	1	0	11085201	PMID:11085201; Original text:Fluvoxamine < or = 300 mg/day for 6 to 8 weeks was as effective as imipramine in patients with panic disorder, and significantly more effective than placebo.
imipramine	chemical_to_anatomy	, and	1	0	11085201	PMID:11085201; Original text:Fluvoxamine < or = 300 mg/day for 6 to 8 weeks was as effective as imipramine in patients with panic disorder, and significantly more effective than placebo.
fluvoxamine	chemical_to_anatomy	, and	2	0	11085201|8911223	PMID:11085201; Original text:Fluvoxamine < or = 300 mg/day for 6 to 8 weeks was as effective as imipramine in patients with panic disorder, and significantly more effective than placebo.|PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
panic disorder	disease_to_anatomy	, and	1	0	11085201	PMID:11085201; Original text:Fluvoxamine < or = 300 mg/day for 6 to 8 weeks was as effective as imipramine in patients with panic disorder, and significantly more effective than placebo.
25-ohd	chemical_to_disease	autism	1	0	25876214	PMID:25876214; Original text:The mean 25-OHD levels in patients with severe autism were significantly lower than those in patients with mild/moderate autism.
, eye	anatomy	contact	2	0	25876214|19284641	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.|PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
contact	anatomy	of the	1	0	25876214	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.
, and	anatomy	contact	2	0	25876214|19284641	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.|PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
, eye	anatomy	of the	1	0	25876214	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.
, and	anatomy	, eye	2	0	25876214|19284641	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.|PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
vitamin d3	chemical_to_anatomy	contact	1	0	25876214	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.
vitamin d3	chemical_to_anatomy	, eye	1	0	25876214	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.
vitamin d3	chemical_to_anatomy	of the	2	0	25876214|27868194	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.|PMID:27868194; Original text:The autism symptoms of the children improved significantly, following 4-month vitamin D3 supplementation, but not in the placebo group.
vitamin d3	chemical_to_anatomy	, and	1	0	25876214	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.
inflammation	disease	vascular disease	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
inflammation	disease	traumatic injury	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
degenerative disease	disease	inflammation	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
traumatic injury	disease	vascular disease	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
degenerative disease	disease	vascular disease	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
degenerative disease	disease	traumatic injury	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
of systemic	anatomy	of the	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
, and	anatomy	of systemic	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
inflammation	disease_to_anatomy	of systemic	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
inflammation	disease_to_anatomy	of the	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
inflammation	disease_to_anatomy	, and	2	0	33942547|19852789	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.|PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
vascular disease	disease_to_anatomy	of systemic	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
vascular disease	disease_to_anatomy	of the	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
vascular disease	disease_to_anatomy	, and	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
traumatic injury	disease_to_anatomy	of systemic	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
traumatic injury	disease_to_anatomy	of the	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
traumatic injury	disease_to_anatomy	, and	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
degenerative disease	disease_to_anatomy	of systemic	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
degenerative disease	disease_to_anatomy	of the	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
degenerative disease	disease_to_anatomy	, and	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
spectrum disorders	disease_to_anatomy	of the	1	0	28734011	PMID:28734011; Original text:The pooled point estimates of the latter cohorts showed a significant association with spectrum disorders which strengthens our previous suggestion of confounding by indication.
induced pluripotent stem cells	anatomy	pluripotent stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
, induced	anatomy	induced pluripotent stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent stem cells	anatomy	of the	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent stem	anatomy	induced pluripotent stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent stem cells	anatomy	pluripotent stem	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent stem cells	anatomy	stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent	anatomy	induced pluripotent stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
, induced	anatomy	pluripotent stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
of the	anatomy	pluripotent stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent stem	anatomy	pluripotent stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
pluripotent stem	anatomy	pluripotent stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
pluripotent stem cells	anatomy	stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent	anatomy	pluripotent stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
, induced	anatomy	of the	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
, induced	anatomy	induced pluripotent stem	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
, induced	anatomy	pluripotent stem	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
, induced	anatomy	stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
, induced	anatomy	induced pluripotent	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent stem	anatomy	of the	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
of the	anatomy	pluripotent stem	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
of the	anatomy	stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent	anatomy	of the	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent stem	anatomy	pluripotent stem	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent stem	anatomy	stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent	anatomy	induced pluripotent stem	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
pluripotent stem	anatomy	stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent	anatomy	pluripotent stem	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
induced pluripotent	anatomy	stem cells	1	0	26826498	PMID:26826498; Original text:We also highlight technical advances using genome-editing technologies in patient-specific, induced pluripotent stem cells to support drug discovery efforts, including the interpretation of the functional significance of rare genetic variants of unknown significance and for the purpose of creating cell type- and pathway-selective functional reporter assays.
isoprostanes	chemical_to_disease	rett syndrome	1	0	21888765	PMID:21888765; Original text:F2-isoprostanes were significantly higher in the early stages as compared with the late natural progression of classic Rett syndrome.
, upper	anatomy	upper body	1	0	31422168	PMID:31422168; Original text:The results demonstrated significant improvements in core strength (p = 0.00), upper body strength (p = 0.00), flexibility (p = 0.01) and cardiorespiratory endurance (p = 0.00) in the surfing group.
(p	anatomy	, upper	1	0	31422168	PMID:31422168; Original text:The results demonstrated significant improvements in core strength (p = 0.00), upper body strength (p = 0.00), flexibility (p = 0.01) and cardiorespiratory endurance (p = 0.00) in the surfing group.
(p	anatomy	upper body	1	0	31422168	PMID:31422168; Original text:The results demonstrated significant improvements in core strength (p = 0.00), upper body strength (p = 0.00), flexibility (p = 0.01) and cardiorespiratory endurance (p = 0.00) in the surfing group.
(p	anatomy	body fat	1	0	31422168	PMID:31422168; Original text:Body composition measurements on the surfing group demonstrated a significant reduction in total body fat % (p = 0.016) and fat free mass (p = 0.008) and a significant improvement in bone mineral density (p = 0.004) pre to post surf therapy.
autism	disease	epileptiform activity	1	0	25847431	PMID:25847431; Original text:The clinical significance of epileptiform activity in patients with autism is controversial.
asd	disease	asds	1	0	26448791	PMID:26448791; Original text:A an existing computer decision support system module to improve primary care management of ASD in pediatric practice led to significant improvements in physician-reported use of validated screening tools to screen for ASDs.
foxp3	mechanism	toll-like receptor-4	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism	foxp3	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism	toll-like receptor-4	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
b cells	anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
, memory	anatomy	b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
b cells	anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
b cells	anatomy	lymphocyte	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
, and	anatomy	b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
b cells	anatomy	cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
, memory	anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
memory b	anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
lymphocyte	anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
, and	anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cells	anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
, memory	anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
, memory	anatomy	lymphocyte	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
, and	anatomy	, memory	3	0	29427532|22964437|27721995	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.|PMID:22964437; Original text:The consequences may include alterations in daytime behavior, memory, and learning in patients, and significant stress in caretakers.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
, memory	anatomy	cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
lymphocyte	anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
, and	anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cells	anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
, and	anatomy	lymphocyte	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cells	anatomy	lymphocyte	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
, and	anatomy	cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	, memory	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	lymphocyte	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	, and	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	, memory	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	lymphocyte	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	, and	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	, memory	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	lymphocyte	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	, and	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
i	anatomy	of the	1	0	29427532	PMID:29427532; Original text:Significant improvements from baseline to study endpoint were observed in several subscales of the CCC-2, SRS, CGI-I, CGI-S, and ADOS, including Associated Maladaptive Behaviors (P ≤ .043), Reciprocal Social Interaction (P = .015), Communication (P < .001), and Stereotyped Behaviors and Repetitive Interests (P ≤ .013).
(p	anatomy	i	1	0	29427532	PMID:29427532; Original text:Significant improvements from baseline to study endpoint were observed in several subscales of the CCC-2, SRS, CGI-I, CGI-S, and ADOS, including Associated Maladaptive Behaviors (P ≤ .043), Reciprocal Social Interaction (P = .015), Communication (P < .001), and Stereotyped Behaviors and Repetitive Interests (P ≤ .013).
, and	anatomy	i	1	0	29427532	PMID:29427532; Original text:Significant improvements from baseline to study endpoint were observed in several subscales of the CCC-2, SRS, CGI-I, CGI-S, and ADOS, including Associated Maladaptive Behaviors (P ≤ .043), Reciprocal Social Interaction (P = .015), Communication (P < .001), and Stereotyped Behaviors and Repetitive Interests (P ≤ .013).
asd	disease	psychosis	1	0	33218931	PMID:33218931; Original text:The 22q11.2 microdeletion syndrome (The 22q11.2 microdeletion syndrome) is caused by a recurrent genetic mutation that carries significantly increased risk for developing psychosis and/or ASD.
, and	anatomy	part of	1	0	9809262	PMID:9809262; Original text:In the experimental group, there were greater gains in language abilities, significant increases in caregivers' knowledge about autism, greater perception of control on the part of mothers, and greater parent satisfaction.
group	anatomy	part of	1	0	9809262	PMID:9809262; Original text:In the experimental group, there were greater gains in language abilities, significant increases in caregivers' knowledge about autism, greater perception of control on the part of mothers, and greater parent satisfaction.
, greater	anatomy	part of	1	0	9809262	PMID:9809262; Original text:In the experimental group, there were greater gains in language abilities, significant increases in caregivers' knowledge about autism, greater perception of control on the part of mothers, and greater parent satisfaction.
, and	anatomy	group	8	0	9809262|15068403|19015968|24979315|32305492|32347624|9442997|34797272	PMID:9809262; Original text:In the experimental group, there were greater gains in language abilities, significant increases in caregivers' knowledge about autism, greater perception of control on the part of mothers, and greater parent satisfaction.|PMID:15068403; Original text:The difference between the two treatments was significant as indicated by the effect of group, and the between-subjects factor (F = 4.17, d.f.|PMID:19015968; Original text:Results revealed, in comparison with the control group, that the treatment group significantly improved their knowledge of social skills, increased frequency of hosted get-togethers, and improved overall social skills as reported by parents.|PMID:24979315; Original text:Relative to the care-as-usual group, significant short-term improvements were found in the intervention group on parent-reported child behavior problems, dysfunctional parenting styles, parenting confidence, and parental stress, parental conflict, and relationship happiness.|PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:9442997; Original text:A significant effect of informant was found for the PDD group, and this effect was particularly pronounced when children with autism were considered separately.|PMID:34797272; Original text:Results revealed that all dimensions of job stress (perception of stress sources, stress manifestation, and total Teachers' Stress Inventory scores) reduced significantly at posttest and follow up assessments among the yoga group, compared to the a group-randomized waitlist control.
, and	anatomy	, greater	2	0	9809262|26792761	PMID:9809262; Original text:In the experimental group, there were greater gains in language abilities, significant increases in caregivers' knowledge about autism, greater perception of control on the part of mothers, and greater parent satisfaction.|PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)
, greater	anatomy	group	1	0	9809262	PMID:9809262; Original text:In the experimental group, there were greater gains in language abilities, significant increases in caregivers' knowledge about autism, greater perception of control on the part of mothers, and greater parent satisfaction.
autism	disease_to_anatomy	part of	1	0	9809262	PMID:9809262; Original text:In the experimental group, there were greater gains in language abilities, significant increases in caregivers' knowledge about autism, greater perception of control on the part of mothers, and greater parent satisfaction.
autism	disease_to_anatomy	group	5	0	9809262|15358868|29562612|16948927|9442997	PMID:9809262; Original text:In the experimental group, there were greater gains in language abilities, significant increases in caregivers' knowledge about autism, greater perception of control on the part of mothers, and greater parent satisfaction.|PMID:15358868; Original text:Experiment 3 showed that increases in target-distractor similarity slowed the visual search performance of the control group significantly more than that of the autism group, suggesting that the adults with autism have a superior visual discrimination ability.|PMID:29562612; Original text:Based on semi-blinded assessment, the treatment group, compared to the non-treatment group, had significantly greater improvement in autism symptoms and developmental age.|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).|PMID:9442997; Original text:A significant effect of informant was found for the PDD group, and this effect was particularly pronounced when children with autism were considered separately.
autism	disease_to_anatomy	, greater	1	0	9809262	PMID:9809262; Original text:In the experimental group, there were greater gains in language abilities, significant increases in caregivers' knowledge about autism, greater perception of control on the part of mothers, and greater parent satisfaction.
(primary	anatomy	group (	1	0	24214165	PMID:24214165; Original text:Results show that the children in the treatment group (n = 17) who received 30 sessions of the occupational therapy intervention scored significantly higher (p = 0.003, d = 1.2) on Goal Attainment Scales (primary outcome), and also scored significantly better on measures of caregiver assistance in self-care (p = 0.008 d = 0.9) and socialization (p = 0.04, d = 0.7) than the Usual Care control group (n = 15).
(primary	anatomy	, and	2	0	24214165|32347624	PMID:24214165; Original text:Results show that the children in the treatment group (n = 17) who received 30 sessions of the occupational therapy intervention scored significantly higher (p = 0.003, d = 1.2) on Goal Attainment Scales (primary outcome), and also scored significantly better on measures of caregiver assistance in self-care (p = 0.008 d = 0.9) and socialization (p = 0.04, d = 0.7) than the Usual Care control group (n = 15).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
region of	anatomy	the eye	1	0	24988218	PMID:24988218; Original text:The results reveal that children with autism spectrum disorders have significantly reduced gaze fixation to the eye region of faces.
autism spectrum disorders	disease_to_anatomy	region of	1	0	24988218	PMID:24988218; Original text:The results reveal that children with autism spectrum disorders have significantly reduced gaze fixation to the eye region of faces.
autism spectrum disorders	disease_to_anatomy	the eye	1	0	24988218	PMID:24988218; Original text:The results reveal that children with autism spectrum disorders have significantly reduced gaze fixation to the eye region of faces.
autism spectrum disorders	disease	impairments in gaze fixation to the eyes	1	0	24988218	PMID:24988218; Original text:The results of the meta-analyses indicate that autism spectrum disorders patients have significant impairments in gaze fixation to the eyes.
autism spectrum disorders	disease_to_anatomy	of the	8	0	24988218|22784311|28065825|15863467|23123089|16649827|22801412|32840005	PMID:24988218; Original text:The results of the meta-analyses indicate that autism spectrum disorders patients have significant impairments in gaze fixation to the eyes.|PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:28065825; Original text:There is general consensus that electroencephalogram coherence patterns differ between individuals with and without autism spectrum disorders; however, the exact nature of the differences and their clinical significance remain unclear.|PMID:15863467; Original text:Diagnostic criteria, age of the sample, and urban or rural location were associated with estimated prevalence of all all autism spectrum disorders.|PMID:23123089; Original text:Use of the a frequency modulation system resulted in significant average improvements in speech recognition in noise for the children with autism spectrum disorders and attention-deficit hyperactivity disorder as well as large effect sizes.|PMID:16649827; Original text:Awareness of the impact and prevalence of autism spectrum disorders has significantly increased in recent years.|PMID:22801412; Original text:Second, neuroimaging studies have advanced our understanding of the 'wider' neural systems underlying Autism Spectrum Disorders; and significantly contributed to our knowledge of the complex neurobiology associated with the condition.|PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
impairments in gaze fixation to the eyes	disease_to_anatomy	of the	1	0	24988218	PMID:24988218; Original text:The results of the meta-analyses indicate that autism spectrum disorders patients have significant impairments in gaze fixation to the eyes.
(p	anatomy	platelet	2	0	15292671|12858328	PMID:15292671; Original text:Significantly lower platelet-poor plasma serotonin levels were observed in the autistic group as compared to the controls (p = 0.03).|PMID:12858328; Original text:A significant elevation in platelet-poor plasma 5-HT levels in adult autistic patients was reached 60 min after meal administration (p < 0.03 vs control and p = 0.05 vs baseline) and a significant decrease was noted after 120 min (p < 0.01 vs baseline).
serotonin	chemical_to_disease	autistic	5	0	15292671|15733932|15733932|2936877|15730889	"PMID:15292671; Original text:Significantly lower platelet-poor plasma serotonin levels were observed in the autistic group as compared to the controls (p = 0.03).|PMID:15733932; Original text:serotoninP administration significantly increased the levels of serotonin in autistic youngsters but not in normal controls.|PMID:15733932; Original text:Following serotoninP challenge the serotonin levels were significantly higher in autistic patients than in healthy volunteers.|PMID:2936877; Original text:A double-blind cross-over study on the effect of fenfluramine versus placebo in seven autistic boys over a period of 8 months demonstrated a significant decrease in blood serotonin levels during the fenfluramine phase in all subjects.|PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	chemical_to_anatomy	(p	2	0	15292671|26746121	PMID:15292671; Original text:Significantly lower platelet-poor plasma serotonin levels were observed in the autistic group as compared to the controls (p = 0.03).|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
serotonin	chemical_to_anatomy	platelet	2	0	15292671|15292671	PMID:15292671; Original text:Significantly lower platelet-poor plasma serotonin levels were observed in the autistic group as compared to the controls (p = 0.03).|PMID:15292671; Original text:In addition, platelet-poor plasma serotonin levels were inversely correlated with the Overt Aggression Scale scores among subjects with autism (r = -0.64, p < 0.05).
autistic	disease_to_anatomy	platelet	3	0	15292671|24613076|12858328	PMID:15292671; Original text:Significantly lower platelet-poor plasma serotonin levels were observed in the autistic group as compared to the controls (p = 0.03).|PMID:24613076; Original text:Altogether, elevated 5-HT blood levels were recorded in 28.3% in whole blood and 22.5% in platelet-rich plasma samples of autistic individuals, as reported in 15 and 4 studies, respectively.|PMID:12858328; Original text:A significant elevation in platelet-poor plasma 5-HT levels in adult autistic patients was reached 60 min after meal administration (p < 0.03 vs control and p = 0.05 vs baseline) and a significant decrease was noted after 120 min (p < 0.01 vs baseline).
autism	disease_to_anatomy	platelet	1	0	15292671	PMID:15292671; Original text:In addition, platelet-poor plasma serotonin levels were inversely correlated with the Overt Aggression Scale scores among subjects with autism (r = -0.64, p < 0.05).
autism spectrum disorder	disease	schizophrenia	2	0	28929285|33434711	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
autism spectrum disorder	disease	genomic disorders	1	0	28929285	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.
intellectual disability	disease	schizophrenia	3	0	28929285|33434711|24123946	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:24123946; Original text:The del15q11.2 was found to be significantly associated with intellectual disability, schizophrenia, epilepsy, and disorder.
genomic disorders	disease	intellectual disability	1	0	28929285	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.
genomic disorders	disease	schizophrenia	1	0	28929285	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.
schizophrenia	disease_to_anatomy	, and	6	0	28929285|29688876|33434711|21863344|24123946|19736351	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.|PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:21863344; Original text:Empathy, for instance, is a rather elaborated human ability, and several recent studies point to significant impairments in patients suffering from psychiatric disorders, such as schizophrenia or autism.|PMID:24123946; Original text:The del15q11.2 was found to be significantly associated with intellectual disability, schizophrenia, epilepsy, and disorder.|PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).
genomic disorders	disease_to_anatomy	, and	1	0	28929285	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.
vitamin b12	nutrient	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	s-adenosylmethionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	vitamin b12	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	glutathione	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	glutathione	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	methionine	2	0	33414386|24676906	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
glutathione	chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	vitamin b9	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	s-adenosylhomocysteine	2	0	33414386|24676906	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
s-adenosylmethionine	chemical	vitamin b12	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylmethionine	chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	s-adenosylmethionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	s-adenosylmethionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	s-adenosylmethionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylmethionine	chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylmethionine	chemical	vitamin b9	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical	s-adenosylmethionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	vitamin b12	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	vitamin b12	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	vitamin b12	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	chemical	vitamin b9	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical	vitamin b12	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b9	chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	cysteine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	methionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	vitamin b9	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	s-adenosylhomocysteine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	methionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	vitamin b9	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	s-adenosylhomocysteine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	vitamin b9	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	s-adenosylhomocysteine	2	0	33414386|24676906	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
vitamin b9	chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical	vitamin b9	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
, and	anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_chemical	glutathione	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_chemical	s-adenosylmethionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_chemical	vitamin b12	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_chemical	cysteine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_chemical	calcium	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_chemical	methionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_chemical	vitamin b9	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_chemical	s-adenosylhomocysteine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_chemical	glutathione	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_chemical	s-adenosylmethionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_chemical	vitamin b12	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_chemical	cysteine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_chemical	calcium	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_chemical	methionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_chemical	vitamin b9	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_chemical	s-adenosylhomocysteine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_chemical	glutathione	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_chemical	s-adenosylmethionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_chemical	vitamin b12	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_chemical	vitamin d	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_chemical	cysteine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_chemical	calcium	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_chemical	methionine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_chemical	vitamin e	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_chemical	vitamin b9	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_chemical	s-adenosylhomocysteine	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	nutrient_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	nutrient_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	nutrient_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical_to_anatomy	, and	2	0	33414386|19852789	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
s-adenosylmethionine	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylmethionine	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical_to_anatomy	, and	2	0	33414386|22129897	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
calcium	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical_to_anatomy	, and	2	0	33414386|32173856	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
vitamin e	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b9	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b9	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
serotonin transporter	mechanism	sert	1	0	28738293	PMID:28738293; Original text:However, the increased serotonin transporter (SERT) level in the striatum after treatment was correlated significantly with increased negative emotional response to human faces.
serotonin	chemical_to_mechanism	serotonin transporter	1	0	28738293	PMID:28738293; Original text:However, the increased serotonin transporter (SERT) level in the striatum after treatment was correlated significantly with increased negative emotional response to human faces.
serotonin	chemical_to_mechanism	sert	1	0	28738293	PMID:28738293; Original text:However, the increased serotonin transporter (SERT) level in the striatum after treatment was correlated significantly with increased negative emotional response to human faces.
serotonin	chemical_to_anatomy	striatum	1	0	28738293	PMID:28738293; Original text:However, the increased serotonin transporter (SERT) level in the striatum after treatment was correlated significantly with increased negative emotional response to human faces.
serotonin transporter	mechanism_to_anatomy	striatum	1	0	28738293	PMID:28738293; Original text:However, the increased serotonin transporter (SERT) level in the striatum after treatment was correlated significantly with increased negative emotional response to human faces.
sert	mechanism_to_anatomy	striatum	1	0	28738293	PMID:28738293; Original text:However, the increased serotonin transporter (SERT) level in the striatum after treatment was correlated significantly with increased negative emotional response to human faces.
fragile x syndrome	disease	visuospatial impairments	1	0	30231625	PMID:30231625; Original text:Children with Fragile X syndrome also exhibit significant visuospatial impairments.
medial prefrontal	anatomy	prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
medial prefrontal cortex	anatomy	prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
(p	anatomy	prefrontal cortex	3	0	24352377|25149412|25149412	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).|PMID:25149412; Original text:At the neural level, the peptide significantly enhanced the originally-diminished brain activity in the right anterior insula during inferring others' social emotions (P = 0.004), but not in the dorsomedial prefrontal cortex during inferring others' beliefs (P = 0.858).
cortex (	anatomy	prefrontal cortex	4	0	24352377|25292351|26336909|18485420	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
medial prefrontal	anatomy	medial prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
(p	anatomy	medial prefrontal	1	0	24352377	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).
cortex (	anatomy	medial prefrontal	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
(p	anatomy	medial prefrontal cortex	1	0	24352377	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).
cortex (	anatomy	medial prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
(p	anatomy	cortex (	1	0	24352377	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).
oxytocin	chemical_to_anatomy	prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	chemical_to_anatomy	medial prefrontal	4	0	24352377|26336909|26336909|30262887	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).|PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
oxytocin	chemical_to_anatomy	medial prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	chemical_to_anatomy	cortex (	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	mechanism_to_anatomy	prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	mechanism_to_anatomy	medial prefrontal	4	0	24352377|26336909|26336909|30262887	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).|PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
oxytocin	mechanism_to_anatomy	medial prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	mechanism_to_anatomy	cortex (	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
area (	anatomy	of the	2	0	24352377|26994483	PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).|PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
(p	anatomy	area (	1	0	24352377	PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).
, and	anatomy	area (	1	0	24352377	PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).
oxytocin	chemical_to_anatomy	area (	1	0	24352377	PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).
lamotrigine	chemical_to_anatomy	scales	1	0	11450816	PMID:11450816; Original text:We did not find any significant differences in improvements between lamotrigine or placebo groups on the Autism Behavior Checklist, the Aberrant Behavior Checklist, the Vineland Adaptive Behavior scales, the PL-ADOS, or the CARS.
of the brain	anatomy	the brain	2	0	21219189|28799778	PMID:21219189; Original text:The functional significance of the brain's white matter was not fully appreciated until new imaging methods were developed to visualize fiber pathways and connections in the living brain.|PMID:28799778; Original text:The literature strongly suggests that Tryptophan has a significant role in the correct functionality of the brain-gut axis and immunology.
of the brain	anatomy	white matter	1	0	21219189	PMID:21219189; Original text:The functional significance of the brain's white matter was not fully appreciated until new imaging methods were developed to visualize fiber pathways and connections in the living brain.
of the	anatomy	of the brain	2	0	21219189|28799778	PMID:21219189; Original text:The functional significance of the brain's white matter was not fully appreciated until new imaging methods were developed to visualize fiber pathways and connections in the living brain.|PMID:28799778; Original text:The literature strongly suggests that Tryptophan has a significant role in the correct functionality of the brain-gut axis and immunology.
the brain	anatomy	white matter	1	0	21219189	PMID:21219189; Original text:The functional significance of the brain's white matter was not fully appreciated until new imaging methods were developed to visualize fiber pathways and connections in the living brain.
of the	anatomy	the brain	2	0	21219189|28799778	PMID:21219189; Original text:The functional significance of the brain's white matter was not fully appreciated until new imaging methods were developed to visualize fiber pathways and connections in the living brain.|PMID:28799778; Original text:The literature strongly suggests that Tryptophan has a significant role in the correct functionality of the brain-gut axis and immunology.
of the	anatomy	white matter	2	0	21219189|21692142	PMID:21219189; Original text:The functional significance of the brain's white matter was not fully appreciated until new imaging methods were developed to visualize fiber pathways and connections in the living brain.|PMID:21692142; Original text:Each of the significant the activation likelihood estimation clusters was analyzed separately for age effects on gray and white matter density changes.
iloperidone	chemical	paliperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	iloperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	iloperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	iloperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical	quetiapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical	quetiapine xr	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical	olanzapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	iloperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical	risperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	paliperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	paliperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	paliperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical	quetiapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical	quetiapine xr	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical	paliperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	paliperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical	risperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	asenapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	asenapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	quetiapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	quetiapine xr	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	olanzapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	fluoxetine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	risperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	aripiprazole	3	0	22784311|22784311|31063671	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
aripiprazole	chemical	quetiapine	2	0	22784311|22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
aripiprazole	chemical	quetiapine xr	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	olanzapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	fluoxetine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	risperidone	5	0	22784311|22784311|31063671|31063671|31063671	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.|PMID:31063671; Original text:Improvement was greatest in the risperidone group at every assessment period and was statistically significantly better than that in the aripiprazole group at weeks 3 and 6 (p<0.05).|PMID:31063671; Original text:Mean weight gain in the aripiprazole group was significantly less than that in the risperidone group at week 4 (0.62 vs 1.38 kg, p=0.033) and week 10 (1.61 vs 3.31 kg, p<0.001), but the difference became nonsignificant for the 31 patients completing the 3-month extension phase (4.36 vs 5.55 kg, p=0.26).|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
a	chemical	quetiapine	2	0	22784311|22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
a	chemical	quetiapine xr	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	olanzapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	fluoxetine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	risperidone	3	0	22784311|22784311|31063671	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
quetiapine	chemical	quetiapine xr	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical	quetiapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	quetiapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine	chemical	risperidone	2	0	22784311|22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
olanzapine	chemical	quetiapine xr	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	quetiapine xr	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine xr	chemical	risperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	olanzapine	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical	risperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	risperidone	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
autism spectrum disorders	disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
bipolar depression	disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
autism spectrum disorders	disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical_to_disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical_to_disease	autism spectrum disorders	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical_to_disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical_to_disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical_to_disease	autism spectrum disorders	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical_to_disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical_to_disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical_to_disease	autism spectrum disorders	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical_to_disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical_to_disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical_to_disease	autism spectrum disorders	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical_to_disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical_to_disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical_to_disease	autism spectrum disorders	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical_to_disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine	chemical_to_disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine	chemical_to_disease	autism spectrum disorders	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine	chemical_to_disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine xr	chemical_to_disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine xr	chemical_to_disease	autism spectrum disorders	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine xr	chemical_to_disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical_to_disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical_to_disease	autism spectrum disorders	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical_to_disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical_to_disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical_to_disease	autism spectrum disorders	2	0	22784311|31638682	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:31638682; Original text:In this preliminary study of children and adolescents with autism spectrum disorders, treatment with fluoxetine compared with placebo resulted in significantly lower scores for obsessive-compulsive behaviors at 16 weeks.
fluoxetine	chemical_to_disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
risperidone	chemical_to_disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
risperidone	chemical_to_disease	autism spectrum disorders	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
risperidone	chemical_to_disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical_to_anatomy	of the	2	0	22784311|31063671	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
aripiprazole	chemical_to_anatomy	, and	4	0	22784311|22784311|20973712|19797985	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.|PMID:20973712; Original text:Statistically significantly greater improvement was seen with aripiprazole versus placebo (p < 0.05) for all arms in both trials on the the Aberrant Behavior Checklist-Irritability total subscale score and on the following individual the Aberrant Behavior Checklist-Irritability items: Mood changes quickly, cries/screams inappropriately, and stamps feet/bangs objects.|PMID:19797985; Original text:At week 8, mean weight change (last observation carried forward) was as follows: placebo +0.3 kg, aripiprazole 5 mg/day +1.3 kg, 10 mg/day +1.3 kg, and 15 mg/day +1.5 kg; all p < .05 versus placebo.
a	chemical_to_anatomy	of the	2	0	22784311|31063671	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
a	chemical_to_anatomy	, and	2	0	22784311|22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
quetiapine	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine	chemical_to_anatomy	, and	2	0	22784311|22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
quetiapine xr	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine xr	chemical_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical_to_anatomy	, and	2	0	22784311|26792761	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)
fluoxetine	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
risperidone	chemical_to_anatomy	of the	7	0	22784311|18080171|24828014|24828014|31063671|15492353|15492353	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).|PMID:24828014; Original text:Six of the 48 subjects met two criteria for responders to risperidone, and the median values of interleukin (interleukin)-5 were significantly higher (p=0.005) in the overall responder group than in nonresponders.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.|PMID:15492353; Original text:Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the the Aberrant Behavior Checklist (primary endpoint) compared with those who were taking placebo.|PMID:15492353; Original text:Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the the Aberrant Behavior Checklist; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom.
mdd	disease_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
mdd	disease_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
autism spectrum disorders	disease_to_anatomy	, and	13	0	22784311|15863467|31665947|23123089|23452684|23452684|26210844|28342168|23965288|22801412|19365716|32840005|22118062	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:15863467; Original text:Diagnostic criteria, age of the sample, and urban or rural location were associated with estimated prevalence of all all autism spectrum disorders.|PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:23123089; Original text:Given the significantly better speech recognition in noise, increased on-task behaviors, and improved teacher ratings of listening behaviors with the a frequency modulation system, these devices may be a viable option for children who have autism spectrum disorders and attention-deficit hyperactivity disorder in the classroom.|PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.|PMID:26210844; Original text:Mean scores were significantly different in subjects with autism spectrum disorders, those with developmental delay/non-autism spectrum disorders, and those with no developmental concerns (20.8 vs 13 vs 10.6, respectively; P < .0001).|PMID:28342168; Original text:After adjusting for potential covariates, having autism spectrum disorders was associated with significantly lower trabecular bone mineral density and bone strength at the radius, and with marginally lower total body less head bone mineral content (p < 0.09).|PMID:23965288; Original text:Pretreatment Developmental Disability-Child Global Assessment Scale scores correlated with severity of autism spectrum disorders core symptoms (r = -.388, p = .034), pragmatic communication (r = .407, p = .032), and verbal ability (r = .449, p = .013) and did not correlate with severity of anxiety symptoms or with parent-reported adaptive behavior.|PMID:22801412; Original text:Most important, several risk gene variants have now been identified that significantly contribute to Autism Spectrum Disorders susceptibility, many linked to synaptic functioning, excitation-inhibition balance, and brain connectivity.|PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.|PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.|PMID:22118062; Original text:  These data suggest that significant improvements can be made in peer social connections for children with autism spectrum disorders in general education classrooms with a brief intervention, and that these gains persist over time.
bipolar depression	disease_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
bipolar depression	disease_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
anxiety disorder	disease	olanzapine	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
anxiety disorder	disease	dementia	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
anxiety disorder	disease	obsessive-compulsive disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
dementia	disease	olanzapine	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
obsessive-compulsive disorder	disease	olanzapine	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
dementia	disease	obsessive-compulsive disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
aripiprazole	chemical_to_disease	anxiety disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
aripiprazole	chemical_to_disease	olanzapine	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
aripiprazole	chemical_to_disease	dementia	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
aripiprazole	chemical_to_disease	obsessive-compulsive disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
quetiapine	chemical_to_disease	anxiety disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
quetiapine	chemical_to_disease	olanzapine	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
quetiapine	chemical_to_disease	dementia	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
quetiapine	chemical_to_disease	obsessive-compulsive disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
a	chemical_to_disease	anxiety disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
a	chemical_to_disease	olanzapine	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
a	chemical_to_disease	dementia	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
a	chemical_to_disease	obsessive-compulsive disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
risperidone	chemical_to_disease	anxiety disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
risperidone	chemical_to_disease	olanzapine	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
risperidone	chemical_to_disease	dementia	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
risperidone	chemical_to_disease	obsessive-compulsive disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
anxiety disorder	disease_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
olanzapine	disease_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
dementia	disease_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
obsessive-compulsive disorder	disease_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
brain barrier	anatomy	of the	1	0	29966749	PMID:29966749; Original text:Additionally, we discuss the clinical significance of the The blood-brain barrier in diagnosis (genetic markers, dynamic contrast-enhanced-magnetic resonance imaging, and blood biomarkers) and in treatment (drug delivery).
blood-brain barrier	anatomy	brain barrier	1	0	29966749	PMID:29966749; Original text:Additionally, we discuss the clinical significance of the The blood-brain barrier in diagnosis (genetic markers, dynamic contrast-enhanced-magnetic resonance imaging, and blood biomarkers) and in treatment (drug delivery).
, and	anatomy	brain barrier	1	0	29966749	PMID:29966749; Original text:Additionally, we discuss the clinical significance of the The blood-brain barrier in diagnosis (genetic markers, dynamic contrast-enhanced-magnetic resonance imaging, and blood biomarkers) and in treatment (drug delivery).
blood-brain barrier	anatomy	of the	1	0	29966749	PMID:29966749; Original text:Additionally, we discuss the clinical significance of the The blood-brain barrier in diagnosis (genetic markers, dynamic contrast-enhanced-magnetic resonance imaging, and blood biomarkers) and in treatment (drug delivery).
, and	anatomy	blood-brain barrier	1	0	29966749	PMID:29966749; Original text:Additionally, we discuss the clinical significance of the The blood-brain barrier in diagnosis (genetic markers, dynamic contrast-enhanced-magnetic resonance imaging, and blood biomarkers) and in treatment (drug delivery).
methionine	chemical	sah	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sah	chemical	sam	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
methionine	chemical	sam	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sah	disease	sam	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
, and	anatomy	levels of	6	0	32173856|29298441|22070180|26290524|32305492|24246273	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).|PMID:29298441; Original text:Plasma levels of growth factor-β1 significantly increased to 85% immediately after auditory integrative training (20.13 ± 12 ng/mL, p < 0.05), to 95% 1 month after auditory integrative training (21.2 ± 11 ng/mL, p < 0.01), and to 105% 3 months after auditory integrative training (22.25 ± 16 ng/mL, p < 0.01) compared to before auditory integrative training (10.85 ± 8 ng/mL).|PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).|PMID:26290524; Original text:Families in caregiver-mediated module reported lower levels of treatment adherence, which was significantly predicted by site, condition, caregiver stress, and child nonverbal intelligence quotient.|PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
sah	chemical_to_disease	sah	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sah	chemical_to_disease	sam	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
methionine	chemical_to_disease	sah	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
methionine	chemical_to_disease	sam	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sam	chemical_to_disease	sah	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sam	chemical_to_disease	sam	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sah	chemical_to_anatomy	levels of	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sah	chemical_to_anatomy	, and	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
methionine	chemical_to_anatomy	levels of	2	0	32173856|24676906	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).|PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
sam	chemical_to_anatomy	levels of	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sam	chemical_to_anatomy	, and	2	0	32173856|22151477	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).|PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
sah	disease_to_anatomy	levels of	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sah	disease_to_anatomy	, and	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sam	disease_to_anatomy	levels of	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sam	disease_to_anatomy	, and	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
autism	disease_to_mechanism	beta-casomorphin	1	0	31813108	PMID:31813108; Original text:A 6-month GFCF diet do not induce significant changes in behavioral symptoms of autism and urinary beta-casomorphin concentrations.
autism	disease	fever	1	0	33720503	PMID:33720503; Original text:Analyses demonstrated a statistically significant association of maternal infection/fever with autism in offspring (OR = 1.32; 95% CI = 1.20-1.46).
fever	disease	infection	1	0	33720503	PMID:33720503; Original text:Analyses demonstrated a statistically significant association of maternal infection/fever with autism in offspring (OR = 1.32; 95% CI = 1.20-1.46).
autism	disease	infection	2	0	33720503|33720503	PMID:33720503; Original text:Analyses demonstrated a statistically significant association of maternal infection/fever with autism in offspring (OR = 1.32; 95% CI = 1.20-1.46).|PMID:33720503; Original text:This study is a meta-analysis of the association of maternal infection during pregnancy and subsequent autism in offspring.
infection	disease_to_anatomy	of the	1	0	33720503	PMID:33720503; Original text:This study is a meta-analysis of the association of maternal infection during pregnancy and subsequent autism in offspring.
depression	disease	psychiatric disorders	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
depression	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
cancer	disease	depression	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
depression	disease	schizophrenia	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bipolar disorder	disease	depression	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
autism spectrum disorders	disease	depression	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
psychiatric disorders	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
cancer	disease	psychiatric disorders	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
cancer	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
schizophrenia	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bipolar disorder	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
autism spectrum disorders	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
cancer	disease	schizophrenia	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bipolar disorder	disease	cancer	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
autism spectrum disorders	disease	cancer	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
, a	anatomy	group of	2	0	27748930|12535477	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.|PMID:12535477; Original text:Study interventions had a significant focus on parent-implemented early intervention, compared to a group of children who received no treatment, a waiting list group or a different form of intervention.
depression	disease_to_anatomy	, a	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
depression	disease_to_anatomy	group of	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
psychiatric disorders	disease_to_anatomy	, a	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
psychiatric disorders	disease_to_anatomy	group of	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
suicidality	disease_to_anatomy	, a	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
suicidality	disease_to_anatomy	group of	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
cancer	disease_to_anatomy	, a	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
cancer	disease_to_anatomy	group of	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
schizophrenia	disease_to_anatomy	, a	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
schizophrenia	disease_to_anatomy	group of	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bipolar disorder	disease_to_anatomy	, a	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bipolar disorder	disease_to_anatomy	group of	2	0	27748930|26276916	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.|PMID:26276916; Original text:Previous studies have clearly indicated that in the group of patients with an early onset of the bipolar disorder the occurrence of suicidal thoughts and intentions were significantly increased.
autism spectrum disorders	disease_to_anatomy	, a	2	0	27748930|31665947	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.|PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism spectrum disorders	disease_to_anatomy	group of	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
serotonin	chemical	serotoninp	2	0	15733932|15733932	PMID:15733932; Original text:serotoninP administration significantly increased the levels of serotonin in autistic youngsters but not in normal controls.|PMID:15733932; Original text:Following serotoninP challenge the serotonin levels were significantly higher in autistic patients than in healthy volunteers.
serotoninp	chemical_to_disease	autistic	2	0	15733932|15733932	PMID:15733932; Original text:serotoninP administration significantly increased the levels of serotonin in autistic youngsters but not in normal controls.|PMID:15733932; Original text:Following serotoninP challenge the serotonin levels were significantly higher in autistic patients than in healthy volunteers.
serotoninp	chemical_to_anatomy	levels of	1	0	15733932	PMID:15733932; Original text:serotoninP administration significantly increased the levels of serotonin in autistic youngsters but not in normal controls.
serotonin	chemical_to_anatomy	levels of	3	0	15733932|32305492|26746121	PMID:15733932; Original text:serotoninP administration significantly increased the levels of serotonin in autistic youngsters but not in normal controls.|PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
autistic	disease_to_anatomy	levels of	5	0	15733932|24676906|24167375|15673999|34049201	PMID:15733932; Original text:serotoninP administration significantly increased the levels of serotonin in autistic youngsters but not in normal controls.|PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.|PMID:24167375; Original text:The urinary levels of homocysteine and essential amino acids in both the untreated and treated autistic children are significantly less than those in the controls.|PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).|PMID:34049201; Original text:There were significant differences in the levels of copper (copper) in the hair and serum between autistic children and the control group.
inherited	disease	neurologically	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
neurological deterioration	disease	neurologically	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
metabolic diseases	disease	neurologically	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
inherited	disease	neurological deterioration	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
inherited	disease	metabolic diseases	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
metabolic diseases	disease	neurological deterioration	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
hematopoietic stem	anatomy	stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
hematopoietic stem	anatomy	hematopoietic stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
hematopoietic stem	anatomy	transplantation	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
hematopoietic stem cell	anatomy	stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
stem cell	anatomy	transplantation	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
hematopoietic stem cell	anatomy	transplantation	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
neurologically	disease_to_anatomy	hematopoietic stem	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
neurologically	disease_to_anatomy	stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
neurologically	disease_to_anatomy	hematopoietic stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
neurologically	disease_to_anatomy	transplantation	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
inherited	disease_to_anatomy	hematopoietic stem	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
inherited	disease_to_anatomy	stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
inherited	disease_to_anatomy	hematopoietic stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
inherited	disease_to_anatomy	transplantation	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
neurological deterioration	disease_to_anatomy	hematopoietic stem	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
neurological deterioration	disease_to_anatomy	stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
neurological deterioration	disease_to_anatomy	hematopoietic stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
neurological deterioration	disease_to_anatomy	transplantation	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
metabolic diseases	disease_to_anatomy	hematopoietic stem	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
metabolic diseases	disease_to_anatomy	stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
metabolic diseases	disease_to_anatomy	hematopoietic stem cell	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
metabolic diseases	disease_to_anatomy	transplantation	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
apraxia of speech	disease	autism	1	0	22450249	PMID:22450249; Original text:Autism, childhood apraxia of speech and central auditory processing disorder are associated with significant disability.
auditory processing disorder	disease	autism	1	0	22450249	PMID:22450249; Original text:Autism, childhood apraxia of speech and central auditory processing disorder are associated with significant disability.
apraxia of speech	disease	auditory processing disorder	1	0	22450249	PMID:22450249; Original text:Autism, childhood apraxia of speech and central auditory processing disorder are associated with significant disability.
autism	disease	autism spectrum disorder	3	0	26577969|28934215|23782128	PMID:26577969; Original text:Significant differences were detected on Autism Spectrum Disorder (Autism Spectrum Disorder) by Childhood Autism Rating Scale, Social Responsiveness Scale and Autism Treatment Evaluation Checklist scales, following 2 weeks of camel milk consumption, but not in the placebo group.|PMID:28934215; Original text:No changes were observed for meeting the autism spectrum disorder criteria over time (risk difference [RD] = -0.01, 95% CI -0.03 to 0.01), but a significant change for meeting autism criteria over time (RD = -0.18, 95% CI -0.29 to -0.07).|PMID:23782128; Original text:(DSM-IV-TR) criteria for an autism spectrum disorder (disorder) on the Autism Diagnostic Interview-Revised (-Revised) and the Autism Diagnostic Observation Schedule (the Autism Diagnostic Observation Schedule), and had significant symptoms of attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder).
scale	anatomy	scales	1	0	26577969	PMID:26577969; Original text:Significant differences were detected on Autism Spectrum Disorder (Autism Spectrum Disorder) by Childhood Autism Rating Scale, Social Responsiveness Scale and Autism Treatment Evaluation Checklist scales, following 2 weeks of camel milk consumption, but not in the placebo group.
autism	disease_to_anatomy	scales	1	0	26577969	PMID:26577969; Original text:Significant differences were detected on Autism Spectrum Disorder (Autism Spectrum Disorder) by Childhood Autism Rating Scale, Social Responsiveness Scale and Autism Treatment Evaluation Checklist scales, following 2 weeks of camel milk consumption, but not in the placebo group.
autism	disease_to_anatomy	scale	3	0	26577969|26258842|27752075	PMID:26577969; Original text:Significant differences were detected on Autism Spectrum Disorder (Autism Spectrum Disorder) by Childhood Autism Rating Scale, Social Responsiveness Scale and Autism Treatment Evaluation Checklist scales, following 2 weeks of camel milk consumption, but not in the placebo group.|PMID:26258842; Original text:Prior to intervention(s) no statistically significant differences in scores on the the Autism Behavior Checklist, the Childhood Autism Rating Scale, disease, or global improvement were found between the two groups.|PMID:27752075; Original text:Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group.
autism spectrum disorder	disease_to_anatomy	scales	1	0	26577969	PMID:26577969; Original text:Significant differences were detected on Autism Spectrum Disorder (Autism Spectrum Disorder) by Childhood Autism Rating Scale, Social Responsiveness Scale and Autism Treatment Evaluation Checklist scales, following 2 weeks of camel milk consumption, but not in the placebo group.
autism spectrum disorder	disease_to_anatomy	scale	1	0	26577969	PMID:26577969; Original text:Significant differences were detected on Autism Spectrum Disorder (Autism Spectrum Disorder) by Childhood Autism Rating Scale, Social Responsiveness Scale and Autism Treatment Evaluation Checklist scales, following 2 weeks of camel milk consumption, but not in the placebo group.
amino acid	chemical	tryptophan	1	0	8911222	PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).
tryptophan	chemical_to_anatomy	of the	2	0	8911222|28799778	PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).|PMID:28799778; Original text:The literature strongly suggests that Tryptophan has a significant role in the correct functionality of the brain-gut axis and immunology.
tryptophan	chemical_to_anatomy	(p	3	0	8911222|8911222|26746121	PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).|PMID:8911222; Original text:Tryptophan depletion led to a significant increase in behaviors such as whirling, flapping, pacing, banging and hitting self, rocking, and toe walking (P < .05).|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
amino acid	chemical_to_anatomy	of the	1	0	8911222	PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).
amino acid	chemical_to_anatomy	(p	1	0	8911222	PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).
tryptophan	chemical_to_anatomy	, and	1	0	8911222	PMID:8911222; Original text:Tryptophan depletion led to a significant increase in behaviors such as whirling, flapping, pacing, banging and hitting self, rocking, and toe walking (P < .05).
atomoxetine	chemical_to_anatomy	, mixed	1	0	22721596	PMID:22721596; Original text:Baseline mean disorder-RS scores for atomoxetine versus placebo were 40.7 and 38.6; after 8 weeks, mixed-effect model repeated-measure means were 31.6 (95% confidence interval 29.2-33.9) and 38.3 (36.0-40.6), respectively, with a difference in least square means of -6.7
(primary	anatomy	group	2	0	23212807|32347624	PMID:23212807; Original text:Mean baseline (range 27-29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose-(-12.4 [6.5]; p < 0.001), but not low-dose (-7.4 [8.1]; p = 0.164) group, versus placebo (-3.5 [10.7]).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
irritability	disease_to_anatomy	group	3	0	23212807|32347624|19284641	PMID:23212807; Original text:Mean baseline (range 27-29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose-(-12.4 [6.5]; p < 0.001), but not low-dose (-7.4 [8.1]; p = 0.164) group, versus placebo (-3.5 [10.7]).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:19284641; Original text:In the tre1.3 atmosphereent group compared to the control group, mean changes on the Aberrant Behavior Checklist total score and subscales were similar except a greater number of children improved in irritability (p = 0.0311).
autistic traits	disease	behavioral addiction	1	0	34325098	PMID:34325098; Original text:Results included 27 studies that found a positive correlation (15 of significance, 12 of unknown significance) between a behavioral addiction and either disorder or Autistic traits, 1 found a significant negative correlation, 3 did not find a correlation.
, 1	anatomy	, 3	1	0	34325098	PMID:34325098; Original text:Results included 27 studies that found a positive correlation (15 of significance, 12 of unknown significance) between a behavioral addiction and either disorder or Autistic traits, 1 found a significant negative correlation, 3 did not find a correlation.
autistic traits	disease_to_anatomy	, 3	1	0	34325098	PMID:34325098; Original text:Results included 27 studies that found a positive correlation (15 of significance, 12 of unknown significance) between a behavioral addiction and either disorder or Autistic traits, 1 found a significant negative correlation, 3 did not find a correlation.
autistic traits	disease_to_anatomy	, 1	1	0	34325098	PMID:34325098; Original text:Results included 27 studies that found a positive correlation (15 of significance, 12 of unknown significance) between a behavioral addiction and either disorder or Autistic traits, 1 found a significant negative correlation, 3 did not find a correlation.
behavioral addiction	disease_to_anatomy	, 3	1	0	34325098	PMID:34325098; Original text:Results included 27 studies that found a positive correlation (15 of significance, 12 of unknown significance) between a behavioral addiction and either disorder or Autistic traits, 1 found a significant negative correlation, 3 did not find a correlation.
behavioral addiction	disease_to_anatomy	, 1	1	0	34325098	PMID:34325098; Original text:Results included 27 studies that found a positive correlation (15 of significance, 12 of unknown significance) between a behavioral addiction and either disorder or Autistic traits, 1 found a significant negative correlation, 3 did not find a correlation.
asd	disease	memory	1	0	28102493	PMID:28102493; Original text:A significant working memory impairment (Cohen's d = -0.61) was identified in the individuals with ASD, however, this impairment was not associated with age.
, post	anatomy	group (	1	0	15935993	PMID:15935993; Original text:Analysis of variance of magnetic resonance imaging and post-mortem %Diff values by age group (young child, older child, adult) and measurement type (magnetic resonance imaging, post-mortem brain weight) revealed a significant main effect of both age and measurement type, with the youngest ages (the youngest ages) showing the greatest deviation from normal.
, adult	anatomy	group (	1	0	15935993	PMID:15935993; Original text:Analysis of variance of magnetic resonance imaging and post-mortem %Diff values by age group (young child, older child, adult) and measurement type (magnetic resonance imaging, post-mortem brain weight) revealed a significant main effect of both age and measurement type, with the youngest ages (the youngest ages) showing the greatest deviation from normal.
, adult	anatomy	, post	1	0	15935993	PMID:15935993; Original text:Analysis of variance of magnetic resonance imaging and post-mortem %Diff values by age group (young child, older child, adult) and measurement type (magnetic resonance imaging, post-mortem brain weight) revealed a significant main effect of both age and measurement type, with the youngest ages (the youngest ages) showing the greatest deviation from normal.
dha	chemical	epa	3	0	28379964|28218722|29562612	PMID:28379964; Original text:In the ω-3 supplementation group, higher baseline body weight predicted less plasma accumulation of both EPA [B = -0.047, (95% CI = -0.077; -0.017), β = -0.54, p = 0.003] and DHA [B = -0.02, (95% CI = -0.034; -0.007), β = -0.52, p = 0.004].|PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).|PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
epa	chemical_to_anatomy	group	1	0	28379964	PMID:28379964; Original text:In the ω-3 supplementation group, higher baseline body weight predicted less plasma accumulation of both EPA [B = -0.047, (95% CI = -0.077; -0.017), β = -0.54, p = 0.003] and DHA [B = -0.02, (95% CI = -0.034; -0.007), β = -0.52, p = 0.004].
dha	chemical_to_anatomy	group	1	0	28379964	PMID:28379964; Original text:In the ω-3 supplementation group, higher baseline body weight predicted less plasma accumulation of both EPA [B = -0.047, (95% CI = -0.077; -0.017), β = -0.54, p = 0.003] and DHA [B = -0.02, (95% CI = -0.034; -0.007), β = -0.52, p = 0.004].
developmental disorders	disease_to_anatomy	groups	1	0	31501953	PMID:31501953; Original text:Compared with developmental disorders (developmental disorders) groups, effect size was significantly positive for sensory over-responsivity and Seeking; whereas compared with other clinical groups, only sensory over-responsivity was significant.
anhedonia	disease	irritability	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
irritability	disease	somatic complaints	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
anhedonia	disease	depression	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
depression	disease	somatic complaints	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
anhedonia	disease	somatic complaints	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
, and	anatomy	, somatic	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
irritability	disease_to_anatomy	, somatic	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
depression	disease_to_anatomy	, somatic	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
anhedonia	disease_to_anatomy	, and	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
anhedonia	disease_to_anatomy	, somatic	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
somatic complaints	disease_to_anatomy	, and	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
somatic complaints	disease_to_anatomy	, somatic	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
area (	anatomy	inferior frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
area (	anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
area (	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate cortex	anatomy	area (	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate	anatomy	area (	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
area (	anatomy	frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
area (	anatomy	cortex)	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
area (	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
area (	anatomy	cingulate cortex	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
area (	anatomy	cortex (	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
area (	anatomy	inferior frontal	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
inferior frontal gyrus	anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
inferior frontal gyrus	anatomy	of the	2	0	26994483|25817280	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
inferior frontal gyrus	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate cortex	anatomy	inferior frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate	anatomy	inferior frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
frontal gyrus	anatomy	inferior frontal gyrus	3	0	26994483|29517857|25817280	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:29517857; Original text:Second, the left inferior frontal gyrus, a region for socio-emotional processing, tracked individual gains in emotion recognition with decreased activation to social versus nonsocial stimuli.|PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
cortex)	anatomy	inferior frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
inferior frontal gyrus	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cingulate cortex	anatomy	inferior frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex (	anatomy	inferior frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
inferior frontal	anatomy	inferior frontal gyrus	3	0	26994483|29517857|25817280	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:29517857; Original text:Second, the left inferior frontal gyrus, a region for socio-emotional processing, tracked individual gains in emotion recognition with decreased activation to social versus nonsocial stimuli.|PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
motor area	anatomy	of the	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
motor area	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate cortex	anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate	anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
frontal gyrus	anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex)	anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
motor area	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cingulate cortex	anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex (	anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
inferior frontal	anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
of the	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate cortex	anatomy	of the	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate	anatomy	of the	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
frontal gyrus	anatomy	of the	2	0	26994483|25817280	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
cortex)	anatomy	of the	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
of the	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cingulate cortex	anatomy	of the	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex (	anatomy	of the	2	0	26994483|14561452	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
anterior cingulate cortex	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
frontal gyrus	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex)	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
supplementary motor	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cingulate cortex	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex (	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
inferior frontal	anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate	anatomy	anterior cingulate cortex	6	0	26994483|22848344|22848344|26336909|26769980|22426803	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).|PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate cortex	anatomy	frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate cortex	anatomy	cortex)	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate cortex	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate cortex	anatomy	cingulate cortex	6	0	26994483|22848344|22848344|26336909|26769980|22426803	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).|PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate cortex	anatomy	cortex (	2	0	26994483|26336909	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
anterior cingulate cortex	anatomy	inferior frontal	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate	anatomy	frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate	anatomy	cortex)	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
anterior cingulate	anatomy	cingulate cortex	6	0	26994483|22848344|22848344|26336909|26769980|22426803	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).|PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate	anatomy	cortex (	2	0	26994483|26336909	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
anterior cingulate	anatomy	inferior frontal	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex)	anatomy	frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
frontal gyrus	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cingulate cortex	anatomy	frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex (	anatomy	frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
frontal gyrus	anatomy	inferior frontal	3	0	26994483|29517857|25817280	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:29517857; Original text:Second, the left inferior frontal gyrus, a region for socio-emotional processing, tracked individual gains in emotion recognition with decreased activation to social versus nonsocial stimuli.|PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
cortex)	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cingulate cortex	anatomy	cortex)	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex (	anatomy	cortex)	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex)	anatomy	inferior frontal	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cingulate cortex	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex (	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
inferior frontal	anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cingulate cortex	anatomy	cortex (	3	0	26994483|25292351|26336909	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.|PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
cingulate cortex	anatomy	inferior frontal	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
cortex (	anatomy	inferior frontal	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	area (	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	inferior frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	of the	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	anterior cingulate cortex	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	anterior cingulate	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	cortex)	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	cingulate cortex	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	cortex (	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	inferior frontal	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
catatonic	disease	declines in motor movements	1	0	16697293	PMID:16697293; Original text:Clinicians might also need to assess for signs of significant declines in motor movements, as this appears to be a useful diagnostic indicator of catatonic-like symptoms.
adhd	disease	disorder(asd	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
autism spectrum	disease	disorder(asd	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
attention-deficit/hyperactivity disorder	disease	disorder(asd	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
adhd	disease	autism spectrum	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
adhd	disease	attention-deficit/hyperactivity disorder	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
attention-deficit/hyperactivity disorder	disease	autism spectrum	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
fra(x)	mechanism	fra(x) males	1	0	3513570	PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.
autism	disease_to_mechanism	fra(x)	1	0	3513570	PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.
autism	disease_to_mechanism	fra(x) males	1	0	3513570	PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.
autistic	disease_to_mechanism	fra(x)	1	0	3513570	PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.
autistic	disease_to_mechanism	fra(x) males	1	0	3513570	PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.
mercury	chemical_to_anatomy	of the	1	0	19106436	PMID:19106436; Original text:In conclusion, the overwhelming preponderance of the evidence favours acceptance that mercury exposure is capable of causing some disorders.
asperger's disorder	disease_to_anatomy	of the	1	0	14959806	PMID:14959806; Original text:More consistent approaches to diagnosis and more rigorous assessment methods have significantly advanced research, although the boundaries of the 'broader phenotype' remain to be defined and the validity of Asperger's disorder as a discrete syndrome remains controversial.
autism	disease	language delay	1	0	25346345	PMID:25346345; Original text:Fifty-three children with autism and significant language delay between 2 and 6 years old were randomized to Pivotal Response TreatmentG (N = 27) or psychoeducation group (PEG;
autism	disease_to_anatomy	group (	3	0	25346345|16948927|8986845	PMID:25346345; Original text:Fifty-three children with autism and significant language delay between 2 and 6 years old were randomized to Pivotal Response TreatmentG (N = 27) or psychoeducation group (PEG;|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).|PMID:8986845; Original text:13 (76%) of the Asperger syndrome patients were rated as pedantic compared to 4 (31%) of the high-functioning autism group (chi 2 = 6.3; p = .01).
language delay	disease_to_anatomy	group (	1	0	25346345	PMID:25346345; Original text:Fifty-three children with autism and significant language delay between 2 and 6 years old were randomized to Pivotal Response TreatmentG (N = 27) or psychoeducation group (PEG;
autistic	disease	seizure	1	0	7854533	PMID:7854533; Original text:Measures of these structures in autistic patients and normal healthy volunteers differed nonsignificantly, by less than 1.4%, regardless of whether or not the autistic patients were retarded or had a history of seizure episodes.
of the	anatomy	portion of	1	0	7854533	PMID:7854533; Original text:By contrast, measures of vermian lobules VI and VII and the posterior portion of the corpus callosum in these same autistic and normal volunteers differed significantly, by more than 9.9%.
of the	anatomy	portion of the	1	0	7854533	PMID:7854533; Original text:By contrast, measures of vermian lobules VI and VII and the posterior portion of the corpus callosum in these same autistic and normal volunteers differed significantly, by more than 9.9%.
portion of	anatomy	portion of the	1	0	7854533	PMID:7854533; Original text:By contrast, measures of vermian lobules VI and VII and the posterior portion of the corpus callosum in these same autistic and normal volunteers differed significantly, by more than 9.9%.
corpus callosum	anatomy	portion of	1	0	7854533	PMID:7854533; Original text:By contrast, measures of vermian lobules VI and VII and the posterior portion of the corpus callosum in these same autistic and normal volunteers differed significantly, by more than 9.9%.
corpus callosum	anatomy	portion of the	1	0	7854533	PMID:7854533; Original text:By contrast, measures of vermian lobules VI and VII and the posterior portion of the corpus callosum in these same autistic and normal volunteers differed significantly, by more than 9.9%.
autistic	disease_to_anatomy	portion of	1	0	7854533	PMID:7854533; Original text:By contrast, measures of vermian lobules VI and VII and the posterior portion of the corpus callosum in these same autistic and normal volunteers differed significantly, by more than 9.9%.
autistic	disease_to_anatomy	portion of the	1	0	7854533	PMID:7854533; Original text:By contrast, measures of vermian lobules VI and VII and the posterior portion of the corpus callosum in these same autistic and normal volunteers differed significantly, by more than 9.9%.
autistic	disease_to_anatomy	corpus callosum	1	0	7854533	PMID:7854533; Original text:By contrast, measures of vermian lobules VI and VII and the posterior portion of the corpus callosum in these same autistic and normal volunteers differed significantly, by more than 9.9%.
arsenic	chemical	cadmium	1	0	28716727	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.
cadmium	chemical	mercury	1	0	28716727	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.
arsenic	chemical	mercury	1	0	28716727	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.
cadmium	chemical_to_anatomy	, and	1	0	28716727	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.
arsenic	chemical_to_anatomy	, and	1	0	28716727	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.
mercury	chemical_to_anatomy	, and	2	0	28716727|28965590	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.|PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
bipolar disorder	disease	suicidal thoughts	1	0	26276916	PMID:26276916; Original text:Previous studies have clearly indicated that in the group of patients with an early onset of the bipolar disorder the occurrence of suicidal thoughts and intentions were significantly increased.
group of	anatomy	of the	2	0	26276916|22650115	PMID:26276916; Original text:Previous studies have clearly indicated that in the group of patients with an early onset of the bipolar disorder the occurrence of suicidal thoughts and intentions were significantly increased.|PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
bipolar disorder	disease_to_anatomy	of the	1	0	26276916	PMID:26276916; Original text:Previous studies have clearly indicated that in the group of patients with an early onset of the bipolar disorder the occurrence of suicidal thoughts and intentions were significantly increased.
suicidal thoughts	disease_to_anatomy	of the	1	0	26276916	PMID:26276916; Original text:Previous studies have clearly indicated that in the group of patients with an early onset of the bipolar disorder the occurrence of suicidal thoughts and intentions were significantly increased.
suicidal thoughts	disease_to_anatomy	group of	1	0	26276916	PMID:26276916; Original text:Previous studies have clearly indicated that in the group of patients with an early onset of the bipolar disorder the occurrence of suicidal thoughts and intentions were significantly increased.
group	anatomy	group (	3	0	24839884|26889605|16948927	PMID:24839884; Original text:Children in the omega-3 fatty acid group had a greater reduction in hyperactivity (-5.3 points) compared to the placebo group (-2.6 points), but the difference was not statistically significant (1.9-point greater improvement in the omega-3 group, 95% CI = -2.2 to 5.2).|PMID:26889605; Original text:The primary outcome measure - the clinician rated the Clinical Global Impressions-Improvement score - was statistically significantly better (lower) in the methyl B12 group (2.4) than in the placebo group (3.1) (0.7 greater improvement in the methyl B12 group, 95% CI 1.2-0.2, p = 0.005).|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
hyperactivity	disease_to_anatomy	group (	1	0	24839884	PMID:24839884; Original text:Children in the omega-3 fatty acid group had a greater reduction in hyperactivity (-5.3 points) compared to the placebo group (-2.6 points), but the difference was not statistically significant (1.9-point greater improvement in the omega-3 group, 95% CI = -2.2 to 5.2).
hyperactivity	disease_to_anatomy	group	2	0	24839884|32347624	PMID:24839884; Original text:Children in the omega-3 fatty acid group had a greater reduction in hyperactivity (-5.3 points) compared to the placebo group (-2.6 points), but the difference was not statistically significant (1.9-point greater improvement in the omega-3 group, 95% CI = -2.2 to 5.2).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
areas of	anatomy	of the	1	0	32567574	PMID:32567574; Original text:The elective areas of the individual plan have to deal on how to reach autonomy in daily living and related skills, obtaining and maintaining a job, as well as starting and reinforcing significant relationships.
autism spectrum disorder	disease	obesity	1	0	34520698	PMID:34520698; Original text:Obesity represents a significant threat to quality of life and overall health for typically and a typically developing children with those diagnosed with Autism Spectrum Disorder (Autism Spectrum Disorder) having obesity prevalence at least as high as their typically developing counterparts.
asd	disease	depressive disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
bipolar disorder	disease	depressive disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
depressive disorder	disease	obsessive compulsive disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
asd	disease	bipolar disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
asd	disease	obsessive compulsive disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
bipolar disorder	disease	obsessive compulsive disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
, and	anatomy	, major	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
depressive disorder	disease_to_anatomy	, and	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
depressive disorder	disease_to_anatomy	, major	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
asd	disease_to_anatomy	, major	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
bipolar disorder	disease_to_anatomy	, and	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
bipolar disorder	disease_to_anatomy	, major	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
obsessive compulsive disorder	disease_to_anatomy	, and	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
obsessive compulsive disorder	disease_to_anatomy	, major	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
, and	anatomy	scale	6	0	26258842|25313065|15930063|34257640|27278054|12585724	PMID:26258842; Original text:Total scores of the the Autism Behavior Checklist, the Childhood Autism Rating Scale, and disease were decreased in both groups after 3 months (p<0.05) compared with the scores prior to treatment.|PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).|PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).|PMID:34257640; Original text:A within-group comparison showed that real transcranial direct current stimulation, but not sham transcranial direct current stimulation, can significantly reduce the scores of Scale, Children's Sleep Habits Questionnaire (Children's Sleep Habits Questionnaire), and general impressions in Scale (15th item).|PMID:27278054; Original text:Both groups showed a significant improvement in attention-deficit/hyperactivity disorder symptoms after 24 weeks of treatment (attention-deficit/hyperactivity disorder Rating Scale, Conners Parent Rating Scale-Hyperactivity, and Clinical Global Improvement-Severity Scale).|PMID:12585724; Original text:Outcome measures were the Childhood Autism Rating Scale, the Gilliam Autism Rating Scale, the Expressive and Receptive One-Word Picture Vocabulary tests, and Clinical Global Impressions of Change.
foxp3+domain-3+	mechanism	il-17+domain-3+	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
ifn-γ+domain-3+	mechanism	il-17+domain-3+	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
foxp3+domain-3+	mechanism	ifn-γ+domain-3+	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
il-17+domain-3+	mechanism_to_anatomy	, and	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
foxp3+domain-3+	mechanism_to_anatomy	, and	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
ifn-γ+domain-3+	mechanism_to_anatomy	, and	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
clomipramine	chemical	haloperidol	1	0	11476129	PMID:11476129; Original text:However, significantly fewer individuals receiving clomipramine versus haloperidol were able to complete the trial (37.5% vs. 69.7%, respectively) for reasons related to both side effects and efficacy or behavior problems.
asperger syndrome	disease	autism	2	0	20162344|8986845	PMID:20162344; Original text:Across 27 students age 11-14 with a high functioning autism/Asperger Syndrome diagnosis, results indicated significant improvement on parent reports of social skills and executive functioning.|PMID:8986845; Original text:13 (76%) of the Asperger syndrome patients were rated as pedantic compared to 4 (31%) of the high-functioning autism group (chi 2 = 6.3; p = .01).
attention	disease	depressive	1	0	23503544	PMID:23503544; Original text:Significant, but modest, decreases in the severity of depressive symptoms (CDRS before vs after scores: 65.5 ± 10.8 vs 58.3 ± 8.2; paired t test, 3.1; df, 10; P =0.01) and attention-deficit/hyperactivity disorder symptoms (Attention Deficit/Hyperactivity Disorder Rating Scale before vs after: 36.4 ± 5 vs 32.8 ± 5; paired-t test, 2.94; df, 10; P = 0.015) were obtained after reboxetine treatment.
reboxetine	chemical_to_disease	depressive	1	0	23503544	PMID:23503544; Original text:Significant, but modest, decreases in the severity of depressive symptoms (CDRS before vs after scores: 65.5 ± 10.8 vs 58.3 ± 8.2; paired t test, 3.1; df, 10; P =0.01) and attention-deficit/hyperactivity disorder symptoms (Attention Deficit/Hyperactivity Disorder Rating Scale before vs after: 36.4 ± 5 vs 32.8 ± 5; paired-t test, 2.94; df, 10; P = 0.015) were obtained after reboxetine treatment.
reboxetine	chemical_to_disease	attention	1	0	23503544	PMID:23503544; Original text:Significant, but modest, decreases in the severity of depressive symptoms (CDRS before vs after scores: 65.5 ± 10.8 vs 58.3 ± 8.2; paired t test, 3.1; df, 10; P =0.01) and attention-deficit/hyperactivity disorder symptoms (Attention Deficit/Hyperactivity Disorder Rating Scale before vs after: 36.4 ± 5 vs 32.8 ± 5; paired-t test, 2.94; df, 10; P = 0.015) were obtained after reboxetine treatment.
reboxetine	chemical_to_anatomy	test	1	0	23503544	PMID:23503544; Original text:Significant, but modest, decreases in the severity of depressive symptoms (CDRS before vs after scores: 65.5 ± 10.8 vs 58.3 ± 8.2; paired t test, 3.1; df, 10; P =0.01) and attention-deficit/hyperactivity disorder symptoms (Attention Deficit/Hyperactivity Disorder Rating Scale before vs after: 36.4 ± 5 vs 32.8 ± 5; paired-t test, 2.94; df, 10; P = 0.015) were obtained after reboxetine treatment.
depressive	disease_to_anatomy	test	1	0	23503544	PMID:23503544; Original text:Significant, but modest, decreases in the severity of depressive symptoms (CDRS before vs after scores: 65.5 ± 10.8 vs 58.3 ± 8.2; paired t test, 3.1; df, 10; P =0.01) and attention-deficit/hyperactivity disorder symptoms (Attention Deficit/Hyperactivity Disorder Rating Scale before vs after: 36.4 ± 5 vs 32.8 ± 5; paired-t test, 2.94; df, 10; P = 0.015) were obtained after reboxetine treatment.
attention	disease_to_anatomy	test	1	0	23503544	PMID:23503544; Original text:Significant, but modest, decreases in the severity of depressive symptoms (CDRS before vs after scores: 65.5 ± 10.8 vs 58.3 ± 8.2; paired t test, 3.1; df, 10; P =0.01) and attention-deficit/hyperactivity disorder symptoms (Attention Deficit/Hyperactivity Disorder Rating Scale before vs after: 36.4 ± 5 vs 32.8 ± 5; paired-t test, 2.94; df, 10; P = 0.015) were obtained after reboxetine treatment.
attention-deficit/hyperactivity disorder	disease	depression	1	0	23503544	PMID:23503544; Original text:A significant positive correlation was found between the changes in the total scores of the depression and the attention-deficit/hyperactivity disorder severity (Spearman correlation r = 0.65
depression	disease_to_anatomy	of the	2	0	23503544|24408892	PMID:23503544; Original text:A significant positive correlation was found between the changes in the total scores of the depression and the attention-deficit/hyperactivity disorder severity (Spearman correlation r = 0.65|PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).
neurological abnormalities	disease_to_anatomy	of the	1	0	21842186	PMID:21842186; Original text:Population heterogeneity and practical limitations inherent to the study of children currently limit a comprehensive understanding of the significance of specific neurological abnormalities in relation to observed deficits.
cerebellum	anatomy	of cerebellum	1	0	22370873	PMID:22370873; Original text:There has been significant advancement in various aspects of scientific knowledge concerning the role of cerebellum in the etiopathogenesis of autism.
autism	disease_to_anatomy	cerebellum	1	0	22370873	PMID:22370873; Original text:There has been significant advancement in various aspects of scientific knowledge concerning the role of cerebellum in the etiopathogenesis of autism.
autism	disease_to_anatomy	of cerebellum	1	0	22370873	PMID:22370873; Original text:There has been significant advancement in various aspects of scientific knowledge concerning the role of cerebellum in the etiopathogenesis of autism.
n	disease	negative	1	0	16401163	PMID:16401163; Original text:We found a statistically significant improvement from baseline for last-observation-carried-forward (last-observation-carried-forward) analyses as well as for analyses of 12-week completers (N = 9) in our primary outcome measure, Negative Symptoms scores (F = 13.41, p < .0001 for 12-week completers; F = 9.64, p < .0001 for last-observation-carried-forward).
n	disease_to_anatomy	, negative	1	0	16401163	PMID:16401163; Original text:We found a statistically significant improvement from baseline for last-observation-carried-forward (last-observation-carried-forward) analyses as well as for analyses of 12-week completers (N = 9) in our primary outcome measure, Negative Symptoms scores (F = 13.41, p < .0001 for 12-week completers; F = 9.64, p < .0001 for last-observation-carried-forward).
negative	disease_to_anatomy	, negative	1	0	16401163	PMID:16401163; Original text:We found a statistically significant improvement from baseline for last-observation-carried-forward (last-observation-carried-forward) analyses as well as for analyses of 12-week completers (N = 9) in our primary outcome measure, Negative Symptoms scores (F = 13.41, p < .0001 for 12-week completers; F = 9.64, p < .0001 for last-observation-carried-forward).
methyl b12	chemical_to_anatomy	group (	1	0	26889605	PMID:26889605; Original text:The primary outcome measure - the clinician rated the Clinical Global Impressions-Improvement score - was statistically significantly better (lower) in the methyl B12 group (2.4) than in the placebo group (3.1) (0.7 greater improvement in the methyl B12 group, 95% CI 1.2-0.2, p = 0.005).
methyl b12	chemical_to_anatomy	group	1	0	26889605	PMID:26889605; Original text:The primary outcome measure - the clinician rated the Clinical Global Impressions-Improvement score - was statistically significantly better (lower) in the methyl B12 group (2.4) than in the placebo group (3.1) (0.7 greater improvement in the methyl B12 group, 95% CI 1.2-0.2, p = 0.005).
naltrexone	chemical_to_anatomy	, and	4	0	7654128|18439113|8282676|25336035	PMID:7654128; Original text:On the contrary, naltrexone increased the incidence of stereotypic behavior on the Aberrant Behavior Checklist, and the care staff evaluated the effect of the 50-mg/d treatment as being significantly worse than that of the placebo treatment as measured by the Clinical Global Impression Scale.|PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.|PMID:8282676; Original text:In the present study, naltrexone significantly reduced only hyperactivity, and no serious untoward effects were observed.|PMID:25336035; Original text:low-dose naltrexone improved pain tolerance as shown by a significant increase on Cold pressor times for post detoxification patients from 16 seconds to 55 seconds and in fibromyalgia patients from 21 seconds to 42 seconds, and improved relatedness.
language delay	disease	language or cognitive delay	1	0	21406158	"PMID:21406158; Original text:One approach to resolve this question has been to adopt the criterion of absence of clinically significant language or cognitive delay--essentially, the ""absence of language delay."""
autism spectrum disorder	disease	tooth decay	1	0	31931609	PMID:31931609; Original text:After a systematic search in the literature, we found that the salivary pH of individuals diagnosed with Autism Spectrum Disorder was significantly lower, but the results were not clinically significant that can increase their risks to tooth decay.
autism spectrum disorder	disease_to_anatomy	salivary	1	0	31931609	PMID:31931609; Original text:After a systematic search in the literature, we found that the salivary pH of individuals diagnosed with Autism Spectrum Disorder was significantly lower, but the results were not clinically significant that can increase their risks to tooth decay.
tooth decay	disease_to_anatomy	salivary	1	0	31931609	PMID:31931609; Original text:After a systematic search in the literature, we found that the salivary pH of individuals diagnosed with Autism Spectrum Disorder was significantly lower, but the results were not clinically significant that can increase their risks to tooth decay.
epilepsy	disease	sleep problems	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
epilepsy	disease	gastrointestinal conditions	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
gastrointestinal conditions	disease	sleep problems	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
, and	anatomy	of gastrointestinal	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
epilepsy	disease_to_anatomy	of gastrointestinal	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
sleep problems	disease_to_anatomy	of gastrointestinal	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
sleep problems	disease_to_anatomy	, and	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
gastrointestinal conditions	disease_to_anatomy	of gastrointestinal	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
gastrointestinal conditions	disease_to_anatomy	, and	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
catechol-	chemical	serotonin	1	0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
catechol-	chemical	o-methyl	1	0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
o-methyl	chemical	serotonin	1	0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
catechol-	chemical_to_disease	asd	1	0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
serotonin	chemical_to_disease	asd	4	0	28656683|22638012|22638012|32305492	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.|PMID:22638012; Original text:While some individuals with ASD have significant differences in the serotonin system, to our knowledge, no one has investigated its role during facial emotion processing in adults with ASD and control subjects using acute tryptophan depletion (acute tryptophan depletion) and functional magnetic resonance imaging.|PMID:22638012; Original text:Modulation of the processing of facial expressions of emotion by serotonin significantly differs in people with ASD compared with control subjects.|PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
o-methyl	chemical_to_disease	asd	1	0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
catechol-	chemical_to_mechanism	catechol-o-methyl transferase rs4680	1	0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
serotonin	chemical_to_mechanism	catechol-o-methyl transferase rs4680	1	0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
o-methyl	chemical_to_mechanism	catechol-o-methyl transferase rs4680	1	0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
asd	disease_to_mechanism	catechol-o-methyl transferase rs4680	1	0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
negative affect	disease_to_anatomy	, and	1	0	34195911	PMID:34195911; Original text:Observed supportive parent emotion socialization behaviors were significantly associated with more observed adaptive emotion regulation strategies, and decreased observed and adolescent-reported negative affect, whereas non-supportive emotion socialization behaviors were associated with more observed negative affect and less observed adaptive emotion regulation strategies.
autism spectrum disorders	disease	repetitive behaviours	1	0	15132762	PMID:15132762; Original text:Patients with autism spectrum disorders showed a significant increase in repetitive behaviours at end-point following oral m-CPP in comparison to placebo.
m-cpp	chemical_to_disease	repetitive behaviours	1	0	15132762	PMID:15132762; Original text:Patients with autism spectrum disorders showed a significant increase in repetitive behaviours at end-point following oral m-CPP in comparison to placebo.
m-cpp	chemical_to_disease	autism spectrum disorders	2	0	15132762|15132762	PMID:15132762; Original text:Patients with autism spectrum disorders showed a significant increase in repetitive behaviours at end-point following oral m-CPP in comparison to placebo.|PMID:15132762; Original text:Additionally subjects with autism spectrum disorders showed a significantly increased prolactin response to m-CPP compared to normal controls, with neither group responding to placebo.
m-cpp	chemical_to_mechanism	prolactin	1	0	15132762	PMID:15132762; Original text:Additionally subjects with autism spectrum disorders showed a significantly increased prolactin response to m-CPP compared to normal controls, with neither group responding to placebo.
autism spectrum disorders	disease_to_mechanism	prolactin	1	0	15132762	PMID:15132762; Original text:Additionally subjects with autism spectrum disorders showed a significantly increased prolactin response to m-CPP compared to normal controls, with neither group responding to placebo.
decrease of developmental growth	disease_to_mechanism	insulin	1	0	27577546	PMID:27577546; Original text:We found a stronger effect of intranasal insulin, being significant for cognition and social skills, for children older than 3 years, who usually show a decrease of developmental growth.
autism spectrum disorders	disease	repetitive behaviors	2	0	12496956|28577609	PMID:12496956; Original text:Patients with autism spectrum disorders showed a significant reduction in repetitive behaviors following oxytocin infusion in comparison to placebo infusion.|PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
oxytocin	chemical_to_disease	autism spectrum disorders	1	0	12496956	PMID:12496956; Original text:Patients with autism spectrum disorders showed a significant reduction in repetitive behaviors following oxytocin infusion in comparison to placebo infusion.
oxytocin	chemical_to_disease	repetitive behaviors	1	0	12496956	PMID:12496956; Original text:Patients with autism spectrum disorders showed a significant reduction in repetitive behaviors following oxytocin infusion in comparison to placebo infusion.
autism spectrum disorders	disease_to_mechanism	oxytocin	1	0	12496956	PMID:12496956; Original text:Patients with autism spectrum disorders showed a significant reduction in repetitive behaviors following oxytocin infusion in comparison to placebo infusion.
repetitive behaviors	disease_to_mechanism	oxytocin	1	0	12496956	PMID:12496956; Original text:Patients with autism spectrum disorders showed a significant reduction in repetitive behaviors following oxytocin infusion in comparison to placebo infusion.
, and	anatomy	superior temporal	4	0	17706781|23452684|26769980|25149412	PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.|PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
sulcus	anatomy	superior temporal	1	0	17706781	PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.
, and	anatomy	the superior	3	0	17706781|14561452|14561452	PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
sulcus	anatomy	the superior	1	0	17706781	PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.
, and	anatomy	temporal sulcus	2	0	17706781|25149412	PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.|PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
, and	anatomy	sulcus	1	0	17706781	PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.
sulcus	anatomy	temporal	1	0	17706781	PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.
sulcus	anatomy	temporal sulcus	1	0	17706781	PMID:17706781; Original text:I will argue that a common process underlying both of these functional domains is performed by the the superior temporal sulcus, namely analyzing changing sequences of input, either in the auditory or visual domain, and interpreting the communicative significance of those inputs.
folinic acid	chemical_to_disease	autism	1	0	27752075	PMID:27752075; Original text:Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group.
folinic acid	chemical_to_anatomy	of the	1	0	27752075	PMID:27752075; Original text:Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group.
folinic acid	chemical_to_anatomy	scale	1	0	27752075	PMID:27752075; Original text:Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group.
autism	disease	medical disorders	1	0	1950971	PMID:1950971; Original text:No single biomedical etiology has been found, but a significant number of medical disorders occur in association with autism.
deviant behavior	disease_to_anatomy	of the	1	0	25617251	PMID:25617251; Original text:Caregivers of children with a history of institutionalization reported that these children had significantly more deviant behavior than never-institutionalized children on all subdomains of the the Social Communication Questionnaire (all p < 0.001).
communication disorders	disease	intellectual disabilities	1	0	27318612	PMID:27318612; Original text:The purpose of this study was to teach letter-sound correspondence to small groups of students with significant intellectual disabilities and comorbid communication disorders using the ALL (Accessible Literacy Learning) curriculum.
anxiety	disease	difficulty falling asleep	1	0	16379507	"PMID:16379507; Original text:""Difficulty falling asleep"" and anxiety actually favored the risperidone condition at statistically significant levels."
risperidone	chemical_to_disease	difficulty falling asleep	1	0	16379507	"PMID:16379507; Original text:""Difficulty falling asleep"" and anxiety actually favored the risperidone condition at statistically significant levels."
risperidone	chemical_to_disease	anxiety	1	0	16379507	"PMID:16379507; Original text:""Difficulty falling asleep"" and anxiety actually favored the risperidone condition at statistically significant levels."
bacteria	bacteria_to_anatomy	, and	1	0	33427861	PMID:33427861; Original text:Site (Boston, New Haven, and Philadelphia) and ethnicity (Hispanic vs non-Hispanic) moderated the effect of family navigation (treatment × site interaction; P = .03; Boston: HR, 2.07 [95% CI, 1.31-3.26]; New Haven: HR, 1.91 [95% CI, 0.94-3.89]; and Philadelphia: HR, 0.91
hemispheres	anatomy	of cerebellar	1	0	2020537	PMID:2020537; Original text:Also, the only autopsy study to conduct statistical analyses of cerebellar cell loss found statistically significant Purkinje cell loss in both the vermis and hemispheres.
hemispheres	anatomy	purkinje cell	1	0	2020537	PMID:2020537; Original text:Also, the only autopsy study to conduct statistical analyses of cerebellar cell loss found statistically significant Purkinje cell loss in both the vermis and hemispheres.
of cerebellar	anatomy	purkinje cell	1	0	2020537	PMID:2020537; Original text:Also, the only autopsy study to conduct statistical analyses of cerebellar cell loss found statistically significant Purkinje cell loss in both the vermis and hemispheres.
cerebellar	disease_to_anatomy	hemispheres	1	0	2020537	PMID:2020537; Original text:Also, the only autopsy study to conduct statistical analyses of cerebellar cell loss found statistically significant Purkinje cell loss in both the vermis and hemispheres.
cerebellar	disease_to_anatomy	of cerebellar	1	0	2020537	PMID:2020537; Original text:Also, the only autopsy study to conduct statistical analyses of cerebellar cell loss found statistically significant Purkinje cell loss in both the vermis and hemispheres.
cerebellar	disease_to_anatomy	purkinje cell	1	0	2020537	PMID:2020537; Original text:Also, the only autopsy study to conduct statistical analyses of cerebellar cell loss found statistically significant Purkinje cell loss in both the vermis and hemispheres.
naltrexone	chemical	tianeptine	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
clonidine	chemical	tianeptine	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
methylphenidate	chemical	tianeptine	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
risperidone	chemical	tianeptine	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
clonidine	chemical	naltrexone	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
methylphenidate	chemical	naltrexone	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
naltrexone	chemical	risperidone	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
clonidine	chemical	methylphenidate	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
clonidine	chemical	risperidone	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
methylphenidate	chemical	risperidone	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
tianeptine	chemical_to_anatomy	, and	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
clonidine	chemical_to_anatomy	, and	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
aggression	disease	self-injury	2	0	18439113|22549762	PMID:18439113; Original text:Aggression and self-injury may be associated symptoms of autism and can result in significant harm to those affected as well as marked distress for their families.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
autism	disease	self-injury	1	0	18439113	PMID:18439113; Original text:Aggression and self-injury may be associated symptoms of autism and can result in significant harm to those affected as well as marked distress for their families.
depressive	disease	depressive symptoms	1	0	24217336	PMID:24217336; Original text:For depressive symptoms, the risk reduction in clinically significant symptoms did not reach statistical significance (5.7% vs 22.4%; aRR, 0.33; 95% CI, 0.10 to 1.08); however, the reduction in mean depressive symptoms was statistically significant (Quick Inventory of Depressive Symptomatology score, 4.6 with problem-solving education vs 6.9 with usual care; adjusted mean difference, -1.67; 95% CI, -3.17 to -0.18).
hyperactivity	disease_to_mechanism	mdr1	1	0	20166790	PMID:20166790; Original text:Subjects with either C/T or C/C (n = 16) genotypes showed a three-fold greater improvement than T/T MDR1 C3435T genotype (n = 6) (mean decrease of 15.1 +/- 12.6, or 50.7% from baseline, versus 4.5 +/- 5.1, or 15.6% from baseline) in parent-rated ABC Hyperactivity scores over 8 weeks (p = 0.03).
mdr1	mechanism_to_anatomy	(p	1	0	20166790	PMID:20166790; Original text:Subjects with either C/T or C/C (n = 16) genotypes showed a three-fold greater improvement than T/T MDR1 C3435T genotype (n = 6) (mean decrease of 15.1 +/- 12.6, or 50.7% from baseline, versus 4.5 +/- 5.1, or 15.6% from baseline) in parent-rated ABC Hyperactivity scores over 8 weeks (p = 0.03).
, a	anatomy	scale	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
(p	anatomy	scale	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
, abnormal	anatomy	scale	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
(p	anatomy	, a	6	0	25313065|18685284|30933867|24824660|20001837|28036350	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).|PMID:18685284; Original text:Of 40 patients, 12 (30%) were considered as 'improved' on Clinical Global Impressions-Severity scores compared to baseline, a statistically significant difference (p < 0.05).|PMID:30933867; Original text:Comparing the results of both experimental and control groups, a statistically significant difference was found on total CARS score (p < 0.0005).|PMID:24824660; Original text:When combining groups, a statistically significant decrease of 37% was found from baseline to week 8 when study drug was completed using a linear mixed effects model (P = 0.003).|PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.|PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
, a	anatomy	, abnormal	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
, abnormal	anatomy	, and	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
(p	anatomy	, abnormal	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	nutrient_to_chemical	sulforaphane	5	0	25313065|34034808|34034808|34034808|34034808	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).|PMID:34034808; Original text:The effect sizes on the the Ohio Autism Clinical Impressions Scale were non-statistically significant but positive, suggesting a possible trend toward greater improvement in those on treatment with Sulforaphane (Cohen's d 0.21; 95% CI - 0.46, 0.88 and 0.10; 95% CI - 0.52, 0.72, respectively).|PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.|PMID:34034808; Original text:We were unable to document significant changes in clinical assessments during clinical visits in those taking Sulforaphane compared to placebo.|PMID:34034808; Original text:Sulforaphane led to small yet non-statistically significant changes in the total and all subscale scores of the primary outcome measure, while for secondary outcome measures, caregivers' assessments of children taking Sulforaphane showed statistically significant improvements compared to those taking placebo on the the Aberrant Behavior Checklist but not the Scale-2.
sulforaphane	nutrient_to_disease	abnormal behavior	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	nutrient_to_anatomy	scale	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	nutrient_to_anatomy	, a	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	nutrient_to_anatomy	, and	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	nutrient_to_anatomy	(p	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	nutrient_to_anatomy	, abnormal	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	chemical_to_disease	abnormal behavior	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	chemical_to_anatomy	scale	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	chemical_to_anatomy	, a	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	chemical_to_anatomy	, and	2	0	25313065|32347624	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
sulforaphane	chemical_to_anatomy	(p	3	0	25313065|25313065|32347624	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).|PMID:25313065; Original text:After 18 wk, participants receiving placebo experienced minimal change (<3.3%), whereas those receiving sulforaphane showed substantial declines (improvement of behavior): 34% for the Aberrant Behavior Checklist (P < 0.001, comparing treatments) and 17% for Social Responsiveness Scale scores (P = 0.017).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
sulforaphane	chemical_to_anatomy	, abnormal	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
abnormal behavior	disease_to_anatomy	scale	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
abnormal behavior	disease_to_anatomy	, a	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
abnormal behavior	disease_to_anatomy	, and	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
abnormal behavior	disease_to_anatomy	(p	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
abnormal behavior	disease_to_anatomy	, abnormal	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
mercury	chemical_to_disease	pervasive developmental disorder	2	0	25382662|25382662	PMID:25382662; Original text:Cases diagnosed with pervasive developmental disorder received significantly more organic an organic mercury within the first 6 months of life (odds ratio (odds ratio) = 1.97, p < 0.001)|PMID:25382662; Original text:On a per microgram of organic an organic mercury basis, cases diagnosed with a pervasive developmental disorder in comparison to controls were at significantly greater odds (odds ratio = 1.0197, p < 0.0001) of receiving increasing organic an organic mercury exposure within the first 15 months of life, whereas cases diagnosed febrile seizure were no more likely than controls (odds ratio = 0.999, p > 0.20) to have received increasing organic an organic mercury exposure within the first 15 months of life.
mercury	chemical_to_disease	febrile seizure	2	0	25382662|25382662	PMID:25382662; Original text:and first 15 months of life (odds ratio = 3.94, p < 0.0001) than controls, whereas cases diagnosed with febrile seizure were no more likely than controls to have received increased organic an organic mercury.|PMID:25382662; Original text:On a per microgram of organic an organic mercury basis, cases diagnosed with a pervasive developmental disorder in comparison to controls were at significantly greater odds (odds ratio = 1.0197, p < 0.0001) of receiving increasing organic an organic mercury exposure within the first 15 months of life, whereas cases diagnosed febrile seizure were no more likely than controls (odds ratio = 0.999, p > 0.20) to have received increasing organic an organic mercury exposure within the first 15 months of life.
febrile seizure	disease	per	1	0	25382662	PMID:25382662; Original text:On a per microgram of organic an organic mercury basis, cases diagnosed with a pervasive developmental disorder in comparison to controls were at significantly greater odds (odds ratio = 1.0197, p < 0.0001) of receiving increasing organic an organic mercury exposure within the first 15 months of life, whereas cases diagnosed febrile seizure were no more likely than controls (odds ratio = 0.999, p > 0.20) to have received increasing organic an organic mercury exposure within the first 15 months of life.
per	disease	pervasive developmental disorder	1	0	25382662	PMID:25382662; Original text:On a per microgram of organic an organic mercury basis, cases diagnosed with a pervasive developmental disorder in comparison to controls were at significantly greater odds (odds ratio = 1.0197, p < 0.0001) of receiving increasing organic an organic mercury exposure within the first 15 months of life, whereas cases diagnosed febrile seizure were no more likely than controls (odds ratio = 0.999, p > 0.20) to have received increasing organic an organic mercury exposure within the first 15 months of life.
febrile seizure	disease	pervasive developmental disorder	1	0	25382662	PMID:25382662; Original text:On a per microgram of organic an organic mercury basis, cases diagnosed with a pervasive developmental disorder in comparison to controls were at significantly greater odds (odds ratio = 1.0197, p < 0.0001) of receiving increasing organic an organic mercury exposure within the first 15 months of life, whereas cases diagnosed febrile seizure were no more likely than controls (odds ratio = 0.999, p > 0.20) to have received increasing organic an organic mercury exposure within the first 15 months of life.
mercury	chemical_to_disease	per	1	0	25382662	PMID:25382662; Original text:On a per microgram of organic an organic mercury basis, cases diagnosed with a pervasive developmental disorder in comparison to controls were at significantly greater odds (odds ratio = 1.0197, p < 0.0001) of receiving increasing organic an organic mercury exposure within the first 15 months of life, whereas cases diagnosed febrile seizure were no more likely than controls (odds ratio = 0.999, p > 0.20) to have received increasing organic an organic mercury exposure within the first 15 months of life.
memantine	chemical_to_disease	autism	1	0	27043118	PMID:27043118; Original text:Treatment with memantine was associated with significant reduction on informant-rated (SRS-A, -28 ± 25; P < 0.001) and clinician-rated (Clinical Global Impression-Improvement subscale ≤2, 83%) measures of autism severity.
memantine	chemical_to_anatomy	(clinical	1	0	27043118	PMID:27043118; Original text:Treatment with memantine was associated with significant reduction on informant-rated (SRS-A, -28 ± 25; P < 0.001) and clinician-rated (Clinical Global Impression-Improvement subscale ≤2, 83%) measures of autism severity.
autism	disease_to_anatomy	(clinical	1	0	27043118	PMID:27043118; Original text:Treatment with memantine was associated with significant reduction on informant-rated (SRS-A, -28 ± 25; P < 0.001) and clinician-rated (Clinical Global Impression-Improvement subscale ≤2, 83%) measures of autism severity.
memantine	chemical_to_disease	adhd	1	0	27043118	PMID:27043118; Original text:In addition, memantine treatment was associated with significant improvement in ADHD and anxiety symptom severity.
memantine	chemical_to_disease	anxiety	1	0	27043118	PMID:27043118; Original text:In addition, memantine treatment was associated with significant improvement in ADHD and anxiety symptom severity.
irritability	disease	stereotypic behavior	2	0	26208985|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
irritability	disease	social withdrawal	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
irritability	disease	lethargy	6	0	26208985|19772883|18685284|32168067|30980177|26802979	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:19772883; Original text:The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in the Aberrant Behavior Checklist-Community subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:26802979; Original text:Significant (P<0.01) interactions between treatment and baseline severity were observed for parent ABC ratings of irritability and lethargy only.
inappropriate speech	disease	irritability	4	0	26208985|18685284|22419332|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
social withdrawal	disease	stereotypic behavior	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
lethargy	disease	stereotypic behavior	2	0	26208985|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
inappropriate speech	disease	stereotypic behavior	2	0	26208985|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
hyperactivity	disease	stereotypic behavior	2	0	26208985|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
lethargy	disease	social withdrawal	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
inappropriate speech	disease	social withdrawal	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
hyperactivity	disease	social withdrawal	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
inappropriate speech	disease	lethargy	4	0	26208985|18685284|30980177|29027815	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:29027815; Original text:No significant improvements were obtained on the lethargy/social withdrawal, stereotypic behavior, and inappropriate speech subscale scores.
hyperactivity	disease	lethargy	5	0	26208985|19772883|18685284|32168067|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:19772883; Original text:The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in the Aberrant Behavior Checklist-Community subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
hyperactivity	disease	inappropriate speech	6	0	26208985|18685284|11392343|22419332|30980177|33029705	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:11392343; Original text:However, in the amantadine-treated group there were statistically significant improvements in absolute changes in clinician-rated ABC-CVs for hyperactivity (amantadine -6.4 versus placebo -2.1; p = .046) and inappropriate speech (-1.9 versus 0.4; p = .008).|PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:33029705; Original text:The repeated measures analysis showed significant effect for time × treatment interaction on inappropriate speech (F = 3.51; df = 1.61; P = 0.044), stereotypic behavior (F = 4.02; df = 1.37; P = 0.036), and hyperactivity/noncompliance (F = 6.79; df = 1.66; P = 0.003) subscale scores.
irritability	disease_to_anatomy	level of	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
stereotypic behavior	disease_to_anatomy	level of	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
social withdrawal	disease_to_anatomy	level of	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
lethargy	disease_to_anatomy	level of	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
inappropriate speech	disease_to_anatomy	level of	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
hyperactivity	disease_to_anatomy	level of	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
disrupted brain connectivity	disease	molecular lesions	1	0	27282107	PMID:27282107; Original text:Here, I review the extent and significance of brain somatic mutations and provide my perspective regarding these mutations as potential molecular lesions underlying relatively common conditions with disrupted brain connectivity.
disrupted brain connectivity	disease_to_anatomy	of brain	1	0	27282107	PMID:27282107; Original text:Here, I review the extent and significance of brain somatic mutations and provide my perspective regarding these mutations as potential molecular lesions underlying relatively common conditions with disrupted brain connectivity.
molecular lesions	disease_to_anatomy	of brain	1	0	27282107	PMID:27282107; Original text:Here, I review the extent and significance of brain somatic mutations and provide my perspective regarding these mutations as potential molecular lesions underlying relatively common conditions with disrupted brain connectivity.
mitochondria	anatomy	of the	1	0	32892956	PMID:32892956; Original text:Recent research has identified a type of dysfunction of mitochondria in which the activity of the electron transport chain is significantly increased.
naltrexone	chemical_to_disease	irritability	1	0	8570776	PMID:8570776; Original text:Naltrexone treatment failed to produce significant changes in social behavior, but it did reduce irritability and target scores on behavior checklists.
autism	disease	developmental disorder	2	0	15749246|9648034	PMID:15749246; Original text:Autism is a complex developmental disorder without an established single etiology but with significant contributions from genetic studies, functional research, and neuropsychiatric and neuroradiologic investigations.|PMID:9648034; Original text:Describes treatment of autism, a severe, chronic developmental disorder that results in significant lifelong disability for most persons, with few persons ever functioning in an independent and typical lifestyle.
developmental disorder	disease_to_anatomy	, and	1	0	15749246	PMID:15749246; Original text:Autism is a complex developmental disorder without an established single etiology but with significant contributions from genetic studies, functional research, and neuropsychiatric and neuroradiologic investigations.
ataxia syndrome	disease	fragile x syndrome	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x syndrome	disease	ovarian insufficiency	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x syndrome	disease	tremor	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x	disease	fragile x syndrome	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ataxia syndrome	disease	ovarian insufficiency	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ataxia syndrome	disease	tremor	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ataxia syndrome	disease	fragile x	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ovarian insufficiency	disease	tremor	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x	disease	ovarian insufficiency	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x	disease	tremor	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x syndrome	disease_to_mechanism	fmr1 gene	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ataxia syndrome	disease_to_mechanism	fmr1 gene	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ovarian insufficiency	disease_to_mechanism	fmr1 gene	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
tremor	disease_to_mechanism	fmr1 gene	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x	disease_to_mechanism	fmr1 gene	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
impressions	disease	irritability	1	0	19858761	PMID:19858761; Original text:Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, combined treatment showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04).
hyperactivity	disease	impressions	1	0	19858761	PMID:19858761; Original text:Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, combined treatment showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04).
impressions	disease_to_anatomy	, and	1	0	19858761	PMID:19858761; Original text:Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, combined treatment showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04).
, alpha	anatomy	, heart	1	0	34237553	PMID:34237553; Original text:Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity.
cortisol	chemical_to_mechanism	alpha-amylase	1	0	34237553	PMID:34237553; Original text:Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity.
cortisol	chemical_to_anatomy	, alpha	1	0	34237553	PMID:34237553; Original text:Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity.
cortisol	chemical_to_anatomy	, heart	1	0	34237553	PMID:34237553; Original text:Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity.
alpha-amylase	mechanism_to_anatomy	, alpha	1	0	34237553	PMID:34237553; Original text:Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity.
alpha-amylase	mechanism_to_anatomy	, heart	1	0	34237553	PMID:34237553; Original text:Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity.
autistic symptoms	disease_to_anatomy	, and	2	0	18416666|8498878	PMID:18416666; Original text:However, recent studies indicate that co-occurrence of clinically significant disorder and autistic symptoms is common, and that some genes may influence both disorders.|PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
gray matter	anatomy	of gray	1	0	23707581	PMID:23707581; Original text:Linear regression analysis of gray matter (gray matter) volume changes (known to occur with development) revealed a significant decrease of gray matter volume with Age for Motor (F(1,30)=17.92; p<0.001) and Visual F(1,16)=14.41; p<0.005 but not the Auditory ROI (p=0.55).
of gray	anatomy	of gray matter	1	0	23707581	PMID:23707581; Original text:Linear regression analysis of gray matter (gray matter) volume changes (known to occur with development) revealed a significant decrease of gray matter volume with Age for Motor (F(1,30)=17.92; p<0.001) and Visual F(1,16)=14.41; p<0.005 but not the Auditory ROI (p=0.55).
gray matter	anatomy	of gray matter	1	0	23707581	PMID:23707581; Original text:Linear regression analysis of gray matter (gray matter) volume changes (known to occur with development) revealed a significant decrease of gray matter volume with Age for Motor (F(1,30)=17.92; p<0.001) and Visual F(1,16)=14.41; p<0.005 but not the Auditory ROI (p=0.55).
decrease of gray matter volume	disease_to_anatomy	of gray	1	0	23707581	PMID:23707581; Original text:Linear regression analysis of gray matter (gray matter) volume changes (known to occur with development) revealed a significant decrease of gray matter volume with Age for Motor (F(1,30)=17.92; p<0.001) and Visual F(1,16)=14.41; p<0.005 but not the Auditory ROI (p=0.55).
decrease of gray matter volume	disease_to_anatomy	gray matter	1	0	23707581	PMID:23707581; Original text:Linear regression analysis of gray matter (gray matter) volume changes (known to occur with development) revealed a significant decrease of gray matter volume with Age for Motor (F(1,30)=17.92; p<0.001) and Visual F(1,16)=14.41; p<0.005 but not the Auditory ROI (p=0.55).
decrease of gray matter volume	disease_to_anatomy	of gray matter	1	0	23707581	PMID:23707581; Original text:Linear regression analysis of gray matter (gray matter) volume changes (known to occur with development) revealed a significant decrease of gray matter volume with Age for Motor (F(1,30)=17.92; p<0.001) and Visual F(1,16)=14.41; p<0.005 but not the Auditory ROI (p=0.55).
epilepsy	disease	mental retardation	1	0	19319661	PMID:19319661; Original text:The most significant clinical features were mental retardation, epilepsy and autistic behaviour, and these symptoms did not worsen, in contrast to other reports.
autistic behaviour	disease	mental retardation	1	0	19319661	PMID:19319661; Original text:The most significant clinical features were mental retardation, epilepsy and autistic behaviour, and these symptoms did not worsen, in contrast to other reports.
autistic behaviour	disease	epilepsy	1	0	19319661	PMID:19319661; Original text:The most significant clinical features were mental retardation, epilepsy and autistic behaviour, and these symptoms did not worsen, in contrast to other reports.
mental retardation	disease_to_anatomy	, and	4	0	19319661|10425586|19736351|23471985	PMID:19319661; Original text:The most significant clinical features were mental retardation, epilepsy and autistic behaviour, and these symptoms did not worsen, in contrast to other reports.|PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.|PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).|PMID:23471985; Original text:As a posthoc analysis, we conducted genome-wide association scans on several organizational and topological network measures derived from the matrices to discover variants in and around genes associated with autism (autism), development (NEDD4), and mental retardation (UBE2A) significantly associated with connectivity.
autistic behaviour	disease_to_anatomy	, and	1	0	19319661	PMID:19319661; Original text:The most significant clinical features were mental retardation, epilepsy and autistic behaviour, and these symptoms did not worsen, in contrast to other reports.
glutathione	chemical_to_anatomy	group	1	0	19852790	PMID:19852790; Original text:For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases).
serotonin	chemical_to_disease	autism spectrum disorders	2	0	27667009|27667009	PMID:27667009; Original text:The meta-analysis of case-control studies demonstrated a significantly increased risk of autism spectrum disorders in the children whose mothers were prenatally exposed to prenatal selective serotonin reuptake inhibitors during different exposure time windows (except third trimester).|PMID:27667009; Original text:The significant association between preconception-only prenatal selective serotonin reuptake inhibitor exposure and autism spectrum disorders in the children and negative/inconsistent findings among cohort studies weaken the significant associations detected in this meta-analysis.
serotonin	chemical_to_mechanism	serotonin reuptake	1	0	27667009	PMID:27667009; Original text:The meta-analysis of case-control studies demonstrated a significantly increased risk of autism spectrum disorders in the children whose mothers were prenatally exposed to prenatal selective serotonin reuptake inhibitors during different exposure time windows (except third trimester).
autism spectrum disorders	disease_to_mechanism	serotonin reuptake	1	0	27667009	PMID:27667009; Original text:The meta-analysis of case-control studies demonstrated a significantly increased risk of autism spectrum disorders in the children whose mothers were prenatally exposed to prenatal selective serotonin reuptake inhibitors during different exposure time windows (except third trimester).
serotonin	chemical_to_mechanism	serotonin	2	0	27667009|15730889	"PMID:27667009; Original text:The significant association between preconception-only prenatal selective serotonin reuptake inhibitor exposure and autism spectrum disorders in the children and negative/inconsistent findings among cohort studies weaken the significant associations detected in this meta-analysis.|PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
autism spectrum disorders	disease_to_mechanism	serotonin	1	0	27667009	PMID:27667009; Original text:The significant association between preconception-only prenatal selective serotonin reuptake inhibitor exposure and autism spectrum disorders in the children and negative/inconsistent findings among cohort studies weaken the significant associations detected in this meta-analysis.
pervasive developmental disorders	disease	sleep disturbance	1	0	21570809	PMID:21570809; Original text:Sleep disturbance is a significant problem in the general pediatric population, and it occurs even more frequently in children with pervasive developmental disorders (pervasive developmental disorders).
sleep disturbance	disease_to_anatomy	, and	1	0	21570809	PMID:21570809; Original text:Sleep disturbance is a significant problem in the general pediatric population, and it occurs even more frequently in children with pervasive developmental disorders (pervasive developmental disorders).
pervasive developmental disorders	disease_to_anatomy	, and	1	0	21570809	PMID:21570809; Original text:Sleep disturbance is a significant problem in the general pediatric population, and it occurs even more frequently in children with pervasive developmental disorders (pervasive developmental disorders).
activator protein 1	mechanism	nuclear factor kappa b	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
activator protein 1	mechanism	ap-1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
activator protein 1	mechanism	nf-κb	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
ap-1	mechanism	nuclear factor kappa b	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
nf-κb	mechanism	nuclear factor kappa b	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
ap-1	mechanism	nf-κb	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
b (	anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
glutathione	chemical_to_disease	neuroinflammation	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
glutathione	chemical_to_mechanism	activator protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
glutathione	chemical_to_mechanism	nuclear factor kappa b	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
glutathione	chemical_to_mechanism	ap-1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
glutathione	chemical_to_mechanism	nf-κb	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
glutathione	chemical_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
glutathione	chemical_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
neuroinflammation	disease_to_mechanism	activator protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
neuroinflammation	disease_to_mechanism	nuclear factor kappa b	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
neuroinflammation	disease_to_mechanism	ap-1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
neuroinflammation	disease_to_mechanism	nf-κb	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
neuroinflammation	disease_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
neuroinflammation	disease_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
activator protein 1	mechanism_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
activator protein 1	mechanism_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
nuclear factor kappa b	mechanism_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
nuclear factor kappa b	mechanism_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
ap-1	mechanism_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
ap-1	mechanism_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
nf-κb	mechanism_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
nf-κb	mechanism_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
mitochondrial	anatomy	neuronal	2	0	32745763|33493659	PMID:32745763; Original text:Mitochondrial dysfunction, as well as neuronal apoptosis, may also provide a significant link between glutathione metabolism and disorder.|PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
glutathione	chemical_to_disease	mitochondrial dysfunction	2	0	32745763|33493659	PMID:32745763; Original text:Mitochondrial dysfunction, as well as neuronal apoptosis, may also provide a significant link between glutathione metabolism and disorder.|PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
glutathione	chemical_to_anatomy	mitochondrial	3	0	32745763|33493659|34034808	PMID:32745763; Original text:Mitochondrial dysfunction, as well as neuronal apoptosis, may also provide a significant link between glutathione metabolism and disorder.|PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.|PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
glutathione	chemical_to_anatomy	neuronal	2	0	32745763|33493659	PMID:32745763; Original text:Mitochondrial dysfunction, as well as neuronal apoptosis, may also provide a significant link between glutathione metabolism and disorder.|PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
mitochondrial dysfunction	disease_to_anatomy	mitochondrial	2	0	32745763|33493659	PMID:32745763; Original text:Mitochondrial dysfunction, as well as neuronal apoptosis, may also provide a significant link between glutathione metabolism and disorder.|PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
mitochondrial dysfunction	disease_to_anatomy	neuronal	2	0	32745763|33493659	PMID:32745763; Original text:Mitochondrial dysfunction, as well as neuronal apoptosis, may also provide a significant link between glutathione metabolism and disorder.|PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
oxidized glutathione	chemical	reduced glutathione	2	0	32745763|22151477	PMID:32745763; Original text:Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma reduced glutathione and oxidized glutathione levels as well as reduced glutathione:oxidized glutathione ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively).|PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
oxidized glutathione	chemical_to_disease	autistic	1	0	32745763	PMID:32745763; Original text:Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma reduced glutathione and oxidized glutathione levels as well as reduced glutathione:oxidized glutathione ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively).
reduced glutathione	chemical_to_disease	autistic	1	0	32745763	PMID:32745763; Original text:Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma reduced glutathione and oxidized glutathione levels as well as reduced glutathione:oxidized glutathione ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively).
oxidized glutathione	chemical_to_anatomy	(p	1	0	32745763	PMID:32745763; Original text:Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma reduced glutathione and oxidized glutathione levels as well as reduced glutathione:oxidized glutathione ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively).
reduced glutathione	chemical_to_anatomy	(p	1	0	32745763	PMID:32745763; Original text:Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma reduced glutathione and oxidized glutathione levels as well as reduced glutathione:oxidized glutathione ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively).
, and	anatomy	26	1	0	16048456	PMID:16048456; Original text:At a cut-off of 26, the the Autism Spectrum Quotient-J had satisfactory sensitivity, specificity, and negative predictive value, but it had low positive predictive value (0.24) possibly due to the facts that the 25 mild 25 normally intelligent high-functioning pervasive developmental disorder patients scored lower and the controls scored higher on the the Autism Spectrum Quotient-J than British counterparts on the the Autism Spectrum Quotient.
pervasive developmental disorder	disease_to_anatomy	26	1	0	16048456	PMID:16048456; Original text:At a cut-off of 26, the the Autism Spectrum Quotient-J had satisfactory sensitivity, specificity, and negative predictive value, but it had low positive predictive value (0.24) possibly due to the facts that the 25 mild 25 normally intelligent high-functioning pervasive developmental disorder patients scored lower and the controls scored higher on the the Autism Spectrum Quotient-J than British counterparts on the the Autism Spectrum Quotient.
pervasive developmental disorder	disease_to_anatomy	, and	2	0	16048456|11459079	PMID:16048456; Original text:At a cut-off of 26, the the Autism Spectrum Quotient-J had satisfactory sensitivity, specificity, and negative predictive value, but it had low positive predictive value (0.24) possibly due to the facts that the 25 mild 25 normally intelligent high-functioning pervasive developmental disorder patients scored lower and the controls scored higher on the the Autism Spectrum Quotient-J than British counterparts on the the Autism Spectrum Quotient.|PMID:11459079; Original text:We studied 9 Caucasian boys, 3.8-8.1 years old, with a DSM-IV diagnosis of a pervasive developmental disorder, living with their families, receiving no chronic medications, and without significant gastrointestinal symptoms.
end of	anatomy	of the	7	0	20500784|15673999|26978327|18080171|23821414|31063671|17187010	PMID:20500784; Original text:There was a significant decrease in overall scores of stress levels for participants over the course of the study and there was a significant increase in the four factors of quality of life that were measured (satisfaction, independence, competence and social interaction) as well as the total score for quality of life from baseline to the end of the intervention 12 months later.|PMID:15673999; Original text:Vitamin C levels were measured at the end of the study, and the placebo group had levels that were significantly below average for typical children, whereas the supplement group had near-average levels.|PMID:26978327; Original text:A trend for improvement at the end of the 48 week extension was observed.|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:23821414; Original text:Children in the riluzole group experienced significantly more increases in their appetite and bodyweight than children in the placebo group by the end of the study.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.|PMID:17187010; Original text:A significant (p<0.01) overall improvement from the 70-79th percentile of severity (median baseline score=87) at baseline to the 40-49th percentile of severity (median end of study period score=63) at the end of the study was observed for patients treated for a median of approximately 4 months.
, cell	anatomy	neuronal	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
cell	anatomy	neuronal	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, a	anatomy	neuronal	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
brain	anatomy	neuronal	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, cell-matrix	anatomy	neuronal	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, cell	anatomy	cell	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, a	anatomy	, cell	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, cell	anatomy	brain	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, cell	anatomy	, cell-matrix	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, a	anatomy	cell	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
brain	anatomy	cell	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, cell-matrix	anatomy	cell	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, a	anatomy	, cell-matrix	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
, cell-matrix	anatomy	brain	1	0	29704525	PMID:29704525; Original text:Cell-cell, cell-matrix interactions and systemic influences are known to be important in defining neuronal connectivity in the developing brain, thus, a systems-based model offers significant advantages over cell-based models for screening chemicals for effects on neuronal connectivity.
infertility	disease	obese	1	0	31767240	PMID:31767240; Original text:Meta-analysis was only possible for infertility which was significantly more prevalent in obese (OR=1.49 95%CI 1.30-1.70) and overweight (OR=1.18 95%CI 1.11-1.26) men.
substance abuse	disease	trauma	1	0	17574799	PMID:17574799; Original text:Female survivors of childhood abuse did not improve in treatment as much as their nonabused peers in psychological functioning (p < .001), substance abuse (p < .01), or continuing trauma exposure (p < .01) .
substance abuse	disease_to_anatomy	(p	1	0	17574799	PMID:17574799; Original text:Female survivors of childhood abuse did not improve in treatment as much as their nonabused peers in psychological functioning (p < .001), substance abuse (p < .01), or continuing trauma exposure (p < .01) .
trauma	disease_to_anatomy	(p	1	0	17574799	PMID:17574799; Original text:Female survivors of childhood abuse did not improve in treatment as much as their nonabused peers in psychological functioning (p < .001), substance abuse (p < .01), or continuing trauma exposure (p < .01) .
is	anatomy	of the	1	0	16160627	PMID:16160627; Original text:Post hoc analysis looking at the 3 core symptoms of autism, that is, social interaction, communication, and stereotyped behaviors, revealed a significant improvement of the social interaction score after 6 months of active treatment.
, and	anatomy	is	1	0	16160627	PMID:16160627; Original text:Post hoc analysis looking at the 3 core symptoms of autism, that is, social interaction, communication, and stereotyped behaviors, revealed a significant improvement of the social interaction score after 6 months of active treatment.
autism	disease_to_anatomy	is	1	0	16160627	PMID:16160627; Original text:Post hoc analysis looking at the 3 core symptoms of autism, that is, social interaction, communication, and stereotyped behaviors, revealed a significant improvement of the social interaction score after 6 months of active treatment.
autism	disease	cognitive impairment	2	0	10425586|10425586	PMID:10425586; Original text:This review addresses the issues and challenges related to the differential diagnosis of autism in preschool children with significant cognitive impairment.|PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
autism	disease	mental retardation	6	0	10425586|9813776|21219265|19736351|23471985|3052070	"PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.|PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.|PMID:21219265; Original text:The risk was also very significant for autism associated with mental retardation.|PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).|PMID:23471985; Original text:As a posthoc analysis, we conducted genome-wide association scans on several organizational and topological network measures derived from the matrices to discover variants in and around genes associated with autism (autism), development (NEDD4), and mental retardation (UBE2A) significantly associated with connectivity.|PMID:3052070; Original text:We examined 31 studies which investigated the association of fra(X) syndrome with either inherited mental retardation or ""autism"" and found that the conclusion of those researchers could be significantly affected by sample size."
autism	disease	cognitive	1	0	10425586	PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
cognitive impairment	disease	mental retardation	1	0	10425586	PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
cognitive	disease	mental retardation	1	0	10425586	PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
cognitive	disease	cognitive impairment	1	0	10425586	PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
cognitive impairment	disease_to_anatomy	, and	1	0	10425586	PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
cognitive	disease_to_anatomy	, and	2	0	10425586|25161109	PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.|PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
asd	disease	autism spectrum disorders	3	0	24391123|31665947|25246292	PMID:24391123; Original text:Dental care is a significant unmet health care need for children with autism spectrum disorders (ASD).|PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:25246292; Original text:Coa statistically significant pooled treatment effect sizenitive-behavioral therapy (Coa statistically significant pooled treatment effect sizenitive-behavioral therapy) has been developed and modified to treat anxiety symptoms in youth with hia statistically significant pooled treatment effect sizeh-functionina statistically significant pooled treatment effect size autism spectrum disorders (ASD) but has yielded varyina statistically significant pooled treatment effect size findina statistically significant pooled treatment effect sizes.
2	anatomy	group a	1	0	24391123	PMID:24391123; Original text:Between visits 1 and 2, mean anxiety and behavior scores decreased significantly by 0.8 points (P = .03) for subjects within groups C and D. Significant changes were not observed within groups A and B. Mean anxiety and behavior scores did not differ significantly between groups over time, although group A versus C pairwise comparisons showed a trend toward significance (P = .06).
2	anatomy	and 2	1	0	24391123	PMID:24391123; Original text:Between visits 1 and 2, mean anxiety and behavior scores decreased significantly by 0.8 points (P = .03) for subjects within groups C and D. Significant changes were not observed within groups A and B. Mean anxiety and behavior scores did not differ significantly between groups over time, although group A versus C pairwise comparisons showed a trend toward significance (P = .06).
(p	anatomy	group a	1	0	24391123	PMID:24391123; Original text:Between visits 1 and 2, mean anxiety and behavior scores decreased significantly by 0.8 points (P = .03) for subjects within groups C and D. Significant changes were not observed within groups A and B. Mean anxiety and behavior scores did not differ significantly between groups over time, although group A versus C pairwise comparisons showed a trend toward significance (P = .06).
and 2	anatomy	group a	1	0	24391123	PMID:24391123; Original text:Between visits 1 and 2, mean anxiety and behavior scores decreased significantly by 0.8 points (P = .03) for subjects within groups C and D. Significant changes were not observed within groups A and B. Mean anxiety and behavior scores did not differ significantly between groups over time, although group A versus C pairwise comparisons showed a trend toward significance (P = .06).
(p	anatomy	and 2	2	0	24391123|16948927	PMID:24391123; Original text:Between visits 1 and 2, mean anxiety and behavior scores decreased significantly by 0.8 points (P = .03) for subjects within groups C and D. Significant changes were not observed within groups A and B. Mean anxiety and behavior scores did not differ significantly between groups over time, although group A versus C pairwise comparisons showed a trend toward significance (P = .06).|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
anxiety	disease_to_anatomy	2	1	0	24391123	PMID:24391123; Original text:Between visits 1 and 2, mean anxiety and behavior scores decreased significantly by 0.8 points (P = .03) for subjects within groups C and D. Significant changes were not observed within groups A and B. Mean anxiety and behavior scores did not differ significantly between groups over time, although group A versus C pairwise comparisons showed a trend toward significance (P = .06).
anxiety	disease_to_anatomy	group a	1	0	24391123	PMID:24391123; Original text:Between visits 1 and 2, mean anxiety and behavior scores decreased significantly by 0.8 points (P = .03) for subjects within groups C and D. Significant changes were not observed within groups A and B. Mean anxiety and behavior scores did not differ significantly between groups over time, although group A versus C pairwise comparisons showed a trend toward significance (P = .06).
anxiety	disease_to_anatomy	(p	3	0	24391123|20001837|24408892	PMID:24391123; Original text:Between visits 1 and 2, mean anxiety and behavior scores decreased significantly by 0.8 points (P = .03) for subjects within groups C and D. Significant changes were not observed within groups A and B. Mean anxiety and behavior scores did not differ significantly between groups over time, although group A versus C pairwise comparisons showed a trend toward significance (P = .06).|PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.|PMID:24408892; Original text:Analyses of parental outcome reveal a significant decrease in maternal state anxiety in the a treatment group after controlling for potential confounding variables (p < 0.05).
anxiety	disease_to_anatomy	and 2	1	0	24391123	PMID:24391123; Original text:Between visits 1 and 2, mean anxiety and behavior scores decreased significantly by 0.8 points (P = .03) for subjects within groups C and D. Significant changes were not observed within groups A and B. Mean anxiety and behavior scores did not differ significantly between groups over time, although group A versus C pairwise comparisons showed a trend toward significance (P = .06).
autism spectrum disorder	disease	behavioral disturbance	1	0	24231171	PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.
behavioral disturbance	disease	intellectual disability	1	0	24231171	PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.
, and	anatomy	risks	1	0	24231171	PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.
autism spectrum disorder	disease_to_anatomy	risks	1	0	24231171	PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.
behavioral disturbance	disease_to_anatomy	, and	1	0	24231171	PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.
behavioral disturbance	disease_to_anatomy	risks	1	0	24231171	PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.
intellectual disability	disease_to_anatomy	risks	1	0	24231171	PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.
schizophrenia	disease_to_anatomy	body of	1	0	12457383	PMID:12457383; Original text:Although a growing body of evidence supports the hypothesis that exposure to obstetric complications (obstetric complications) increases the vulnerability for schizophrenia, some questions remain unanswered regarding the diagnostic specificity and the etiological significance of this association.
aripiprazole	chemical_to_disease	irritability	5	0	20973712|19797985|27344135|19948625|28004215	PMID:20973712; Original text:Statistically significantly greater improvement was seen with aripiprazole versus placebo (p < 0.05) for all arms in both trials on the the Aberrant Behavior Checklist-Irritability total subscale score and on the following individual the Aberrant Behavior Checklist-Irritability items: Mood changes quickly, cries/screams inappropriately, and stamps feet/bangs objects.|PMID:19797985; Original text:At week 8, all aripiprazole doses produced significantly greater improvement than placebo in mean Aberrant Behavior Checklist Irritability subscale scores (5 mg/day, -12.4; 10 mg/day, -13.2; 15 mg/day, -14.4; versus placebo, -8.4; all p < .05).|PMID:27344135; Original text:One long-term, placebo discontinuation study found that relapse rates did not differ between children/adolescents randomised to continue aripiprazole versus children/adolescents randomised to receive placebo, suggesting that re-evaluation of aripiprazole use after a period of stabilisation in irritability symptoms is warranted.|PMID:19948625; Original text:Mean improvement in Aberrant Behavior Checklist irritability subscale score was significantly greater with aripiprazole than with placebo from week 1 through week 8.|PMID:28004215; Original text:Aripiprazole produced a significant improvement in the mean parent/caregiver-rated Aberrant Behavior Checklist Japanese Version irritability subscale score relative to placebo from week 3 through week 8.
aripiprazole	chemical_to_anatomy	(p	2	0	20973712|24502859	PMID:20973712; Original text:Statistically significantly greater improvement was seen with aripiprazole versus placebo (p < 0.05) for all arms in both trials on the the Aberrant Behavior Checklist-Irritability total subscale score and on the following individual the Aberrant Behavior Checklist-Irritability items: Mood changes quickly, cries/screams inappropriately, and stamps feet/bangs objects.|PMID:24502859; Original text:The difference in time to relapse between aripiprazole and placebo was not statistically significant (P = .097).
tantrum	chemical_to_anatomy	of the	1	0	20973712	PMID:20973712; Original text:Several additional items measuring tantrum-like behaviors improved in the flexibly dosed trial and at least one arm of the fixed-dose trial (p < 0.05).
tantrum	chemical_to_anatomy	(p	1	0	20973712	PMID:20973712; Original text:Several additional items measuring tantrum-like behaviors improved in the flexibly dosed trial and at least one arm of the fixed-dose trial (p < 0.05).
fluoxetine	chemical_to_disease	repetitive behaviors	2	0	22193531|22193531	PMID:22193531; Original text:There was a significant treatment-by-time interaction indicating a significantly greater reduction in repetitive behaviors across time for fluoxetine than for placebo.|PMID:22193531; Original text:Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and the Clinical Global Impression rating of obsessive-compulsive symptoms, as well as on the the Clinical Global Impression overall improvement rating.
compulsion	disease	repetitive behaviors	1	0	22193531	PMID:22193531; Original text:Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and the Clinical Global Impression rating of obsessive-compulsive symptoms, as well as on the the Clinical Global Impression overall improvement rating.
compulsion	disease	obsessive-compulsive symptoms	1	0	22193531	PMID:22193531; Original text:Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and the Clinical Global Impression rating of obsessive-compulsive symptoms, as well as on the the Clinical Global Impression overall improvement rating.
obsessive-compulsive symptoms	disease	repetitive behaviors	1	0	22193531	PMID:22193531; Original text:Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and the Clinical Global Impression rating of obsessive-compulsive symptoms, as well as on the the Clinical Global Impression overall improvement rating.
fluoxetine	chemical_to_disease	compulsion	1	0	22193531	PMID:22193531; Original text:Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and the Clinical Global Impression rating of obsessive-compulsive symptoms, as well as on the the Clinical Global Impression overall improvement rating.
fluoxetine	chemical_to_disease	obsessive-compulsive symptoms	1	0	22193531	PMID:22193531; Original text:Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and the Clinical Global Impression rating of obsessive-compulsive symptoms, as well as on the the Clinical Global Impression overall improvement rating.
aripiprazole	chemical_to_anatomy	8	2	0	19797985|19797985	PMID:19797985; Original text:At week 8, all aripiprazole doses produced significantly greater improvement than placebo in mean Aberrant Behavior Checklist Irritability subscale scores (5 mg/day, -12.4; 10 mg/day, -13.2; 15 mg/day, -14.4; versus placebo, -8.4; all p < .05).|PMID:19797985; Original text:At week 8, mean weight change (last observation carried forward) was as follows: placebo +0.3 kg, aripiprazole 5 mg/day +1.3 kg, 10 mg/day +1.3 kg, and 15 mg/day +1.5 kg; all p < .05 versus placebo.
irritability	disease_to_anatomy	8	1	0	19797985	PMID:19797985; Original text:At week 8, all aripiprazole doses produced significantly greater improvement than placebo in mean Aberrant Behavior Checklist Irritability subscale scores (5 mg/day, -12.4; 10 mg/day, -13.2; 15 mg/day, -14.4; versus placebo, -8.4; all p < .05).
, and	anatomy	8	1	0	19797985	PMID:19797985; Original text:At week 8, mean weight change (last observation carried forward) was as follows: placebo +0.3 kg, aripiprazole 5 mg/day +1.3 kg, 10 mg/day +1.3 kg, and 15 mg/day +1.5 kg; all p < .05 versus placebo.
5-ht	chemical_to_disease	autistic	2	0	24613076|12858328	PMID:24613076; Original text:Significantly higher 5-HT levels in autistic patients compared to controls were recorded both in whole blood (whole blood)|PMID:12858328; Original text:A significant elevation in platelet-poor plasma 5-HT levels in adult autistic patients was reached 60 min after meal administration (p < 0.03 vs control and p = 0.05 vs baseline) and a significant decrease was noted after 120 min (p < 0.01 vs baseline).
5-ht	chemical_to_anatomy	whole blood	1	0	24613076	PMID:24613076; Original text:Significantly higher 5-HT levels in autistic patients compared to controls were recorded both in whole blood (whole blood)
autistic	disease_to_anatomy	whole blood	2	0	24613076|24613076	PMID:24613076; Original text:Significantly higher 5-HT levels in autistic patients compared to controls were recorded both in whole blood (whole blood)|PMID:24613076; Original text:Altogether, elevated 5-HT blood levels were recorded in 28.3% in whole blood and 22.5% in platelet-rich plasma samples of autistic individuals, as reported in 15 and 4 studies, respectively.
rich plasma	anatomy	whole blood	1	0	24613076	PMID:24613076; Original text:Altogether, elevated 5-HT blood levels were recorded in 28.3% in whole blood and 22.5% in platelet-rich plasma samples of autistic individuals, as reported in 15 and 4 studies, respectively.
platelet	anatomy	rich plasma	1	0	24613076	PMID:24613076; Original text:Altogether, elevated 5-HT blood levels were recorded in 28.3% in whole blood and 22.5% in platelet-rich plasma samples of autistic individuals, as reported in 15 and 4 studies, respectively.
platelet-rich plasma	anatomy	rich plasma	1	0	24613076	PMID:24613076; Original text:Altogether, elevated 5-HT blood levels were recorded in 28.3% in whole blood and 22.5% in platelet-rich plasma samples of autistic individuals, as reported in 15 and 4 studies, respectively.
platelet	anatomy	whole blood	1	0	24613076	PMID:24613076; Original text:Altogether, elevated 5-HT blood levels were recorded in 28.3% in whole blood and 22.5% in platelet-rich plasma samples of autistic individuals, as reported in 15 and 4 studies, respectively.
platelet-rich plasma	anatomy	whole blood	1	0	24613076	PMID:24613076; Original text:Altogether, elevated 5-HT blood levels were recorded in 28.3% in whole blood and 22.5% in platelet-rich plasma samples of autistic individuals, as reported in 15 and 4 studies, respectively.
platelet	anatomy	platelet-rich plasma	1	0	24613076	PMID:24613076; Original text:Altogether, elevated 5-HT blood levels were recorded in 28.3% in whole blood and 22.5% in platelet-rich plasma samples of autistic individuals, as reported in 15 and 4 studies, respectively.
autistic	disease_to_anatomy	rich plasma	1	0	24613076	PMID:24613076; Original text:Altogether, elevated 5-HT blood levels were recorded in 28.3% in whole blood and 22.5% in platelet-rich plasma samples of autistic individuals, as reported in 15 and 4 studies, respectively.
autistic	disease_to_anatomy	platelet-rich plasma	1	0	24613076	PMID:24613076; Original text:Altogether, elevated 5-HT blood levels were recorded in 28.3% in whole blood and 22.5% in platelet-rich plasma samples of autistic individuals, as reported in 15 and 4 studies, respectively.
anger	disease	autistic symptoms	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
desipramine	chemical_to_disease	anger	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
desipramine	chemical_to_disease	autistic symptoms	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
clomipramine	chemical_to_disease	anger	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
clomipramine	chemical_to_disease	autistic symptoms	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
desipramine	chemical_to_anatomy	, and	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
desipramine	chemical_to_anatomy	(p	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
clomipramine	chemical_to_anatomy	, and	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
clomipramine	chemical_to_anatomy	(p	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
anger	disease_to_anatomy	, and	2	0	8498878|9934941	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease_to_anatomy	(p	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
autistic symptoms	disease_to_anatomy	(p	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
amantadine	chemical_to_disease	irritability	1	0	24201232	PMID:24201232; Original text:Among ABC-C subscales, Hyperactivity and Irritability showed significantly greater reduction in the amantadine group than the placebo group.
amantadine	chemical_to_disease	hyperactivity	2	0	24201232|11392343	PMID:24201232; Original text:Among ABC-C subscales, Hyperactivity and Irritability showed significantly greater reduction in the amantadine group than the placebo group.|PMID:11392343; Original text:However, in the amantadine-treated group there were statistically significant improvements in absolute changes in clinician-rated ABC-CVs for hyperactivity (amantadine -6.4 versus placebo -2.1; p = .046) and inappropriate speech (-1.9 versus 0.4; p = .008).
casein-	mechanism	gluten-	1	0	15106205	PMID:15106205; Original text:However, the fourth outcome, reduction in autistic traits, reported a significant beneficial treatment effect for the combined gluten- and casein- free diet.
autistic traits	disease_to_mechanism	casein-	1	0	15106205	PMID:15106205; Original text:However, the fourth outcome, reduction in autistic traits, reported a significant beneficial treatment effect for the combined gluten- and casein- free diet.
autistic traits	disease_to_mechanism	gluten-	1	0	15106205	PMID:15106205; Original text:However, the fourth outcome, reduction in autistic traits, reported a significant beneficial treatment effect for the combined gluten- and casein- free diet.
, a	anatomy	inferior frontal gyrus	1	0	29517857	PMID:29517857; Original text:Second, the left inferior frontal gyrus, a region for socio-emotional processing, tracked individual gains in emotion recognition with decreased activation to social versus nonsocial stimuli.
gyrus	anatomy	inferior frontal gyrus	1	0	29517857	PMID:29517857; Original text:Second, the left inferior frontal gyrus, a region for socio-emotional processing, tracked individual gains in emotion recognition with decreased activation to social versus nonsocial stimuli.
, a	anatomy	frontal gyrus	1	0	29517857	PMID:29517857; Original text:Second, the left inferior frontal gyrus, a region for socio-emotional processing, tracked individual gains in emotion recognition with decreased activation to social versus nonsocial stimuli.
frontal gyrus	anatomy	gyrus	2	0	29517857|23452684	PMID:29517857; Original text:Second, the left inferior frontal gyrus, a region for socio-emotional processing, tracked individual gains in emotion recognition with decreased activation to social versus nonsocial stimuli.|PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
, a	anatomy	inferior frontal	1	0	29517857	PMID:29517857; Original text:Second, the left inferior frontal gyrus, a region for socio-emotional processing, tracked individual gains in emotion recognition with decreased activation to social versus nonsocial stimuli.
, a	anatomy	gyrus	1	0	29517857	PMID:29517857; Original text:Second, the left inferior frontal gyrus, a region for socio-emotional processing, tracked individual gains in emotion recognition with decreased activation to social versus nonsocial stimuli.
gyrus	anatomy	inferior frontal	1	0	29517857	PMID:29517857; Original text:Second, the left inferior frontal gyrus, a region for socio-emotional processing, tracked individual gains in emotion recognition with decreased activation to social versus nonsocial stimuli.
, and	anatomy	sensory motor	1	0	15930063	PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).
i)	anatomy	sensory motor	3	0	15930063|18080171|18080171	PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
scale	anatomy	sensory motor	1	0	15930063	PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).
, and	anatomy	i)	2	0	15930063|20195737	PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).|PMID:20195737; Original text:Rigorous meta-analysis techniques including random effects models, forest and funnel plots, I (I), publication bias, fail-safe analysis, and moderator variable analyses determined a significant standardized mean difference effect equal to 1.I0 (SE = 0.144; p <0.0001; Z = 10.49).
i)	anatomy	scale	1	0	15930063	PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).
risperidone	chemical_to_anatomy	i)	3	0	15930063|18080171|18080171	PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
risperidone	chemical_to_disease	maladaptive behavior	1	0	15930063	PMID:15930063; Original text:Risperidone also resulted in significantly greater reductions in scores on the Children's Yale-Brown Obsessive Compulsive Scale and Vineland maladaptive behavior domain.
anxiety	disease	irritability	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease	irritability	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease	depression	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
depression	disease	hyperactivity	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
aggression	disease	anxiety	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease	anxiety	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anxiety	disease	hyperactivity	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease	autism	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
autism	disease	hyperactivity	2	0	9934941|32168067	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
aggression	disease	anger	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
aggression	disease	hyperactivity	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease	hyperactivity	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
, motor	anatomy	, sensory	2	0	9934941|27721995	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
, sensory	anatomy	reactions	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
, and	anatomy	, motor	3	0	9934941|21263444|27721995	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
, motor	anatomy	reactions	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
, and	anatomy	reactions	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
irritability	disease_to_anatomy	, sensory	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
irritability	disease_to_anatomy	, motor	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
irritability	disease_to_anatomy	reactions	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
depression	disease_to_anatomy	, sensory	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
depression	disease_to_anatomy	, motor	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
depression	disease_to_anatomy	reactions	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anxiety	disease_to_anatomy	, sensory	2	0	9934941|27721995	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
anxiety	disease_to_anatomy	, motor	2	0	9934941|27721995	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
anxiety	disease_to_anatomy	reactions	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
autism	disease_to_anatomy	, sensory	2	0	9934941|27721995	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
autism	disease_to_anatomy	, motor	2	0	9934941|27721995	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
autism	disease_to_anatomy	reactions	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
aggression	disease_to_anatomy	, sensory	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
aggression	disease_to_anatomy	, motor	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
aggression	disease_to_anatomy	reactions	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease_to_anatomy	, sensory	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease_to_anatomy	, motor	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease_to_anatomy	reactions	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
hyperactivity	disease_to_anatomy	, sensory	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
hyperactivity	disease_to_anatomy	, motor	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
hyperactivity	disease_to_anatomy	reactions	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
component of	anatomy	of the	2	0	8879465|3623815	PMID:8879465; Original text:These preliminary results encourage our research on this chromosome, which could be considered as a significant genetic component of the multifactorial etiology of autism.|PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.
chromosome	anatomy	component of	1	0	8879465	PMID:8879465; Original text:These preliminary results encourage our research on this chromosome, which could be considered as a significant genetic component of the multifactorial etiology of autism.
chromosome	anatomy	of the	1	0	8879465	PMID:8879465; Original text:These preliminary results encourage our research on this chromosome, which could be considered as a significant genetic component of the multifactorial etiology of autism.
autism	disease_to_anatomy	component of	1	0	8879465	PMID:8879465; Original text:These preliminary results encourage our research on this chromosome, which could be considered as a significant genetic component of the multifactorial etiology of autism.
autism	disease_to_anatomy	chromosome	2	0	8879465|11525418	PMID:8879465; Original text:These preliminary results encourage our research on this chromosome, which could be considered as a significant genetic component of the multifactorial etiology of autism.|PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
glutathione	chemical	homocysteine	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	chemical	methionine	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	chemical	s-adenosylhomocysteine	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
level of	anatomy	levels of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	nutrient_to_chemical	homocysteine	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	nutrient_to_chemical	glutathione	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	nutrient_to_chemical	methionine	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	nutrient_to_chemical	s-adenosylhomocysteine	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	nutrient_to_disease	autistic	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	nutrient_to_mechanism	methionine synthase	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	nutrient_to_anatomy	levels of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	nutrient_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	chemical_to_disease	autistic	2	0	24676906|24167375	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.|PMID:24167375; Original text:The urinary levels of homocysteine and essential amino acids in both the untreated and treated autistic children are significantly less than those in the controls.
glutathione	chemical_to_disease	autistic	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
methionine	chemical_to_disease	autistic	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
s-adenosylhomocysteine	chemical_to_disease	autistic	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	chemical_to_mechanism	methionine synthase	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
glutathione	chemical_to_mechanism	methionine synthase	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
methionine	chemical_to_mechanism	methionine synthase	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
s-adenosylhomocysteine	chemical_to_mechanism	methionine synthase	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	chemical_to_anatomy	levels of	2	0	24676906|24167375	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.|PMID:24167375; Original text:The urinary levels of homocysteine and essential amino acids in both the untreated and treated autistic children are significantly less than those in the controls.
homocysteine	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
glutathione	chemical_to_anatomy	levels of	2	0	24676906|22129897	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.|PMID:22129897; Original text:Recent evidence shows that subjects diagnosed with an autism spectrum disorder (disorder) have significantly lower levels of glutathione than typically developing children.
glutathione	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
methionine	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
s-adenosylhomocysteine	chemical_to_anatomy	levels of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
s-adenosylhomocysteine	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
autistic	disease_to_mechanism	methionine synthase	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
methionine synthase	mechanism_to_anatomy	levels of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
methionine synthase	mechanism_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
folate	chemical	mercury	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
mercury	chemical	vitamin b₁₂.	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
folate	chemical	vitamin b₁₂.	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
autistic	disease	nutritional deficiencies	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
mercury	chemical_to_disease	autistic	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
mercury	chemical_to_disease	nutritional deficiencies	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
folate	chemical_to_disease	autistic	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
folate	chemical_to_disease	nutritional deficiencies	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
vitamin b₁₂.	chemical_to_disease	autistic	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
vitamin b₁₂.	chemical_to_disease	nutritional deficiencies	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
mercury	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
folate	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
vitamin b₁₂.	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
nutritional deficiencies	disease_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
glutathione	chemical	gssg	1	0	20804367	PMID:20804367; Original text:More notably, these responders exhibited significantly increased plasma concentrations of glutathione and glutathione/GSSG.
methyl b12	chemical_to_disease	autism	1	0	20804367	PMID:20804367; Original text:Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism.
methyl b12	chemical_to_anatomy	of the	1	0	20804367	PMID:20804367; Original text:Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism.
glutamine	chemical	p<0.05	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	p<0.05	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical	p<0.05	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical	p<0.05	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical	p<0.05	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.05	chemical	phosphocreatine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	glutamine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical	glutamine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamine	chemical	p<0.001	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical	glutamine	2	0	22848344|30262887	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).|PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamine	chemical	phosphocreatine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	creatine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	p<0.001	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	glutamate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	phosphocreatine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical	p<0.001	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical	glutamate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical	phosphocreatine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical	p<0.001	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical	phosphocreatine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical	phosphocreatine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate cortex	anatomy	cortex	2	0	22848344|22426803	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate cortex	anatomy	cortex	2	0	22848344|22426803	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate	anatomy	cortex	2	0	22848344|22426803	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
creatine	nutrient_to_chemical	p<0.05	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	nutrient_to_chemical	glutamine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	nutrient_to_chemical	cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	nutrient_to_chemical	p<0.001	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	nutrient_to_chemical	glutamate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	nutrient_to_chemical	phosphocreatine	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	nutrient_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	nutrient_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	nutrient_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	nutrient_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.05	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.05	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.05	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.05	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamine	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamine	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamine	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamine	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
phosphocreatine	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
phosphocreatine	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
phosphocreatine	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
phosphocreatine	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
n-acetyl-aspartate	chemical	n-acetyl-aspartyl-glutamate	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
, and	anatomy	cingulate cortex	3	0	22848344|26769980|22426803	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, and	anatomy	anterior cingulate cortex	3	0	22848344|26769980|22426803	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, and	anatomy	anterior cingulate	3	0	22848344|26769980|22426803	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
glutamine	nutrient_to_chemical	n-acetyl-aspartate	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
glutamine	nutrient_to_chemical	n-acetyl-aspartyl-glutamate	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
glutamine	nutrient_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
glutamine	nutrient_to_anatomy	, and	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
glutamine	nutrient_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
glutamine	nutrient_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartate	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartate	chemical_to_anatomy	, and	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartate	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartate	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartyl-glutamate	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartyl-glutamate	chemical_to_anatomy	, and	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartyl-glutamate	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartyl-glutamate	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
, and	anatomy	, can	2	0	34257640|32892962	PMID:34257640; Original text:A within-group comparison showed that real transcranial direct current stimulation, but not sham transcranial direct current stimulation, can significantly reduce the scores of Scale, Children's Sleep Habits Questionnaire (Children's Sleep Habits Questionnaire), and general impressions in Scale (15th item).|PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
, can	anatomy	scale	1	0	34257640	PMID:34257640; Original text:A within-group comparison showed that real transcranial direct current stimulation, but not sham transcranial direct current stimulation, can significantly reduce the scores of Scale, Children's Sleep Habits Questionnaire (Children's Sleep Habits Questionnaire), and general impressions in Scale (15th item).
, and	anatomy	field of	2	0	21378114|24246273	PMID:21378114; Original text:The study types differed significantly with respect to low-pass filtering, task regression, and whole-brain field of view.|PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
the	mechanism	the serotonin transporter gene polymorphisms	1	0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
serotonin	chemical_to_mechanism	the serotonin transporter gene polymorphisms	1	0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
serotonin	chemical_to_mechanism	the	1	0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
serotonin	chemical_to_anatomy	of the	4	0	18286633|18286633|3623815|22638012	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.|PMID:18286633; Original text:However, there was significant heterogeneity by ethnicity; family based studies of US mixed population samples showed preferential transmission of the S allele of The serotonin transporter geneLPR (S allele:|PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.|PMID:22638012; Original text:Modulation of the processing of facial expressions of emotion by serotonin significantly differs in people with ASD compared with control subjects.
autism	disease_to_mechanism	the serotonin transporter gene polymorphisms	1	0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
autism	disease_to_mechanism	the	1	0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
the serotonin transporter gene polymorphisms	mechanism_to_anatomy	of the	1	0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
the	mechanism_to_anatomy	of the	1	0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
s allele	mechanism	serotonin transporter genelpr	1	0	18286633	PMID:18286633; Original text:However, there was significant heterogeneity by ethnicity; family based studies of US mixed population samples showed preferential transmission of the S allele of The serotonin transporter geneLPR (S allele:
serotonin	chemical_to_mechanism	serotonin transporter genelpr	1	0	18286633	PMID:18286633; Original text:However, there was significant heterogeneity by ethnicity; family based studies of US mixed population samples showed preferential transmission of the S allele of The serotonin transporter geneLPR (S allele:
serotonin	chemical_to_mechanism	s allele	1	0	18286633	PMID:18286633; Original text:However, there was significant heterogeneity by ethnicity; family based studies of US mixed population samples showed preferential transmission of the S allele of The serotonin transporter geneLPR (S allele:
serotonin transporter genelpr	mechanism_to_anatomy	of the	1	0	18286633	PMID:18286633; Original text:However, there was significant heterogeneity by ethnicity; family based studies of US mixed population samples showed preferential transmission of the S allele of The serotonin transporter geneLPR (S allele:
s allele	mechanism_to_anatomy	of the	1	0	18286633	PMID:18286633; Original text:However, there was significant heterogeneity by ethnicity; family based studies of US mixed population samples showed preferential transmission of the S allele of The serotonin transporter geneLPR (S allele:
tryptophan	chemical_to_anatomy	of the brain	1	0	28799778	PMID:28799778; Original text:The literature strongly suggests that Tryptophan has a significant role in the correct functionality of the brain-gut axis and immunology.
tryptophan	chemical_to_anatomy	the brain	1	0	28799778	PMID:28799778; Original text:The literature strongly suggests that Tryptophan has a significant role in the correct functionality of the brain-gut axis and immunology.
catatonia	disease	psychiatric	1	0	16697303	PMID:16697303; Original text:Catatonia should be assessed in any patient with spectrum disorders when there is an obvious and marked deterioration in movement, pattern of activities, self-care, and practical skills, compared with previous levels, through a comprehensive diagnostic evaluation of medical and psychiatric symptoms.
psychiatric	disease	spectrum disorders	1	0	16697303	PMID:16697303; Original text:Catatonia should be assessed in any patient with spectrum disorders when there is an obvious and marked deterioration in movement, pattern of activities, self-care, and practical skills, compared with previous levels, through a comprehensive diagnostic evaluation of medical and psychiatric symptoms.
catatonia	disease	spectrum disorders	1	0	16697303	PMID:16697303; Original text:Catatonia should be assessed in any patient with spectrum disorders when there is an obvious and marked deterioration in movement, pattern of activities, self-care, and practical skills, compared with previous levels, through a comprehensive diagnostic evaluation of medical and psychiatric symptoms.
psychiatric	disease_to_anatomy	, and	1	0	16697303	PMID:16697303; Original text:Catatonia should be assessed in any patient with spectrum disorders when there is an obvious and marked deterioration in movement, pattern of activities, self-care, and practical skills, compared with previous levels, through a comprehensive diagnostic evaluation of medical and psychiatric symptoms.
spectrum disorders	disease_to_anatomy	, and	3	0	16697303|28965590|33403915	PMID:16697303; Original text:Catatonia should be assessed in any patient with spectrum disorders when there is an obvious and marked deterioration in movement, pattern of activities, self-care, and practical skills, compared with previous levels, through a comprehensive diagnostic evaluation of medical and psychiatric symptoms.|PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.|PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
mental health	disease	mental health problems	2	0	16670650|16670650	PMID:16670650; Original text:Both treatments resulted in significant and progressive improvement in overall mental health at follow-up (F = 2, 97, p =.007) and mental health significantly improved over time in the 54% of principal caregivers who had the highest levels of mental health problems.|PMID:16670650; Original text:A 20-week parent education and skills training program for parents of young children newly diagnosed with autism provides significant improvements in parental mental health and adjustment, justifying its addition to early intervention programs at least for parents with mental health problems.
2	anatomy	levels of	1	0	16670650	PMID:16670650; Original text:Both treatments resulted in significant and progressive improvement in overall mental health at follow-up (F = 2, 97, p =.007) and mental health significantly improved over time in the 54% of principal caregivers who had the highest levels of mental health problems.
mental health	disease_to_anatomy	2	1	0	16670650	PMID:16670650; Original text:Both treatments resulted in significant and progressive improvement in overall mental health at follow-up (F = 2, 97, p =.007) and mental health significantly improved over time in the 54% of principal caregivers who had the highest levels of mental health problems.
mental health	disease_to_anatomy	levels of	1	0	16670650	PMID:16670650; Original text:Both treatments resulted in significant and progressive improvement in overall mental health at follow-up (F = 2, 97, p =.007) and mental health significantly improved over time in the 54% of principal caregivers who had the highest levels of mental health problems.
mental health problems	disease_to_anatomy	2	1	0	16670650	PMID:16670650; Original text:Both treatments resulted in significant and progressive improvement in overall mental health at follow-up (F = 2, 97, p =.007) and mental health significantly improved over time in the 54% of principal caregivers who had the highest levels of mental health problems.
mental health problems	disease_to_anatomy	levels of	1	0	16670650	PMID:16670650; Original text:Both treatments resulted in significant and progressive improvement in overall mental health at follow-up (F = 2, 97, p =.007) and mental health significantly improved over time in the 54% of principal caregivers who had the highest levels of mental health problems.
autism	disease	mental health	1	0	16670650	PMID:16670650; Original text:A 20-week parent education and skills training program for parents of young children newly diagnosed with autism provides significant improvements in parental mental health and adjustment, justifying its addition to early intervention programs at least for parents with mental health problems.
autism	disease	mental health problems	1	0	16670650	PMID:16670650; Original text:A 20-week parent education and skills training program for parents of young children newly diagnosed with autism provides significant improvements in parental mental health and adjustment, justifying its addition to early intervention programs at least for parents with mental health problems.
[123i]-nor-β-cit	chemical	dopamine	1	0	22015434	PMID:22015434; Original text:Good clinical responders (n=6) had a decrease (p=0.031) in striatal dopamine transporter binding as assessed using single-photon emission computed tomography with [123I]-nor-β-CIT, whereas poor responders had a trend to an increase.
dopamine	chemical_to_mechanism	striatal dopamine transporter	1	0	22015434	PMID:22015434; Original text:Good clinical responders (n=6) had a decrease (p=0.031) in striatal dopamine transporter binding as assessed using single-photon emission computed tomography with [123I]-nor-β-CIT, whereas poor responders had a trend to an increase.
[123i]-nor-β-cit	chemical_to_mechanism	striatal dopamine transporter	1	0	22015434	PMID:22015434; Original text:Good clinical responders (n=6) had a decrease (p=0.031) in striatal dopamine transporter binding as assessed using single-photon emission computed tomography with [123I]-nor-β-CIT, whereas poor responders had a trend to an increase.
pentoxifylline	chemical_to_disease	irritability	1	0	19772883	PMID:19772883; Original text:The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in the Aberrant Behavior Checklist-Community subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech.
pentoxifylline	chemical_to_disease	lethargy	1	0	19772883	PMID:19772883; Original text:The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in the Aberrant Behavior Checklist-Community subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech.
pentoxifylline	chemical_to_disease	hyperactivity	1	0	19772883	PMID:19772883; Original text:The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in the Aberrant Behavior Checklist-Community subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech.
inositol	nutrient_to_chemical	inositol	3	0	9169302|9169302|9169302	PMID:9169302; Original text:Significant overall benefit for inositol compared to placebo was found at week 4 on the Hamilton Depression Scale.|PMID:9169302; Original text:Frequency and severity of panic attacks and severity of agoraphobia declined significantly with inositol compared to placebo.|PMID:9169302; Original text:Inositol significantly reduced scores of obsessive compulsive disorder symptoms compared with placebo.
agoraphobia	disease	panic attacks	1	0	9169302	PMID:9169302; Original text:Frequency and severity of panic attacks and severity of agoraphobia declined significantly with inositol compared to placebo.
inositol	nutrient_to_disease	agoraphobia	1	0	9169302	PMID:9169302; Original text:Frequency and severity of panic attacks and severity of agoraphobia declined significantly with inositol compared to placebo.
inositol	nutrient_to_disease	panic attacks	1	0	9169302	PMID:9169302; Original text:Frequency and severity of panic attacks and severity of agoraphobia declined significantly with inositol compared to placebo.
inositol	chemical_to_disease	agoraphobia	1	0	9169302	PMID:9169302; Original text:Frequency and severity of panic attacks and severity of agoraphobia declined significantly with inositol compared to placebo.
inositol	chemical_to_disease	panic attacks	1	0	9169302	PMID:9169302; Original text:Frequency and severity of panic attacks and severity of agoraphobia declined significantly with inositol compared to placebo.
inositol	nutrient_to_disease	obsessive compulsive disorder symptoms	1	0	9169302	PMID:9169302; Original text:Inositol significantly reduced scores of obsessive compulsive disorder symptoms compared with placebo.
inositol	chemical_to_disease	obsessive compulsive disorder symptoms	1	0	9169302	PMID:9169302; Original text:Inositol significantly reduced scores of obsessive compulsive disorder symptoms compared with placebo.
glucose	chemical_to_disease	alzheimer	1	0	9169302	PMID:9169302; Original text:A double-blind controlled crossover trial of 6 g of inositol daily vs. glucose for one month each was carried out in eleven Alzheimer patients, with on clearly significant therapeutic effects.
brain overgrowth	disease_to_anatomy	(p	1	0	23706681	PMID:23706681; Original text:In systematic review, comparisons with locally recruited control subjects were significantly less likely to identify Early brain overgrowth in disorder than norm-based studies (p < .001).
end of	anatomy	group of	1	0	26770664	PMID:26770664; Original text:However, an overall significant improvement in SRS total raw score was observed from baseline to end of treatment for the entire group of children with spectrum disorders.
spectrum disorders	disease_to_anatomy	group of	1	0	26770664	PMID:26770664; Original text:However, an overall significant improvement in SRS total raw score was observed from baseline to end of treatment for the entire group of children with spectrum disorders.
spectrum disorders	disease_to_anatomy	end of	1	0	26770664	PMID:26770664; Original text:However, an overall significant improvement in SRS total raw score was observed from baseline to end of treatment for the entire group of children with spectrum disorders.
autism spectrum disorder	disease	substance use disorder	2	0	32471596|33526236	PMID:32471596; Original text:Individuals with autism spectrum disorder (disorder) have a significantly higher risk for developing a substance use disorder (a substance use disorder) than the general population yet literature addressing cooccurring disorder and a substance use disorder is scarce.|PMID:33526236; Original text:Individuals with autism spectrum disorder (disorder) have a significantly higher risk for developing a substance use disorder (a substance use disorder) than the general population yet literature addressing cooccurring disorder and a substance use disorder is scarce.
risperidone	chemical_to_mechanism	prolactin	2	0	16730335|15142390	PMID:16730335; Original text:After 8 weeks of risperidone, prolactin increased to 39.0 +/- 19.2 ng/ml, compared with 10.1 +/-|PMID:15142390; Original text:In all children, serum prolactin levels increased significantly (p < 0.001) from 166 +/- 88 UI/mL at baseline to 504 +/- 207 UI/mL at week 12 of risperidone treatment.
autistic	disease	cognitive and behavioral impairments	1	0	21826280	PMID:21826280; Original text:We propose that alteration of the expression and/or timing of critical period circuit refinement in primary sensory brain areas may significantly contribute to autistic phenotypes, including cognitive and behavioral impairments.
cognitive and behavioral impairments	disease_to_anatomy	of the	1	0	21826280	PMID:21826280; Original text:We propose that alteration of the expression and/or timing of critical period circuit refinement in primary sensory brain areas may significantly contribute to autistic phenotypes, including cognitive and behavioral impairments.
amino acids	chemical_to_disease	autism	1	0	24167375	PMID:24167375; Original text:There are many reports about the significant roles of some amino acids in neurobiology and treatment of autism.
amino acids	chemical	homocysteine	1	0	24167375	PMID:24167375; Original text:The urinary levels of homocysteine and essential amino acids in both the untreated and treated autistic children are significantly less than those in the controls.
amino acids	chemical_to_disease	autistic	2	0	24167375|21299356	PMID:24167375; Original text:The urinary levels of homocysteine and essential amino acids in both the untreated and treated autistic children are significantly less than those in the controls.|PMID:21299356; Original text:Covering the literature from 1943 to the present in the PubMed and Ovid Medline databases, this review summarizes evidence of hormones, metabolites, amino acids, and other biomarkers present in significantly different quantities in autistic subjects compared to age- and sex-matched controls.
amino acids	chemical_to_anatomy	levels of	1	0	24167375	PMID:24167375; Original text:The urinary levels of homocysteine and essential amino acids in both the untreated and treated autistic children are significantly less than those in the controls.
cannabidiol	chemical_to_anatomy	brain	1	0	31237191	PMID:31237191; Original text:The 'fractional amplitude of low-frequency fluctuations' (fALFF) was measured across the whole brain, and, where its major non-intoxicating component cannabidiol significantly altered fALFF, we tested if functional connectivity (functional connectivity) of those regions was also affected by its major non-intoxicating component cannabidiol.
cannabidiol	chemical_to_anatomy	, and	1	0	31237191	PMID:31237191; Original text:The 'fractional amplitude of low-frequency fluctuations' (fALFF) was measured across the whole brain, and, where its major non-intoxicating component cannabidiol significantly altered fALFF, we tested if functional connectivity (functional connectivity) of those regions was also affected by its major non-intoxicating component cannabidiol.
cerebellar vermis	anatomy	fusiform gyrus	1	0	31237191	PMID:31237191; Original text:its major non-intoxicating component cannabidiol significantly increased fALFF in the cerebellar vermis and the right fusiform gyrus.
cannabidiol	chemical_to_anatomy	cerebellar vermis	1	0	31237191	PMID:31237191; Original text:its major non-intoxicating component cannabidiol significantly increased fALFF in the cerebellar vermis and the right fusiform gyrus.
cannabidiol	chemical_to_anatomy	fusiform gyrus	1	0	31237191	PMID:31237191; Original text:its major non-intoxicating component cannabidiol significantly increased fALFF in the cerebellar vermis and the right fusiform gyrus.
cannabidiol	chemical_to_disease	asd	2	0	31237191|30758329	PMID:31237191; Original text:Within the ASD group only, its major non-intoxicating component cannabidiol also significantly altered vermal functional connectivity with several of its subcortical (striatal) and cortical targets, but did not affect fusiform functional connectivity with other regions in either group.|PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
autism spectrum disorder	disease_to_anatomy	(p	3	0	29146048|26792761|25149412	PMID:29146048; Original text:The meta-analysis of the literature suggested a weak but significant association between autism spectrum disorder diagnosis and increased cerebellar volume (p = .049, uncorrected), but the analysis of ABIDE did not show any relationship.|PMID:26792761; Original text:Greater T2DM incidence was associated with second-generation antipsychotic prescription (P ≤ .050) and less autism spectrum disorder diagnosis (P = .048)|PMID:25149412; Original text:In the case-control study, 17 males with autism spectrum disorder showed significant behavioural deficits in inferring others' social emotions (P = 0.018) but not in inferring others' beliefs (P = 0.064) compared with 17 typically developing demographically-matched male participants.
agitation	disease	irritability	1	0	23782127	PMID:23782127; Original text:The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks.
agitation	disease	hyperactivity	1	0	23782127	PMID:23782127; Original text:The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks.
agitation	disease_to_anatomy	, and	1	0	23782127	PMID:23782127; Original text:The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks.
schizoid	disease	stimulatory	1	0	8463192	PMID:8463192; Original text:Asperger subjects tended to look less at the other person, to make more self-stimulatory gestures, and to look at the interviewer significantly less than normal subjects, and substantially less than schizoid subjects, during the periods when the interviewer was vocalizing although there were no such differences when the interviewer was listening.
stimulatory	disease_to_anatomy	, and	1	0	8463192	PMID:8463192; Original text:Asperger subjects tended to look less at the other person, to make more self-stimulatory gestures, and to look at the interviewer significantly less than normal subjects, and substantially less than schizoid subjects, during the periods when the interviewer was vocalizing although there were no such differences when the interviewer was listening.
schizoid	disease_to_anatomy	, and	1	0	8463192	PMID:8463192; Original text:Asperger subjects tended to look less at the other person, to make more self-stimulatory gestures, and to look at the interviewer significantly less than normal subjects, and substantially less than schizoid subjects, during the periods when the interviewer was vocalizing although there were no such differences when the interviewer was listening.
pcbs	chemical	polychlorinated biphenyls	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
parts of	anatomy	parts of the	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
of the	anatomy	parts of	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
of the	anatomy	parts of the	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
polychlorinated biphenyls	chemical_to_anatomy	parts of	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
polychlorinated biphenyls	chemical_to_anatomy	parts of the	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
polychlorinated biphenyls	chemical_to_anatomy	of the	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
pcbs	chemical_to_anatomy	parts of	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
pcbs	chemical_to_anatomy	parts of the	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
pcbs	chemical_to_anatomy	of the	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
mitochondrial	anatomy	the brain	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
mast cell	anatomy	mitochondrial	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
mitochondrial	anatomy	secretion of	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
mitochondrial	anatomy	secretion	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
mast cell	anatomy	the brain	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
secretion of	anatomy	the brain	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
secretion	anatomy	the brain	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
mast cell	anatomy	secretion of	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
mast cell	anatomy	secretion	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
secretion	anatomy	secretion of	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_disease	asd	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_mechanism	neurotensin	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_anatomy	mitochondrial	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_anatomy	the brain	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_anatomy	mast cell	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_anatomy	secretion of	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_anatomy	secretion	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
asd	disease_to_anatomy	the brain	2	0	23688533|21692142	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.|PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
asd	disease_to_anatomy	mast cell	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
asd	disease_to_anatomy	secretion of	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
asd	disease_to_anatomy	secretion	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
neurotensin	mechanism_to_anatomy	the brain	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
neurotensin	mechanism_to_anatomy	mast cell	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
neurotensin	mechanism_to_anatomy	secretion of	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
neurotensin	mechanism_to_anatomy	secretion	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
autism	disease	epilepsy	1	0	19454962	PMID:19454962; Original text:However, critical review of the literature reveals that the rate in idiopathic cases with normal lower intelligence quotient is still significantly above the population risk suggesting that autism itself is associated with an increased risk of epilepsy.
, and	anatomy	acids	1	0	21299356	PMID:21299356; Original text:Covering the literature from 1943 to the present in the PubMed and Ovid Medline databases, this review summarizes evidence of hormones, metabolites, amino acids, and other biomarkers present in significantly different quantities in autistic subjects compared to age- and sex-matched controls.
amino acids	chemical_to_anatomy	, and	1	0	21299356	PMID:21299356; Original text:Covering the literature from 1943 to the present in the PubMed and Ovid Medline databases, this review summarizes evidence of hormones, metabolites, amino acids, and other biomarkers present in significantly different quantities in autistic subjects compared to age- and sex-matched controls.
amino acids	chemical_to_anatomy	acids	1	0	21299356	PMID:21299356; Original text:Covering the literature from 1943 to the present in the PubMed and Ovid Medline databases, this review summarizes evidence of hormones, metabolites, amino acids, and other biomarkers present in significantly different quantities in autistic subjects compared to age- and sex-matched controls.
autistic	disease_to_anatomy	acids	1	0	21299356	PMID:21299356; Original text:Covering the literature from 1943 to the present in the PubMed and Ovid Medline databases, this review summarizes evidence of hormones, metabolites, amino acids, and other biomarkers present in significantly different quantities in autistic subjects compared to age- and sex-matched controls.
nucleus neurons	anatomy	reticular nucleus	1	0	29673480	PMID:29673480; Original text:Because the thalamic reticular nucleus neurons express several disorder-relevant genes identified through genome-wide association studies, exploring the consequences of different the thalamic reticular nucleus disruptions may be of broad translational significance.
nucleus neurons	anatomy	thalamic	1	0	29673480	PMID:29673480; Original text:Because the thalamic reticular nucleus neurons express several disorder-relevant genes identified through genome-wide association studies, exploring the consequences of different the thalamic reticular nucleus disruptions may be of broad translational significance.
reticular nucleus	anatomy	thalamic	1	0	29673480	PMID:29673480; Original text:Because the thalamic reticular nucleus neurons express several disorder-relevant genes identified through genome-wide association studies, exploring the consequences of different the thalamic reticular nucleus disruptions may be of broad translational significance.
autism spectrum disorder	disease	autoimmune disease	1	0	31191521	PMID:31191521; Original text:For example, mothers of children with Autism Spectrum Disorder (Autism Spectrum Disorder) are significantly more likely to have an autoimmune disease than women of neurotypically developing children.
gdm	disease	pgdm	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
gdm	disease	pregestational	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
gdm	disease	malformations	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
pgdm	disease	pregestational	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
malformations	disease	pgdm	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
malformations	disease	pregestational	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
fingertips	anatomy	systems	1	0	20623006	PMID:20623006; Original text:Out of total of 48 acupuncture points present on ten fingertips of both hands and associated to organs/organ systems, autistic children differed significantly from controls (p < 0.05) in 36 (images without filter) and 12 (images with filter), siblings differed significantly from controls (p < 0.05) in 12 (images without filter) and seven (images with filter), autistic children differed significantly (p < 0.05) from siblings in eight (images without filter) and one (images with filter), fathers of autistic children differed significantly (p < 0.05) from controls in 14 (images without filter) and three (images with filter) and mothers of autistic children differed significantly (p < 0.05) from controls in five (images without filter) and nine (images with filter
(p	anatomy	systems	1	0	20623006	PMID:20623006; Original text:Out of total of 48 acupuncture points present on ten fingertips of both hands and associated to organs/organ systems, autistic children differed significantly from controls (p < 0.05) in 36 (images without filter) and 12 (images with filter), siblings differed significantly from controls (p < 0.05) in 12 (images without filter) and seven (images with filter), autistic children differed significantly (p < 0.05) from siblings in eight (images without filter) and one (images with filter), fathers of autistic children differed significantly (p < 0.05) from controls in 14 (images without filter) and three (images with filter) and mothers of autistic children differed significantly (p < 0.05) from controls in five (images without filter) and nine (images with filter
(p	anatomy	fingertips	1	0	20623006	PMID:20623006; Original text:Out of total of 48 acupuncture points present on ten fingertips of both hands and associated to organs/organ systems, autistic children differed significantly from controls (p < 0.05) in 36 (images without filter) and 12 (images with filter), siblings differed significantly from controls (p < 0.05) in 12 (images without filter) and seven (images with filter), autistic children differed significantly (p < 0.05) from siblings in eight (images without filter) and one (images with filter), fathers of autistic children differed significantly (p < 0.05) from controls in 14 (images without filter) and three (images with filter) and mothers of autistic children differed significantly (p < 0.05) from controls in five (images without filter) and nine (images with filter
autistic	disease_to_anatomy	systems	1	0	20623006	PMID:20623006; Original text:Out of total of 48 acupuncture points present on ten fingertips of both hands and associated to organs/organ systems, autistic children differed significantly from controls (p < 0.05) in 36 (images without filter) and 12 (images with filter), siblings differed significantly from controls (p < 0.05) in 12 (images without filter) and seven (images with filter), autistic children differed significantly (p < 0.05) from siblings in eight (images without filter) and one (images with filter), fathers of autistic children differed significantly (p < 0.05) from controls in 14 (images without filter) and three (images with filter) and mothers of autistic children differed significantly (p < 0.05) from controls in five (images without filter) and nine (images with filter
autistic	disease_to_anatomy	fingertips	1	0	20623006	PMID:20623006; Original text:Out of total of 48 acupuncture points present on ten fingertips of both hands and associated to organs/organ systems, autistic children differed significantly from controls (p < 0.05) in 36 (images without filter) and 12 (images with filter), siblings differed significantly from controls (p < 0.05) in 12 (images without filter) and seven (images with filter), autistic children differed significantly (p < 0.05) from siblings in eight (images without filter) and one (images with filter), fathers of autistic children differed significantly (p < 0.05) from controls in 14 (images without filter) and three (images with filter) and mothers of autistic children differed significantly (p < 0.05) from controls in five (images without filter) and nine (images with filter
(p	anatomy	, general	1	0	28464438	PMID:28464438; Original text:The subjects' ability to play, general behavioral and emotional symptoms were significantly diminished after treatment (p < 0.05).
gws	mechanism	gws loci	1	0	28540026	PMID:28540026; Original text:Previous ASD the past decade genome-wide association studies have identified genome-wide significant (GWS) risk loci; however, these studies were of only of low statistical power to identify GWS loci at the lower effect sizes (odds ratio (odds ratio) <1.15).
asd	disease_to_mechanism	gws loci	1	0	28540026	PMID:28540026; Original text:Previous ASD the past decade genome-wide association studies have identified genome-wide significant (GWS) risk loci; however, these studies were of only of low statistical power to identify GWS loci at the lower effect sizes (odds ratio (odds ratio) <1.15).
asd	disease_to_mechanism	gws	1	0	28540026	PMID:28540026; Original text:Previous ASD the past decade genome-wide association studies have identified genome-wide significant (GWS) risk loci; however, these studies were of only of low statistical power to identify GWS loci at the lower effect sizes (odds ratio (odds ratio) <1.15).
cognitive or psychiatric symptoms	disease	posterior fossa arachnoid cyst	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
cognitive or psychiatric symptoms	disease	neurodevelopmental or psychiatric symptoms	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
neurodevelopmental or psychiatric symptoms	disease	posterior fossa arachnoid cyst	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
of primary	anatomy	posterior fossa	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
arachnoid	anatomy	of primary	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
arachnoid	anatomy	posterior fossa	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
cognitive or psychiatric symptoms	disease_to_anatomy	of primary	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
cognitive or psychiatric symptoms	disease_to_anatomy	posterior fossa	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
cognitive or psychiatric symptoms	disease_to_anatomy	arachnoid	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
posterior fossa arachnoid cyst	disease_to_anatomy	of primary	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
posterior fossa arachnoid cyst	disease_to_anatomy	posterior fossa	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
posterior fossa arachnoid cyst	disease_to_anatomy	arachnoid	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
neurodevelopmental or psychiatric symptoms	disease_to_anatomy	of primary	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
neurodevelopmental or psychiatric symptoms	disease_to_anatomy	posterior fossa	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
neurodevelopmental or psychiatric symptoms	disease_to_anatomy	arachnoid	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
aseptic meningitis	disease	rubella	1	0	22336803	PMID:22336803; Original text:The highest risk of association with aseptic meningitis was observed within the third week after immunisation with Urabe-containing rubella (risk ratio (risk ratio) 14.28; 95% confidence interval (95% confidence interval) from 7.93 to 25.71) and within the third (risk ratio 22.5; 95% 95% confidence interval 11.8 to 42.9) or fifth (risk ratio 15.6; 95% 95% confidence interval 10.3 to 24.2) weeks after immunisation with the vaccine prepared with the Leningrad-Zagreb strain.
risperidone	chemical_to_anatomy	(p	8	0	16282839|15142390|18080171|18080171|18080171|16948927|14627879|16239862	PMID:16282839; Original text:The rates of correctly guessing individual treatment assignment (risperidone or placebo) were significantly greater than chance for both clinical evaluators and parents (P < 0.001).|PMID:15142390; Original text:In all children, serum prolactin levels increased significantly (p < 0.001) from 166 +/- 88 UI/mL at baseline to 504 +/- 207 UI/mL at week 12 of risperidone treatment.|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Compared to haloperidol, risperidone led to a significantly greater reduction in the Aberrant Behavior Checklist (the Aberrant Behavior Checklist) and Turgay DSM-IV Pervasive Developmental Disorder (Turgay DSM-IV Pervasive Developmental Disorder) scale scores (P < 0.05 and P < 0.01).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).|PMID:14627879; Original text:Mean ratings at 8 weeks were 2.8 +/- 1.2 on risperidone and 4.5 +/- 1.3 on placebo (p <.001).|PMID:16239862; Original text:Risperidone was superior to placebo in preventing relapse: this occurred in 3 of 12 patients continuing on risperidone versus 8 of 12 who switched to placebo (p = .049).
autism-spectrum disorders	disease	schizophrenia	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
default mode network	anatomy	network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
default mode network	anatomy	the ventral	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
default mode	anatomy	default mode network	2	0	29688876|33403915	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.|PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
, and	anatomy	default mode network	2	0	29688876|33403915	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.|PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
, cortical	anatomy	default mode network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
default mode network	anatomy	mode network	2	0	29688876|33403915	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.|PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
default mode network	anatomy	networks	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
network	anatomy	the ventral	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
default mode	anatomy	network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
, and	anatomy	network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
, cortical	anatomy	network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
mode network	anatomy	network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
network	anatomy	networks	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
default mode	anatomy	the ventral	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
, and	anatomy	the ventral	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
, cortical	anatomy	the ventral	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
mode network	anatomy	the ventral	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
networks	anatomy	the ventral	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
, and	anatomy	default mode	2	0	29688876|33403915	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.|PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
, cortical	anatomy	default mode	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
default mode	anatomy	mode network	2	0	29688876|33403915	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.|PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
default mode	anatomy	networks	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
, and	anatomy	, cortical	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
, and	anatomy	mode network	2	0	29688876|33403915	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.|PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
, and	anatomy	networks	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
, cortical	anatomy	mode network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
, cortical	anatomy	networks	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
mode network	anatomy	networks	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
autism-spectrum disorders	disease_to_anatomy	default mode network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
autism-spectrum disorders	disease_to_anatomy	network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
autism-spectrum disorders	disease_to_anatomy	the ventral	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
autism-spectrum disorders	disease_to_anatomy	default mode	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
autism-spectrum disorders	disease_to_anatomy	, and	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
autism-spectrum disorders	disease_to_anatomy	, cortical	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
autism-spectrum disorders	disease_to_anatomy	mode network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
autism-spectrum disorders	disease_to_anatomy	networks	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
schizophrenia	disease_to_anatomy	default mode network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
schizophrenia	disease_to_anatomy	network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
schizophrenia	disease_to_anatomy	the ventral	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
schizophrenia	disease_to_anatomy	default mode	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
schizophrenia	disease_to_anatomy	, cortical	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
schizophrenia	disease_to_anatomy	mode network	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
schizophrenia	disease_to_anatomy	networks	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
benzene	chemical	pcb 28	1	0	25887094	PMID:25887094; Original text:Changes in serum benzene and PCB 28 concentrations showed significant negative correlations with age.
anxiety	disease_to_mechanism	kappa-opioid receptor	1	0	32705569	PMID:32705569; Original text:The anxiety study showed that blocking the kappa-opioid receptor significantly affects functional magnetic resonance imaging ventral striatal activation in the monetary incentive delay task in anticipation of gain.
hemispheres	anatomy	volume)	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
nuclei (	anatomy	volume)	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
cerebral hemispheres	anatomy	volume)	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
of cerebral	anatomy	volume)	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
hemispheres	anatomy	nuclei (	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
cerebral hemispheres	anatomy	hemispheres	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
hemispheres	anatomy	of cerebral	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
cerebral hemispheres	anatomy	nuclei (	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
nuclei (	anatomy	of cerebral	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
cerebral hemispheres	anatomy	of cerebral	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
asperger's syndrome	disease_to_anatomy	volume)	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
asperger's syndrome	disease_to_anatomy	hemispheres	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
asperger's syndrome	disease_to_anatomy	nuclei (	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
asperger's syndrome	disease_to_anatomy	cerebral hemispheres	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
asperger's syndrome	disease_to_anatomy	of cerebral	1	0	12077008	PMID:12077008; Original text:We found significant age-related differences in volume of cerebral hemispheres and caudate nuclei (controls, but not people with Asperger's syndrome, had age-related reductions in volume).
, and	anatomy	white matter	1	0	12077008	PMID:12077008; Original text:Also, people with Asperger's syndrome had significantly less grey matter in fronto-striatal and cerebellar regions than controls, and widespread differences in white matter.
grey matter	anatomy	white matter	1	0	12077008	PMID:12077008; Original text:Also, people with Asperger's syndrome had significantly less grey matter in fronto-striatal and cerebellar regions than controls, and widespread differences in white matter.
, and	anatomy	grey matter	1	0	12077008	PMID:12077008; Original text:Also, people with Asperger's syndrome had significantly less grey matter in fronto-striatal and cerebellar regions than controls, and widespread differences in white matter.
asperger's syndrome	disease_to_anatomy	white matter	1	0	12077008	PMID:12077008; Original text:Also, people with Asperger's syndrome had significantly less grey matter in fronto-striatal and cerebellar regions than controls, and widespread differences in white matter.
asperger's syndrome	disease_to_anatomy	, and	1	0	12077008	PMID:12077008; Original text:Also, people with Asperger's syndrome had significantly less grey matter in fronto-striatal and cerebellar regions than controls, and widespread differences in white matter.
asperger's syndrome	disease_to_anatomy	grey matter	1	0	12077008	PMID:12077008; Original text:Also, people with Asperger's syndrome had significantly less grey matter in fronto-striatal and cerebellar regions than controls, and widespread differences in white matter.
asperger's syndrome	disease_to_anatomy	, sensorimotor	1	0	12077008	PMID:12077008; Original text:Moreover, sensorimotor gating was significantly impaired in Asperger's syndrome.
oxygen	chemical_to_disease	autism	3	0	22987458|22987458|19284641	PMID:22987458; Original text:The mean total the Autism Treatment Evaluation Checklist score scores by both parents and clinicians were significantly improved after intervention in both arms of the study compared to the score before intervention (P < 0.001 in both groups by parents, P = 0.015 in hyperbaric oxygen therapy group and P = 0.004 in sham group by clinician).|PMID:22987458; Original text:There were no statistically significant differences in average percentage changes of total the Autism Treatment Evaluation Checklist score score and all subscales scores when comparing the hyperbaric oxygen therapy and sham air groups, either by parents or clinicians.|PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
oxygen	chemical_to_anatomy	of the	1	0	22987458	PMID:22987458; Original text:The mean total the Autism Treatment Evaluation Checklist score scores by both parents and clinicians were significantly improved after intervention in both arms of the study compared to the score before intervention (P < 0.001 in both groups by parents, P = 0.015 in hyperbaric oxygen therapy group and P = 0.004 in sham group by clinician).
oxygen	chemical_to_anatomy	(p	2	0	22987458|22987458	PMID:22987458; Original text:The mean total the Autism Treatment Evaluation Checklist score scores by both parents and clinicians were significantly improved after intervention in both arms of the study compared to the score before intervention (P < 0.001 in both groups by parents, P = 0.015 in hyperbaric oxygen therapy group and P = 0.004 in sham group by clinician).|PMID:22987458; Original text:On the other hand, for change scores (the Clinical Global ImpressionC) the clinicians indicated greater improvement following hyperbaric oxygen therapy (P = 0.03), but the parents found no such difference (P = 0.28).
oxygen	chemical_to_anatomy	groups	1	0	22987458	PMID:22987458; Original text:There were no statistically significant differences in average percentage changes of total the Autism Treatment Evaluation Checklist score score and all subscales scores when comparing the hyperbaric oxygen therapy and sham air groups, either by parents or clinicians.
autism	disease_to_anatomy	groups	1	0	22987458	PMID:22987458; Original text:There were no statistically significant differences in average percentage changes of total the Autism Treatment Evaluation Checklist score score and all subscales scores when comparing the hyperbaric oxygen therapy and sham air groups, either by parents or clinicians.
social anxiety	disease	social anxiety disorder	1	0	12462859	PMID:12462859; Original text:Social anxiety disorder is well suited to the spectrum concept because it has trait-like qualities of early onset, chronicity, and no empirically derived threshold that demarcates normal from clinically significant trait social anxiety.
social anxiety	disease_to_anatomy	, and	1	0	12462859	PMID:12462859; Original text:Social anxiety disorder is well suited to the spectrum concept because it has trait-like qualities of early onset, chronicity, and no empirically derived threshold that demarcates normal from clinically significant trait social anxiety.
social anxiety disorder	disease_to_anatomy	, and	1	0	12462859	PMID:12462859; Original text:Social anxiety disorder is well suited to the spectrum concept because it has trait-like qualities of early onset, chronicity, and no empirically derived threshold that demarcates normal from clinically significant trait social anxiety.
social	disease	social anxiety disorder	1	0	12462859	PMID:12462859; Original text:For several other disorders that share a prominent focus on social comparison, significant subgroups of patients seem to have features of social anxiety disorder.
irritability	disease	stereotyped behavior	1	0	18685284	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).
lethargy	disease	stereotyped behavior	1	0	18685284	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).
inappropriate speech	disease	stereotyped behavior	1	0	18685284	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).
hyperactivity	disease	stereotyped behavior	1	0	18685284	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).
stereotyped behavior	disease_to_anatomy	(p	1	0	18685284	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).
lethargy	disease_to_anatomy	(p	2	0	18685284|24849255	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:24849255; Original text:Secondary measures were not statistically significant with the exception of ABC-lethargy (p = 0.046) and total Short Sensory Profile score (p = 0.009).
inappropriate speech	disease_to_anatomy	(p	1	0	18685284	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).
oxytocin	mechanism	vasopressin	1	0	25416642	PMID:25416642; Original text:Here we extend our previous work by significantly increasing the number of participants to enable the use of more stringent statistical thresholds that permit more precise localization of oxytocin and vasopressin effects in the brain.
oxytocin	chemical_to_mechanism	vasopressin	1	0	25416642	PMID:25416642; Original text:Here we extend our previous work by significantly increasing the number of participants to enable the use of more stringent statistical thresholds that permit more precise localization of oxytocin and vasopressin effects in the brain.
oxytocin	chemical_to_anatomy	the brain	1	0	25416642	PMID:25416642; Original text:Here we extend our previous work by significantly increasing the number of participants to enable the use of more stringent statistical thresholds that permit more precise localization of oxytocin and vasopressin effects in the brain.
oxytocin	mechanism_to_anatomy	the brain	1	0	25416642	PMID:25416642; Original text:Here we extend our previous work by significantly increasing the number of participants to enable the use of more stringent statistical thresholds that permit more precise localization of oxytocin and vasopressin effects in the brain.
vasopressin	mechanism_to_anatomy	the brain	1	0	25416642	PMID:25416642; Original text:Here we extend our previous work by significantly increasing the number of participants to enable the use of more stringent statistical thresholds that permit more precise localization of oxytocin and vasopressin effects in the brain.
(i)	anatomy	, and	1	0	20195737	PMID:20195737; Original text:Rigorous meta-analysis techniques including random effects models, forest and funnel plots, I (I), publication bias, fail-safe analysis, and moderator variable analyses determined a significant standardized mean difference effect equal to 1.I0 (SE = 0.144; p <0.0001; Z = 10.49).
(i)	anatomy	i)	3	0	20195737|28869842|29484149	PMID:20195737; Original text:Rigorous meta-analysis techniques including random effects models, forest and funnel plots, I (I), publication bias, fail-safe analysis, and moderator variable analyses determined a significant standardized mean difference effect equal to 1.I0 (SE = 0.144; p <0.0001; Z = 10.49).|PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.|PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
(i	anatomy	(i)	3	0	20195737|28869842|29484149	PMID:20195737; Original text:Rigorous meta-analysis techniques including random effects models, forest and funnel plots, I (I), publication bias, fail-safe analysis, and moderator variable analyses determined a significant standardized mean difference effect equal to 1.I0 (SE = 0.144; p <0.0001; Z = 10.49).|PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.|PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
(i	anatomy	, and	1	0	20195737	PMID:20195737; Original text:Rigorous meta-analysis techniques including random effects models, forest and funnel plots, I (I), publication bias, fail-safe analysis, and moderator variable analyses determined a significant standardized mean difference effect equal to 1.I0 (SE = 0.144; p <0.0001; Z = 10.49).
(i	anatomy	i)	3	0	20195737|28869842|29484149	PMID:20195737; Original text:Rigorous meta-analysis techniques including random effects models, forest and funnel plots, I (I), publication bias, fail-safe analysis, and moderator variable analyses determined a significant standardized mean difference effect equal to 1.I0 (SE = 0.144; p <0.0001; Z = 10.49).|PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.|PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
mental handicap	disease_to_anatomy	field of	1	0	1544010	PMID:1544010; Original text:The disorder has considerable significance for psychiatrists, particularly, but by no means exclusively, those working in the field of mental handicap and with children.
extrapyramidal symptoms	disease_to_anatomy	(p	1	0	15068403	PMID:15068403; Original text:No significant difference was observed between the two groups in terms of extrapyramidal symptoms (P = 0.23).
, and	anatomy	hemisphere	1	0	10384736	PMID:10384736; Original text:Data from healthy elderly subjects, and a small group of left hemisphere patients (who received the tasks in modified form), suggest that this impairment on mental state tasks is not a function of task difficulty.
group of	anatomy	hemisphere	1	0	10384736	PMID:10384736; Original text:Data from healthy elderly subjects, and a small group of left hemisphere patients (who received the tasks in modified form), suggest that this impairment on mental state tasks is not a function of task difficulty.
mitochondrial dysfunction	disease	neuronal apoptosis	1	0	33493659	PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
glutathione	chemical_to_disease	neuronal apoptosis	1	0	33493659	PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
neuronal apoptosis	disease_to_anatomy	mitochondrial	1	0	33493659	PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
neuronal apoptosis	disease_to_anatomy	neuronal	1	0	33493659	PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
(p	anatomy	, greater	2	0	26792761|21853373	PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)|PMID:21853373; Original text:Compared to controls, subjects receiving the intervention reported significantly more satisfaction (p = 0.0004), greater shared decision making (p = 0.0005) and fewer unmet needs (p = 0.067).
olanzapine	chemical_to_disease	t2dm	1	0	26792761	PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)
olanzapine	chemical_to_anatomy	(p	1	0	26792761	PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)
olanzapine	chemical_to_anatomy	, greater	1	0	26792761	PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)
t2dm	disease_to_anatomy	, and	1	0	26792761	PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)
t2dm	disease_to_anatomy	(p	2	0	26792761|26792761	PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)|PMID:26792761; Original text:Greater T2DM incidence was associated with second-generation antipsychotic prescription (P ≤ .050) and less autism spectrum disorder diagnosis (P = .048)
t2dm	disease_to_anatomy	, greater	1	0	26792761	PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)
psychiatric	disease	t2dm	1	0	26792761	PMID:26792761; Original text:Similarly, compared with psychiatric controls, antipsychotic-exposed youth had significantly higher cumulative T2DM risk (OR, 2.09; 95% CI, 1.50-52.90; P < .0001) and incidence rate ratio (incidence rate ratio, 1.79; 95% CI, 1.31-2.44; P < .0001).
autism spectrum disorder	disease	t2dm	1	0	26792761	PMID:26792761; Original text:Greater T2DM incidence was associated with second-generation antipsychotic prescription (P ≤ .050) and less autism spectrum disorder diagnosis (P = .048)
, a	anatomy	groups	2	0	30933867|24824660	PMID:30933867; Original text:Comparing the results of both experimental and control groups, a statistically significant difference was found on total CARS score (p < 0.0005).|PMID:24824660; Original text:When combining groups, a statistically significant decrease of 37% was found from baseline to week 8 when study drug was completed using a linear mixed effects model (P = 0.003).
attention-deficit/hyperactivity disorder	disease	neurological problems	1	0	33372183	PMID:33372183; Original text:Neurological problems were significantly associated with a diagnosis of Attention-deficit/hyperactivity disorder.
oxytocin	chemical_to_mechanism	oxytocin receptor gene	2	0	25092245|25092245	PMID:25092245; Original text:Thus, a meta-analytic review of extant studies is needed to determine whether The oxytocin receptor gene shows association with disorder, and to elucidate which specific single-nucleotide polymorphisms have a significant effect on disorder.|PMID:25092245; Original text:The oxytocin receptor gene single-nucleotide polymorphisms included 3941 individuals with disorder from 11 independent samples, although analyses of each individual SNP included a subset of this total.
oxytocin receptor gene	mechanism_to_anatomy	, a	1	0	25092245	PMID:25092245; Original text:Thus, a meta-analytic review of extant studies is needed to determine whether The oxytocin receptor gene shows association with disorder, and to elucidate which specific single-nucleotide polymorphisms have a significant effect on disorder.
oxytocin receptor gene	mechanism_to_anatomy	, and	1	0	25092245	PMID:25092245; Original text:Thus, a meta-analytic review of extant studies is needed to determine whether The oxytocin receptor gene shows association with disorder, and to elucidate which specific single-nucleotide polymorphisms have a significant effect on disorder.
asperger	disease	autistic	1	0	9690938	PMID:9690938; Original text:The autistic group's performance on the false belief, belief term comprehension, and belief term expression tasks was significantly poorer than that of the Asperger, language impaired, and normal groups.
asperger	disease_to_anatomy	of the	1	0	9690938	PMID:9690938; Original text:The autistic group's performance on the false belief, belief term comprehension, and belief term expression tasks was significantly poorer than that of the Asperger, language impaired, and normal groups.
chromosome	anatomy	x	1	0	29972105	PMID:29972105; Original text:Moreover, given that Klinefelter Syndrome subjects have an additional X, genes on the extra-chromosome could also exert a significant impact.
klinefelter syndrome	disease_to_anatomy	x	1	0	29972105	PMID:29972105; Original text:Moreover, given that Klinefelter Syndrome subjects have an additional X, genes on the extra-chromosome could also exert a significant impact.
klinefelter syndrome	disease_to_anatomy	chromosome	1	0	29972105	PMID:29972105; Original text:Moreover, given that Klinefelter Syndrome subjects have an additional X, genes on the extra-chromosome could also exert a significant impact.
blood	mechanism	brain	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
blood brain	anatomy	of blood	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
autism spectrum disorders	disease_to_mechanism	blood	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
autism spectrum disorders	disease_to_mechanism	brain	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
autism spectrum disorders	disease_to_anatomy	of blood	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
autism spectrum disorders	disease_to_anatomy	blood brain	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
blood	mechanism_to_anatomy	of blood	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
blood	mechanism_to_anatomy	blood brain	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
brain	mechanism_to_anatomy	of blood	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
brain	mechanism_to_anatomy	blood brain	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
's disease	disease	alzheimer	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
alzheimer	disease	cognitive impairment	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
alzheimer	disease	schizophrenia	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
alzheimer	disease	snippet	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
's disease	disease	cognitive impairment	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
's disease	disease	schizophrenia	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
's disease	disease	snippet	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
cognitive impairment	disease	schizophrenia	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
cognitive impairment	disease	snippet	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
schizophrenia	disease	snippet	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
alzheimer	disease_to_mechanism	nap	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
's disease	disease_to_mechanism	nap	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
cognitive impairment	disease_to_mechanism	nap	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
schizophrenia	disease_to_mechanism	nap	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
snippet	disease_to_mechanism	nap	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
echolalia	disease_to_anatomy	, and	1	0	26161804	PMID:26161804; Original text:Recent contributions to the literature reflect significant disagreement regarding how echolalia should be defined, understood, and managed.
edc	chemical	estrogen	1	0	34358505	PMID:34358505; Original text:This is a significant area of study as early brain development is heavily mediated by estrogen and could be particularly sensitive to EDC exposure.
edc	chemical_to_anatomy	area of	1	0	34358505	PMID:34358505; Original text:This is a significant area of study as early brain development is heavily mediated by estrogen and could be particularly sensitive to EDC exposure.
estrogen	chemical_to_anatomy	area of	1	0	34358505	PMID:34358505; Original text:This is a significant area of study as early brain development is heavily mediated by estrogen and could be particularly sensitive to EDC exposure.
alcoholic disorder	disease	autism spectrum disorder	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
alcoholic disorder	disease	depressive disorder	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
alcoholic disorder	disease	psychotic disorders	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
autism spectrum disorder	disease	depressive disorder	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
autism spectrum disorder	disease	psychotic disorders	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
depressive disorder	disease	psychotic disorders	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
of all	anatomy	of the	1	0	15863467	PMID:15863467; Original text:Diagnostic criteria, age of the sample, and urban or rural location were associated with estimated prevalence of all all autism spectrum disorders.
, and	anatomy	of all	3	0	15863467|25161109|10425581	PMID:15863467; Original text:Diagnostic criteria, age of the sample, and urban or rural location were associated with estimated prevalence of all all autism spectrum disorders.|PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.|PMID:10425581; Original text:Analysis of all three scales revealed no statistically significant differences, and parent reports were equally distributed.
autism spectrum disorders	disease_to_anatomy	of all	1	0	15863467	PMID:15863467; Original text:Diagnostic criteria, age of the sample, and urban or rural location were associated with estimated prevalence of all all autism spectrum disorders.
of the	anatomy	set of	1	0	30356093	PMID:30356093; Original text:Within-individual aggregations of a finite set of early inherited neurobehavioral susceptibilities-each individually common in the population-may account for a significant share of the heritability of disorder.
5-methyltetrahydrofolate	chemical_to_mechanism	fra	1	0	22230883	PMID:22230883; Original text:In 16 children, the concentration of blocking FRA significantly correlated with cerebrospinal fluid 5-methyltetrahydrofolate concentrations, which were below the normative mean in every case.
5-methyltetrahydrofolate	chemical_to_anatomy	cerebrospinal fluid	1	0	22230883	PMID:22230883; Original text:In 16 children, the concentration of blocking FRA significantly correlated with cerebrospinal fluid 5-methyltetrahydrofolate concentrations, which were below the normative mean in every case.
fra	mechanism_to_anatomy	cerebrospinal fluid	1	0	22230883	PMID:22230883; Original text:In 16 children, the concentration of blocking FRA significantly correlated with cerebrospinal fluid 5-methyltetrahydrofolate concentrations, which were below the normative mean in every case.
(p	anatomy	group	5	0	31725473|20001837|32347624|19284641|16948927	PMID:31725473; Original text:Compared with the placebo group, children receiving propentofylline showed greater improvements in the Childhood Autism Rating Scale score (P = 0.037) from baseline to the study endpoint.|PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:19284641; Original text:In the tre1.3 atmosphereent group compared to the control group, mean changes on the Aberrant Behavior Checklist total score and subscales were similar except a greater number of children improved in irritability (p = 0.0311).|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
propentofylline	chemical_to_anatomy	(p	1	0	31725473	PMID:31725473; Original text:Compared with the placebo group, children receiving propentofylline showed greater improvements in the Childhood Autism Rating Scale score (P = 0.037) from baseline to the study endpoint.
propentofylline	chemical_to_anatomy	group	1	0	31725473	PMID:31725473; Original text:Compared with the placebo group, children receiving propentofylline showed greater improvements in the Childhood Autism Rating Scale score (P = 0.037) from baseline to the study endpoint.
rg7713	chemical_to_disease	fear	1	0	27711048	PMID:27711048; Original text:RG7713 reduced ability to detect lust (ES=-0.8, p=0.03) and fear (ES=-0.7, p=0.07) in affective speech recognition.
autism	disease_to_anatomy	field of	1	0	28715464	PMID:28715464; Original text:A significant increase in overall adaptation and social skills (median 8 and 7.7 points) in the the Social-Emotional Profile was demonstrated in addition to a significant reduction in the the Childhood Autism Rating Scale score (median: 4 points), including in the field of social relationships.
anxiety	disease_to_anatomy	of the	4	0	22588377|22588377|31351241|11466160	PMID:22588377; Original text:Twenty-two children (ages 8-14; IQ ≥ 70) with disorder and clinically significant anxiety were randomly assigned to 16 sessions of the Coping Cat program (cognitive-behavioral therapy; CBT) or a 16-week waitlist.|PMID:22588377; Original text:Results provide preliminary evidence that a modified version of the Coping Cat program may be a feasible and effective program for reducing clinically significant levels of anxiety in children with high-functioning disorder.|PMID:31351241; Original text:Statistically significant and large improvements were also found in post-treatment teacher and parent reports of child anxiety as well as a behavioral measure of the child speaking to an unknown adult.|PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.
levels of	anatomy	of the	3	0	22588377|32635367|32329237	PMID:22588377; Original text:Results provide preliminary evidence that a modified version of the Coping Cat program may be a feasible and effective program for reducing clinically significant levels of anxiety in children with high-functioning disorder.|PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.|PMID:32329237; Original text:Families and staff recommended the intervention, children receiving the intervention demonstrated significantly more improvement in unblinded ratings of clinical severity, data from physicians indicated a positive effect of the intervention on levels of staffing and restraints and attending medical providers universally reported satisfaction and benefit of the intervention.
anxiety	disease_to_anatomy	levels of	2	0	22588377|21660428	"PMID:22588377; Original text:Results provide preliminary evidence that a modified version of the Coping Cat program may be a feasible and effective program for reducing clinically significant levels of anxiety in children with high-functioning disorder.|PMID:21660428; Original text:Children in both programs showed significantly lower levels of generalized anxiety and total anxiety symptoms at 6-month follow-up on SCAS-C. Clinician ratings on the CGI-S demonstrated an increase in the percentage of participants rated as ""Normal"" and ""Borderline"" for both programs."
bifidobacterium species bacteria	bacteria_to_disease	attention deficit hyperactivity disorder	1	0	25760553	PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).
bifidobacterium species bacteria	bacteria_to_disease	asperger syndrome	1	0	25760553	PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).
bifidobacterium species bacteria	bacteria_to_anatomy	group (	1	0	25760553	PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).
bifidobacterium species bacteria	bacteria_to_anatomy	(p	1	0	25760553	PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).
attention deficit hyperactivity disorder	disease_to_anatomy	(p	1	0	25760553	PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).
asperger syndrome	disease_to_anatomy	(p	1	0	25760553	PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).
autism	disease	tuberous sclerosis	4	0	15542389|32563542|10473304|9813776	PMID:15542389; Original text:Incidence of autism associated with Tuberous Sclerosis may be significantly higher than the rates of cardiac and renal abnormalities, for which screening is routinely conducted in this population.|PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.|PMID:10473304; Original text:On average, medical conditions of potential causal significance were found in 6% of subjects with autism, with tuberous sclerosis having a consistently strong association with autism.|PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
autism	disease	cardiac and renal abnormalities	1	0	15542389	PMID:15542389; Original text:Incidence of autism associated with Tuberous Sclerosis may be significantly higher than the rates of cardiac and renal abnormalities, for which screening is routinely conducted in this population.
cardiac and renal abnormalities	disease	tuberous sclerosis	1	0	15542389	PMID:15542389; Original text:Incidence of autism associated with Tuberous Sclerosis may be significantly higher than the rates of cardiac and renal abnormalities, for which screening is routinely conducted in this population.
nervous system	anatomy	system	1	0	28562301	PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
of the	anatomy	system	1	0	28562301	PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
central nervous	anatomy	system	1	0	28562301	PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
central nervous system	anatomy	system	1	0	28562301	PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
pain	disease_to_anatomy	nervous system	1	0	28562301	PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
pain	disease_to_anatomy	of the	2	0	28562301|28562301	PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.|PMID:28562301; Original text:Despite the significance of the problem, this population remains vulnerable to underrecognition and undertreatment of pain.
pain	disease_to_anatomy	central nervous	1	0	28562301	PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
pain	disease_to_anatomy	system	1	0	28562301	PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
pain	disease_to_anatomy	central nervous system	1	0	28562301	PMID:28562301; Original text:Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment.
mental	disease	mental disorders	1	0	31914909	PMID:31914909; Original text:Pro and their nutrient sources can improve mental health and psychological function and can be offered as new medicines for common mental disorders, however, more clinical studies are necessary to conduct regarding the clinical significance of the effects and their bioequivalence or superiority against current treatments.
mental disorders	disease_to_anatomy	of the	1	0	31914909	PMID:31914909; Original text:Pro and their nutrient sources can improve mental health and psychological function and can be offered as new medicines for common mental disorders, however, more clinical studies are necessary to conduct regarding the clinical significance of the effects and their bioequivalence or superiority against current treatments.
mental	disease_to_anatomy	of the	1	0	31914909	PMID:31914909; Original text:Pro and their nutrient sources can improve mental health and psychological function and can be offered as new medicines for common mental disorders, however, more clinical studies are necessary to conduct regarding the clinical significance of the effects and their bioequivalence or superiority against current treatments.
dysmorphic features	disease	focal epilepsy	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
focal epilepsy	disease	repetitive behaviours	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
deficient expressive language	disease	focal epilepsy	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
focal epilepsy	disease	intellectual disability	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
dysmorphic features	disease	repetitive behaviours	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
deficient expressive language	disease	dysmorphic features	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
dysmorphic features	disease	intellectual disability	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
deficient expressive language	disease	repetitive behaviours	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
intellectual disability	disease	repetitive behaviours	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
deficient expressive language	disease	intellectual disability	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
focal epilepsy	disease_to_anatomy	, focal	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
dysmorphic features	disease_to_anatomy	, focal	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
repetitive behaviours	disease_to_anatomy	, focal	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
deficient expressive language	disease_to_anatomy	, focal	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
intellectual disability	disease_to_anatomy	, focal	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
constipation	disease	diarrhea	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
constipation	disease	indigestion	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
constipation	disease	in	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
abdominal pain	disease	constipation	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
diarrhea	disease	indigestion	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
diarrhea	disease	in	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
abdominal pain	disease	diarrhea	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
in	disease	indigestion	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
abdominal pain	disease	indigestion	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
abdominal pain	disease	in	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
, and	anatomy	end of	2	0	28122648|15673999	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.|PMID:15673999; Original text:Vitamin C levels were measured at the end of the study, and the placebo group had levels that were significantly below average for typical children, whereas the supplement group had near-average levels.
constipation	disease_to_anatomy	, and	2	0	28122648|31665947	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.|PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
constipation	disease_to_anatomy	end of	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
diarrhea	disease_to_anatomy	, and	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
diarrhea	disease_to_anatomy	end of	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
indigestion	disease_to_anatomy	, and	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
indigestion	disease_to_anatomy	end of	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
in	disease_to_anatomy	, and	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
in	disease_to_anatomy	end of	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
abdominal pain	disease_to_anatomy	, and	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
abdominal pain	disease_to_anatomy	end of	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
brain abnormalities	disease	learning disability	1	0	9463598	PMID:9463598; Original text:Brain abnormalities can be detected in cases of idiopathic and non-idiopathic learning disability, but their significance is not clear due to discrepancies in study findings and the small cohorts involved.
fenfluramine	chemical_to_disease	autistic	2	0	2977280|2936877	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.|PMID:2936877; Original text:A double-blind cross-over study on the effect of fenfluramine versus placebo in seven autistic boys over a period of 8 months demonstrated a significant decrease in blood serotonin levels during the fenfluramine phase in all subjects.
fenfluramine	chemical_to_mechanism	beta-endorphin	1	0	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
fenfluramine	chemical_to_anatomy	group (	1	0	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
fenfluramine	chemical_to_anatomy	(p	1	0	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
autistic	disease_to_mechanism	beta-endorphin	1	0	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
beta-endorphin	mechanism_to_anatomy	group (	1	0	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
beta-endorphin	mechanism_to_anatomy	(p	1	0	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
growth factor-β1	mechanism_to_anatomy	levels of	1	0	29298441	PMID:29298441; Original text:Plasma levels of growth factor-β1 significantly increased to 85% immediately after auditory integrative training (20.13 ± 12 ng/mL, p < 0.05), to 95% 1 month after auditory integrative training (21.2 ± 11 ng/mL, p < 0.01), and to 105% 3 months after auditory integrative training (22.25 ± 16 ng/mL, p < 0.01) compared to before auditory integrative training (10.85 ± 8 ng/mL).
growth factor-β1	mechanism_to_anatomy	, and	1	0	29298441	PMID:29298441; Original text:Plasma levels of growth factor-β1 significantly increased to 85% immediately after auditory integrative training (20.13 ± 12 ng/mL, p < 0.05), to 95% 1 month after auditory integrative training (21.2 ± 11 ng/mL, p < 0.01), and to 105% 3 months after auditory integrative training (22.25 ± 16 ng/mL, p < 0.01) compared to before auditory integrative training (10.85 ± 8 ng/mL).
brainstem	anatomy	neural networks	1	0	25248666	PMID:25248666; Original text:Such reduced noise, perhaps a function of atypical brainstem activation, would enhance detection and discrimination in autism spectrum disorder but at significant cost, foregoing the widespread benefits of noise in neural networks.
autism spectrum disorder	disease_to_anatomy	brainstem	1	0	25248666	PMID:25248666; Original text:Such reduced noise, perhaps a function of atypical brainstem activation, would enhance detection and discrimination in autism spectrum disorder but at significant cost, foregoing the widespread benefits of noise in neural networks.
autism spectrum disorder	disease_to_anatomy	neural networks	1	0	25248666	PMID:25248666; Original text:Such reduced noise, perhaps a function of atypical brainstem activation, would enhance detection and discrimination in autism spectrum disorder but at significant cost, foregoing the widespread benefits of noise in neural networks.
bulimia nervosa	disease	ptsd	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
asd	disease	ptsd	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
polycystic ovary syndrome	disease	ptsd	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
asd	disease	bulimia nervosa	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
bulimia nervosa	disease	polycystic ovary syndrome	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
asd	disease	polycystic ovary syndrome	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
ptsd	disease_to_anatomy	, and	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
bulimia nervosa	disease_to_anatomy	, and	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
polycystic ovary syndrome	disease_to_anatomy	, and	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
autism	disease	constipation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
constipation	disease	diarrhea).areas	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
asd	disease	constipation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism spectrum disorders	disease	constipation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism	disease	diarrhea).areas	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism	disease	autism spectrum disorders	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
asd	disease	diarrhea).areas	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism spectrum disorders	disease	diarrhea).areas	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
, gastrointestinal	anatomy	transplant	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
, a	anatomy	transplant	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
, and	anatomy	transplant	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
transplant	anatomy	transplantation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
, a	anatomy	, gastrointestinal	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
, and	anatomy	, gastrointestinal	2	0	31665947|21263444	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
, gastrointestinal	anatomy	transplantation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
, a	anatomy	transplantation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
, and	anatomy	transplantation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
constipation	disease_to_anatomy	transplant	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
constipation	disease_to_anatomy	, gastrointestinal	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
constipation	disease_to_anatomy	, a	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
constipation	disease_to_anatomy	transplantation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism	disease_to_anatomy	transplant	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism	disease_to_anatomy	, gastrointestinal	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism	disease_to_anatomy	, a	5	0	31665947|28217829|9648034|9648034|12010627	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.|PMID:9648034; Original text:Describes treatment of autism, a severe, chronic developmental disorder that results in significant lifelong disability for most persons, with few persons ever functioning in an independent and typical lifestyle.|PMID:9648034; Original text:Within the past decade, a number of studies have reported significant changes in the outcomes of very young children with autism following intensive comprehensive treatment.|PMID:12010627; Original text:Over the past decade, a significant upswing in research has occurred to examine the biologic basis of autism.
autism	disease_to_anatomy	transplantation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
diarrhea).areas	disease_to_anatomy	transplant	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
diarrhea).areas	disease_to_anatomy	, gastrointestinal	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
diarrhea).areas	disease_to_anatomy	, a	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
diarrhea).areas	disease_to_anatomy	, and	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
diarrhea).areas	disease_to_anatomy	transplantation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
asd	disease_to_anatomy	transplant	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
asd	disease_to_anatomy	, gastrointestinal	2	0	31665947|21263444	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease_to_anatomy	, a	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
asd	disease_to_anatomy	transplantation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism spectrum disorders	disease_to_anatomy	transplant	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism spectrum disorders	disease_to_anatomy	, gastrointestinal	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism spectrum disorders	disease_to_anatomy	transplantation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
galantamine	chemical	risperidone	1	0	24132248	PMID:24132248; Original text:Irritability subscale were equally randomized to receive either galantamine (up to 24 mg/day) or placebo, in addition to risperidone (up to 2 mg/day), for 10 weeks.
galantamine	chemical_to_disease	irritability	1	0	24132248	PMID:24132248; Original text:Irritability subscale were equally randomized to receive either galantamine (up to 24 mg/day) or placebo, in addition to risperidone (up to 2 mg/day), for 10 weeks.
asperger syndrome	disease_to_anatomy	, a	1	0	15292669	PMID:15292669; Original text:In spectral power analysis, a statistically nonsignificant trend towards decreased relative delta power and increased theta power in slow-wave sleep was found in the Asperger syndrome group.
of the	anatomy	part of	1	0	22805709	PMID:22805709; Original text:These mutations, although individually rare, may capture a significant part of the heritability for complex genetic diseases that is not detectable by genome-wide association studies.
part of	anatomy	part of the	1	0	22805709	PMID:22805709; Original text:These mutations, although individually rare, may capture a significant part of the heritability for complex genetic diseases that is not detectable by genome-wide association studies.
of the	anatomy	part of the	1	0	22805709	PMID:22805709; Original text:These mutations, although individually rare, may capture a significant part of the heritability for complex genetic diseases that is not detectable by genome-wide association studies.
genetic diseases	disease_to_anatomy	part of	1	0	22805709	PMID:22805709; Original text:These mutations, although individually rare, may capture a significant part of the heritability for complex genetic diseases that is not detectable by genome-wide association studies.
genetic diseases	disease_to_anatomy	of the	1	0	22805709	PMID:22805709; Original text:These mutations, although individually rare, may capture a significant part of the heritability for complex genetic diseases that is not detectable by genome-wide association studies.
genetic diseases	disease_to_anatomy	part of the	1	0	22805709	PMID:22805709; Original text:These mutations, although individually rare, may capture a significant part of the heritability for complex genetic diseases that is not detectable by genome-wide association studies.
sulforaphane	nutrient_to_disease	autism	1	0	34034808	PMID:34034808; Original text:The effect sizes on the the Ohio Autism Clinical Impressions Scale were non-statistically significant but positive, suggesting a possible trend toward greater improvement in those on treatment with Sulforaphane (Cohen's d 0.21; 95% CI - 0.46, 0.88 and 0.10; 95% CI - 0.52, 0.72, respectively).
sulforaphane	nutrient_to_anatomy	positive	1	0	34034808	PMID:34034808; Original text:The effect sizes on the the Ohio Autism Clinical Impressions Scale were non-statistically significant but positive, suggesting a possible trend toward greater improvement in those on treatment with Sulforaphane (Cohen's d 0.21; 95% CI - 0.46, 0.88 and 0.10; 95% CI - 0.52, 0.72, respectively).
sulforaphane	chemical_to_disease	autism	1	0	34034808	PMID:34034808; Original text:The effect sizes on the the Ohio Autism Clinical Impressions Scale were non-statistically significant but positive, suggesting a possible trend toward greater improvement in those on treatment with Sulforaphane (Cohen's d 0.21; 95% CI - 0.46, 0.88 and 0.10; 95% CI - 0.52, 0.72, respectively).
sulforaphane	chemical_to_anatomy	positive	1	0	34034808	PMID:34034808; Original text:The effect sizes on the the Ohio Autism Clinical Impressions Scale were non-statistically significant but positive, suggesting a possible trend toward greater improvement in those on treatment with Sulforaphane (Cohen's d 0.21; 95% CI - 0.46, 0.88 and 0.10; 95% CI - 0.52, 0.72, respectively).
autism	disease_to_anatomy	positive	1	0	34034808	PMID:34034808; Original text:The effect sizes on the the Ohio Autism Clinical Impressions Scale were non-statistically significant but positive, suggesting a possible trend toward greater improvement in those on treatment with Sulforaphane (Cohen's d 0.21; 95% CI - 0.46, 0.88 and 0.10; 95% CI - 0.52, 0.72, respectively).
glutathione	chemical	sulforaphane	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
, mitochondrial	anatomy	mitochondrial	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
sulforaphane	nutrient_to_chemical	glutathione	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
sulforaphane	nutrient_to_anatomy	, mitochondrial	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
sulforaphane	nutrient_to_anatomy	mitochondrial	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
sulforaphane	chemical_to_anatomy	, mitochondrial	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
sulforaphane	chemical_to_anatomy	mitochondrial	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
glutathione	chemical_to_anatomy	, mitochondrial	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
sulforaphane	nutrient_to_anatomy	of the	1	0	34034808	PMID:34034808; Original text:Sulforaphane led to small yet non-statistically significant changes in the total and all subscale scores of the primary outcome measure, while for secondary outcome measures, caregivers' assessments of children taking Sulforaphane showed statistically significant improvements compared to those taking placebo on the the Aberrant Behavior Checklist but not the Scale-2.
sulforaphane	chemical_to_anatomy	of the	1	0	34034808	PMID:34034808; Original text:Sulforaphane led to small yet non-statistically significant changes in the total and all subscale scores of the primary outcome measure, while for secondary outcome measures, caregivers' assessments of children taking Sulforaphane showed statistically significant improvements compared to those taking placebo on the the Aberrant Behavior Checklist but not the Scale-2.
, a	anatomy	of the	6	0	32112261|14561452|34279715|21822764|10382131|28036350	"PMID:32112261; Original text:Regarding the treatment, a meta-analysis of behavioral interventions, including only three randomized controlled trials, found significant effects in terms of increase in total sleep time (24.41 min, 95% CI 5.71-43.11, P = 0.01), decrease in sleep-onset latency (- 18.31 min, 95% CI - 30.84 to - 5.77, P = 0.004), and a significant effect on sleep efficiency (5.59, 95% CI 0.87-10.31, P = 0.02), albeit the risk of bias of the included studies was rated ""high"" in relation to issues with the blinding.|PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:34279715; Original text:Analysis of the subset of studies that examined all offspring and controlled for confounder factors revealed that the use of assisted reproductive technology is associated with a higher risk of disorder (RR = 1.11, 95% CI = 1.03-1.19, p < 0.009), while in the case of studies that focused on singletons, a statistically significant association between assisted reproductive technology and disorder was not observed (|PMID:21822764; Original text:Although social behaviour improved significantly as a result of watching The Transporters, a significant improvement in social behaviour was however, also observed in the Thomas the Tank Engine condition suggesting the unique content of The Transporters DVD was not pivotal to the improvement of social behaviour in general.|PMID:10382131; Original text:Macrocephaly (head circumference > 97th centile) was observed in 16.7% of the sample, a significantly higher proportion than that expected.|PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome."
comb	chemical_to_anatomy	group (	1	0	22265360	PMID:22265360; Original text:Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively).
comb	chemical_to_anatomy	, and	1	0	22265360	PMID:22265360; Original text:Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively).
comb	chemical_to_anatomy	(p	2	0	22265360|22265360	PMID:22265360; Original text:Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively).|PMID:22265360; Original text:Using logistic regression, children in the COMB group were twice as likely to make at least 6 months' gain (equal to the passage of time) in the Vineland Communication Age Equivalent score compared with MED (p = .02).
comb	chemical	med	1	0	22265360	PMID:22265360; Original text:Using logistic regression, children in the COMB group were twice as likely to make at least 6 months' gain (equal to the passage of time) in the Vineland Communication Age Equivalent score compared with MED (p = .02).
med	chemical_to_anatomy	(p	1	0	22265360	PMID:22265360; Original text:Using logistic regression, children in the COMB group were twice as likely to make at least 6 months' gain (equal to the passage of time) in the Vineland Communication Age Equivalent score compared with MED (p = .02).
vitamin d supplementation	nutrient_to_chemical	vitamin d	1	0	28217829	PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.
vitamin d supplementation	nutrient_to_disease	autism	1	0	28217829	PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.
vitamin d supplementation	nutrient_to_disease	autistic	1	0	28217829	PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.
vitamin d supplementation	nutrient_to_anatomy	, a	1	0	28217829	PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.
vitamin d	chemical_to_disease	autism	1	0	28217829	PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.
vitamin d	chemical_to_disease	autistic	1	0	28217829	PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.
vitamin d	chemical_to_anatomy	, a	1	0	28217829	PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.
olanzapine	chemical_to_disease	weight gain	2	0	17069543|17069543	PMID:17069543; Original text:Olanzapine was associated with significant weight gain (7.5 +/- 4.8 lbs vs. 1.5 +/- 1.5 lbs on placebo).|PMID:17069543; Original text:Olanzapine may be a promising treatment for improving global functioning of pervasive developmental disorders, but the risk of significant weight gain remains a concern.
developmental disorders	disease	weight gain	1	0	17069543	PMID:17069543; Original text:Olanzapine may be a promising treatment for improving global functioning of pervasive developmental disorders, but the risk of significant weight gain remains a concern.
olanzapine	chemical_to_disease	developmental disorders	1	0	17069543	PMID:17069543; Original text:Olanzapine may be a promising treatment for improving global functioning of pervasive developmental disorders, but the risk of significant weight gain remains a concern.
psychiatric	disease	psychiatric disease	1	0	34057596	PMID:34057596; Original text:The significance of serum neural autoantibodies associated with psychiatric symptoms in children remains often unclear, but might be relevant for the extent and occurrence of psychiatric disease manifestation in later life, as well as therapy and outcome.
neurocognitive disturbances	disease_to_anatomy	, and	1	0	34273950	PMID:34273950; Original text:This phenotype is therefore associated with neurocognitive disturbances and social cognition, indicating potential functional maladjustment in the affected subjects, and a potentially significant impact on quality of life.
posterior cingulate cortex	anatomy	prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
dorsolateral prefrontal cortex	anatomy	prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
cingulate cortex	anatomy	prefrontal cortex	2	0	25292351|26336909	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
posterior cingulate	anatomy	prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
dorsolateral prefrontal	anatomy	prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
dorsolateral prefrontal cortex	anatomy	posterior cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
cingulate cortex	anatomy	posterior cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
cortex (	anatomy	posterior cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
posterior cingulate	anatomy	posterior cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
dorsolateral prefrontal	anatomy	posterior cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
cingulate cortex	anatomy	dorsolateral prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
cortex (	anatomy	dorsolateral prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
dorsolateral prefrontal cortex	anatomy	posterior cingulate	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
dorsolateral prefrontal	anatomy	dorsolateral prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
cingulate cortex	anatomy	posterior cingulate	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
cingulate cortex	anatomy	dorsolateral prefrontal	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
cortex (	anatomy	posterior cingulate	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
cortex (	anatomy	dorsolateral prefrontal	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
dorsolateral prefrontal	anatomy	posterior cingulate	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_disease	asd	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	posterior cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	dorsolateral prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	cortex (	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	posterior cingulate	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	dorsolateral prefrontal	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
asd	disease_to_anatomy	prefrontal cortex	2	0	25292351|30758329	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.|PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
asd	disease_to_anatomy	posterior cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
asd	disease_to_anatomy	dorsolateral prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
asd	disease_to_anatomy	cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
asd	disease_to_anatomy	cortex (	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
asd	disease_to_anatomy	posterior cingulate	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
asd	disease_to_anatomy	dorsolateral prefrontal	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
autism spectrum disorders	disease	obsessive-compulsive behaviors	1	0	31638682	PMID:31638682; Original text:In this preliminary study of children and adolescents with autism spectrum disorders, treatment with fluoxetine compared with placebo resulted in significantly lower scores for obsessive-compulsive behaviors at 16 weeks.
fluoxetine	chemical_to_disease	obsessive-compulsive behaviors	1	0	31638682	PMID:31638682; Original text:In this preliminary study of children and adolescents with autism spectrum disorders, treatment with fluoxetine compared with placebo resulted in significantly lower scores for obsessive-compulsive behaviors at 16 weeks.
asthma	disease_to_anatomy	of the	1	0	32997856	PMID:32997856; Original text:We performed a meta-analysis of 23 of the studies, which showed a significant association between asthma and disorder: odds ratio (odds ratio) 1.52 (1.42-1.63)
asthma	disease_to_anatomy	and 3	1	0	32997856	PMID:32997856; Original text:Seventeen asthma-ASD studies were included, whereof 7 showed a positive association and 3 a negative association; 8/17 were population-based with a cross-sectional study design and 4/17 had a low risk of bias.
attention	disease	hyperactivity	1	0	27278054	PMID:27278054; Original text:Both groups showed a significant improvement in attention-deficit/hyperactivity disorder symptoms after 24 weeks of treatment (attention-deficit/hyperactivity disorder Rating Scale, Conners Parent Rating Scale-Hyperactivity, and Clinical Global Improvement-Severity Scale).
attention	disease_to_anatomy	, and	1	0	27278054	PMID:27278054; Original text:Both groups showed a significant improvement in attention-deficit/hyperactivity disorder symptoms after 24 weeks of treatment (attention-deficit/hyperactivity disorder Rating Scale, Conners Parent Rating Scale-Hyperactivity, and Clinical Global Improvement-Severity Scale).
attention	disease_to_anatomy	scale	1	0	27278054	PMID:27278054; Original text:Both groups showed a significant improvement in attention-deficit/hyperactivity disorder symptoms after 24 weeks of treatment (attention-deficit/hyperactivity disorder Rating Scale, Conners Parent Rating Scale-Hyperactivity, and Clinical Global Improvement-Severity Scale).
hyperactivity	disease_to_anatomy	scale	1	0	27278054	PMID:27278054; Original text:Both groups showed a significant improvement in attention-deficit/hyperactivity disorder symptoms after 24 weeks of treatment (attention-deficit/hyperactivity disorder Rating Scale, Conners Parent Rating Scale-Hyperactivity, and Clinical Global Improvement-Severity Scale).
attention-deficit hyperactivity disorder	disease	autism spectrum disorders	3	0	23123089|23123089|23123089	PMID:23123089; Original text:Use of the a frequency modulation system resulted in significant average improvements in speech recognition in noise for the children with autism spectrum disorders and attention-deficit hyperactivity disorder as well as large effect sizes.|PMID:23123089; Original text:When compared to typically functioning peers, children with autism spectrum disorders and attention-deficit hyperactivity disorder had significantly poorer average speech recognition performance in noise without the a frequency modulation system but comparable average performance when the a frequency modulation system was used.|PMID:23123089; Original text:Given the significantly better speech recognition in noise, increased on-task behaviors, and improved teacher ratings of listening behaviors with the a frequency modulation system, these devices may be a viable option for children who have autism spectrum disorders and attention-deficit hyperactivity disorder in the classroom.
attention-deficit hyperactivity disorder	disease_to_anatomy	of the	1	0	23123089	PMID:23123089; Original text:Use of the a frequency modulation system resulted in significant average improvements in speech recognition in noise for the children with autism spectrum disorders and attention-deficit hyperactivity disorder as well as large effect sizes.
, and	anatomy	system	1	0	23123089	PMID:23123089; Original text:Given the significantly better speech recognition in noise, increased on-task behaviors, and improved teacher ratings of listening behaviors with the a frequency modulation system, these devices may be a viable option for children who have autism spectrum disorders and attention-deficit hyperactivity disorder in the classroom.
attention-deficit hyperactivity disorder	disease_to_anatomy	system	1	0	23123089	PMID:23123089; Original text:Given the significantly better speech recognition in noise, increased on-task behaviors, and improved teacher ratings of listening behaviors with the a frequency modulation system, these devices may be a viable option for children who have autism spectrum disorders and attention-deficit hyperactivity disorder in the classroom.
attention-deficit hyperactivity disorder	disease_to_anatomy	, and	2	0	23123089|33376247	PMID:23123089; Original text:Given the significantly better speech recognition in noise, increased on-task behaviors, and improved teacher ratings of listening behaviors with the a frequency modulation system, these devices may be a viable option for children who have autism spectrum disorders and attention-deficit hyperactivity disorder in the classroom.|PMID:33376247; Original text:When combining the presence of magnetic resonance imaging findings, facial morphological variants, and genetic copy number variants, statistically significant relationships were found with disorder and attention-deficit hyperactivity disorder diagnoses (p = 0.0006 and p = 0.002, respectively).
autism spectrum disorders	disease_to_anatomy	system	1	0	23123089	PMID:23123089; Original text:Given the significantly better speech recognition in noise, increased on-task behaviors, and improved teacher ratings of listening behaviors with the a frequency modulation system, these devices may be a viable option for children who have autism spectrum disorders and attention-deficit hyperactivity disorder in the classroom.
9	anatomy	of the	1	0	15590241	PMID:15590241; Original text:Journal of the Association of the Academy of Minority Physicians, 9, 9-15] reported an uncontrolled trial of secretin with three participants with autism, which apparently resulted in significant behavioral improvement.
autism	disease_to_anatomy	9	1	0	15590241	PMID:15590241; Original text:Journal of the Association of the Academy of Minority Physicians, 9, 9-15] reported an uncontrolled trial of secretin with three participants with autism, which apparently resulted in significant behavioral improvement.
secretin	mechanism_to_anatomy	9	1	0	15590241	PMID:15590241; Original text:Journal of the Association of the Academy of Minority Physicians, 9, 9-15] reported an uncontrolled trial of secretin with three participants with autism, which apparently resulted in significant behavioral improvement.
hyperactive behavior	disease	hyperactivity	1	0	32381101	PMID:32381101; Original text:A favorable effect was also found for social behavior (Social Responsiveness Scale) (t(11) = 4.01, p = .002, d = .549) and hyperactive behavior (ABC-hyperactivity subscale) (t(12) = 3.65, p = .003, d = .686).
autism	disease	chromosomal abnormalities	2	0	15121991|11525418	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.|PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
autism	disease	chromosomal	1	0	15121991	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.
chromosomal	disease	chromosomal abnormalities	1	0	15121991	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.
, chromosomal	anatomy	and 3	1	0	15121991	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.
autism	disease_to_anatomy	and 3	2	0	15121991|11466160	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.|PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.
autism	disease_to_anatomy	, chromosomal	1	0	15121991	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.
chromosomal abnormalities	disease_to_anatomy	and 3	1	0	15121991	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.
chromosomal abnormalities	disease_to_anatomy	, chromosomal	1	0	15121991	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.
chromosomal	disease_to_anatomy	and 3	1	0	15121991	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.
chromosomal	disease_to_anatomy	, chromosomal	1	0	15121991	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.
hemiplegia	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
spasticity	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
intellectual disability	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
quadriplegia	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease	hemiplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
hemiplegia	disease	spasticity	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	hemiplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
hemiplegia	disease	intellectual disability	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
hemiplegia	disease	quadriplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease	spasticity	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	diplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease	intellectual disability	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease	quadriplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	spasticity	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
intellectual disability	disease	spasticity	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
quadriplegia	disease	spasticity	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	intellectual disability	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	quadriplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
intellectual disability	disease	quadriplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
tri	disease_to_anatomy	, and	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
hemiplegia	disease_to_anatomy	, and	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease_to_anatomy	, and	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
spasticity	disease_to_anatomy	, and	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease_to_anatomy	, and	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
quadriplegia	disease_to_anatomy	, and	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
of the	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
parietal	anatomy	superior parietal	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
of the lateral	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, a	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, and	anatomy	superior parietal	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
superior parietal	anatomy	the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
intraparietal sulcus	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
superior parietal	anatomy	the superior	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
lobe (	anatomy	superior parietal	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
parietal lobe	anatomy	superior parietal	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
cortex (	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
occipital cortex	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
of the	anatomy	parietal	2	0	14561452|8759044	"PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
of the	anatomy	of the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
of the	anatomy	the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
intraparietal sulcus	anatomy	of the	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
lobe (	anatomy	of the	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
of the	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
occipital cortex	anatomy	of the	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
of the lateral	anatomy	parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, a	anatomy	parietal	2	0	14561452|22426803	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
parietal	anatomy	the lateral	2	0	14561452|21692142	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
intraparietal sulcus	anatomy	parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
parietal	anatomy	the superior	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
lobe (	anatomy	parietal	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
parietal	anatomy	parietal lobe	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
cortex (	anatomy	parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
occipital cortex	anatomy	parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, a	anatomy	of the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, and	anatomy	of the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
of the lateral	anatomy	the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
intraparietal sulcus	anatomy	of the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
of the lateral	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
lobe (	anatomy	of the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
of the lateral	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
cortex (	anatomy	of the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
occipital cortex	anatomy	of the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, a	anatomy	the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, a	anatomy	intraparietal sulcus	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, a	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, a	anatomy	lobe (	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, a	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, a	anatomy	cortex (	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, a	anatomy	occipital cortex	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, and	anatomy	the lateral	2	0	14561452|21692142	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
, and	anatomy	intraparietal sulcus	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, and	anatomy	lobe (	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, and	anatomy	parietal lobe	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, and	anatomy	cortex (	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
, and	anatomy	occipital cortex	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
intraparietal sulcus	anatomy	the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
the lateral	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
lobe (	anatomy	the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
parietal lobe	anatomy	the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
cortex (	anatomy	the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
occipital cortex	anatomy	the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
intraparietal sulcus	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
intraparietal sulcus	anatomy	lobe (	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
intraparietal sulcus	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
cortex (	anatomy	intraparietal sulcus	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
intraparietal sulcus	anatomy	occipital cortex	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
lobe (	anatomy	the superior	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
parietal lobe	anatomy	the superior	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
cortex (	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
occipital cortex	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
lobe (	anatomy	parietal lobe	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
cortex (	anatomy	lobe (	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
lobe (	anatomy	occipital cortex	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
cortex (	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
occipital cortex	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
cortex (	anatomy	occipital cortex	2	0	14561452|14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).|PMID:14561452; Original text:Autistic subjects, in contrast, showed activation in the bilateral ventral occipital cortex (P<0.03) and striate cortex (P<0.05).
autistic	disease_to_anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
autistic	disease_to_anatomy	parietal	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
autistic	disease_to_anatomy	of the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
autistic	disease_to_anatomy	the lateral	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
autistic	disease_to_anatomy	intraparietal sulcus	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
autistic	disease_to_anatomy	lobe (	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
autistic	disease_to_anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
autistic	disease_to_anatomy	cortex (	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
autistic	disease_to_anatomy	occipital cortex	1	0	14561452	PMID:14561452; Original text:Within the task condition, a region-of-interest comparison of attend-left versus attend-right conditions indicated that modulation of activation in the autistic brain as a function of the lateral focus of spatial attention was abnormally decreased in the left ventral occipital cortex (P<0.03), abnormally increased in the left intraparietal sulcus (P<0.01), and abnormally variable in the superior parietal lobe (P<0.03).
medial frontal gyrus	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
frontal gyrus	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
middle temporal gyrus	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
superior parietal	anatomy	temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
middle temporal	anatomy	superior parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
superior parietal	anatomy	temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	medial frontal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
frontal gyrus	anatomy	medial frontal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal gyrus	anatomy	parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal	anatomy	medial frontal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal gyrus	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, and	anatomy	medial frontal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal gyrus	anatomy	middle temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal gyrus	anatomy	temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal gyrus	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
lobe (	anatomy	medial frontal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal gyrus	anatomy	middle temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal gyrus	anatomy	temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	frontal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	medial frontal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, and	anatomy	, left	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	middle temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	lobe (	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	middle temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, left	anatomy	temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
frontal gyrus	anatomy	parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
frontal gyrus	anatomy	medial frontal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
frontal gyrus	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, and	anatomy	frontal gyrus	2	0	14561452|23452684	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
frontal gyrus	anatomy	middle temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
frontal gyrus	anatomy	temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
frontal gyrus	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
frontal gyrus	anatomy	lobe (	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
frontal gyrus	anatomy	middle temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
frontal gyrus	anatomy	temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal	anatomy	parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
middle temporal gyrus	anatomy	parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
parietal	anatomy	temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
middle temporal	anatomy	parietal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, and	anatomy	medial frontal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal	anatomy	middle temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal	anatomy	temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
lobe (	anatomy	medial frontal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal	anatomy	middle temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
medial frontal	anatomy	temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
middle temporal gyrus	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
temporal gyrus	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
middle temporal	anatomy	the superior	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
, and	anatomy	middle temporal gyrus	2	0	14561452|26769980	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	temporal gyrus	3	0	14561452|23452684|26769980	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	middle temporal	2	0	14561452|26769980	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal gyrus	anatomy	temporal gyrus	2	0	14561452|26769980	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal gyrus	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
lobe (	anatomy	middle temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
middle temporal	anatomy	middle temporal gyrus	2	0	14561452|26769980	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal gyrus	anatomy	temporal	2	0	14561452|26769980	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
parietal lobe	anatomy	temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
lobe (	anatomy	temporal gyrus	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
middle temporal	anatomy	temporal gyrus	2	0	14561452|26769980	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
temporal	anatomy	temporal gyrus	3	0	14561452|23452684|26769980	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal	anatomy	parietal lobe	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
parietal lobe	anatomy	temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
lobe (	anatomy	middle temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
lobe (	anatomy	temporal	1	0	14561452	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).
middle temporal	anatomy	temporal	2	0	14561452|26769980	PMID:14561452; Original text:In normal subjects, the task evoked activation in a network of cortical regions including the superior parietal lobe (P<0.001), left middle temporal gyrus (P=0.002), left inferior (P<0.001) and middle (P<0.02) frontal gyri, and medial frontal gyrus (P<0.02).|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex (	anatomy	striate cortex	1	0	14561452	PMID:14561452; Original text:Autistic subjects, in contrast, showed activation in the bilateral ventral occipital cortex (P<0.03) and striate cortex (P<0.05).
occipital cortex	anatomy	striate cortex	1	0	14561452	PMID:14561452; Original text:Autistic subjects, in contrast, showed activation in the bilateral ventral occipital cortex (P<0.03) and striate cortex (P<0.05).
autism spectrum disorders	disease	functional impairment	1	0	19309326	PMID:19309326; Original text:Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment.
anxiety disorders	disease	autism spectrum disorders	1	0	19309326	PMID:19309326; Original text:Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment.
anxiety disorders	disease	functional impairment	1	0	19309326	PMID:19309326; Original text:Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment.
b6	chemical	vitamin	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b(6	chemical	vitamin	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b(6	chemical	b6	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
group of	anatomy	levels of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
vitamin	chemical_to_disease	autistic	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b6	chemical_to_disease	autistic	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b(6	chemical_to_disease	autistic	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
vitamin	chemical_to_anatomy	levels of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
vitamin	chemical_to_anatomy	group of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b6	chemical_to_anatomy	levels of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b6	chemical_to_anatomy	group of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b(6	chemical_to_anatomy	levels of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b(6	chemical_to_anatomy	group of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
autistic	disease_to_anatomy	group of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
vitamin c	chemical_to_anatomy	of the	1	0	15673999	PMID:15673999; Original text:Vitamin C levels were measured at the end of the study, and the placebo group had levels that were significantly below average for typical children, whereas the supplement group had near-average levels.
vitamin c	chemical_to_anatomy	end of	1	0	15673999	PMID:15673999; Original text:Vitamin C levels were measured at the end of the study, and the placebo group had levels that were significantly below average for typical children, whereas the supplement group had near-average levels.
vitamin c	chemical_to_anatomy	, and	1	0	15673999	PMID:15673999; Original text:Vitamin C levels were measured at the end of the study, and the placebo group had levels that were significantly below average for typical children, whereas the supplement group had near-average levels.
ear-occlusion	disease	hyperactivity	1	0	10755175	PMID:10755175; Original text:Significant differences tended to show that the control condition was superior on parent-rated measures of hyperactivity and on direct observational measures of ear-occlusion.
ear-occlusion	disease_to_anatomy	of ear	1	0	10755175	PMID:10755175; Original text:Significant differences tended to show that the control condition was superior on parent-rated measures of hyperactivity and on direct observational measures of ear-occlusion.
hyperactivity	disease_to_anatomy	of ear	1	0	10755175	PMID:10755175; Original text:Significant differences tended to show that the control condition was superior on parent-rated measures of hyperactivity and on direct observational measures of ear-occlusion.
pyruvate	chemical	ubiquinone	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
lactate	chemical	pyruvate	2	0	21263444|21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
carnitine	chemical	pyruvate	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
lactate	chemical	ubiquinone	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
carnitine	chemical	ubiquinone	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
carnitine	chemical	lactate	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
carnitine	nutrient_to_chemical	pyruvate	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
carnitine	nutrient_to_chemical	ubiquinone	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
carnitine	nutrient_to_chemical	lactate	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
carnitine	nutrient_to_chemical	carnitine	2	0	21263444|29562612	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.|PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	nutrient_to_disease	asd	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
carnitine	nutrient_to_anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
pyruvate	chemical_to_disease	asd	2	0	21263444|21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
ubiquinone	chemical_to_disease	asd	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
lactate	chemical_to_disease	asd	2	0	21263444|21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
carnitine	chemical_to_disease	asd	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
pyruvate	chemical_to_anatomy	mitochondrial	2	0	21263444|21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
ubiquinone	chemical_to_anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
lactate	chemical_to_anatomy	mitochondrial	2	0	21263444|21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
carnitine	chemical_to_anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
mitochondrial disease	disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease	mitochondrial disease	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
mitochondrial disease	disease	motor delay	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease	mitochondrial disease	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease	mitochondrial disease	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
motor delay	disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease	motor delay	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease	developmental regression	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease	gastrointestinal abnormalities	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease	motor delay	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease	motor delay	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease	gastrointestinal abnormalities	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
, motor	anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
, gastrointestinal	anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
, and	anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
, female	anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
, gastrointestinal	anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
, female	anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
, female	anatomy	, gastrointestinal	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
, and	anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_disease	mitochondrial disease	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_disease	developmental regression	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_disease	motor delay	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_disease	gastrointestinal abnormalities	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_disease	mitochondrial disease	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_disease	developmental regression	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_disease	motor delay	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_disease	gastrointestinal abnormalities	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_anatomy	, gastrointestinal	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_anatomy	, and	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_anatomy	, gastrointestinal	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_anatomy	, and	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
mitochondrial disease	disease_to_anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
mitochondrial disease	disease_to_anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
mitochondrial disease	disease_to_anatomy	, gastrointestinal	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
mitochondrial disease	disease_to_anatomy	, and	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
mitochondrial disease	disease_to_anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
seizures	disease_to_anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
seizures	disease_to_anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
seizures	disease_to_anatomy	, gastrointestinal	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
seizures	disease_to_anatomy	, and	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
seizures	disease_to_anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease_to_anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease_to_anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease_to_anatomy	, gastrointestinal	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease_to_anatomy	, and	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease_to_anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
motor delay	disease_to_anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
motor delay	disease_to_anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
motor delay	disease_to_anatomy	, gastrointestinal	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
motor delay	disease_to_anatomy	, and	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
motor delay	disease_to_anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease_to_anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease_to_anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease_to_anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease_to_anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease_to_anatomy	, gastrointestinal	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease_to_anatomy	, and	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease_to_anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
[3h]-par	chemical_to_disease	autistic	1	0	11071017	PMID:11071017; Original text:The results showed a significantly higher density of [3H]-Par binding sites in autistic children than in healthy control subjects.
[3h]-par	chemical_to_mechanism	[3h]-par	1	0	11071017	PMID:11071017; Original text:The results showed a significantly higher density of [3H]-Par binding sites in autistic children than in healthy control subjects.
autistic	disease_to_mechanism	[3h]-par	1	0	11071017	PMID:11071017; Original text:The results showed a significantly higher density of [3H]-Par binding sites in autistic children than in healthy control subjects.
autism	disease	hyperhomocysteinemia	1	0	27755291	PMID:27755291; Original text:The meta-analysis of nine studies showed hyperhomocysteinemia as a significant risk factor for autism in both fixed-effects (P<0.0001) and random-effects (P=0.026) models.
hippocampus	anatomy	the hippocampus	1	0	21948742	PMID:21948742; Original text:We compared, using magnetic resonance imaging, the in vivo anatomy of the hippocampus in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ.
of the	anatomy	the hippocampus	1	0	21948742	PMID:21948742; Original text:We compared, using magnetic resonance imaging, the in vivo anatomy of the hippocampus in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ.
of the hippocampus	anatomy	the hippocampus	1	0	21948742	PMID:21948742; Original text:We compared, using magnetic resonance imaging, the in vivo anatomy of the hippocampus in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ.
hippocampus	anatomy	of the	1	0	21948742	PMID:21948742; Original text:We compared, using magnetic resonance imaging, the in vivo anatomy of the hippocampus in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ.
hippocampus	anatomy	of the hippocampus	1	0	21948742	PMID:21948742; Original text:We compared, using magnetic resonance imaging, the in vivo anatomy of the hippocampus in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ.
of the	anatomy	of the hippocampus	1	0	21948742	PMID:21948742; Original text:We compared, using magnetic resonance imaging, the in vivo anatomy of the hippocampus in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ.
asperger syndrome	disease_to_anatomy	the hippocampus	1	0	21948742	PMID:21948742; Original text:We compared, using magnetic resonance imaging, the in vivo anatomy of the hippocampus in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ.
asperger syndrome	disease_to_anatomy	hippocampus	1	0	21948742	PMID:21948742; Original text:We compared, using magnetic resonance imaging, the in vivo anatomy of the hippocampus in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ.
asperger syndrome	disease_to_anatomy	of the	3	0	21948742|21948742|8986845	PMID:21948742; Original text:We compared, using magnetic resonance imaging, the in vivo anatomy of the hippocampus in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ.|PMID:21948742; Original text:Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.|PMID:8986845; Original text:13 (76%) of the Asperger syndrome patients were rated as pedantic compared to 4 (31%) of the high-functioning autism group (chi 2 = 6.3; p = .01).
asperger syndrome	disease_to_anatomy	of the hippocampus	1	0	21948742	PMID:21948742; Original text:We compared, using magnetic resonance imaging, the in vivo anatomy of the hippocampus in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ.
, and	anatomy	and left	2	0	21948742|23452684	PMID:21948742; Original text:However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01).|PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
amygdala	anatomy	and left	1	0	21948742	PMID:21948742; Original text:However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01).
, right	anatomy	and left	1	0	21948742	PMID:21948742; Original text:However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01).
, and	anatomy	amygdala	2	0	21948742|21948742	PMID:21948742; Original text:However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01).|PMID:21948742; Original text:There was a significant group difference in aging of left amygdala; controls, but not individuals with Asperger syndrome, had a significant age-related increase in volume (r = 0.486, P<0.01, and r = 0.007, P = 0.97, z = 1.995).
, and	anatomy	, right	1	0	21948742	PMID:21948742; Original text:However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01).
, right	anatomy	amygdala	1	0	21948742	PMID:21948742; Original text:However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01).
asperger syndrome	disease_to_anatomy	and left	1	0	21948742	PMID:21948742; Original text:However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01).
asperger syndrome	disease_to_anatomy	, and	2	0	21948742|21948742	PMID:21948742; Original text:However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01).|PMID:21948742; Original text:There was a significant group difference in aging of left amygdala; controls, but not individuals with Asperger syndrome, had a significant age-related increase in volume (r = 0.486, P<0.01, and r = 0.007, P = 0.97, z = 1.995).
asperger syndrome	disease_to_anatomy	amygdala	3	0	21948742|21948742|21948742	PMID:21948742; Original text:However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01).|PMID:21948742; Original text:There was a significant group difference in aging of left amygdala; controls, but not individuals with Asperger syndrome, had a significant age-related increase in volume (r = 0.486, P<0.01, and r = 0.007, P = 0.97, z = 1.995).|PMID:21948742; Original text:Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.
asperger syndrome	disease_to_anatomy	, right	1	0	21948742	PMID:21948742; Original text:However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01).
, and	anatomy	, z	1	0	21948742	PMID:21948742; Original text:There was a significant group difference in aging of left amygdala; controls, but not individuals with Asperger syndrome, had a significant age-related increase in volume (r = 0.486, P<0.01, and r = 0.007, P = 0.97, z = 1.995).
, z	anatomy	amygdala	1	0	21948742	PMID:21948742; Original text:There was a significant group difference in aging of left amygdala; controls, but not individuals with Asperger syndrome, had a significant age-related increase in volume (r = 0.486, P<0.01, and r = 0.007, P = 0.97, z = 1.995).
asperger syndrome	disease_to_anatomy	, z	1	0	21948742	PMID:21948742; Original text:There was a significant group difference in aging of left amygdala; controls, but not individuals with Asperger syndrome, had a significant age-related increase in volume (r = 0.486, P<0.01, and r = 0.007, P = 0.97, z = 1.995).
of the amygdala	anatomy	the amygdala	2	0	21948742|32161366	"PMID:21948742; Original text:Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
of the	anatomy	the amygdala	2	0	21948742|32161366	"PMID:21948742; Original text:Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
amygdala	anatomy	the amygdala	2	0	21948742|32161366	"PMID:21948742; Original text:Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
of the	anatomy	of the amygdala	2	0	21948742|32161366	"PMID:21948742; Original text:Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
amygdala	anatomy	of the amygdala	2	0	21948742|32161366	"PMID:21948742; Original text:Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
amygdala	anatomy	of the	3	0	21948742|22395004|32161366	"PMID:21948742; Original text:Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.|PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
asperger syndrome	disease_to_anatomy	the amygdala	1	0	21948742	PMID:21948742; Original text:Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.
asperger syndrome	disease_to_anatomy	of the amygdala	1	0	21948742	PMID:21948742; Original text:Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.
amantadine	chemical_to_disease	inappropriate speech	1	0	11392343	PMID:11392343; Original text:However, in the amantadine-treated group there were statistically significant improvements in absolute changes in clinician-rated ABC-CVs for hyperactivity (amantadine -6.4 versus placebo -2.1; p = .046) and inappropriate speech (-1.9 versus 0.4; p = .008).
dietdhd	disease	dietdos	1	0	20406576	PMID:20406576; Original text:diett this point, there was a significant improvement to mean diet group scores (time*treatment interaction) on sub-domains of dietDOS, GdietRS and dietDHD-IV measures.
dietdos	disease_to_anatomy	point	1	0	20406576	PMID:20406576; Original text:diett this point, there was a significant improvement to mean diet group scores (time*treatment interaction) on sub-domains of dietDOS, GdietRS and dietDHD-IV measures.
dietdhd	disease_to_anatomy	point	1	0	20406576	PMID:20406576; Original text:diett this point, there was a significant improvement to mean diet group scores (time*treatment interaction) on sub-domains of dietDOS, GdietRS and dietDHD-IV measures.
, red	anatomy	whole blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, red	anatomy	red blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, red	anatomy	cells (	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, and	anatomy	, red	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, red	anatomy	blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, red	anatomy	red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, red	anatomy	, red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
red blood cells	anatomy	whole blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
cells (	anatomy	whole blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, and	anatomy	whole blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
blood cells	anatomy	whole blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
red blood	anatomy	whole blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, red blood	anatomy	whole blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
cells (	anatomy	red blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, and	anatomy	red blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
blood cells	anatomy	red blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
red blood	anatomy	red blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, red blood	anatomy	red blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, and	anatomy	cells (	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
blood cells	anatomy	cells (	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
cells (	anatomy	red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, red blood	anatomy	cells (	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, and	anatomy	blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, and	anatomy	red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, and	anatomy	, red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
blood cells	anatomy	red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, red blood	anatomy	blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
, red blood	anatomy	red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_disease	spectrum disorders	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	, red	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	whole blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	red blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	cells (	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	, red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
spectrum disorders	disease_to_anatomy	, red	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
spectrum disorders	disease_to_anatomy	whole blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
spectrum disorders	disease_to_anatomy	red blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
spectrum disorders	disease_to_anatomy	cells (	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
spectrum disorders	disease_to_anatomy	blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
spectrum disorders	disease_to_anatomy	red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
spectrum disorders	disease_to_anatomy	, red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
interleukin)-1beta	mechanism	interleukin-8	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-8	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-8	mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-6	mechanism	interleukin-8	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism	interleukin-8	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	interleukin-8	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin)-1beta	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin)-1beta	mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin)-1beta	mechanism	interleukin-6	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism	interleukin)-1beta	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	interleukin)-1beta	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
monocyte chemotactic protein-1	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-6	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-6	mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism	interleukin-6	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	interleukin-6	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism	interleukin	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
group	anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	interleukin-8	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	interleukin)-1beta	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	transforming growth factor-β1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	monocyte chemotactic protein-1	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	interleukin-6	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	interleukin	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	interferon-gamma	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_anatomy	group	2	0	24934179|32305492	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).|PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
interleukin-8	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-8	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin)-1beta	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin)-1beta	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
transforming growth factor-β1	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
transforming growth factor-β1	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
monocyte chemotactic protein-1	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
monocyte chemotactic protein-1	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-6	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-6	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_anatomy	of superficial	1	0	19708861	PMID:19708861; Original text:There is a need for caution in interpreting the significance of superficial similarities between ASD and the behavioural phenotypes of certain genetically determined syndromes.
inferior frontal	anatomy	the inferior	2	0	33608048|25817280	PMID:33608048; Original text:Also, within disorder individuals, brain functional differences were shifted significantly towards control levels during response inhibition in the inferior frontal and premotor cortices.|PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
, brain	anatomy	the inferior	1	0	33608048	PMID:33608048; Original text:Also, within disorder individuals, brain functional differences were shifted significantly towards control levels during response inhibition in the inferior frontal and premotor cortices.
, brain	anatomy	inferior frontal	1	0	33608048	PMID:33608048; Original text:Also, within disorder individuals, brain functional differences were shifted significantly towards control levels during response inhibition in the inferior frontal and premotor cortices.
, insular	anatomy	, temporal	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, temporal	anatomy	of the	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, hippocampal	anatomy	, temporal	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, temporal	anatomy	grey matter	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, temporal	anatomy	amygdala	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, temporal	anatomy	regions	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, insular	anatomy	of the	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, hippocampal	anatomy	, insular	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, insular	anatomy	grey matter	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, insular	anatomy	temporal	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, insular	anatomy	amygdala	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, insular	anatomy	regions	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, hippocampal	anatomy	of the	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
grey matter	anatomy	of the	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
of the	anatomy	regions	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, hippocampal	anatomy	grey matter	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, hippocampal	anatomy	temporal	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, hippocampal	anatomy	amygdala	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
, hippocampal	anatomy	regions	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
grey matter	anatomy	temporal	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
amygdala	anatomy	grey matter	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
grey matter	anatomy	regions	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
amygdala	anatomy	temporal	2	0	22395004|32161366	"PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
regions	anatomy	temporal	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
amygdala	anatomy	regions	1	0	22395004	PMID:22395004; Original text:There are increases in the grey matter volume of the sensorimotor and parietooccipital regions, as well as significant reductions in amygdala, hippocampal, insular, temporal and inferior-frontal grey matter volumes.
risperidone	chemical_to_disease	pdd	1	0	10933118	PMID:10933118; Original text:Risperidone significantly ameliorated behavioral symptoms of PDD in 10 out of 11 subjects, with the effects on core symptoms being of smaller amplitude and of slower onset.
weight gain	disease	weight loss	1	0	10933118	PMID:10933118; Original text:Weight gain was common, although the rate of increase lessened over a period of time; after drug withdrawal, considerable weight loss was observed in the patient who had previously shown the most significant increase.
anxiety	disease	ocd	1	0	23389964	PMID:23389964; Original text:Both treatments produced a significant reduction in particularly obsessive compulsive disorder symptoms, within-group effect sizes of 1.01 Group cognitive behavioral treatment group and 0.6 for the OCD or anxiety management group.
obsessive compulsive disorder	disease	ocd	1	0	23389964	PMID:23389964; Original text:Both treatments produced a significant reduction in particularly obsessive compulsive disorder symptoms, within-group effect sizes of 1.01 Group cognitive behavioral treatment group and 0.6 for the OCD or anxiety management group.
anxiety	disease	obsessive compulsive disorder	1	0	23389964	PMID:23389964; Original text:Both treatments produced a significant reduction in particularly obsessive compulsive disorder symptoms, within-group effect sizes of 1.01 Group cognitive behavioral treatment group and 0.6 for the OCD or anxiety management group.
end of	anatomy	group (	2	0	23389964|18080171	PMID:23389964; Original text:There were no statistically significant differences between the two groups at end of treatment, although more responders in the Group cognitive behavioral treatment group (45 versus 20%).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
anterior cingulate cortex	anatomy	prefrontal cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
anterior cingulate	anatomy	prefrontal cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
cortex and	anatomy	prefrontal cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
anterior cingulate cortex	anatomy	medial prefrontal	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
anterior cingulate	anatomy	medial prefrontal	2	0	26336909|26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).
cingulate cortex	anatomy	medial prefrontal	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
cortex and	anatomy	medial prefrontal	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
anterior cingulate cortex	anatomy	medial prefrontal cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
anterior cingulate	anatomy	medial prefrontal cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
cingulate cortex	anatomy	medial prefrontal cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
cortex and	anatomy	medial prefrontal cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
anterior cingulate cortex	anatomy	cortex and	2	0	26336909|26769980	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	cortex and	2	0	26336909|26769980	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	cortex and	2	0	26336909|26769980	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex (	anatomy	cortex and	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	chemical_to_anatomy	anterior cingulate cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	chemical_to_anatomy	anterior cingulate	2	0	26336909|26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).
oxytocin	chemical_to_anatomy	cingulate cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	chemical_to_anatomy	cortex and	2	0	26336909|32161366	"PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	anterior cingulate cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	mechanism_to_anatomy	anterior cingulate	2	0	26336909|26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).
oxytocin	mechanism_to_anatomy	cingulate cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	mechanism_to_anatomy	cortex and	2	0	26336909|32161366	"PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
autistic	disease_to_anatomy	medial prefrontal	1	0	26336909	PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).
autistic	disease_to_anatomy	anterior cingulate	1	0	26336909	PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).
asd	disease	obsessive-compulsive disorder symptomology	1	0	29082426	PMID:29082426; Original text:However, the significant overlap of ASD features with anxiety and obsessive-compulsive disorder symptomology makes differential diagnosis of these disorders particularly challenging.
anxiety	disease	obsessive-compulsive disorder symptomology	1	0	29082426	PMID:29082426; Original text:However, the significant overlap of ASD features with anxiety and obsessive-compulsive disorder symptomology makes differential diagnosis of these disorders particularly challenging.
anxiety	disease	asd	4	0	29082426|25424398|25246292|25602249	PMID:29082426; Original text:However, the significant overlap of ASD features with anxiety and obsessive-compulsive disorder symptomology makes differential diagnosis of these disorders particularly challenging.|PMID:25424398; Original text:Thirty-one children (11-16 years) with ASD and clinically significant anxiety were randomly assigned to receive 16 weekly a personalized, modular cognitive-behavioral therapy sessions or an equivalent duration of TAU.|PMID:25246292; Original text:The present report is a systematic review and meta-analysis examinina statistically significant pooled treatment effect size the efficacy of Coa statistically significant pooled treatment effect sizenitive-behavioral therapy for anxiety amona statistically significant pooled treatment effect size youth with ASD.|PMID:25602249; Original text:It is well established that the prevalence of anxiety in youth with an ASD is significantly greater than the prevalence of anxiety in the general population.
level of	anatomy	of the	1	0	31682573	PMID:31682573; Original text:The meta-analysis was conducted on five of the trials and did not show a significant effect, with a high level of heterogeneity detected (n=they82 [33.4%, they82/545], 5 randomized controlled trials; pooled standardized mean difference=-0.39;
fenfluramine	chemical	serotonin	2	0	3623815|2936877	PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.|PMID:2936877; Original text:A double-blind cross-over study on the effect of fenfluramine versus placebo in seven autistic boys over a period of 8 months demonstrated a significant decrease in blood serotonin levels during the fenfluramine phase in all subjects.
serotonin	chemical_to_anatomy	component of	1	0	3623815	PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.
fenfluramine	chemical_to_anatomy	component of	1	0	3623815	PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.
fenfluramine	chemical_to_anatomy	of the	1	0	3623815	PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.
metformin	chemical	riomet	1	0	29620914	PMID:29620914; Original text:We studied the effects of metformin (Riomet®) concentrate on spatial and verbal memory in 51 youth with disorder, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management.
metformin	chemical_to_anatomy	, and	1	0	29620914	PMID:29620914; Original text:We studied the effects of metformin (Riomet®) concentrate on spatial and verbal memory in 51 youth with disorder, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management.
riomet	chemical_to_anatomy	, and	1	0	29620914	PMID:29620914; Original text:We studied the effects of metformin (Riomet®) concentrate on spatial and verbal memory in 51 youth with disorder, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management.
zonulin	mechanism	zonulin peptide family	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin peptide family	mechanism_to_anatomy	levels of	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin peptide family	mechanism_to_anatomy	of the	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin peptide family	mechanism_to_anatomy	(p	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin	mechanism_to_anatomy	levels of	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin	mechanism_to_anatomy	of the	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin	mechanism_to_anatomy	(p	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
group	anatomy	of the	1	0	15358868	PMID:15358868; Original text:Experiment 3 showed that increases in target-distractor similarity slowed the visual search performance of the control group significantly more than that of the autism group, suggesting that the adults with autism have a superior visual discrimination ability.
, and	anatomy	segments of	1	0	33663814	PMID:33663814; Original text:Building on the foundation of existing work in this area will require tackling significant challenges, including greater inclusion of often marginalized segments of society, and conducting larger, properly powered studies.
asd	disease_to_anatomy	(ci	1	0	27120988	PMID:27120988; Original text:This random-effects meta-analysis of spoken-language outcomes for children with ASD who received early intervention as compared with usual treatments yielded a significant overall mean effect size of g = 0.26 (CI = 0.11 to 0.42).
autism	disease	neurodevelopmental disorders	3	0	30563709|15090875|20969835	PMID:30563709; Original text:Advances in sequencing technology have significantly expanded our understanding of the genetics of autism and neurodevelopmental disorders (neurodevelopmental disorders).|PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.|PMID:20969835; Original text:We present initial evidence offering proof of concept that brain anatomy can be used to accurately distinguish adults with autism from healthy controls, and from some other neurodevelopmental disorders (some other neurodevelopmental disorders).
neurodevelopmental disorders	disease_to_anatomy	of the	1	0	30563709	PMID:30563709; Original text:Advances in sequencing technology have significantly expanded our understanding of the genetics of autism and neurodevelopmental disorders (neurodevelopmental disorders).
myelination	anatomy	white matter	1	0	17531541	PMID:17531541; Original text:One final point is the initial overgrowth of white matter in the first 2 years of life in autistic children, followed later by arrested growth, resulting in aberrant connectivity; myelination of white matter will likely be significant in the etiology of autism.
autism	disease_to_anatomy	white matter	1	0	17531541	PMID:17531541; Original text:One final point is the initial overgrowth of white matter in the first 2 years of life in autistic children, followed later by arrested growth, resulting in aberrant connectivity; myelination of white matter will likely be significant in the etiology of autism.
autism	disease_to_anatomy	myelination	1	0	17531541	PMID:17531541; Original text:One final point is the initial overgrowth of white matter in the first 2 years of life in autistic children, followed later by arrested growth, resulting in aberrant connectivity; myelination of white matter will likely be significant in the etiology of autism.
autistic	disease_to_anatomy	white matter	1	0	17531541	PMID:17531541; Original text:One final point is the initial overgrowth of white matter in the first 2 years of life in autistic children, followed later by arrested growth, resulting in aberrant connectivity; myelination of white matter will likely be significant in the etiology of autism.
autistic	disease_to_anatomy	myelination	1	0	17531541	PMID:17531541; Original text:One final point is the initial overgrowth of white matter in the first 2 years of life in autistic children, followed later by arrested growth, resulting in aberrant connectivity; myelination of white matter will likely be significant in the etiology of autism.
citalopram	chemical_to_anatomy	of the	1	0	24061784	PMID:24061784; Original text:Specifically, participants in the placebo group were significantly less likely than participants in the citalopram group to respond at week 12 if they entered the study more symptomatic on each of the 3 composite measures, and they were at least 2 times less likely to be responders.
citalopram	chemical_to_anatomy	, and	1	0	24061784	PMID:24061784; Original text:Specifically, participants in the placebo group were significantly less likely than participants in the citalopram group to respond at week 12 if they entered the study more symptomatic on each of the 3 composite measures, and they were at least 2 times less likely to be responders.
autism	disease	disruptive behavior	1	0	24061784	PMID:24061784; Original text:Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12.
autism	disease	mood	1	0	24061784	PMID:24061784; Original text:Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12.
disruptive behavior	disease	mood	1	0	24061784	PMID:24061784; Original text:Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12.
disruptive behavior	disease_to_anatomy	, and	1	0	24061784	PMID:24061784; Original text:Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12.
mood	disease_to_anatomy	, and	1	0	24061784	PMID:24061784; Original text:Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12.
asd	disease	social-emotional problems	1	0	33888566	PMID:33888566; Original text:These findings indicate that cognitive behavioral therapy may significantly improve the symptoms of ASD and social-emotional problems in children or adolescents with ASD.
riluzole	chemical_to_mechanism	extracellular signal-related kinase	1	0	21059347	PMID:21059347; Original text:Overall, riluzole use was not associated with significant clinical improvement despite uniform correction of peripheral Extracellular signal-related kinase activation.
riluzole	chemical_to_anatomy	of peripheral	1	0	21059347	PMID:21059347; Original text:Overall, riluzole use was not associated with significant clinical improvement despite uniform correction of peripheral Extracellular signal-related kinase activation.
extracellular signal-related kinase	mechanism_to_anatomy	of peripheral	1	0	21059347	PMID:21059347; Original text:Overall, riluzole use was not associated with significant clinical improvement despite uniform correction of peripheral Extracellular signal-related kinase activation.
complex	anatomy	of the	1	0	32563542	PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.
autism	disease_to_anatomy	complex	1	0	32563542	PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.
tuberous sclerosis	disease_to_anatomy	of the	1	0	32563542	PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.
autistic symptoms	disease_to_anatomy	of the	1	0	9512308	PMID:9512308; Original text:Only in one child was there a very significant improvement, with almost total amelioration of autistic symptoms over the time period of the four infusions.
biotin	chemical	vitamin k	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
biotin	nutrient_to_chemical	biotin	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
biotin	nutrient_to_chemical	vitamin k	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
biotin	nutrient_to_anatomy	levels of	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
biotin	nutrient_to_anatomy	(p	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
biotin	chemical_to_anatomy	levels of	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
biotin	chemical_to_anatomy	(p	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
vitamin k	chemical_to_anatomy	levels of	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
vitamin k	chemical_to_anatomy	(p	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
atp	chemical	nadph	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	nitrotyrosine	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	sam	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	reduced glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	s	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	oxidized glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	nadh	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	gssg	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	sulfate	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	gsh	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	nitrotyrosine	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	sam	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	reduced glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	s	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	oxidized glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	nadph	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	nadph	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	sulfate	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	nadph	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical	sam	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical	reduced glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical	s	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical	oxidized glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	nitrotyrosine	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	nitrotyrosine	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical	sulfate	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	nitrotyrosine	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
reduced glutathione	chemical	sam	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
s	chemical	sam	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
oxidized glutathione	chemical	sam	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	sam	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	sam	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
sam	chemical	sulfate	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	sam	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
reduced glutathione	chemical	s	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	reduced glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	reduced glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
reduced glutathione	chemical	sulfate	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	reduced glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
oxidized glutathione	chemical	s	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	s	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	s	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
s	chemical	sulfate	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	s	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	oxidized glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	oxidized glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
oxidized glutathione	chemical	sulfate	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	oxidized glutathione	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	nadh	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	sulfate	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	nadh	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	sulfate	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	gssg	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	sulfate	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
reduced glutathione	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
s	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
oxidized glutathione	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
sulfate	chemical_to_anatomy	, and	2	0	22151477|22129897	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).|PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
gsh	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
sertraline	chemical_to_mechanism	bdnf	1	0	28242040	PMID:28242040; Original text:A significant association was observed between a BDNF polymorphism and improvements for several clinical measures, including the Clinical Global Impression scale (P=0.008) and the cognitive T score (P=0.017) in those treated with sertraline compared to those in the placebo group.
2d6	mechanism	5-httlpr gene	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
2d6	mechanism	cytochrome p450 2c19	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
2d6	mechanism	maoa	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
5-httlpr gene	mechanism	cytochrome p450 2c19	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
5-httlpr gene	mechanism	maoa	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
cytochrome p450 2c19	mechanism	maoa	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
2d6	mechanism_to_anatomy	of the	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
2d6	mechanism_to_anatomy	, and	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
5-httlpr gene	mechanism_to_anatomy	of the	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
5-httlpr gene	mechanism_to_anatomy	, and	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
cytochrome p450 2c19	mechanism_to_anatomy	of the	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
cytochrome p450 2c19	mechanism_to_anatomy	, and	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
maoa	mechanism_to_anatomy	of the	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
maoa	mechanism_to_anatomy	, and	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
epilepsy	disease	seizures	1	0	33200402	PMID:33200402; Original text:The highest diagnostic yield for epilepsy subtypes was observed in individuals with intellectual disability (27.9%) and early onset seizures (36.8%).
epilepsy	disease	intellectual disability	3	0	33200402|24123946|18565495	PMID:33200402; Original text:The highest diagnostic yield for epilepsy subtypes was observed in individuals with intellectual disability (27.9%) and early onset seizures (36.8%).|PMID:24123946; Original text:The del15q11.2 was found to be significantly associated with intellectual disability, schizophrenia, epilepsy, and disorder.|PMID:18565495; Original text:There was a strong discrepancy in relative risk (relative risk) according to IQ, with more autistic patients with intellectual disability having epilepsy (relative risk = .555; 95% confidence interval [CI]: .42-.73; p < .001).
intellectual disability	disease	seizures	1	0	33200402	PMID:33200402; Original text:The highest diagnostic yield for epilepsy subtypes was observed in individuals with intellectual disability (27.9%) and early onset seizures (36.8%).
anxiety symptoms	disease	autism spectrum disorders	1	0	25246292	PMID:25246292; Original text:Coa statistically significant pooled treatment effect sizenitive-behavioral therapy (Coa statistically significant pooled treatment effect sizenitive-behavioral therapy) has been developed and modified to treat anxiety symptoms in youth with hia statistically significant pooled treatment effect sizeh-functionina statistically significant pooled treatment effect size autism spectrum disorders (ASD) but has yielded varyina statistically significant pooled treatment effect size findina statistically significant pooled treatment effect sizes.
anxiety symptoms	disease	asd	1	0	25246292	PMID:25246292; Original text:Coa statistically significant pooled treatment effect sizenitive-behavioral therapy (Coa statistically significant pooled treatment effect sizenitive-behavioral therapy) has been developed and modified to treat anxiety symptoms in youth with hia statistically significant pooled treatment effect sizeh-functionina statistically significant pooled treatment effect size autism spectrum disorders (ASD) but has yielded varyina statistically significant pooled treatment effect size findina statistically significant pooled treatment effect sizes.
epa	chemical	lcpufa	1	0	28218722	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).
dha	chemical	lcpufa	1	0	28218722	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).
lcpufa	chemical_to_disease	autism spectrum disorder	1	0	28218722	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).
epa	chemical_to_disease	autism spectrum disorder	1	0	28218722	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).
dha	chemical_to_disease	autism spectrum disorder	1	0	28218722	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).
lcpufa	chemical_to_anatomy	, and	1	0	28218722	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).
epa	chemical_to_anatomy	, and	2	0	28218722|29562612	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).|PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
dha	chemical_to_anatomy	, and	2	0	28218722|29562612	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).|PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
of joint	anatomy	of the	1	0	25822242	PMID:25822242; Original text:Results yielded significant effects of the JASPER intervention on the primary outcome of joint engagement.
basic fibroblast growth factor	mechanism	vascular endothelial growth factor	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism	nerve growth factor	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
nerve growth factor	mechanism	vascular endothelial growth factor	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
fibroblast	anatomy	vascular endothelial	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
cerebrospinal fluid	anatomy	fibroblast	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
endothelial	anatomy	fibroblast	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
fibroblast	anatomy	transplantation	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
cerebrospinal fluid	anatomy	vascular endothelial	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
endothelial	anatomy	vascular endothelial	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
transplantation	anatomy	vascular endothelial	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
cerebrospinal fluid	anatomy	endothelial	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
cerebrospinal fluid	anatomy	transplantation	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
endothelial	anatomy	transplantation	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism_to_anatomy	fibroblast	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism_to_anatomy	vascular endothelial	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism_to_anatomy	cerebrospinal fluid	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism_to_anatomy	endothelial	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism_to_anatomy	transplantation	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
vascular endothelial growth factor	mechanism_to_anatomy	fibroblast	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
vascular endothelial growth factor	mechanism_to_anatomy	vascular endothelial	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	cerebrospinal fluid	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
vascular endothelial growth factor	mechanism_to_anatomy	endothelial	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	transplantation	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
nerve growth factor	mechanism_to_anatomy	fibroblast	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
nerve growth factor	mechanism_to_anatomy	vascular endothelial	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	cerebrospinal fluid	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
nerve growth factor	mechanism_to_anatomy	endothelial	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	transplantation	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
autism spectrum	disease	linguistic and motor impairments	1	0	28685955	PMID:28685955; Original text:Children with autism spectrum disorder (disorder) show significant linguistic and motor impairments compared to children with typical development (typical development).
prolactin	mechanism_to_anatomy	(p	2	0	15142390|17224713	PMID:15142390; Original text:In all children, serum prolactin levels increased significantly (p < 0.001) from 166 +/- 88 UI/mL at baseline to 504 +/- 207 UI/mL at week 12 of risperidone treatment.|PMID:17224713; Original text:SD prolactin levels increased from 7.8 +/- 8.0 ng/mL at baseline to 33.2 +/- 12.8 ng/mL at week 8 (P < 0.001), with a slight decrease to 28.8 +/-
anxiety	disease	tension	1	0	10200837	PMID:10200837; Original text:Behavioral results indicated a significant reduction in tension and a marginally significant reduction in anxiety for children who received the deep pressure compared with the children who did not.
field of	anatomy	of the	1	0	28322981	PMID:28322981; Original text:However, despite significant progress in this field of research, the characterization of the neurobiological mechanisms by which common genetic risk variants might operate to give rise to disorders symptomatology has proven to be far more difficult than expected.
autistic	disease	epileptic seizures	1	0	1708491	PMID:1708491; Original text:A significant proportion of autistic children experience epileptic seizures and have abnormal EEGs.
not rule	anatomy	rule out	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
not rule	anatomy	not rule out	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
acids	anatomy	not rule	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
not rule out	anatomy	rule out	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
acids	anatomy	rule out	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
acids	anatomy	not rule out	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
omega-3 fatty acids	chemical_to_anatomy	not rule	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
omega-3 fatty acids	chemical_to_anatomy	rule out	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
omega-3 fatty acids	chemical_to_anatomy	not rule out	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
omega-3 fatty acids	chemical_to_anatomy	acids	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
inadequate eye contact	disease	irritability	1	0	22419332	PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.
inadequate eye contact	disease	inappropriate speech	1	0	22419332	PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.
hyperactivity	disease	inadequate eye contact	1	0	22419332	PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.
irritability	disease	stereotypy	3	0	32168067|19284641|32947424	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
autism	disease	stereotypy	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
lethargy	disease	stereotypy	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
hyperactivity	disease	stereotypy	3	0	32168067|19284641|32947424	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
autism	disease	lethargy	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
, and	anatomy	1	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
irritability	disease_to_anatomy	1	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
stereotypy	disease_to_anatomy	of the	2	0	32168067|32947424	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
stereotypy	disease_to_anatomy	1	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
stereotypy	disease_to_anatomy	, and	3	0	32168067|19284641|32947424	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
autism	disease_to_anatomy	1	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
lethargy	disease_to_anatomy	of the	2	0	32168067|30980177	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
lethargy	disease_to_anatomy	1	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
lethargy	disease_to_anatomy	, and	3	0	32168067|30980177|29027815	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:29027815; Original text:No significant improvements were obtained on the lethargy/social withdrawal, stereotypic behavior, and inappropriate speech subscale scores.
hyperactivity	disease_to_anatomy	1	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
eating disorders	disease	obsessive-compulsive disorder	1	0	32503201	PMID:32503201; Original text:(Obsessive-Compulsive Disorder), one on Schizophrenia (Schizophrenia) and one on Eating Disorders (Eating Disorders).
eating disorders	disease	schizophrenia	1	0	32503201	PMID:32503201; Original text:(Obsessive-Compulsive Disorder), one on Schizophrenia (Schizophrenia) and one on Eating Disorders (Eating Disorders).
anorexia nervosa	disease	autism spectrum disorder	1	0	26542816	PMID:26542816; Original text:Seven studies were identified and subsequent meta-analysis indicated that those with Anorexia Nervosa appear to have significant difficulties of a manner characteristic of Autism Spectrum Disorder, relative to controls.
homocysteine	chemical_to_anatomy	of the	1	0	29437021	PMID:29437021; Original text:Some report demonstrated a significant association between the severity of the disorder and the abnormalities in Homocysteine levels.
methylphenidate	chemical_to_disease	hyperactive	1	0	23782128	PMID:23782128; Original text:extended-release methylphenidate treatment was associated with significant declines in hyperactive and impulsive behavior at both home and school.
methylphenidate	chemical_to_disease	attention-deficit/hyperactivity disorder	1	0	23782128	PMID:23782128; Original text:The results of this study suggest that extended-release methylphenidate formulations are efficacious and well-tolerated for children with disorder and significant attention-deficit/hyperactivity disorder symptoms.
attention-deficit/hyperactivity disorder	disease	autism	3	0	23782128|15090875|27988864	PMID:23782128; Original text:(DSM-IV-TR) criteria for an autism spectrum disorder (disorder) on the Autism Diagnostic Interview-Revised (-Revised) and the Autism Diagnostic Observation Schedule (the Autism Diagnostic Observation Schedule), and had significant symptoms of attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder).|PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.|PMID:27988864; Original text:The majority of studies on attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder) and autism found a significant decrease in acid levels in patients versus healthy controls.
attention-deficit/hyperactivity disorder	disease	autism spectrum disorder	2	0	23782128|30658861	PMID:23782128; Original text:(DSM-IV-TR) criteria for an autism spectrum disorder (disorder) on the Autism Diagnostic Interview-Revised (-Revised) and the Autism Diagnostic Observation Schedule (the Autism Diagnostic Observation Schedule), and had significant symptoms of attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder).|PMID:30658861; Original text:Attention-Deficit/Hyperactivity Disorder (Attention-Deficit/Hyperactivity Disorder) and Autism Spectrum Disorder (Autism Spectrum Disorder) are both neurodevelopmental disorders originating in childhood with high associated impairments and public health significance.
attention-deficit/hyperactivity disorder	disease_to_anatomy	, and	3	0	23782128|15090875|30446273	PMID:23782128; Original text:(DSM-IV-TR) criteria for an autism spectrum disorder (disorder) on the Autism Diagnostic Interview-Revised (-Revised) and the Autism Diagnostic Observation Schedule (the Autism Diagnostic Observation Schedule), and had significant symptoms of attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder).|PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.|PMID:30446273; Original text:Assessing the occurrence of ASD and Attention-Deficit/Hyperactivity Disorder would improve the significant cost of healthcare, therapies, and overall daily living for families with children affected by Cerebral Palsy.
fenfluramine	chemical_to_anatomy	, and	1	0	2682347	PMID:2682347; Original text:Electrophysiological data were affected according to the clinical and biochemical responsiveness to fenfluramine: the auditory evoked potential amplitude increased, and the single-trial potential variability decreased at each intensity level only in Six children whose dopaminergic metabolism was significantly modified by fenfluramine treatment.
anxiety	disease	conduct problem	1	0	20001837	PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.
, a	anatomy	group	1	0	20001837	PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.
conduct problem	disease_to_anatomy	, a	1	0	20001837	PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.
conduct problem	disease_to_anatomy	(p	1	0	20001837	PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.
conduct problem	disease_to_anatomy	group	1	0	20001837	PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.
anxiety	disease_to_anatomy	, a	1	0	20001837	PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.
attention deficit hyperactivity disorder	disease	spectrum disorders	1	0	33403915	PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
attention deficit hyperactivity disorder	disease_to_anatomy	default mode network	1	0	33403915	PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
attention deficit hyperactivity disorder	disease_to_anatomy	, and	2	0	33403915|32840005	PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.|PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease_to_anatomy	default mode	1	0	33403915	PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
attention deficit hyperactivity disorder	disease_to_anatomy	mode network	1	0	33403915	PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
spectrum disorders	disease_to_anatomy	default mode network	1	0	33403915	PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
spectrum disorders	disease_to_anatomy	default mode	1	0	33403915	PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
spectrum disorders	disease_to_anatomy	mode network	1	0	33403915	PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
levels of	anatomy	of primary	1	0	31121530	PMID:31121530; Original text:Our results of primary analysis showed that there were no statistically significant differences in the levels of hair lead between children with disorder and healthy individuals (Hedges's g = 0.251; 95% confidence interval: -0.121, 0.623;
levels of	anatomy	of hair	1	0	31121530	PMID:31121530; Original text:Our results of primary analysis showed that there were no statistically significant differences in the levels of hair lead between children with disorder and healthy individuals (Hedges's g = 0.251; 95% confidence interval: -0.121, 0.623;
of hair	anatomy	of primary	1	0	31121530	PMID:31121530; Original text:Our results of primary analysis showed that there were no statistically significant differences in the levels of hair lead between children with disorder and healthy individuals (Hedges's g = 0.251; 95% confidence interval: -0.121, 0.623;
bumetanide	chemical_to_disease	autism	1	0	23233021	PMID:23233021; Original text:Bumetanide reduced significantly the Childhood Autism Rating Scale (the Childhood Autism Rating Scale) (D90-D0; P<0.004 treated vs placebo), Clinical Global Impressions (P<0.017 treated vs placebo) and Autism Diagnostic Observation Schedule values when the most severe cases (the Childhood Autism Rating Scale values above the mean ± s.d.
fatty acid	chemical_to_disease	autism spectrum disorders	1	0	25804268	PMID:25804268; Original text:Blood fatty acid levels were significantly correlated with changes in the core symptoms of Autism Spectrum Disorders.
social	disease	social and attention problems	1	0	25804268	PMID:25804268; Original text:At post-treatment, participants showed significant improvements on all subscales of the Social Responsiveness Scale (P < 0.01) and the Social and Attention Problems syndrome scales of the Child Behavior Checklist (P < 0.05).
social and attention problems	disease_to_anatomy	of the	1	0	25804268	PMID:25804268; Original text:At post-treatment, participants showed significant improvements on all subscales of the Social Responsiveness Scale (P < 0.01) and the Social and Attention Problems syndrome scales of the Child Behavior Checklist (P < 0.05).
social and attention problems	disease_to_anatomy	(p	1	0	25804268	PMID:25804268; Original text:At post-treatment, participants showed significant improvements on all subscales of the Social Responsiveness Scale (P < 0.01) and the Social and Attention Problems syndrome scales of the Child Behavior Checklist (P < 0.05).
social	disease_to_anatomy	(p	1	0	25804268	PMID:25804268; Original text:At post-treatment, participants showed significant improvements on all subscales of the Social Responsiveness Scale (P < 0.01) and the Social and Attention Problems syndrome scales of the Child Behavior Checklist (P < 0.05).
naltrexone	chemical_to_disease	hyperactivity	1	0	8282676	PMID:8282676; Original text:In the present study, naltrexone significantly reduced only hyperactivity, and no serious untoward effects were observed.
stereotypic behavior	disease_to_anatomy	of the	1	0	30980177	PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
stereotypic behavior	disease_to_anatomy	, and	1	0	30980177	PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
inappropriate speech	disease_to_anatomy	of the	1	0	30980177	PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
inappropriate speech	disease_to_anatomy	, and	3	0	30980177|29027815|33029705	PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:29027815; Original text:No significant improvements were obtained on the lethargy/social withdrawal, stereotypic behavior, and inappropriate speech subscale scores.|PMID:33029705; Original text:The repeated measures analysis showed significant effect for time × treatment interaction on inappropriate speech (F = 3.51; df = 1.61; P = 0.044), stereotypic behavior (F = 4.02; df = 1.37; P = 0.036), and hyperactivity/noncompliance (F = 6.79; df = 1.66; P = 0.003) subscale scores.
depression	disease	depressive symptoms	1	0	24408892	PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).
depression	disease_to_anatomy	(p	1	0	24408892	PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).
depressive symptoms	disease_to_anatomy	of the	1	0	24408892	PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).
depressive symptoms	disease_to_anatomy	(p	1	0	24408892	PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).
depressive symptoms	disease_to_anatomy	, and	1	0	24408892	PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).
depressive	disease_to_anatomy	, and	1	0	24408892	PMID:24408892; Original text:In an a randomized controlled trial, participants receiving the PEERS(®) treatment showed significant improvement in social skills knowledge, interpersonal skills, and play/leisure skills, as well as a decrease in depressive symptoms and disorder symptoms.
serotonin	chemical	tryptophan	3	0	22638012|26746121|26746121	PMID:22638012; Original text:While some individuals with ASD have significant differences in the serotonin system, to our knowledge, no one has investigated its role during facial emotion processing in adults with ASD and control subjects using acute tryptophan depletion (acute tryptophan depletion) and functional magnetic resonance imaging.|PMID:26746121; Original text:Positron emission tomography measures of tryptophan metabolism and blood serotonin concentrations were assessed as predictors of buspirone efficacy.|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
tryptophan	chemical_to_disease	asd	1	0	22638012	PMID:22638012; Original text:While some individuals with ASD have significant differences in the serotonin system, to our knowledge, no one has investigated its role during facial emotion processing in adults with ASD and control subjects using acute tryptophan depletion (acute tryptophan depletion) and functional magnetic resonance imaging.
tryptophan	chemical_to_anatomy	system	1	0	22638012	PMID:22638012; Original text:While some individuals with ASD have significant differences in the serotonin system, to our knowledge, no one has investigated its role during facial emotion processing in adults with ASD and control subjects using acute tryptophan depletion (acute tryptophan depletion) and functional magnetic resonance imaging.
serotonin	chemical_to_anatomy	system	1	0	22638012	PMID:22638012; Original text:While some individuals with ASD have significant differences in the serotonin system, to our knowledge, no one has investigated its role during facial emotion processing in adults with ASD and control subjects using acute tryptophan depletion (acute tryptophan depletion) and functional magnetic resonance imaging.
asd	disease_to_anatomy	system	1	0	22638012	PMID:22638012; Original text:While some individuals with ASD have significant differences in the serotonin system, to our knowledge, no one has investigated its role during facial emotion processing in adults with ASD and control subjects using acute tryptophan depletion (acute tryptophan depletion) and functional magnetic resonance imaging.
of facial	anatomy	of the	1	0	22638012	PMID:22638012; Original text:Modulation of the processing of facial expressions of emotion by serotonin significantly differs in people with ASD compared with control subjects.
serotonin	chemical_to_anatomy	of facial	1	0	22638012	PMID:22638012; Original text:Modulation of the processing of facial expressions of emotion by serotonin significantly differs in people with ASD compared with control subjects.
asd	disease_to_anatomy	of facial	1	0	22638012	PMID:22638012; Original text:Modulation of the processing of facial expressions of emotion by serotonin significantly differs in people with ASD compared with control subjects.
depression	disease	respiratory distress	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
preterm birth	disease	respiratory distress	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
convulsions	disease	respiratory distress	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
depression	disease	preterm birth	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
convulsions	disease	depression	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
convulsions	disease	preterm birth	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
serotonin	chemical_to_disease	respiratory distress	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
serotonin	chemical_to_disease	depression	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
serotonin	chemical_to_disease	preterm birth	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
serotonin	chemical_to_disease	convulsions	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
serotonin	chemical_to_anatomy	of respiratory	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
respiratory distress	disease_to_anatomy	of respiratory	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
depression	disease_to_anatomy	of respiratory	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
preterm birth	disease_to_anatomy	of respiratory	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
convulsions	disease_to_anatomy	of respiratory	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
central gyrus	anatomy	hippocampus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
hippocampus	anatomy	superior temporal	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
, and	anatomy	hippocampus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
hippocampus	anatomy	temporal gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
hippocampus	anatomy	superior temporal gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
hippocampus	anatomy	temporal	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
gyrus	anatomy	hippocampus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
central gyrus	anatomy	superior temporal	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
, and	anatomy	central gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
central gyrus	anatomy	temporal gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
central gyrus	anatomy	superior temporal gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
central gyrus	anatomy	temporal	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
central gyrus	anatomy	gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
superior temporal	anatomy	temporal gyrus	2	0	23452684|26769980	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
superior temporal	anatomy	superior temporal gyrus	2	0	23452684|26769980	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	superior temporal	2	0	23452684|26769980	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	superior temporal gyrus	2	0	23452684|26769980	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	gyrus	3	0	23452684|23452684|26769980	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
superior temporal gyrus	anatomy	temporal gyrus	2	0	23452684|26769980	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	temporal gyrus	2	0	23452684|26769980	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
superior temporal gyrus	anatomy	temporal	2	0	23452684|26769980	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	superior temporal gyrus	2	0	23452684|26769980	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	temporal	2	0	23452684|26769980	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorders	disease_to_anatomy	hippocampus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
autism spectrum disorders	disease_to_anatomy	central gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
autism spectrum disorders	disease_to_anatomy	superior temporal	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
autism spectrum disorders	disease_to_anatomy	temporal gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
autism spectrum disorders	disease_to_anatomy	superior temporal gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
autism spectrum disorders	disease_to_anatomy	temporal	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.
autism spectrum disorders	disease_to_anatomy	gyrus	2	0	23452684|23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of social tasks showed that children and adolescents with autism spectrum disorders versus adults had significantly greater hyperactivation in the left post-central gyrus, and greater hypoactivation in the right hippocampus and right superior temporal gyrus.|PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
and left	anatomy	cingulate gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
and left	anatomy	frontal gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
and left	anatomy	gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
cingulate gyrus	anatomy	frontal gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
, and	anatomy	cingulate gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
cingulate gyrus	anatomy	gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
autism spectrum disorders	disease_to_anatomy	and left	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
autism spectrum disorders	disease_to_anatomy	cingulate gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
autism spectrum disorders	disease_to_anatomy	frontal gyrus	1	0	23452684	PMID:23452684; Original text:activation likelihood estimation meta-analyses of nonsocial tasks showed that children with autism spectrum disorders versus adults had significantly greater hyperactivation in the right insula and left cingulate gyrus, and hypoactivation in the right middle frontal gyrus.
methylphenidate	chemical_to_disease	hyperactivity	1	0	29159857	PMID:29159857; Original text:Primary outcomes: the meta-analysis suggested that high-dose methylphenidate (0.43 mg/kg/dose to 0.60 mg/kg/dose) had a significant and clinically relevant benefit on hyperactivity, as rated by teachers (a standardised mean difference -0.78, 95% confidence interval (95% confidence interval)
of the	anatomy	points	1	0	29159857	PMID:29159857; Original text:-1.13 to -0.43; 4 studies, 73 participants; P < 0.001; low-quality evidence) and parents (mean difference (mean difference) -6.61 points, 95% 95% confidence interval -12.19 to -1.03, rated on the hyperactivity subscale of the Aberrant Behviour Checklist, range 0 to 48; 2 studies, 71 participants; P = 0.02; low-quality evidence).
hyperactivity	disease_to_anatomy	points	1	0	29159857	PMID:29159857; Original text:-1.13 to -0.43; 4 studies, 73 participants; P < 0.001; low-quality evidence) and parents (mean difference (mean difference) -6.61 points, 95% 95% confidence interval -12.19 to -1.03, rated on the hyperactivity subscale of the Aberrant Behviour Checklist, range 0 to 48; 2 studies, 71 participants; P = 0.02; low-quality evidence).
, allogeneic	anatomy	scale	1	0	32444220	PMID:32444220; Original text:In a subanalysis of children without intellectual disability (intellectual disability), allogeneic, but not autologous, CB was associated with improvement in a larger percentage of children on the clinician-rated Clinical Global Impression-Improvement scale, but the OR for improvement was not significant.
intellectual disability	disease_to_anatomy	, allogeneic	1	0	32444220	PMID:32444220; Original text:In a subanalysis of children without intellectual disability (intellectual disability), allogeneic, but not autologous, CB was associated with improvement in a larger percentage of children on the clinician-rated Clinical Global Impression-Improvement scale, but the OR for improvement was not significant.
intellectual disability	disease_to_anatomy	scale	1	0	32444220	PMID:32444220; Original text:In a subanalysis of children without intellectual disability (intellectual disability), allogeneic, but not autologous, CB was associated with improvement in a larger percentage of children on the clinician-rated Clinical Global Impression-Improvement scale, but the OR for improvement was not significant.
areas	anatomy	of frontal	1	0	22200338	PMID:22200338; Original text:functional MRI showed recruitment of frontal areas, including the insula, that have significantly different patterns in children (7 to 14 years of age) with autism spectrum disorder compared to typically developing children, indicating that successful performance implicated differing strategies in these two groups of children.
autism spectrum disorder	disease_to_anatomy	of frontal	1	0	22200338	PMID:22200338; Original text:functional MRI showed recruitment of frontal areas, including the insula, that have significantly different patterns in children (7 to 14 years of age) with autism spectrum disorder compared to typically developing children, indicating that successful performance implicated differing strategies in these two groups of children.
autism spectrum disorder	disease_to_anatomy	areas	1	0	22200338	PMID:22200338; Original text:functional MRI showed recruitment of frontal areas, including the insula, that have significantly different patterns in children (7 to 14 years of age) with autism spectrum disorder compared to typically developing children, indicating that successful performance implicated differing strategies in these two groups of children.
cortex and	anatomy	the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
cortex and	anatomy	of the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
cortex and	anatomy	of the	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
cortex and	anatomy	superior temporal	2	0	32161366|26769980	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum."
cortex and	anatomy	temporal	2	0	32161366|26769980	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum."
cortex and	anatomy	orbitofrontal cortex	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
amygdala	anatomy	cortex and	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
cortex and	anatomy	temporal sulcus	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
superior temporal	anatomy	the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
temporal	anatomy	the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
orbitofrontal cortex	anatomy	the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
temporal sulcus	anatomy	the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
of the amygdala	anatomy	superior temporal	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
of the amygdala	anatomy	temporal	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
of the amygdala	anatomy	orbitofrontal cortex	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
of the amygdala	anatomy	temporal sulcus	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
of the	anatomy	orbitofrontal cortex	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
orbitofrontal cortex	anatomy	superior temporal	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
amygdala	anatomy	superior temporal	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
orbitofrontal cortex	anatomy	temporal	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
amygdala	anatomy	orbitofrontal cortex	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
orbitofrontal cortex	anatomy	temporal sulcus	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
amygdala	anatomy	temporal sulcus	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	of the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	superior temporal	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	temporal	2	0	32161366|8759044	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_anatomy	orbitofrontal cortex	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	temporal sulcus	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	of the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	superior temporal	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	temporal	2	0	32161366|8759044	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	orbitofrontal cortex	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	temporal sulcus	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
weight loss	disease_to_anatomy	of the	1	0	30305689	PMID:30305689; Original text:Of the included studies, half (n = 6) demonstrated significant weight loss; including comprehensive (n = 3), pharmaceutical (n = 2), and exercise (n = 1) interventions.
weight loss	disease_to_anatomy	, and	1	0	30305689	PMID:30305689; Original text:Of the included studies, half (n = 6) demonstrated significant weight loss; including comprehensive (n = 3), pharmaceutical (n = 2), and exercise (n = 1) interventions.
fluvoxamine	chemical_to_anatomy	group (	1	0	8911223	PMID:8911223; Original text:Eight (53%) of 15 patients in the fluvoxamine-treated group were categorized as responders compared with none of 15 in the placebo group (P = .001).
fluvoxamine	chemical_to_anatomy	(p	2	0	8911223|8911223	PMID:8911223; Original text:Eight (53%) of 15 patients in the fluvoxamine-treated group were categorized as responders compared with none of 15 in the placebo group (P = .001).|PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
maladaptive behavior	disease	repetitive thoughts	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
aggression	disease	maladaptive behavior	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
aggression	disease	repetitive thoughts	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
fluvoxamine	chemical_to_disease	maladaptive behavior	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
fluvoxamine	chemical_to_disease	repetitive thoughts	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
fluvoxamine	chemical_to_disease	aggression	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
maladaptive behavior	disease_to_anatomy	, and	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
maladaptive behavior	disease_to_anatomy	(p	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
repetitive thoughts	disease_to_anatomy	, and	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
repetitive thoughts	disease_to_anatomy	(p	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
aggression	disease_to_anatomy	(p	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
attention-deficit/hyperactivity disorder	disease	psychiatrically	1	0	29675767	PMID:29675767; Original text:The majority of psychiatrically referred youth with disorder had positive Child Behavior Checklist-emotional dysregulation (CBCL-emotional dysregulation) profile that was significantly higher than in youth with attention-deficit/hyperactivity disorder (82 vs. 53%; p < 0.001).
emotional dysregulation	disease	semotional dysregulation	1	0	29675767	PMID:29675767; Original text:The severe emotional dysregulation (Semotional dysregulation) profile was significantly greater in disorder youth than attention-deficit/hyperactivity disorder (44 vs. 15%; p < 0.001).
attention-deficit/hyperactivity disorder	disease	semotional dysregulation	1	0	29675767	PMID:29675767; Original text:The severe emotional dysregulation (Semotional dysregulation) profile was significantly greater in disorder youth than attention-deficit/hyperactivity disorder (44 vs. 15%; p < 0.001).
attention-deficit/hyperactivity disorder	disease	emotional dysregulation	1	0	29675767	PMID:29675767; Original text:The severe emotional dysregulation (Semotional dysregulation) profile was significantly greater in disorder youth than attention-deficit/hyperactivity disorder (44 vs. 15%; p < 0.001).
stem cells	anatomy	transplantation	1	0	18220912	PMID:18220912; Original text:Although the use of stem cells in cell-replacement therapies by transplantation is obvious, another equally important and interesting application of stem cells is to use them in disease modeling.
vitamin d	chemical_to_disease	autism spectrum disorder	1	0	32294031	PMID:32294031; Original text:Significant vitamin D deficiency is described within children affected by Autism Spectrum Disorder and in pregnant mothers whose offspring will later develop Autism Spectrum Disorder, suggesting a possible role of the hormone as a contributing risk factor in the etiopathogenesis of Autism Spectrum Disorder.
vitamin d	chemical_to_anatomy	of the	2	0	32294031|33383952	PMID:32294031; Original text:Significant vitamin D deficiency is described within children affected by Autism Spectrum Disorder and in pregnant mothers whose offspring will later develop Autism Spectrum Disorder, suggesting a possible role of the hormone as a contributing risk factor in the etiopathogenesis of Autism Spectrum Disorder.|PMID:33383952; Original text:Meta-analysis of 24 case-control studies demonstrated that children and adolescents with disorder had significantly lower vitamin D concentration than that of the control group (mean difference (MD): -7.46 ng/mL, 95% confidence interval (95% confidence interval): -10.26; -4.66 ng/mL, p < 0.0001, I = 98%).
autism spectrum disorder	disease_to_anatomy	brain	1	0	32294031	PMID:32294031; Original text:Therefore, its deficiency during pregnancy and early childhood may significantly impact on a developing brain, leading to possible adverse neuropsychological outcomes including Autism Spectrum Disorder (Autism Spectrum Disorder).
irritability	disease	self	1	0	19519261	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.
irritability	disease	tantrums	2	0	19519261|22549762	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
aggression	disease	self	1	0	19519261	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.
self	disease	tantrums	1	0	19519261	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.
aggression	disease	tantrums	2	0	19519261|22549762	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
self	disease_to_anatomy	, and	1	0	19519261	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.
tantrums	disease_to_anatomy	, and	2	0	19519261|22549762	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
d	chemical	folate	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism	folate receptor alpha	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
, a	anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
, can	anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
, can	anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
, a	anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
, a	anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
, and	anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
, and	anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
,l	anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_chemical	folate	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_chemical	d	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_mechanism	folate receptor alpha	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_mechanism	folate	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_mechanism	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_antibody	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	nutrient_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_mechanism	folate receptor alpha	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_mechanism	folate	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_mechanism	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_mechanism	folate receptor alpha	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_mechanism	folate	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_mechanism	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_antibody	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_antibody	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism_to_antibody	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_antibody	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_antibody	folate receptor alpha autoantibodies	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	antibody_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	antibody_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	antibody_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	antibody_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	antibody_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
polyunsaturated fatty acids	chemical	vitamin d	1	0	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
docosahexaenoic acid	chemical	vitamin d	1	0	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
lcpufas	chemical	vitamin d	1	0	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
docosahexaenoic acid	chemical	polyunsaturated fatty acids	1	0	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
lcpufas	chemical	polyunsaturated fatty acids	1	0	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
docosahexaenoic acid	chemical	lcpufas	1	0	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
vitamin d	chemical_to_disease	autism spectrum	1	0	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
polyunsaturated fatty acids	chemical_to_disease	autism spectrum	1	0	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
docosahexaenoic acid	chemical_to_disease	autism spectrum	1	0	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
lcpufas	chemical_to_disease	autism spectrum	1	0	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
oxytocin	chemical_to_disease	anorexia nervosa	1	0	27183106	PMID:27183106; Original text:None of them (except serum peripheral oxytocin in anorexia nervosa) revealed significant differences.
oxytocin	chemical_to_mechanism	serum peripheral oxytocin	1	0	27183106	PMID:27183106; Original text:None of them (except serum peripheral oxytocin in anorexia nervosa) revealed significant differences.
anorexia nervosa	disease_to_mechanism	serum peripheral oxytocin	1	0	27183106	PMID:27183106; Original text:None of them (except serum peripheral oxytocin in anorexia nervosa) revealed significant differences.
, small	anatomy	of the	1	0	27183106	PMID:27183106; Original text:However, the lack of significant results was associated with high methodological heterogeneity, low quality of the studies, small sample size, and scarce reliability of the methods used in previous studies, which need to be validated and standardized.
, and	anatomy	, small	2	0	27183106|32407557	PMID:27183106; Original text:However, the lack of significant results was associated with high methodological heterogeneity, low quality of the studies, small sample size, and scarce reliability of the methods used in previous studies, which need to be validated and standardized.|PMID:32407557; Original text:We observed larger nonoverlapping data for published compared to unpublished studies, small and nonsignificant differences in log response ratios for published compared to unpublished studies, and significant differences in Hedges' g for published compared to unpublished studies, with published studies showing slightly larger effect.
immunoglobulins	mechanism_to_anatomy	levels of	1	0	30577568	PMID:30577568; Original text:Altered levels of cytokines, chemokines and immunoglobulins were demonstrated in patients with disorders; in particular, proinflammatory mediators were significantly increased.
, synaptic	anatomy	neuronal	1	0	31744938	PMID:31744938; Original text:This review highlights the role of disorder risk genes in gene transcription and translation regulation processes, as well as neuronal activity modulation, synaptic plasticity, disrupted key biological signaling pathways, and the novel candidate genes that play a significant role in the pathophysiology of disorder.
, synaptic	anatomy	pathways	1	0	31744938	PMID:31744938; Original text:This review highlights the role of disorder risk genes in gene transcription and translation regulation processes, as well as neuronal activity modulation, synaptic plasticity, disrupted key biological signaling pathways, and the novel candidate genes that play a significant role in the pathophysiology of disorder.
, and	anatomy	, synaptic	1	0	31744938	PMID:31744938; Original text:This review highlights the role of disorder risk genes in gene transcription and translation regulation processes, as well as neuronal activity modulation, synaptic plasticity, disrupted key biological signaling pathways, and the novel candidate genes that play a significant role in the pathophysiology of disorder.
, synaptic	anatomy	processes	1	0	31744938	PMID:31744938; Original text:This review highlights the role of disorder risk genes in gene transcription and translation regulation processes, as well as neuronal activity modulation, synaptic plasticity, disrupted key biological signaling pathways, and the novel candidate genes that play a significant role in the pathophysiology of disorder.
neuronal	anatomy	pathways	1	0	31744938	PMID:31744938; Original text:This review highlights the role of disorder risk genes in gene transcription and translation regulation processes, as well as neuronal activity modulation, synaptic plasticity, disrupted key biological signaling pathways, and the novel candidate genes that play a significant role in the pathophysiology of disorder.
neuronal	anatomy	processes	1	0	31744938	PMID:31744938; Original text:This review highlights the role of disorder risk genes in gene transcription and translation regulation processes, as well as neuronal activity modulation, synaptic plasticity, disrupted key biological signaling pathways, and the novel candidate genes that play a significant role in the pathophysiology of disorder.
pathways	anatomy	processes	1	0	31744938	PMID:31744938; Original text:This review highlights the role of disorder risk genes in gene transcription and translation regulation processes, as well as neuronal activity modulation, synaptic plasticity, disrupted key biological signaling pathways, and the novel candidate genes that play a significant role in the pathophysiology of disorder.
, and	anatomy	processes	1	0	31744938	PMID:31744938; Original text:This review highlights the role of disorder risk genes in gene transcription and translation regulation processes, as well as neuronal activity modulation, synaptic plasticity, disrupted key biological signaling pathways, and the novel candidate genes that play a significant role in the pathophysiology of disorder.
asd	disease_to_anatomy	(p	2	0	34618724|31595678	PMID:34618724; Original text:The Enhanced training did not have a significant effect on provider-endorsed ASD concerns (p = 0.615) or accuracy of endorsing concerns (p = 0.619).|PMID:31595678; Original text:Children with ASD had a 41.1% greater risk (P = .018) of development of obesity.
alzheimer's disease	disease	autism spectrum disorders	1	0	28901249	PMID:28901249; Original text:In this review paper, an attempt to specify significant correlations between proteins linked to Autism Spectrum Disorders and Alzheimer's Disease is presented.
autism	disease	disability	1	0	9648034	PMID:9648034; Original text:Describes treatment of autism, a severe, chronic developmental disorder that results in significant lifelong disability for most persons, with few persons ever functioning in an independent and typical lifestyle.
developmental disorder	disease	disability	1	0	9648034	PMID:9648034; Original text:Describes treatment of autism, a severe, chronic developmental disorder that results in significant lifelong disability for most persons, with few persons ever functioning in an independent and typical lifestyle.
developmental disorder	disease_to_anatomy	, a	1	0	9648034	PMID:9648034; Original text:Describes treatment of autism, a severe, chronic developmental disorder that results in significant lifelong disability for most persons, with few persons ever functioning in an independent and typical lifestyle.
disability	disease_to_anatomy	, a	1	0	9648034	PMID:9648034; Original text:Describes treatment of autism, a severe, chronic developmental disorder that results in significant lifelong disability for most persons, with few persons ever functioning in an independent and typical lifestyle.
iron	nutrient	magnesium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	nutrient	magnesium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	nutrient	iron	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
cobalt	chemical	magnesium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
cobalt	chemical	iron	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical	cobalt	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
cobalt	chemical	iodine	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	chemical	magnesium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical	magnesium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iodine	chemical	magnesium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical	iron	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iodine	chemical	iron	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical	iodine	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
, and	anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
magnesium	nutrient_to_chemical	cobalt	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
magnesium	nutrient_to_chemical	magnesium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
magnesium	nutrient_to_chemical	iron	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
magnesium	nutrient_to_chemical	chromium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
magnesium	nutrient_to_chemical	iodine	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	nutrient_to_chemical	cobalt	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	nutrient_to_chemical	magnesium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	nutrient_to_chemical	iron	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	nutrient_to_chemical	chromium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	nutrient_to_chemical	iodine	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	nutrient_to_chemical	cobalt	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	nutrient_to_chemical	magnesium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	nutrient_to_chemical	iron	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	nutrient_to_chemical	chromium	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	nutrient_to_chemical	iodine	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
magnesium	nutrient_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
magnesium	nutrient_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	nutrient_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	nutrient_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	nutrient_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	nutrient_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
cobalt	chemical_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
cobalt	chemical_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
magnesium	chemical_to_anatomy	, and	2	0	28665792|3886023	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).|PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
magnesium	chemical_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	chemical_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	chemical_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iodine	chemical_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iodine	chemical_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
copper	nutrient	zinc	1	0	28665792	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).
copper	chemical	zinc	1	0	28665792	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).
copper	nutrient_to_chemical	copper	2	0	28665792|34049201	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).|PMID:34049201; Original text:There were significant differences in the levels of copper (copper) in the hair and serum between autistic children and the control group.
copper	nutrient_to_chemical	zinc	1	0	28665792	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).
zinc	nutrient_to_chemical	copper	1	0	28665792	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).
zinc	nutrient_to_chemical	zinc	1	0	28665792	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).
copper	nutrient_to_anatomy	levels of	2	0	28665792|34049201	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).|PMID:34049201; Original text:There were significant differences in the levels of copper (copper) in the hair and serum between autistic children and the control group.
zinc	nutrient_to_anatomy	levels of	1	0	28665792	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).
copper	chemical_to_anatomy	levels of	2	0	28665792|34049201	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).|PMID:34049201; Original text:There were significant differences in the levels of copper (copper) in the hair and serum between autistic children and the control group.
zinc	chemical_to_anatomy	levels of	1	0	28665792	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).
epidermal growth factor	mechanism	il-13	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
autism	disease_to_mechanism	epidermal growth factor	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
autism	disease_to_mechanism	il-13	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
epidermal growth factor	mechanism_to_anatomy	levels of	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
epidermal growth factor	mechanism_to_anatomy	, and	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
il-13	mechanism_to_anatomy	levels of	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
il-13	mechanism_to_anatomy	, and	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
, positive	anatomy	groups	1	0	33711288	PMID:33711288; Original text:With repeat screening, positive predictive value increased for all screen groups, but the increase was not significant.
dehydroepiandrosterone-sulphate	chemical	serotoninp-	1	0	18580847	PMID:18580847; Original text:The serotoninP-induced plasma dehydroepiandrosterone-sulphate responses were significantly higher in autistic patients than in controls.
serotoninp-	chemical_to_disease	autistic	1	0	18580847	PMID:18580847; Original text:The serotoninP-induced plasma dehydroepiandrosterone-sulphate responses were significantly higher in autistic patients than in controls.
dehydroepiandrosterone-sulphate	chemical_to_disease	autistic	2	0	18580847|18580847	PMID:18580847; Original text:The serotoninP-induced plasma dehydroepiandrosterone-sulphate responses were significantly higher in autistic patients than in controls.|PMID:18580847; Original text:In baseline conditions, the cortisol/plasma dehydroepiandrosterone-sulphate ratio was significantly higher in autistic patients than in controls.
cortisol	chemical	dehydroepiandrosterone-sulphate	1	0	18580847	PMID:18580847; Original text:In baseline conditions, the cortisol/plasma dehydroepiandrosterone-sulphate ratio was significantly higher in autistic patients than in controls.
cortisol	chemical_to_disease	autistic	1	0	18580847	PMID:18580847; Original text:In baseline conditions, the cortisol/plasma dehydroepiandrosterone-sulphate ratio was significantly higher in autistic patients than in controls.
autism spectrum disorders	disease	respiratory sinus arrhythmia	2	0	32818581|32818581	PMID:32818581; Original text:respiratory sinus arrhythmia reactivity was significantly lower in autism spectrum disorders group for all situations, with the largest effect size for social stress (g=-0.7246, p < 0.0001).|PMID:32818581; Original text:Individuals with autism spectrum disorders had a significantly lower baseline Heart rate variability for parasympathetic indices in hierarchical order (Hedges'g=-0.5168, p < 0.0001) and respiratory sinus arrhythmia (g=-0.5860, p=0.0010).
rsa	bacteria_to_disease	respiratory sinus arrhythmia	1	0	32818581	PMID:32818581; Original text:respiratory sinus arrhythmia reactivity was significantly lower in autism spectrum disorders group for all situations, with the largest effect size for social stress (g=-0.7246, p < 0.0001).
rsa	bacteria_to_disease	autism spectrum disorders	1	0	32818581	PMID:32818581; Original text:respiratory sinus arrhythmia reactivity was significantly lower in autism spectrum disorders group for all situations, with the largest effect size for social stress (g=-0.7246, p < 0.0001).
autism spectrum disorders	disease_to_anatomy	of heart	1	0	32818581	PMID:32818581; Original text:The reactivity of Heart rate variability in situations of social stress (g=-0.4647, p = 0.0033) and social debriefing (g=-0.5001, p = 0.0007) was also significantly lower in subjects with autism spectrum disorders.
carnitine	chemical_to_disease	autism	1	0	21629200	PMID:21629200; Original text:Significant correlations between changes in serum free-carnitine levels and positive clinical changes were observed for hand muscle strength (R2=0.23, P=0.046), cognitive scores (R2=0.27, P=0.019), and Childhood Autism Rating Scale scores (R2=0.20, P=0.047).
carnitine	chemical_to_anatomy	, and	2	0	21629200|29562612	PMID:21629200; Original text:Significant correlations between changes in serum free-carnitine levels and positive clinical changes were observed for hand muscle strength (R2=0.23, P=0.046), cognitive scores (R2=0.27, P=0.019), and Childhood Autism Rating Scale scores (R2=0.20, P=0.047).|PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
l	chemical_to_disease	asd	1	0	21629200	PMID:21629200; Original text:L-carnitine therapy (50 mg/kilogram-bodyweight/day) administered for 3-months significantly improved several clinical measurements of ASD severity, but subsequent studies are recommended.
body of	anatomy	of the	1	0	27386975	PMID:27386975; Original text:Along with the many positive short-term medical effects that breastfeeding confers, physicians should be aware of the growing body of research suggesting that there are also significant long-term neurodevelopmental benefits of breastfeeding.
brodmann area 10	anatomy	prefrontal cortex	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
brodmann area	anatomy	brodmann area 10	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
brodmann area 10	anatomy	cortex (	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
area 10	anatomy	brodmann area 10	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
brodmann area	anatomy	prefrontal cortex	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
area 10	anatomy	prefrontal cortex	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
brodmann area	anatomy	cortex (	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
area 10	anatomy	brodmann area	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
area 10	anatomy	cortex (	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
spectrum disorders	disease_to_anatomy	brodmann area 10	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
spectrum disorders	disease_to_anatomy	prefrontal cortex	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
spectrum disorders	disease_to_anatomy	brodmann area	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
spectrum disorders	disease_to_anatomy	cortex (	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
spectrum disorders	disease_to_anatomy	area 10	1	0	18485420	PMID:18485420; Original text:However, on a new test of executive function (selection between stimulus-oriented and stimulus-independent thought), the spectrum disorders group exhibited significantly greater signal-change in medial rostral prefrontal cortex (especially Brodmann Area 10) in the comparison of stimulus-oriented versus stimulus-independent attention.
asd	disease	schz	2	0	28314733|28314733	PMID:28314733; Original text:The poor understanding of the genetics of ASD and SCHZ is a significant hurdle to developing effective treatments for these costly conditions.|PMID:28314733; Original text:Continuous efforts to understand the genetic basis of ASD and SCHZ will soon lead to significant progress in the mechanistic understanding of these prominent psychiatric disorders and enable the development of disease-modifying therapies for these devastating conditions.
schz	disease_to_anatomy	of the	1	0	28314733	PMID:28314733; Original text:The poor understanding of the genetics of ASD and SCHZ is a significant hurdle to developing effective treatments for these costly conditions.
asd	disease	psychiatric disorders	1	0	28314733	PMID:28314733; Original text:Continuous efforts to understand the genetic basis of ASD and SCHZ will soon lead to significant progress in the mechanistic understanding of these prominent psychiatric disorders and enable the development of disease-modifying therapies for these devastating conditions.
psychiatric disorders	disease	schz	1	0	28314733	PMID:28314733; Original text:Continuous efforts to understand the genetic basis of ASD and SCHZ will soon lead to significant progress in the mechanistic understanding of these prominent psychiatric disorders and enable the development of disease-modifying therapies for these devastating conditions.
buspirone	chemical_to_disease	irritability	1	0	25451017	PMID:25451017; Original text:Irritability subscale score significantly decreased during this trial in both groups (buspirone group: declined from 25.7 [SD 5.7] to 16.3 [SD 8.5]; placebo group: declined from 24.7 [SD 7.6] to 18.2 [SD 7.7]).
paliperidone	chemical_to_disease	irritability	1	0	22549762	PMID:22549762; Original text:Paliperidone treatment was associated with significant improvement in irritability and was generally well tolerated.
autistic disorder	disease	irritability	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
irritability	disease	self-injury	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
autistic disorder	disease	self-injury	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
aggression	disease	autistic disorder	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
autistic disorder	disease	tantrums	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
self-injury	disease	tantrums	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
autistic disorder	disease_to_anatomy	, and	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
self-injury	disease_to_anatomy	, and	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
melatonin	chemical_to_anatomy	, and	2	0	19968048|12804129	PMID:19968048; Original text:The conclusions from a nonparametric repeated-measures technique indicate that mean night sleep duration was longer on melatonin than placebo by 21 minutes (p = .02), mean sleep-onset latency was shorter by 28 minutes (p = .0001), and mean sleep-onset time was earlier by 42 minutes (p = .02).|PMID:12804129; Original text:Despite the short duration of the treatment, behavioral measures also displayed a significant improvement, and most of the effect disappeared after the discontinuation of the melatonin (p = 0.001).
melatonin	chemical_to_anatomy	(p	2	0	19968048|12804129	PMID:19968048; Original text:The conclusions from a nonparametric repeated-measures technique indicate that mean night sleep duration was longer on melatonin than placebo by 21 minutes (p = .02), mean sleep-onset latency was shorter by 28 minutes (p = .0001), and mean sleep-onset time was earlier by 42 minutes (p = .02).|PMID:12804129; Original text:Despite the short duration of the treatment, behavioral measures also displayed a significant improvement, and most of the effect disappeared after the discontinuation of the melatonin (p = 0.001).
autistic disorders	disease	repetitive behaviors	1	0	10649829	PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
sumatriptan	chemical_to_disease	autistic disorders	1	0	10649829	PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
sumatriptan	chemical_to_disease	repetitive behaviors	1	0	10649829	PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
autistic disorders	disease_to_mechanism	growth hormone	1	0	10649829	PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
repetitive behaviors	disease_to_mechanism	growth hormone	1	0	10649829	PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
autistic disorders	disease_to_anatomy	growth hormone	1	0	10649829	PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
repetitive behaviors	disease_to_anatomy	growth hormone	1	0	10649829	PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
autism spectrum disorders	disease	communication deficit	1	0	26577688	PMID:26577688; Original text:We concluded that teaching Karate techniques to children with autism spectrum disorders leads to significant reduction in their communication deficit.
autism spectrum disorder	disease	neurological disorder	1	0	23965928	PMID:23965928; Original text:Autism spectrum disorder (disorder) is a neurological disorder in which a significant number of the children experience a developmental regression characterized by a loss of previously acquired skills and abilities.
autism spectrum disorder	disease	developmental regression	1	0	23965928	PMID:23965928; Original text:Autism spectrum disorder (disorder) is a neurological disorder in which a significant number of the children experience a developmental regression characterized by a loss of previously acquired skills and abilities.
developmental regression	disease	neurological disorder	1	0	23965928	PMID:23965928; Original text:Autism spectrum disorder (disorder) is a neurological disorder in which a significant number of the children experience a developmental regression characterized by a loss of previously acquired skills and abilities.
neurological disorder	disease_to_anatomy	of the	1	0	23965928	PMID:23965928; Original text:Autism spectrum disorder (disorder) is a neurological disorder in which a significant number of the children experience a developmental regression characterized by a loss of previously acquired skills and abilities.
developmental regression	disease_to_anatomy	of the	1	0	23965928	PMID:23965928; Original text:Autism spectrum disorder (disorder) is a neurological disorder in which a significant number of the children experience a developmental regression characterized by a loss of previously acquired skills and abilities.
autism spectrum disorders	disease	neurodevelopmental disorders	1	0	28577609	PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
neurodevelopmental disorders	disease	repetitive behaviors	1	0	28577609	PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
impaired social communication	disease	neurodevelopmental disorders	1	0	28577609	PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
autism spectrum disorders	disease	impaired social communication	1	0	28577609	PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
impaired social communication	disease	repetitive behaviors	1	0	28577609	PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
spectrum disorders	disease	wlc	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
(i	anatomy	group	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
(i)	anatomy	group	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
group	anatomy	i)	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
wlc	disease_to_anatomy	(i	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
wlc	disease_to_anatomy	(i)	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
wlc	disease_to_anatomy	i)	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
wlc	disease_to_anatomy	group	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
spectrum disorders	disease_to_anatomy	(i	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
spectrum disorders	disease_to_anatomy	(i)	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
spectrum disorders	disease_to_anatomy	i)	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
spectrum disorders	disease_to_anatomy	group	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
quetiapine	chemical_to_disease	autistic	1	0	21996644	PMID:21996644; Original text:Nonsignificant changes were obtained in autistic behavior after quetiapine treatment (the Clinical Global Impression-Severity: 4.0 ± 0.6 vs the Clinical Global Impression-Severity after: 3.1 ± 1.1; 2-tailed paired t = 1.93; df = 10; P = 0.08).
quetiapine	chemical_to_disease	aggressive behavior	1	0	21996644	PMID:21996644; Original text:Severity of aggressive behavior decreased significantly after quetiapine treatment (Overt Aggression Scale: 2.1 ± 0.94 vs 1.3 ± 0.64, respectively; 2-tailed paired t = 2.37; df =10; P = 0.028).
group b	anatomy	groups	1	0	18315511	PMID:18315511; Original text:Both groups, whose mean age range was 5.5 years+/-1.22 years, showed a significant improvement in cognitive and expressive language skills pre- and post-therapy, which was highly significant among group B children treated with scalp AP (attention 2.8+/-0.8 in group A versus 3.5+/-0.8 in group B; receptive semantics were 7+/-3.8 in group A versus 9.4+/-3.1 in group B).
group a	anatomy	groups	1	0	18315511	PMID:18315511; Original text:Both groups, whose mean age range was 5.5 years+/-1.22 years, showed a significant improvement in cognitive and expressive language skills pre- and post-therapy, which was highly significant among group B children treated with scalp AP (attention 2.8+/-0.8 in group A versus 3.5+/-0.8 in group B; receptive semantics were 7+/-3.8 in group A versus 9.4+/-3.1 in group B).
group a	anatomy	group b	1	0	18315511	PMID:18315511; Original text:Both groups, whose mean age range was 5.5 years+/-1.22 years, showed a significant improvement in cognitive and expressive language skills pre- and post-therapy, which was highly significant among group B children treated with scalp AP (attention 2.8+/-0.8 in group A versus 3.5+/-0.8 in group B; receptive semantics were 7+/-3.8 in group A versus 9.4+/-3.1 in group B).
areas of	anatomy	of joint	1	0	20145986	PMID:20145986; Original text:Compared to caregivers and toddlers randomized to the waitlist control group the immediate treatment (the immediate treatment) group made significant improvements in targeted areas of joint engagement.
anterior cingulate	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
postcentral gyrus	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
postcentral gyrus	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal gyrus	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
postcentral gyrus	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
postcentral gyrus	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
parahippocampal gyrus	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
postcentral gyrus	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior temporal	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	anterior cingulate	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	anterior cingulate	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	anterior cingulate	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	cerebellum	2	0	26769980|22426803	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate	anatomy	gray matter	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	cortex and	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	anterior cingulate cortex	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	cingulate cortex	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	cerebellum	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior temporal	anatomy	gray matter	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, postcentral	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
superior temporal	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal gyrus	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
parahippocampal gyrus	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior temporal	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior temporal	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	cortex and	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	cortex and	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	cortex and	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	cortex and	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cortex and	anatomy	gray matter	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	anterior cingulate cortex	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	cingulate cortex	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	cerebellum	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, postcentral	anatomy	gray matter	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal gyrus	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
temporal gyrus	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
temporal	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
parahippocampal gyrus	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
superior temporal gyrus	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior temporal	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal gyrus	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
middle temporal gyrus	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior temporal	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
parahippocampal gyrus	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior temporal	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
parahippocampal gyrus	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior temporal	anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
parahippocampal gyrus	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior temporal	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	anterior cingulate cortex	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	cingulate cortex	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	cerebellum	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, superior	anatomy	gray matter	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	cerebellum	2	0	26769980|22426803	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate cortex	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
anterior cingulate cortex	anatomy	gray matter	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	cingulate cortex	2	0	26769980|22426803	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cingulate cortex	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cingulate cortex	anatomy	gray matter	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior temporal	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
cerebellum	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	cerebellum	2	0	26769980|22426803	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cerebellum	anatomy	gray matter	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gyrus, superior	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
, and	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
gray matter	anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	postcentral gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	anterior cingulate	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	gyrus, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	middle temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	cortex and	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	, postcentral	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	temporal gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	middle temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	parahippocampal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	anterior cingulate cortex	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	cingulate cortex	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	superior temporal gyrus	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	cerebellum	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	gyrus, superior	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	gyrus, superior temporal	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
autism spectrum disorder	disease_to_anatomy	gray matter	1	0	26769980	PMID:26769980; Original text:The voxel-wise meta-analysis revealed that relative to controls, adults with autism spectrum disorder had significantly increased gray matter volume in the middle temporal gyrus, superior temporal gyrus, postcentral gyrus and parahippocampal gyrus, and reduced gray matter volume in the anterior cingulate cortex and cerebellum.
of male	anatomy	of the	1	0	26769980	PMID:26769980; Original text:Variations in gray matter volume were significantly associated with the mean age and mean total IQ score of the patients, as well as with the percentage of male patients with autism.
gray matter	anatomy	of male	1	0	26769980	PMID:26769980; Original text:Variations in gray matter volume were significantly associated with the mean age and mean total IQ score of the patients, as well as with the percentage of male patients with autism.
gray matter	anatomy	of the	1	0	26769980	PMID:26769980; Original text:Variations in gray matter volume were significantly associated with the mean age and mean total IQ score of the patients, as well as with the percentage of male patients with autism.
autism	disease_to_anatomy	of male	1	0	26769980	PMID:26769980; Original text:Variations in gray matter volume were significantly associated with the mean age and mean total IQ score of the patients, as well as with the percentage of male patients with autism.
autism	disease_to_anatomy	gray matter	1	0	26769980	PMID:26769980; Original text:Variations in gray matter volume were significantly associated with the mean age and mean total IQ score of the patients, as well as with the percentage of male patients with autism.
, and	anatomy	site	3	0	26290524|26290524|25861158	PMID:26290524; Original text:Attendance was significantly predicted by socioeconomic status, site, and treatment condition.|PMID:26290524; Original text:Families in caregiver-mediated module reported lower levels of treatment adherence, which was significantly predicted by site, condition, caregiver stress, and child nonverbal intelligence quotient.|PMID:25861158; Original text:tDCS also significantly increased at the stimulation site, and an increase in tDCS was significantly associated with improvements in the two domains of autism treatment evaluation checklist impacted by tDCS.
levels of	anatomy	site	1	0	26290524	PMID:26290524; Original text:Families in caregiver-mediated module reported lower levels of treatment adherence, which was significantly predicted by site, condition, caregiver stress, and child nonverbal intelligence quotient.
serotonin	chemical	sertraline	1	0	8778118	PMID:8778118; Original text:Although the treatment prescribed for these problems has traditionally been neuroleptic medication, serotonin reuptake inhibitors such as sertraline may result in significant clinical improvement as well as fewer side effects.
pten	chemical_to_disease	autism spectrum disorders	1	0	24136242	PMID:24136242; Original text:Particularly, accumulated data suggest that the effect of PTEN on neural stem-cell development contributes significantly to the pathophysiology of autism spectrum disorders.
pten	chemical_to_mechanism	pten	1	0	24136242	PMID:24136242; Original text:Particularly, accumulated data suggest that the effect of PTEN on neural stem-cell development contributes significantly to the pathophysiology of autism spectrum disorders.
pten	chemical_to_anatomy	neural stem	1	0	24136242	PMID:24136242; Original text:Particularly, accumulated data suggest that the effect of PTEN on neural stem-cell development contributes significantly to the pathophysiology of autism spectrum disorders.
autism spectrum disorders	disease_to_mechanism	pten	1	0	24136242	PMID:24136242; Original text:Particularly, accumulated data suggest that the effect of PTEN on neural stem-cell development contributes significantly to the pathophysiology of autism spectrum disorders.
autism spectrum disorders	disease_to_anatomy	neural stem	1	0	24136242	PMID:24136242; Original text:Particularly, accumulated data suggest that the effect of PTEN on neural stem-cell development contributes significantly to the pathophysiology of autism spectrum disorders.
pten	mechanism_to_anatomy	neural stem	1	0	24136242	PMID:24136242; Original text:Particularly, accumulated data suggest that the effect of PTEN on neural stem-cell development contributes significantly to the pathophysiology of autism spectrum disorders.
cholesterol	chemical	synthesize	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
steroid	chemical	synthesize	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
cholesterol	chemical	steroid	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
synthesize	chemical_to_disease	smith-lemli-opitz syndrome	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
cholesterol	chemical_to_disease	smith-lemli-opitz syndrome	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
steroid	chemical_to_disease	smith-lemli-opitz syndrome	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
synthesize	chemical_to_anatomy	of the	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
cholesterol	chemical_to_anatomy	of the	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
steroid	chemical_to_anatomy	of the	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
smith-lemli-opitz syndrome	disease_to_anatomy	of the	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
autism spectrum disorder	disease	behavioural deficits	1	0	25149412	PMID:25149412; Original text:In the case-control study, 17 males with autism spectrum disorder showed significant behavioural deficits in inferring others' social emotions (P = 0.018) but not in inferring others' beliefs (P = 0.064) compared with 17 typically developing demographically-matched male participants.
behavioural deficits	disease_to_anatomy	(p	1	0	25149412	PMID:25149412; Original text:In the case-control study, 17 males with autism spectrum disorder showed significant behavioural deficits in inferring others' social emotions (P = 0.018) but not in inferring others' beliefs (P = 0.064) compared with 17 typically developing demographically-matched male participants.
posterior superior	anatomy	prefrontal cortex	1	0	25149412	PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
, and	anatomy	posterior superior	1	0	25149412	PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
(p	anatomy	posterior superior	1	0	25149412	PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
posterior superior temporal	anatomy	prefrontal cortex	1	0	25149412	PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
prefrontal cortex	anatomy	superior temporal	1	0	25149412	PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
, and	anatomy	prefrontal cortex	4	0	25149412|34018333|34018333|22457638	PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).|PMID:34018333; Original text:Our results show that activation of the the ventromedial prefrontal cortex with anodal Transcranial direct current stimulation significantly improved mind in children with disorder compared with both, r-temporoparietal junction Transcranial direct current stimulation, and sham stimulation.|PMID:34018333; Original text:Specifically, precursors of mind (e.g., emotion recognition, perception, and imitation) and elementary mind skills (e.g., first-order mental state reasoning) were significantly improved by anodal the ventromedial prefrontal cortex Transcranial direct current stimulation.|PMID:22457638; Original text:Genes regulating cell cycle also exhibited autism-specific number variations in DNA derived from prefrontal cortex, and these genes were significantly associated with autism in genome-wide association study datasets.
prefrontal cortex	anatomy	temporal	2	0	25149412|24374754	PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).|PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
prefrontal cortex	anatomy	temporal sulcus	1	0	25149412	PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
, and	anatomy	posterior superior temporal	1	0	25149412	PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
(p	anatomy	posterior superior temporal	1	0	25149412	PMID:25149412; Original text:They also showed significantly less activity in the right anterior insula and posterior superior temporal sulcus during inferring others' social emotions, and in the dorsomedial prefrontal cortex during inferring others' beliefs compared with the typically developing participants (P < 0.001 and cluster size > 10 voxels).
bifidobacteriales	bacteria	bifidobacterium longum	1	0	32305492	PMID:32305492; Original text:We found that gut microbiota was in a state of dysbiosis and significantly lower levels of Bifidobacteriales and Bifidobacterium longum were observed at the discovery stage in children with ASD.
bifidobacterium longum	bacteria_to_disease	asd	1	0	32305492	PMID:32305492; Original text:We found that gut microbiota was in a state of dysbiosis and significantly lower levels of Bifidobacteriales and Bifidobacterium longum were observed at the discovery stage in children with ASD.
bifidobacteriales	bacteria_to_disease	asd	1	0	32305492	PMID:32305492; Original text:We found that gut microbiota was in a state of dysbiosis and significantly lower levels of Bifidobacteriales and Bifidobacterium longum were observed at the discovery stage in children with ASD.
bifidobacterium longum	bacteria_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:We found that gut microbiota was in a state of dysbiosis and significantly lower levels of Bifidobacteriales and Bifidobacterium longum were observed at the discovery stage in children with ASD.
bifidobacteriales	bacteria_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:We found that gut microbiota was in a state of dysbiosis and significantly lower levels of Bifidobacteriales and Bifidobacterium longum were observed at the discovery stage in children with ASD.
asd	disease_to_anatomy	levels of	2	0	32305492|32305492	PMID:32305492; Original text:We found that gut microbiota was in a state of dysbiosis and significantly lower levels of Bifidobacteriales and Bifidobacterium longum were observed at the discovery stage in children with ASD.|PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
b . longum	bacteria	clostridium	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
bifidobacteriales	bacteria	clostridium	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
b . longum	bacteria	bifidobacteriales	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
autism	disease	gastrointestinal symptoms	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
clostridium	bacteria_to_chemical	fos	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
b . longum	bacteria_to_chemical	fos	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
bifidobacteriales	bacteria_to_chemical	fos	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
clostridium	bacteria_to_disease	autism	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
clostridium	bacteria_to_disease	gastrointestinal symptoms	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
b . longum	bacteria_to_disease	autism	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
b . longum	bacteria_to_disease	gastrointestinal symptoms	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
bifidobacteriales	bacteria_to_disease	autism	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
bifidobacteriales	bacteria_to_disease	gastrointestinal symptoms	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
fos	chemical_to_disease	autism	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
fos	chemical_to_disease	gastrointestinal symptoms	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
dopamine	chemical	homovanillic acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical	serotonin	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical	propionic acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical	dopamine	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical	dopamine	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical	serotonin	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical	propionic acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical	homovanillic acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical	homovanillic acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical	serotonin	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical	serotonin	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical	serotonin	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical	propionic acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical	propionic acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical	butyric acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine metabolism disorder	disease	hyperserotonergic	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
asd	disease	dopamine metabolism disorder	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
asd	disease	hyperserotonergic	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acid	anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
group	anatomy	levels of	2	0	32305492|29316336	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:29316336; Original text:Relative to the Control group, parents in the Tutorial group reported significantly higher use of evidence-based instructional strategies and higher levels of child engagement during routines at T2 and T3.
, and	anatomy	acid	2	0	32305492|29562612	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
acid	anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical_to_disease	dopamine metabolism disorder	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical_to_disease	hyperserotonergic	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical_to_disease	asd	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical_to_disease	dopamine metabolism disorder	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical_to_disease	hyperserotonergic	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical_to_disease	asd	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
serotonin	chemical_to_disease	dopamine metabolism disorder	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
serotonin	chemical_to_disease	hyperserotonergic	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_disease	dopamine metabolism disorder	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_disease	hyperserotonergic	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_disease	asd	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_disease	dopamine metabolism disorder	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_disease	hyperserotonergic	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_disease	asd	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_disease	dopamine metabolism disorder	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_disease	hyperserotonergic	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_disease	asd	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical_to_anatomy	, and	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical_to_anatomy	, and	2	0	32305492|3886023	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
homovanillic acid	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
serotonin	chemical_to_anatomy	, and	3	0	32305492|15730889|6502317	"PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors.|PMID:6502317; Original text:Significant correlations emerged among the amount of clinical response, initially high verbal IQs, and low blood serotonin concentrations."
serotonin	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
serotonin	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_anatomy	, and	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_anatomy	, and	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_anatomy	, and	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine metabolism disorder	disease_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine metabolism disorder	disease_to_anatomy	, and	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine metabolism disorder	disease_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine metabolism disorder	disease_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
hyperserotonergic	disease_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
hyperserotonergic	disease_to_anatomy	, and	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
hyperserotonergic	disease_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
hyperserotonergic	disease_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
asd	disease_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
5-ht	chemical	carbohydrate-	1	0	12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.
of the	anatomy	platelet	1	0	12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.
carbohydrate-	chemical_to_anatomy	of the	1	0	12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.
carbohydrate-	chemical_to_anatomy	platelet	1	0	12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.
5-ht	chemical_to_anatomy	of the	1	0	12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.
5-ht	chemical_to_anatomy	platelet	2	0	12858328|12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.|PMID:12858328; Original text:A significant elevation in platelet-poor plasma 5-HT levels in adult autistic patients was reached 60 min after meal administration (p < 0.03 vs control and p = 0.05 vs baseline) and a significant decrease was noted after 120 min (p < 0.01 vs baseline).
5-ht	chemical_to_anatomy	(p	1	0	12858328	PMID:12858328; Original text:A significant elevation in platelet-poor plasma 5-HT levels in adult autistic patients was reached 60 min after meal administration (p < 0.03 vs control and p = 0.05 vs baseline) and a significant decrease was noted after 120 min (p < 0.01 vs baseline).
prader-willi syndrome disorder	disease	restricted or repetitive behaviors	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
prader-willi syndrome	disease	restricted or repetitive behaviors	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
restricted or repetitive behaviors	disease	social-communication impairment	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
prader-willi syndrome	disease	prader-willi syndrome disorder	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
prader-willi syndrome disorder	disease	social-communication impairment	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
prader-willi syndrome	disease	social-communication impairment	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
restricted or repetitive behaviors	disease_to_anatomy	levels of	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
prader-willi syndrome disorder	disease_to_anatomy	levels of	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
prader-willi syndrome	disease_to_anatomy	levels of	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
social-communication impairment	disease_to_anatomy	levels of	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
developmental delay/	disease	schizophrenia	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
autism spectrum disorder	disease	developmental delay/	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
developmental delay/	disease	neurodevelopmental psychiatric disorders	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
developmental delay/	disease	intellectual disability	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
neurodevelopmental psychiatric disorders	disease	schizophrenia	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
autism spectrum disorder	disease	neurodevelopmental psychiatric disorders	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
intellectual disability	disease	neurodevelopmental psychiatric disorders	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
developmental delay/	disease_to_anatomy	, and	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
neurodevelopmental psychiatric disorders	disease_to_anatomy	, and	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
autistic disorders	disease	pervasive developmental disorders	1	0	22650115	PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
-v	anatomy	of the	1	0	22650115	PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
-v	anatomy	group of	1	0	22650115	PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
autistic disorders	disease_to_anatomy	-v	1	0	22650115	PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
autistic disorders	disease_to_anatomy	of the	1	0	22650115	PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
autistic disorders	disease_to_anatomy	group of	1	0	22650115	PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
pervasive developmental disorders	disease_to_anatomy	-v	1	0	22650115	PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
pervasive developmental disorders	disease_to_anatomy	of the	1	0	22650115	PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
pervasive developmental disorders	disease_to_anatomy	group of	1	0	22650115	PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
autism	disease	tourette's syndrome	1	0	15090875	PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.
neurodevelopmental disorders	disease	tourette's syndrome	1	0	15090875	PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.
attention-deficit/hyperactivity disorder	disease	tourette's syndrome	1	0	15090875	PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.
attention-deficit/hyperactivity disorder	disease	neurodevelopmental disorders	2	0	15090875|30658861	PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.|PMID:30658861; Original text:Attention-Deficit/Hyperactivity Disorder (Attention-Deficit/Hyperactivity Disorder) and Autism Spectrum Disorder (Autism Spectrum Disorder) are both neurodevelopmental disorders originating in childhood with high associated impairments and public health significance.
tourette's syndrome	disease_to_anatomy	, and	1	0	15090875	PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.
serotonin	chemical	serotonin(2ar	1	0	18405062	PMID:18405062; Original text:Our study shows that serotonint-LPR and -1438AG serotonin(2Ar) genotypes did not significantly affect serotonin level.
serotonin(2ar	chemical	serotonint	1	0	18405062	PMID:18405062; Original text:Our study shows that serotonint-LPR and -1438AG serotonin(2Ar) genotypes did not significantly affect serotonin level.
serotonin	chemical	serotonint	1	0	18405062	PMID:18405062; Original text:Our study shows that serotonint-LPR and -1438AG serotonin(2Ar) genotypes did not significantly affect serotonin level.
, sensory motor	anatomy	group (	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
group (	anatomy	i)	2	0	18080171|18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
, sensory	anatomy	group (	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
group (	anatomy	sensory motor	2	0	18080171|18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
, sensory motor	anatomy	i)	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
, sensory	anatomy	, sensory motor	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
(p	anatomy	, sensory motor	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
, sensory motor	anatomy	sensory motor	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
, sensory	anatomy	i)	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
(p	anatomy	i)	2	0	18080171|18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
, sensory	anatomy	sensory motor	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
(p	anatomy	sensory motor	2	0	18080171|18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
risperidone	chemical_to_anatomy	, sensory motor	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
risperidone	chemical_to_anatomy	, sensory	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
haloperidol	chemical	risperidone	1	0	18080171	PMID:18080171; Original text:Compared to haloperidol, risperidone led to a significantly greater reduction in the Aberrant Behavior Checklist (the Aberrant Behavior Checklist) and Turgay DSM-IV Pervasive Developmental Disorder (Turgay DSM-IV Pervasive Developmental Disorder) scale scores (P < 0.05 and P < 0.01).
haloperidol	chemical_to_disease	pervasive developmental disorder	1	0	18080171	PMID:18080171; Original text:Compared to haloperidol, risperidone led to a significantly greater reduction in the Aberrant Behavior Checklist (the Aberrant Behavior Checklist) and Turgay DSM-IV Pervasive Developmental Disorder (Turgay DSM-IV Pervasive Developmental Disorder) scale scores (P < 0.05 and P < 0.01).
risperidone	chemical_to_disease	pervasive developmental disorder	1	0	18080171	PMID:18080171; Original text:Compared to haloperidol, risperidone led to a significantly greater reduction in the Aberrant Behavior Checklist (the Aberrant Behavior Checklist) and Turgay DSM-IV Pervasive Developmental Disorder (Turgay DSM-IV Pervasive Developmental Disorder) scale scores (P < 0.05 and P < 0.01).
haloperidol	chemical_to_anatomy	(p	1	0	18080171	PMID:18080171; Original text:Compared to haloperidol, risperidone led to a significantly greater reduction in the Aberrant Behavior Checklist (the Aberrant Behavior Checklist) and Turgay DSM-IV Pervasive Developmental Disorder (Turgay DSM-IV Pervasive Developmental Disorder) scale scores (P < 0.05 and P < 0.01).
pervasive developmental disorder	disease_to_anatomy	(p	1	0	18080171	PMID:18080171; Original text:Compared to haloperidol, risperidone led to a significantly greater reduction in the Aberrant Behavior Checklist (the Aberrant Behavior Checklist) and Turgay DSM-IV Pervasive Developmental Disorder (Turgay DSM-IV Pervasive Developmental Disorder) scale scores (P < 0.05 and P < 0.01).
end of	anatomy	i)	1	0	18080171	PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
(p	anatomy	end of	1	0	18080171	PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
end of	anatomy	sensory motor	1	0	18080171	PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
i)	anatomy	of the	1	0	18080171	PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
of the	anatomy	sensory motor	1	0	18080171	PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
risperidone	chemical_to_anatomy	end of	2	0	18080171|31063671	PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
homovanillic acid	chemical	magnesium	1	0	3886023	PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
magnesium	chemical	vitamin b6	1	0	3886023	PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
homovanillic acid	chemical	vitamin b6	1	0	3886023	PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
magnesium	chemical_to_disease	ep	1	0	3886023	PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
homovanillic acid	chemical_to_disease	ep	1	0	3886023	PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
vitamin b6	chemical_to_disease	ep	1	0	3886023	PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
ep	disease_to_anatomy	, and	1	0	3886023	PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
autism spectrum	disease	schizophrenia	1	0	30284394	PMID:30284394; Original text:Schizophrenia and autism spectrum disorder (disorder) are significant public health problems.
fibromyalgia	disease	pain	1	0	25336035	PMID:25336035; Original text:low-dose naltrexone improved pain tolerance as shown by a significant increase on Cold pressor times for post detoxification patients from 16 seconds to 55 seconds and in fibromyalgia patients from 21 seconds to 42 seconds, and improved relatedness.
naltrexone	chemical_to_disease	pain	1	0	25336035	PMID:25336035; Original text:low-dose naltrexone improved pain tolerance as shown by a significant increase on Cold pressor times for post detoxification patients from 16 seconds to 55 seconds and in fibromyalgia patients from 21 seconds to 42 seconds, and improved relatedness.
naltrexone	chemical_to_disease	fibromyalgia	1	0	25336035	PMID:25336035; Original text:low-dose naltrexone improved pain tolerance as shown by a significant increase on Cold pressor times for post detoxification patients from 16 seconds to 55 seconds and in fibromyalgia patients from 21 seconds to 42 seconds, and improved relatedness.
pain	disease_to_anatomy	, and	1	0	25336035	PMID:25336035; Original text:low-dose naltrexone improved pain tolerance as shown by a significant increase on Cold pressor times for post detoxification patients from 16 seconds to 55 seconds and in fibromyalgia patients from 21 seconds to 42 seconds, and improved relatedness.
fibromyalgia	disease_to_anatomy	, and	1	0	25336035	PMID:25336035; Original text:low-dose naltrexone improved pain tolerance as shown by a significant increase on Cold pressor times for post detoxification patients from 16 seconds to 55 seconds and in fibromyalgia patients from 21 seconds to 42 seconds, and improved relatedness.
psychiatric	disease_to_anatomy	of the	1	0	19780345	"PMID:19780345; Original text:The current view of the psychiatric significance of inter-ictal spike discharges (inter-ictal spike discharges) in nonepileptic, psychiatric patients is that the discharges are ""incidental"" and are of no clinical significance."
il-1β	mechanism_to_anatomy	(p	1	0	32121236	PMID:32121236; Original text:When only children with elevated IL-1β were included, five outcomes showed greater improvements: OM (P = 0.01) for SRS-total; OM (P = 0.03) for SRS-social communicative functioning; VID (P = 0.01), OM (P = 0.003) and VIDOM (P = 0.01) for SRS-awareness.
, motor	anatomy	of joint	1	0	11918108	PMID:11918108; Original text:Results demonstrated that children in the treatment group improved significantly more than those in the control group on measures of joint attention, social interaction, imitation, daily living skills, motor skills and an adaptive behaviour composite.
serotonin	mechanism	serotonin receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
cortex	anatomy	receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
, and	anatomy	cortex	3	0	15730889|22426803|22457638	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors.|PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.|PMID:22457638; Original text:Genes regulating cell cycle also exhibited autism-specific number variations in DNA derived from prefrontal cortex, and these genes were significantly associated with autism in genome-wide association study datasets."
cortex	anatomy	terminals	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
, and	anatomy	receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
receptors	anatomy	terminals	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
, and	anatomy	terminals	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	chemical_to_mechanism	serotonin receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	chemical_to_anatomy	cortex	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	chemical_to_anatomy	receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	chemical_to_anatomy	terminals	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
autistic	disease_to_mechanism	serotonin	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
autistic	disease_to_mechanism	serotonin receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
autistic	disease_to_anatomy	cortex	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
autistic	disease_to_anatomy	receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
autistic	disease_to_anatomy	terminals	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	mechanism_to_anatomy	cortex	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	mechanism_to_anatomy	receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	mechanism_to_anatomy	, and	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	mechanism_to_anatomy	terminals	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin receptors	mechanism_to_anatomy	cortex	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin receptors	mechanism_to_anatomy	receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin receptors	mechanism_to_anatomy	, and	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin receptors	mechanism_to_anatomy	terminals	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
anxiety	disease	repetitive behaviors	1	0	16649827	PMID:16649827; Original text:Most studies demonstrate significant improvement in global functioning and in symptoms associated with anxiety and repetitive behaviors.
risperidone	chemical	rs6280	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
drd3 ser9gly	mechanism	slc6a4 5-httlpr polymorphism	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
, 3	anatomy	3 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
, 2	anatomy	, 3	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
, 3	anatomy	2 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
, 2	anatomy	3 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
2 of	anatomy	3 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
, 2	anatomy	2 of	2	0	33222504|24828014	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.|PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
rs6280	chemical_to_disease	antidepressants	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
risperidone	chemical_to_disease	antidepressants	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
rs6280	chemical_to_mechanism	slc6a4 5-httlpr polymorphism	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
rs6280	chemical_to_mechanism	drd3 ser9gly	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
risperidone	chemical_to_mechanism	slc6a4 5-httlpr polymorphism	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
risperidone	chemical_to_mechanism	drd3 ser9gly	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
rs6280	chemical_to_anatomy	, 3	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
rs6280	chemical_to_anatomy	3 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
rs6280	chemical_to_anatomy	, 2	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
rs6280	chemical_to_anatomy	2 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
risperidone	chemical_to_anatomy	, 3	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
risperidone	chemical_to_anatomy	3 of	2	0	33222504|16239862	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.|PMID:16239862; Original text:Risperidone was superior to placebo in preventing relapse: this occurred in 3 of 12 patients continuing on risperidone versus 8 of 12 who switched to placebo (p = .049).
risperidone	chemical_to_anatomy	, 2	2	0	33222504|24828014	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.|PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
risperidone	chemical_to_anatomy	2 of	3	0	33222504|24828014|16948927	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.|PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
antidepressants	disease_to_mechanism	slc6a4 5-httlpr polymorphism	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
antidepressants	disease_to_mechanism	drd3 ser9gly	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
antidepressants	disease_to_anatomy	, 3	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
antidepressants	disease_to_anatomy	3 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
antidepressants	disease_to_anatomy	, 2	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
antidepressants	disease_to_anatomy	2 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
slc6a4 5-httlpr polymorphism	mechanism_to_anatomy	, 3	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
slc6a4 5-httlpr polymorphism	mechanism_to_anatomy	3 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
slc6a4 5-httlpr polymorphism	mechanism_to_anatomy	, 2	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
slc6a4 5-httlpr polymorphism	mechanism_to_anatomy	2 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
drd3 ser9gly	mechanism_to_anatomy	, 3	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
drd3 ser9gly	mechanism_to_anatomy	3 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
drd3 ser9gly	mechanism_to_anatomy	, 2	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
drd3 ser9gly	mechanism_to_anatomy	2 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
area of	anatomy	of the	1	0	11408327	PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.
area of	anatomy	area of the	1	0	11408327	PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.
area of the	anatomy	of the	1	0	11408327	PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.
autism	disease_to_anatomy	area of	1	0	11408327	PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.
autism	disease_to_anatomy	area of the	1	0	11408327	PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.
autistic	disease_to_anatomy	area of	1	0	11408327	PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.
autistic	disease_to_anatomy	area of the	1	0	11408327	PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.
dsm - 5	bacteria_to_chemical	aripiprazole	1	0	27344135	PMID:27344135; Original text:One long-term, placebo discontinuation study found that relapse rates did not differ between children/adolescents randomised to continue aripiprazole versus children/adolescents randomised to receive placebo, suggesting that re-evaluation of aripiprazole use after a period of stabilisation in irritability symptoms is warranted.
dsm - 5	bacteria_to_disease	irritability	1	0	27344135	PMID:27344135; Original text:One long-term, placebo discontinuation study found that relapse rates did not differ between children/adolescents randomised to continue aripiprazole versus children/adolescents randomised to receive placebo, suggesting that re-evaluation of aripiprazole use after a period of stabilisation in irritability symptoms is warranted.
alexithymia	disease	autistic	1	0	30399531	PMID:30399531; Original text:There was also a higher prevalence of alexithymia in the disorder group (49.93% compared to 4.89%), with a significantly increased risk of alexithymia in autistic participants.
alexithymia	disease_to_anatomy	group (	1	0	30399531	PMID:30399531; Original text:There was also a higher prevalence of alexithymia in the disorder group (49.93% compared to 4.89%), with a significantly increased risk of alexithymia in autistic participants.
autism	disease	psychiatric disorders	1	0	21863344	PMID:21863344; Original text:Empathy, for instance, is a rather elaborated human ability, and several recent studies point to significant impairments in patients suffering from psychiatric disorders, such as schizophrenia or autism.
autism	disease	schizophrenia	2	0	21863344|19736351	PMID:21863344; Original text:Empathy, for instance, is a rather elaborated human ability, and several recent studies point to significant impairments in patients suffering from psychiatric disorders, such as schizophrenia or autism.|PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).
psychiatric disorders	disease_to_anatomy	, and	1	0	21863344	PMID:21863344; Original text:Empathy, for instance, is a rather elaborated human ability, and several recent studies point to significant impairments in patients suffering from psychiatric disorders, such as schizophrenia or autism.
anxiety	disease	spectrum disorders	2	0	23357440|23357440	PMID:23357440; Original text:To examine the efficacy of a modular cognitive-behavioral therapy (a modular cognitive-behavioral therapy) protocol relative to treatment as usual (TAU) among children with high-functioning autism spectrum disorders (spectrum disorders) and clinically significant anxiety.|PMID:23357440; Original text:A total of 45 children (7-11 years of age) with high-functioning spectrum disorders and clinically significant anxiety were randomized to receive 16 sessions of weekly a modular cognitive-behavioral therapy or TAU for an equivalent duration.
org 2766	chemical_to_disease	hyperactivity	1	0	8866933	PMID:8866933; Original text:The children who responded to ORG 2766, but not those who responded to placebo, manifested significant improvements outside the changes in the defining variables, including a decrease in hyperactivity at school.
diarrhea	disease_to_mechanism	secretin	1	0	11331721	PMID:11331721; Original text:Subgroupings based on cognitive level, the presence or absence of diarrhea, or a history of regression failed to show any significant therapeutic effects of secretin.
inherited cancer syndrome	disease	neurofibromatosis type	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
cognitive	disease	inherited cancer syndrome	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
cognitive	disease	neurofibromatosis type	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
of all	anatomy	type 1	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
, and	anatomy	type 1	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
inherited cancer syndrome	disease_to_anatomy	of all	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
inherited cancer syndrome	disease_to_anatomy	type 1	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
inherited cancer syndrome	disease_to_anatomy	, and	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
neurofibromatosis type	disease_to_anatomy	of all	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
neurofibromatosis type	disease_to_anatomy	type 1	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
neurofibromatosis type	disease_to_anatomy	, and	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
cognitive	disease_to_anatomy	of all	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
cognitive	disease_to_anatomy	type 1	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
, and	anatomy	tests	1	0	12585724	PMID:12585724; Original text:Outcome measures were the Childhood Autism Rating Scale, the Gilliam Autism Rating Scale, the Expressive and Receptive One-Word Picture Vocabulary tests, and Clinical Global Impressions of Change.
scale	anatomy	tests	1	0	12585724	PMID:12585724; Original text:Outcome measures were the Childhood Autism Rating Scale, the Gilliam Autism Rating Scale, the Expressive and Receptive One-Word Picture Vocabulary tests, and Clinical Global Impressions of Change.
autism spectrum disorders	disease_to_anatomy	peripheral blood	1	0	32272227	PMID:32272227; Original text:Significantly elevated C-reactive protein levels in peripheral blood were found in Autism Spectrum Disorders children compared with healthy controls (Hedges' g = 0.527, 95% CI: 0.224-0.830, p = 0.001).
autism spectrum disorders	disease_to_mechanism	peripheral c-reactive protein	1	0	32272227	PMID:32272227; Original text:There was also a significant association between peripheral C-reactive protein concentration and Autism Spectrum Disorders after removing the studies identified by Galbraith plots.
autistic	disease_to_mechanism	peripheral c-reactive protein	1	0	32272227	PMID:32272227; Original text:In our study, peripheral C-reactive protein levels were significantly elevated in autistic children compared with healthy children.
autistic	disease_to_anatomy	, peripheral	1	0	32272227	PMID:32272227; Original text:In our study, peripheral C-reactive protein levels were significantly elevated in autistic children compared with healthy children.
peripheral c-reactive protein	mechanism_to_anatomy	, peripheral	1	0	32272227	PMID:32272227; Original text:In our study, peripheral C-reactive protein levels were significantly elevated in autistic children compared with healthy children.
autism spectrum disorders	disease	psychotic disorders	1	0	28152400	PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
psychotic disorders	disease	schizophrenia	1	0	28152400	PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
psychotic disorders	disease	symptomatic	1	0	28152400	PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
2 of	anatomy	of the	3	0	30501497|24828014|25685703	PMID:30501497; Original text:The Clinical Global Impressions Scale identified statistically significant improvements in 2 of the 3 trials.|PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).|PMID:25685703; Original text:The class probability estimates, P(ASD|fMRI data), from brain-based classifiers significantly correlated with scores on a measure of social functioning, the Social Responsiveness Scale (the Social Responsiveness Scale), as did the most informative features from 2 of the 3 sets of brain-based features.
25(oh)d	chemical	vitamin d3	1	0	28626020	PMID:28626020; Original text:Following vitamin D3 supplementation, there was a significant increase in 25(OH)D to 83.8 nmol/L (p=0.0016) but no effect on the primary endpoint.
vitamin d3 supplementation	nutrient_to_chemical	25(oh)d	1	0	28626020	PMID:28626020; Original text:Following vitamin D3 supplementation, there was a significant increase in 25(OH)D to 83.8 nmol/L (p=0.0016) but no effect on the primary endpoint.
vitamin d3 supplementation	nutrient_to_chemical	vitamin d3	1	0	28626020	PMID:28626020; Original text:Following vitamin D3 supplementation, there was a significant increase in 25(OH)D to 83.8 nmol/L (p=0.0016) but no effect on the primary endpoint.
vitamin d3 supplementation	nutrient_to_anatomy	l (	1	0	28626020	PMID:28626020; Original text:Following vitamin D3 supplementation, there was a significant increase in 25(OH)D to 83.8 nmol/L (p=0.0016) but no effect on the primary endpoint.
25(oh)d	chemical_to_anatomy	l (	1	0	28626020	PMID:28626020; Original text:Following vitamin D3 supplementation, there was a significant increase in 25(OH)D to 83.8 nmol/L (p=0.0016) but no effect on the primary endpoint.
vitamin d3	chemical_to_anatomy	l (	1	0	28626020	PMID:28626020; Original text:Following vitamin D3 supplementation, there was a significant increase in 25(OH)D to 83.8 nmol/L (p=0.0016) but no effect on the primary endpoint.
affective disorders	disease	multiple sclerosis	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
disorder	disease	multiple sclerosis	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
multiple sclerosis	disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
multiple sclerosis	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
autism spectrum	disease	multiple sclerosis	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
ms	disease	multiple sclerosis	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
affective disorders	disease	disorder	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
affective disorders	disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
affective disorders	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
affective disorders	disease	autism spectrum	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
affective disorders	disease	ms	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
disorder	disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
disorder	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
autism spectrum	disease	disorder	3	0	33669008|30475454|34018333	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).|PMID:30475454; Original text:This study compared the effectiveness of a free and open-source app for teaching social and communicative behavior to children with autism spectrum disorder (disorder) to traditional picture card approaches.|PMID:34018333; Original text:Theory of mind (mind) is the ability to attribute subjective mental states to oneself and others and is significantly impaired in autism spectrum disorder (disorder).
disorder	disease	ms	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
parkinson's disease	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
autism spectrum	disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
ms	disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
autism spectrum	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
ms	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
autism spectrum	disease	ms	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
scfa	chemical_to_disease	multiple sclerosis	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
scfa	chemical_to_disease	affective disorders	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
scfa	chemical_to_disease	disorder	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
scfa	chemical_to_disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
scfa	chemical_to_disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
scfa	chemical_to_disease	autism spectrum	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
scfa	chemical_to_disease	ms	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
fatty acids	chemical_to_anatomy	levels of	1	0	33669008	PMID:33669008; Original text:Non-short-chain fatty acids yielded less significantly distinct changes in faecal levels of patients and healthy controls, with the majority of findings were derived from urinary and blood samples.
testosterone	chemical_to_disease	autistic traits	1	0	34750348	PMID:34750348; Original text:Our data do not suggest increased fetal testosterone exposure is associated with increased autistic traits in children.
anxiety	disease	attention deficit hyperactivity disorder	2	0	34750348|31947912	PMID:34750348; Original text:p < 0.001), attention deficit hyperactivity disorder (odds ratio = 1.42, p < 0.001), CTD (odds ratio = 1.44, p = 0.001), anxiety (odds ratio = 1.33, p < 0.001), as well as other behavioral symptoms (odds ratio = 1.45, p < 0.001) in the adjusted analysis.|PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
attention deficit hyperactivity disorder	disease	ctd	1	0	34750348	PMID:34750348; Original text:p < 0.001), attention deficit hyperactivity disorder (odds ratio = 1.42, p < 0.001), CTD (odds ratio = 1.44, p = 0.001), anxiety (odds ratio = 1.33, p < 0.001), as well as other behavioral symptoms (odds ratio = 1.45, p < 0.001) in the adjusted analysis.
anxiety	disease	ctd	1	0	34750348	PMID:34750348; Original text:p < 0.001), attention deficit hyperactivity disorder (odds ratio = 1.42, p < 0.001), CTD (odds ratio = 1.44, p = 0.001), anxiety (odds ratio = 1.33, p < 0.001), as well as other behavioral symptoms (odds ratio = 1.45, p < 0.001) in the adjusted analysis.
asd	disease	obesity	1	0	31595678	PMID:31595678; Original text:Children with ASD had a 41.1% greater risk (P = .018) of development of obesity.
obesity	disease_to_anatomy	(p	1	0	31595678	PMID:31595678; Original text:Children with ASD had a 41.1% greater risk (P = .018) of development of obesity.
autism spectrum disorders	disease	epilepsy	1	0	20558021	PMID:20558021; Original text:The biological and phenotypic heterogeneity of children with autism spectrum disorders (autism spectrum disorders) and epilepsy presents a significant challenge to the development of effective treatment protocols.
of the	anatomy	process of	1	0	30517284	PMID:30517284; Original text:The results of the identified studies confirm the significant importance of these instruments in improving the communicative process of autistic children.
autistic	disease_to_anatomy	process of	1	0	30517284	PMID:30517284; Original text:The results of the identified studies confirm the significant importance of these instruments in improving the communicative process of autistic children.
disorder(+spectrum disorders	disease	spectrum	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
attention-deficit/hyperactivity	disease	spectrum	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
disorders(+attention-deficit/hyperactivity disorder	disease	spectrum	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
attention-deficit/hyperactivity	disease	disorder(+spectrum disorders	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
disorder(+spectrum disorders	disease	disorders(+attention-deficit/hyperactivity disorder	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
attention-deficit/hyperactivity	disease	disorders(+attention-deficit/hyperactivity disorder	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
ot	chemical_to_disease	social deficits	1	0	15749249	PMID:15749249; Original text:In recent studies, we have described persistently reduced CSF OT levels in male rhesus monkeys with significant social deficits.
anxiety	disease	generalized	1	0	21660428	"PMID:21660428; Original text:Children in both programs showed significantly lower levels of generalized anxiety and total anxiety symptoms at 6-month follow-up on SCAS-C. Clinician ratings on the CGI-S demonstrated an increase in the percentage of participants rated as ""Normal"" and ""Borderline"" for both programs."
generalized	disease_to_anatomy	levels of	1	0	21660428	"PMID:21660428; Original text:Children in both programs showed significantly lower levels of generalized anxiety and total anxiety symptoms at 6-month follow-up on SCAS-C. Clinician ratings on the CGI-S demonstrated an increase in the percentage of participants rated as ""Normal"" and ""Borderline"" for both programs."
, memory	anatomy	, sensory	1	0	27721995	PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
, memory	anatomy	, motor	1	0	27721995	PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
autism	disease_to_anatomy	, memory	1	0	27721995	PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
anxiety	disease_to_anatomy	, memory	1	0	27721995	PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.
, and	anatomy	cord blood	1	0	30620122	PMID:30620122; Original text:We have previously reported significant improvements in behavior, including increased social functioning, improved communication abilities, and decreased clinical symptoms in children with disorder, following treatment with a single infusion of autologous cord blood in a phase I open-label trial.
, and	anatomy	trabecular bone	1	0	28342168	PMID:28342168; Original text:After adjusting for potential covariates, having autism spectrum disorders was associated with significantly lower trabecular bone mineral density and bone strength at the radius, and with marginally lower total body less head bone mineral content (p < 0.09).
(p	anatomy	trabecular bone	1	0	28342168	PMID:28342168; Original text:After adjusting for potential covariates, having autism spectrum disorders was associated with significantly lower trabecular bone mineral density and bone strength at the radius, and with marginally lower total body less head bone mineral content (p < 0.09).
and bone	anatomy	trabecular bone	1	0	28342168	PMID:28342168; Original text:After adjusting for potential covariates, having autism spectrum disorders was associated with significantly lower trabecular bone mineral density and bone strength at the radius, and with marginally lower total body less head bone mineral content (p < 0.09).
, and	anatomy	and bone	1	0	28342168	PMID:28342168; Original text:After adjusting for potential covariates, having autism spectrum disorders was associated with significantly lower trabecular bone mineral density and bone strength at the radius, and with marginally lower total body less head bone mineral content (p < 0.09).
(p	anatomy	and bone	1	0	28342168	PMID:28342168; Original text:After adjusting for potential covariates, having autism spectrum disorders was associated with significantly lower trabecular bone mineral density and bone strength at the radius, and with marginally lower total body less head bone mineral content (p < 0.09).
autism spectrum disorders	disease_to_anatomy	trabecular bone	1	0	28342168	PMID:28342168; Original text:After adjusting for potential covariates, having autism spectrum disorders was associated with significantly lower trabecular bone mineral density and bone strength at the radius, and with marginally lower total body less head bone mineral content (p < 0.09).
autism spectrum disorders	disease_to_anatomy	and bone	1	0	28342168	PMID:28342168; Original text:After adjusting for potential covariates, having autism spectrum disorders was associated with significantly lower trabecular bone mineral density and bone strength at the radius, and with marginally lower total body less head bone mineral content (p < 0.09).
anxiety	disease	autism spectrum disorders	2	0	23965288|19365716	PMID:23965288; Original text:Pretreatment Developmental Disability-Child Global Assessment Scale scores correlated with severity of autism spectrum disorders core symptoms (r = -.388, p = .034), pragmatic communication (r = .407, p = .032), and verbal ability (r = .449, p = .013) and did not correlate with severity of anxiety symptoms or with parent-reported adaptive behavior.|PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.
autism spectrum disorders	disease	infantile spasms	1	0	25944453	PMID:25944453; Original text:Only patients with symptomatic Infantile spasms developed autism spectrum disorders (p = 0.003).
infantile spasms	disease_to_anatomy	(p	1	0	25944453	PMID:25944453; Original text:Only patients with symptomatic Infantile spasms developed autism spectrum disorders (p = 0.003).
epileptic	disease	hypsarrhythmia	1	0	25944453	PMID:25944453; Original text:Other risk factors were identified such as having chronic epileptic discharges in the frontotemporal areas after disappearance of hypsarrhythmia (p = 0.005 and p = 0.007) and being of nonwhite origin (p = 0.009).
hypsarrhythmia	disease_to_anatomy	(p	1	0	25944453	PMID:25944453; Original text:Other risk factors were identified such as having chronic epileptic discharges in the frontotemporal areas after disappearance of hypsarrhythmia (p = 0.005 and p = 0.007) and being of nonwhite origin (p = 0.009).
epileptic	disease_to_anatomy	(p	1	0	25944453	PMID:25944453; Original text:Other risk factors were identified such as having chronic epileptic discharges in the frontotemporal areas after disappearance of hypsarrhythmia (p = 0.005 and p = 0.007) and being of nonwhite origin (p = 0.009).
epilepsy	disease	schizophrenia	1	0	24123946	PMID:24123946; Original text:The del15q11.2 was found to be significantly associated with intellectual disability, schizophrenia, epilepsy, and disorder.
sulforaphane	chemical_to_disease	irritability	1	0	32347624	PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
sulforaphane	chemical_to_disease	hyperactivity	1	0	32347624	PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
sulforaphane	chemical_to_anatomy	(primary	1	0	32347624	PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
sulforaphane	chemical_to_anatomy	group	1	0	32347624	PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
divalproex	chemical_to_disease	irritability	1	0	20010551	PMID:20010551; Original text:Overall, 62.5% of divalproex subjects vs 9% of placebo subjects were responders (CGI-irritability OR: 16.7, Fisher's exact p=0.008).
glutathione	chemical	n-acetylcysteine	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
12	anatomy	group (	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
(p	anatomy	12	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
n-acetylcysteine	chemical_to_anatomy	group (	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
n-acetylcysteine	chemical_to_anatomy	(p	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
n-acetylcysteine	chemical_to_anatomy	12	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
glutathione	chemical_to_anatomy	group (	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
glutathione	chemical_to_anatomy	(p	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
glutathione	chemical_to_anatomy	12	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
dravet syndrome	disease	intellectual disability	1	0	32334365	PMID:32334365; Original text:Many patients also have significant deficits in adaptive behavior highlighting that the majority of patients with Dravet syndrome will meet criteria for intellectual disability.
anterior cingulate	anatomy	cingulate gyrus	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
anterior cingulate gyrus	anatomy	cingulate gyrus	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
cingulate gyrus	anatomy	orbitofrontal cortex	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
cingulate gyrus	anatomy	frontal lobe	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
anterior cingulate	anatomy	anterior cingulate gyrus	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
anterior cingulate	anatomy	orbitofrontal cortex	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
anterior cingulate	anatomy	frontal lobe	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
anterior cingulate gyrus	anatomy	orbitofrontal cortex	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
anterior cingulate gyrus	anatomy	frontal lobe	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
frontal lobe	anatomy	orbitofrontal cortex	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
fluoxetine	chemical_to_anatomy	cingulate gyrus	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
fluoxetine	chemical_to_anatomy	anterior cingulate	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
fluoxetine	chemical_to_anatomy	anterior cingulate gyrus	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
fluoxetine	chemical_to_anatomy	orbitofrontal cortex	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
fluoxetine	chemical_to_anatomy	frontal lobe	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
3 of	anatomy	and 3	1	0	11466160	PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.
and 3	anatomy	of the	1	0	11466160	PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.
autism	disease_to_anatomy	3 of	1	0	11466160	PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.
anxiety	disease_to_anatomy	3 of	1	0	11466160	PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.
anxiety	disease_to_anatomy	and 3	1	0	11466160	PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.
cerebellum	anatomy	the brain	1	0	29935204	PMID:29935204; Original text:It indicates that the most significant changes in the brain occur during the second half of gestation and the first three months post-term, in particular in the cortical subplate and cerebellum.
buspirone	chemical	tryptophan	2	0	26746121|26746121	PMID:26746121; Original text:Positron emission tomography measures of tryptophan metabolism and blood serotonin concentrations were assessed as predictors of buspirone efficacy.|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
buspirone	chemical	serotonin	2	0	26746121|26746121	PMID:26746121; Original text:Positron emission tomography measures of tryptophan metabolism and blood serotonin concentrations were assessed as predictors of buspirone efficacy.|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
buspirone	chemical_to_disease	autism	1	0	26746121	PMID:26746121; Original text:There was no difference in the the Autism Diagnostic Observation Schedule Composite Total Score between baseline and 24 weeks among the 3 treatment groups (P = .400); however, the the Autism Diagnostic Observation Schedule Restricted and Repetitive Behavior score showed a time-by-treatment effect (P = .006); the 2.5-mg buspirone group showed significant improvement (P = .003), whereas placebo and 5.0-mg buspirone groups showed no change.
buspirone	chemical_to_anatomy	(p	2	0	26746121|26746121	PMID:26746121; Original text:There was no difference in the the Autism Diagnostic Observation Schedule Composite Total Score between baseline and 24 weeks among the 3 treatment groups (P = .400); however, the the Autism Diagnostic Observation Schedule Restricted and Repetitive Behavior score showed a time-by-treatment effect (P = .006); the 2.5-mg buspirone group showed significant improvement (P = .003), whereas placebo and 5.0-mg buspirone groups showed no change.|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
levels of	anatomy	of blood	2	0	26746121|25234471	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).|PMID:25234471; Original text:In terms of blood levels of metals, no significant difference between the groups was found.
(p	anatomy	of blood	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
buspirone	chemical_to_anatomy	levels of	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
buspirone	chemical_to_anatomy	of blood	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
tryptophan	chemical_to_anatomy	levels of	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
tryptophan	chemical_to_anatomy	of blood	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
serotonin	chemical_to_anatomy	of blood	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
autism	disease_to_anatomy	of all	1	0	32122747	PMID:32122747; Original text:Furthermore, metabolism represent a significant percentage of all autism cases.
asd	disease	sleep disturbances	1	0	31437211	PMID:31437211; Original text:The prevalence of sleep disturbances in children with ASD is 40-80%, with significant effects on quality of life for the children and carers.
serotonin	chemical_to_disease	mental illness	1	0	28129495	PMID:28129495; Original text:In maternal mental illness-restricted analyses, antenatal selective serotonin reuptake inhibitor exposure at any time during pregnancy was nonsignificant.
autism	disease_to_mechanism	nmda receptor gene family	1	0	24605324	PMID:24605324; Original text:Gene expression patterns in the low-line animals show significant enrichment in autism-associated genes and the NMDA receptor gene family was identified among these.
oxytocin	chemical_to_disease	social impairments	1	0	27651096	PMID:27651096; Original text:Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with disorder.
social impairments	disease_to_mechanism	oxytocin	1	0	27651096	PMID:27651096; Original text:Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with disorder.
social impairments	disease_to_anatomy	of the	1	0	27651096	PMID:27651096; Original text:Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with disorder.
developmental disabilities	disease_to_anatomy	, and	1	0	24757919	PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
disorders	disease_to_anatomy	, and	1	0	24757919	PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
neurodevelopmental psychiatric disorders	disease_to_anatomy	of large	1	0	33773394	PMID:33773394; Original text:Many rare genomic variants of large effect size have been identified; all of them together can explain a significant proportion of neurodevelopmental psychiatric disorders.
attention deficit hyperactivity disorder	disease	autistic spectrum disorder	2	0	30909078|31947912	PMID:30909078; Original text:More boys than girls had Attention Deficit Hyperactivity Disorder and autistic spectrum disorder, but in relative terms, the a risk ratio male/female was lower in CWE than the a risk ratio in the general population reported in other studies.|PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
asd	disease	attention-	1	0	20694583	PMID:20694583; Original text:Individuals with co-occurring ASD and attention-deficit/hyperactivity disorder symptoms are more severely impaired, with significant deficits seen in social processing, adaptive functioning, and executive control.
attention-	disease_to_anatomy	, and	1	0	20694583	PMID:20694583; Original text:Individuals with co-occurring ASD and attention-deficit/hyperactivity disorder symptoms are more severely impaired, with significant deficits seen in social processing, adaptive functioning, and executive control.
glutamate	chemical_to_anatomy	ci)	1	0	27390857	PMID:27390857; Original text:The meta-analysis provided evidence for higher blood glutamate levels in disorder [the pooled standardized mean difference = 0.99, 95% confidence interval (95% CI) = 0.58-1.40; P < 0.001] with high heterogeneity (I2 = 86%, P < 0.001) across studies.
n-acetylaspartate	chemical	naa	1	0	25817280	PMID:25817280; Original text:The concentrations of N-acetylaspartate (NAA) in these regions of autism spectrum disorders were significantly decreased compared to those in the control group.
naa	chemical_to_disease	autism spectrum disorders	1	0	25817280	PMID:25817280; Original text:The concentrations of N-acetylaspartate (NAA) in these regions of autism spectrum disorders were significantly decreased compared to those in the control group.
n-acetylaspartate	chemical_to_disease	autism spectrum disorders	1	0	25817280	PMID:25817280; Original text:The concentrations of N-acetylaspartate (NAA) in these regions of autism spectrum disorders were significantly decreased compared to those in the control group.
inferior frontal gyrus	anatomy	pars opercularis	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
inferior frontal gyrus	anatomy	of the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
inferior frontal gyrus	anatomy	the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
of the	anatomy	pars opercularis	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
frontal gyrus	anatomy	pars opercularis	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
of the inferior	anatomy	pars opercularis	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
pars opercularis	anatomy	the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
inferior frontal	anatomy	pars opercularis	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
of the	anatomy	of the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
of the	anatomy	the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
frontal gyrus	anatomy	of the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
frontal gyrus	anatomy	the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
of the inferior	anatomy	the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
inferior frontal	anatomy	of the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
autistic	disease_to_mechanism	hemoglobin	2	0	25817280|25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.|PMID:25817280; Original text:However, the concentrations of oxygenated hemoglobin in this area were significantly elevated in autistic subjects after they were trained to imitate emotional facial expressions.
autistic	disease_to_anatomy	inferior frontal gyrus	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
autistic	disease_to_anatomy	pars opercularis	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
autistic	disease_to_anatomy	frontal gyrus	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
autistic	disease_to_anatomy	of the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
autistic	disease_to_anatomy	the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	inferior frontal gyrus	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	pars opercularis	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	of the	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	frontal gyrus	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	of the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	inferior frontal	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
autistic	disease_to_anatomy	, main	1	0	29796237	PMID:29796237; Original text:In social relatedness and circumscribed interests, main effects of Diagnosis revealed that as expected, autistic adults reported significantly greater lifetime prevalence of symptoms in these domains; an effect of Sex, in circumscribed interests, also suggested that males generally reported more prevalent symptoms than females.
vitamin b6	chemical_to_disease	autism	1	0	16494569	PMID:16494569; Original text:Children with autism had a 75% higher level of total vitamin B6 than the controls (medians of 56 versus 32 ng/mL, respectively, p = 0.00002).
vitamin b6	chemical_to_anatomy	level of	1	0	16494569	PMID:16494569; Original text:Children with autism had a 75% higher level of total vitamin B6 than the controls (medians of 56 versus 32 ng/mL, respectively, p = 0.00002).
macrocephaly	disease_to_anatomy	, a	1	0	10382131	PMID:10382131; Original text:Macrocephaly (head circumference > 97th centile) was observed in 16.7% of the sample, a significantly higher proportion than that expected.
macrocephaly	disease_to_anatomy	of the	1	0	10382131	PMID:10382131; Original text:Macrocephaly (head circumference > 97th centile) was observed in 16.7% of the sample, a significantly higher proportion than that expected.
microcephaly	disease_to_anatomy	of the	1	0	10382131	PMID:10382131; Original text:Microcephaly (head circumference < 3rd centile) was also significantly raised and found in 15.1% of the sample.
medical	disease	microcephaly	1	0	10382131	PMID:10382131; Original text:Microcephaly was significantly associated with the presence of medical disorders.
and	chemical	androgens	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
asperger's syndromed.	disease	hyperandrogenism	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
asperger's syndromed	disease	asperger's syndromed.	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
asperger's syndromed	disease	hyperandrogenism	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
androgens	chemical_to_disease	asperger's syndromed.	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
androgens	chemical_to_disease	hyperandrogenism	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
androgens	chemical_to_disease	asperger's syndromed	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
and	chemical_to_disease	asperger's syndromed.	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
and	chemical_to_disease	hyperandrogenism	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
and	chemical_to_disease	asperger's syndromed	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
androgens	chemical_to_anatomy	of the	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
androgens	chemical_to_anatomy	, and	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
and	chemical_to_anatomy	of the	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
and	chemical_to_anatomy	, and	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
asperger's syndromed.	disease_to_anatomy	of the	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
asperger's syndromed.	disease_to_anatomy	, and	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
hyperandrogenism	disease_to_anatomy	of the	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
hyperandrogenism	disease_to_anatomy	, and	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
asperger's syndromed	disease_to_anatomy	of the	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
asperger's syndromed	disease_to_anatomy	, and	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
cholesterol	chemical	glucose	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
glucose	chemical	triglycerides	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
cholesterol	chemical	triglycerides	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
high-density lipoprotein cholesterol	mechanism	low-density lipoprotein cholesterol	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
glucose	chemical_to_disease	metabolic abnormalities	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
cholesterol	chemical_to_disease	metabolic abnormalities	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
triglycerides	chemical_to_disease	metabolic abnormalities	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
glucose	chemical_to_mechanism	low-density lipoprotein cholesterol	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
glucose	chemical_to_mechanism	high-density lipoprotein cholesterol	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
cholesterol	chemical_to_mechanism	low-density lipoprotein cholesterol	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
cholesterol	chemical_to_mechanism	high-density lipoprotein cholesterol	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
triglycerides	chemical_to_mechanism	low-density lipoprotein cholesterol	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
triglycerides	chemical_to_mechanism	high-density lipoprotein cholesterol	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
glucose	chemical_to_anatomy	, and	2	0	21813076|27126856	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.|PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
cholesterol	chemical_to_anatomy	, and	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
triglycerides	chemical_to_anatomy	, and	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
metabolic abnormalities	disease_to_mechanism	low-density lipoprotein cholesterol	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
metabolic abnormalities	disease_to_mechanism	high-density lipoprotein cholesterol	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
metabolic abnormalities	disease_to_anatomy	, and	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
low-density lipoprotein cholesterol	mechanism_to_anatomy	, and	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
high-density lipoprotein cholesterol	mechanism_to_anatomy	, and	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
autism	disease	pervasive developmental disorder	1	0	15083132	PMID:15083132; Original text:It is well tolerated without any significant side effects and is efficacious in children with autism and pervasive developmental disorder.
3	anatomy	and 3	1	0	23065117	PMID:23065117; Original text:The melodic based communication therapy group progressed significantly in number of verbal attempts after weeks 1 through 4 and number of correct words after weeks 1 and 3, while the traditional group progressed significantly after weeks 4 and 5.
chromosomes	anatomy	sex chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
, and	anatomy	sex chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
chromosome 15	anatomy	sex chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
chromosome	anatomy	sex chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
, and	anatomy	chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
chromosome 15	anatomy	chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
chromosome	anatomy	chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
, and	anatomy	chromosome 15	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
, and	anatomy	chromosome	2	0	11525418|23471985	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.|PMID:23471985; Original text:The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample.
chromosome	anatomy	chromosome 15	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
autism	disease_to_anatomy	sex chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
autism	disease_to_anatomy	chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
autism	disease_to_anatomy	chromosome 15	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
chromosomal abnormalities	disease_to_anatomy	sex chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
chromosomal abnormalities	disease_to_anatomy	chromosomes	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
chromosomal abnormalities	disease_to_anatomy	, and	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
chromosomal abnormalities	disease_to_anatomy	chromosome 15	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
chromosomal abnormalities	disease_to_anatomy	chromosome	1	0	11525418	PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
naa	chemical_to_disease	asd	1	0	22832731	PMID:22832731; Original text:Meta-regression analysis further revealed that the effect size of lower frontal NAA levels linearly declined with older mean age in ASD (n=844, P<0.05 Bonferroni-corrected).
naa	chemical_to_anatomy	of lower	1	0	22832731	PMID:22832731; Original text:Meta-regression analysis further revealed that the effect size of lower frontal NAA levels linearly declined with older mean age in ASD (n=844, P<0.05 Bonferroni-corrected).
asd	disease_to_anatomy	of lower	1	0	22832731	PMID:22832731; Original text:Meta-regression analysis further revealed that the effect size of lower frontal NAA levels linearly declined with older mean age in ASD (n=844, P<0.05 Bonferroni-corrected).
asd	disease	iron	1	0	29540271	PMID:29540271; Original text:However, the reciprocal comorbidity of disorder and ASD and iron levels/iron deficiency was significantly higher than in the children without these disorders.
iron	chemical_to_disease	asd	1	0	29540271	PMID:29540271; Original text:However, the reciprocal comorbidity of disorder and ASD and iron levels/iron deficiency was significantly higher than in the children without these disorders.
iron	chemical_to_disease	iron	2	0	29540271|17352947	PMID:29540271; Original text:However, the reciprocal comorbidity of disorder and ASD and iron levels/iron deficiency was significantly higher than in the children without these disorders.|PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	neurodevelopmental disorders	1	0	30658861	PMID:30658861; Original text:Attention-Deficit/Hyperactivity Disorder (Attention-Deficit/Hyperactivity Disorder) and Autism Spectrum Disorder (Autism Spectrum Disorder) are both neurodevelopmental disorders originating in childhood with high associated impairments and public health significance.
aripiprazole	chemical_to_mechanism	prolactin	1	0	24045605	PMID:24045605; Original text:Serum prolactin levels decreased significantly from 17.3 ± 9.4 ng/mL (aripiprazole) to 2.3 ± 1.7 ng/mL (end point).
vitamin d3	chemical_to_disease	autism	1	0	27868194	PMID:27868194; Original text:The autism symptoms of the children improved significantly, following 4-month vitamin D3 supplementation, but not in the placebo group.
oxygen	chemical_to_anatomy	contact	1	0	19284641	PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
oxygen	chemical_to_anatomy	, eye	1	0	19284641	PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
oxygen	chemical_to_anatomy	, and	1	0	19284641	PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
autism	disease_to_anatomy	contact	1	0	19284641	PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
autism	disease_to_anatomy	, eye	1	0	19284641	PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
stereotypy	disease_to_anatomy	(p	1	0	19284641	PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.
arbaclofen	chemical	mavoglurant	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
fmr1 promoter	mechanism	mglur5	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
fmr1 promoter	mechanism	gabab	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
gabab	mechanism	mglur5	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
arbaclofen	chemical_to_mechanism	fmr1 promoter	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
arbaclofen	chemical_to_mechanism	mglur5	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
arbaclofen	chemical_to_mechanism	gabab	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
mavoglurant	chemical_to_mechanism	fmr1 promoter	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
mavoglurant	chemical_to_mechanism	mglur5	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
mavoglurant	chemical_to_mechanism	gabab	1	0	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
anticonvulsants	disease	seizure	1	0	23666039	PMID:23666039; Original text:On this diet, while still continuing on anticonvulsants, she showed significant improvement in seizure activity.
autism	disease	pdd	2	0	9546298|9442997	PMID:9546298; Original text:Smaller, but still statistically significant effects on symptom severity were also found, though experimental subjects still met diagnostic criteria for autism or PDD.|PMID:9442997; Original text:A significant effect of informant was found for the PDD group, and this effect was particularly pronounced when children with autism were considered separately.
autism spectrum	disease	developmental	1	0	28762296	PMID:28762296; Original text:The link between nutrition and autism spectrum disorder (disorder), which is a complex developmental disorder manifesting itself in significant delays or deviation in interaction and communication, has provided a fresh point of view and signals that nutrition may have a role in the aetiology of disorder, as well as play an active role in treatment by alleviating symptoms.
dcs	chemical_to_disease	impaired	1	0	28138381	PMID:28138381; Original text:Study participants included 60 outpatient youth with disorder, ages 5-11 years, all with IQ above 70, and significantly impaired social functioning who completed a 10-week active treatment phase during which they received weekly single doses of 50 mg of DCS or placebo administered 30 min prior to group social skills training.
dcs	chemical_to_anatomy	, and	1	0	28138381	PMID:28138381; Original text:Study participants included 60 outpatient youth with disorder, ages 5-11 years, all with IQ above 70, and significantly impaired social functioning who completed a 10-week active treatment phase during which they received weekly single doses of 50 mg of DCS or placebo administered 30 min prior to group social skills training.
impaired	disease_to_anatomy	, and	1	0	28138381	PMID:28138381; Original text:Study participants included 60 outpatient youth with disorder, ages 5-11 years, all with IQ above 70, and significantly impaired social functioning who completed a 10-week active treatment phase during which they received weekly single doses of 50 mg of DCS or placebo administered 30 min prior to group social skills training.
autism	disease	pervasive developmental disorders	2	0	17885895|9813776	PMID:17885895; Original text:While both instruments have good psychometric properties, the results of this study suggest that clinicians and researchers should exercise caution when utilising the the Developmental Behaviour Checklist-Autism Screening Algorithm to screen for Pervasive Developmental Disorders in individuals with significant behaviour problems, as this could decrease its diagnostic validity.|PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
gastrointestinal symptoms	disease_to_anatomy	, gastrointestinal	1	0	20204691	PMID:20204691; Original text:Compared with placebo, treatment with enzyme was not associated with clinically significant improvement in behaviour, food variety, gastrointestinal symptoms, sleep quality, engagement with therapist, or the Language Development Survey Vocabulary or Sentence Complexity Scores.
eotaxin	mechanism	monocyte chemoattractant protein-1	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
monocyte	anatomy	of the	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
, 2	anatomy	of the	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
, 2	anatomy	monocyte	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
2 of	anatomy	monocyte	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
risperidone	chemical_to_mechanism	monocyte chemoattractant protein-1	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
risperidone	chemical_to_mechanism	eotaxin	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
risperidone	chemical_to_anatomy	monocyte	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
monocyte chemoattractant protein-1	mechanism_to_anatomy	of the	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
monocyte chemoattractant protein-1	mechanism_to_anatomy	monocyte	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
monocyte chemoattractant protein-1	mechanism_to_anatomy	, 2	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
monocyte chemoattractant protein-1	mechanism_to_anatomy	2 of	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
eotaxin	mechanism_to_anatomy	of the	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
eotaxin	mechanism_to_anatomy	monocyte	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
eotaxin	mechanism_to_anatomy	, 2	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
eotaxin	mechanism_to_anatomy	2 of	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
carnitine	nutrient	coenzyme q10	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	nutrient	folic acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	nutrient	folic acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical	epa	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
epa	chemical	vitamins a	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
epa	chemical	folic acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical	epa	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical	vitamins a	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical	folic acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical	dha	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical	coenzyme q10	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	chemical	vitamins a	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
dha	chemical	vitamins a	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical	vitamins a	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
dha	chemical	folic acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical	folic acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical	dha	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
, and	anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
, b2	anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	nutrient_to_chemical	epa	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	nutrient_to_chemical	coenzyme q10	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	nutrient_to_chemical	vitamins a	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	nutrient_to_chemical	folic acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	nutrient_to_chemical	dha	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	nutrient_to_chemical	carnitine	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	nutrient_to_chemical	epa	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	nutrient_to_chemical	coenzyme q10	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	nutrient_to_chemical	vitamins a	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	nutrient_to_chemical	folic acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	nutrient_to_chemical	dha	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	nutrient_to_chemical	epa	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	nutrient_to_chemical	coenzyme q10	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	nutrient_to_chemical	vitamins a	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	nutrient_to_chemical	folic acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	nutrient_to_chemical	dha	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	nutrient_to_chemical	carnitine	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	nutrient_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	nutrient_to_anatomy	, and	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	nutrient_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	nutrient_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	nutrient_to_anatomy	, and	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	nutrient_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	nutrient_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	nutrient_to_anatomy	, and	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	nutrient_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
epa	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
epa	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical_to_anatomy	, and	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
vitamins a	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
vitamins a	chemical_to_anatomy	, and	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
vitamins a	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	chemical_to_anatomy	, and	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
dha	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
dha	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
group (	anatomy	points	1	0	29562612	PMID:29562612; Original text:There was a significant improvement in nonverbal intellectual ability in the treatment group compared to the non-treatment group (+6.7 ± 11 IQ points vs. -0.6 ± 11 IQ points, p = 0.009) based on a blinded clinical assessment.
autistic disorder	disease	pddnos	1	0	10097993	PMID:10097993; Original text:Only a limited number of items from the ICD-10 and DSM-IV systems for autistic disorder significantly discriminated the PDDNOS group from other disorders.
polyols	chemical_to_disease	gi	1	0	33057858	PMID:33057858; Original text:At follow-up, the low polyols diet group had significant relief in some GI problems compared with both baseline in the group and control group.
autism spectrum disorders	disease_to_anatomy	is	1	0	22801412	PMID:22801412; Original text:The aim of this review is, therefore, to summarize some of these important new findings and highlight their potential significant translational value to the future of Autism Spectrum Disorders research.
autistic mannerisms	disease_to_anatomy	, and	1	0	30143950	PMID:30143950; Original text:The 14-week parent-assisted training significantly improved social skills knowledge and social functioning, and also reduced autistic mannerisms.
arsenic	chemical_to_anatomy	blood	1	0	31549506	PMID:31549506; Original text:In the following meta-analysis, we found statistically significant higher Inorganic arsenic concentrations, in hair and in blood, for children diagnosed with disorder compared with controls across studies.
pb	chemical_to_anatomy	, and	1	0	31549506	PMID:31549506; Original text:However, the findings on Pb exposure were inconsistent, with a significant association for hair Pb, no association for urinary Pb, and an inverse association for blood Pb.
seizures	disease	tuberous sclerosis	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
pervasive developmental disorders	disease	tuberous sclerosis	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
infantile spasms	disease	tuberous sclerosis	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
mental retardation	disease	tuberous sclerosis	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
pervasive developmental disorders	disease	seizures	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
autism	disease	seizures	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
infantile spasms	disease	seizures	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
mental retardation	disease	seizures	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
infantile spasms	disease	pervasive developmental disorders	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
mental retardation	disease	pervasive developmental disorders	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
autism	disease	infantile spasms	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
infantile spasms	disease	mental retardation	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
autistic disorders	disease	developmental disorders	1	0	21219265	PMID:21219265; Original text:The risk was highly significant when considering the strict definition of autistic disorders as opposed to the large definition of other pervasive developmental disorders.
ps128	chemical_to_disease	opposition/defiance behaviors	1	0	30979038	PMID:30979038; Original text:The results showed that PS128 ameliorated opposition/defiance behaviors, and that the total score of The Swanson, Nolan, and Pelham-IV-Taiwan version for younger children (aged 712) improved significantly compared with the placebo group.
ps128	chemical_to_anatomy	of the	1	0	30979038	PMID:30979038; Original text:The results showed that PS128 ameliorated opposition/defiance behaviors, and that the total score of The Swanson, Nolan, and Pelham-IV-Taiwan version for younger children (aged 712) improved significantly compared with the placebo group.
ps128	chemical_to_anatomy	, and	1	0	30979038	PMID:30979038; Original text:The results showed that PS128 ameliorated opposition/defiance behaviors, and that the total score of The Swanson, Nolan, and Pelham-IV-Taiwan version for younger children (aged 712) improved significantly compared with the placebo group.
opposition/defiance behaviors	disease_to_anatomy	of the	1	0	30979038	PMID:30979038; Original text:The results showed that PS128 ameliorated opposition/defiance behaviors, and that the total score of The Swanson, Nolan, and Pelham-IV-Taiwan version for younger children (aged 712) improved significantly compared with the placebo group.
opposition/defiance behaviors	disease_to_anatomy	, and	1	0	30979038	PMID:30979038; Original text:The results showed that PS128 ameliorated opposition/defiance behaviors, and that the total score of The Swanson, Nolan, and Pelham-IV-Taiwan version for younger children (aged 712) improved significantly compared with the placebo group.
25(oh)	chemical_to_anatomy	levels of	1	0	26514973	PMID:26514973; Original text:Levels of serum 25(OH)
, and	anatomy	region of	1	0	11803446	PMID:11803446; Original text:We also demonstrate appropriate criteria for this type of meta-analysis when the most significant study is included, and when that study is used to define a region of interest and then excluded.
metabolic disorders	disease_to_anatomy	of the	1	0	18079313	PMID:18079313; Original text:In some patients, early diagnosis of the metabolic disorders and proper therapeutic interventions may significantly improve the long-term cognitive and behavioral outcome.
, joint	anatomy	areas of	1	0	19365716	PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.
, and	anatomy	, joint	1	0	19365716	PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.
autism spectrum disorders	disease_to_anatomy	areas of	1	0	19365716	PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.
autism spectrum disorders	disease_to_anatomy	, joint	1	0	19365716	PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.
anxiety	disease_to_anatomy	areas of	1	0	19365716	PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.
anxiety	disease_to_anatomy	, joint	1	0	19365716	PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.
asds	disease	fragile x syndrome	1	0	30897358	PMID:30897358; Original text:fragile X syndrome and ASDs, while clinically and genetically distinct, share significant comorbidity, suggesting that there may be a common molecular and/or cellular basis, presumably at the synapse.
gaba	chemical	gaba+	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
cannabidiol	chemical	gaba+	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
cannabidiol	chemical	gaba	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
prefrontal cortex	anatomy	regions	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
gaba+	chemical_to_disease	asd	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
gaba	chemical_to_disease	asd	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
gaba+	chemical_to_anatomy	prefrontal cortex	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
gaba+	chemical_to_anatomy	regions	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
gaba	chemical_to_anatomy	prefrontal cortex	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
gaba	chemical_to_anatomy	regions	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
cannabidiol	chemical_to_anatomy	prefrontal cortex	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
cannabidiol	chemical_to_anatomy	regions	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
asd	disease_to_anatomy	regions	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
corticotropin-releasing factor	mechanism	neurotensin	1	0	25941080	PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
neurotensin	chemical_to_disease	autism	1	0	25941080	PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
neurotensin	chemical_to_mechanism	corticotropin-releasing factor	1	0	25941080	PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
autism	disease_to_mechanism	corticotropin-releasing factor	1	0	25941080	PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
autism	disease_to_mechanism	neurotensin	1	0	25941080	PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
asd	disease_to_mechanism	corticotropin-releasing factor	1	0	25941080	PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
casein	mechanism	gluten-	1	0	19917211	PMID:19917211; Original text:We also show highly significant decreases after introducing a gluten- and casein-free diet with a duration of more than 1 year.
and 2	anatomy	group (	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
2 of	anatomy	group (	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
2 of	anatomy	and 2	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
and 2	anatomy	group	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
(p	anatomy	2 of	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
2 of	anatomy	group	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
risperidone	chemical_to_anatomy	and 2	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
risperidone	chemical_to_anatomy	group	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
autism	disease_to_anatomy	and 2	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
autism	disease_to_anatomy	2 of	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
gaba	chemical	simvastatin	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
(i)	anatomy	white matter	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
i)	anatomy	white matter	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
(i	anatomy	white matter	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
simvastatin	chemical_to_anatomy	(i)	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
simvastatin	chemical_to_anatomy	white matter	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
simvastatin	chemical_to_anatomy	i)	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
simvastatin	chemical_to_anatomy	(i	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
gaba	chemical_to_anatomy	(i)	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
gaba	chemical_to_anatomy	white matter	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
gaba	chemical_to_anatomy	i)	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
gaba	chemical_to_anatomy	(i	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
of brain	anatomy	of the	1	0	25685703	PMID:25685703; Original text:The class probability estimates, P(ASD|fMRI data), from brain-based classifiers significantly correlated with scores on a measure of social functioning, the Social Responsiveness Scale (the Social Responsiveness Scale), as did the most informative features from 2 of the 3 sets of brain-based features.
2 of	anatomy	of brain	1	0	25685703	PMID:25685703; Original text:The class probability estimates, P(ASD|fMRI data), from brain-based classifiers significantly correlated with scores on a measure of social functioning, the Social Responsiveness Scale (the Social Responsiveness Scale), as did the most informative features from 2 of the 3 sets of brain-based features.
gut dysbiosis	disease	gut microbiome	1	0	31837704	PMID:31837704; Original text:More recent data, however, have shown that elevated salt consumption has a significant effect on the immune system and gut microbiome, often resulting in gut dysbiosis and induction of pro-inflammatory pathways.
gut microbiome	disease_to_anatomy	immune system	1	0	31837704	PMID:31837704; Original text:More recent data, however, have shown that elevated salt consumption has a significant effect on the immune system and gut microbiome, often resulting in gut dysbiosis and induction of pro-inflammatory pathways.
gut dysbiosis	disease_to_anatomy	immune system	1	0	31837704	PMID:31837704; Original text:More recent data, however, have shown that elevated salt consumption has a significant effect on the immune system and gut microbiome, often resulting in gut dysbiosis and induction of pro-inflammatory pathways.
riluzole	chemical_to_anatomy	, and	1	0	23821414	PMID:23821414; Original text:Forty-nine patients were enrolled in the study, and forty children completed the trial (dropouts: placebo = 4, riluzole = 5).
riluzole	chemical_to_anatomy	4	1	0	23821414	PMID:23821414; Original text:Forty-nine patients were enrolled in the study, and forty children completed the trial (dropouts: placebo = 4, riluzole = 5).
riluzole	chemical_to_disease	irritability	1	0	23821414	PMID:23821414; Original text:A significantly greater improvement in the study primary outcome (the ABC-C irritability subscale score) was achieved by the riluzole-treated children compared with the placebo group (P = 0.03).
riluzole	chemical_to_anatomy	group (	1	0	23821414	PMID:23821414; Original text:A significantly greater improvement in the study primary outcome (the ABC-C irritability subscale score) was achieved by the riluzole-treated children compared with the placebo group (P = 0.03).
riluzole	chemical_to_anatomy	(p	1	0	23821414	PMID:23821414; Original text:A significantly greater improvement in the study primary outcome (the ABC-C irritability subscale score) was achieved by the riluzole-treated children compared with the placebo group (P = 0.03).
riluzole	chemical_to_disease	increases	1	0	23821414	PMID:23821414; Original text:Children in the riluzole group experienced significantly more increases in their appetite and bodyweight than children in the placebo group by the end of the study.
riluzole	chemical_to_anatomy	of the	1	0	23821414	PMID:23821414; Original text:Children in the riluzole group experienced significantly more increases in their appetite and bodyweight than children in the placebo group by the end of the study.
riluzole	chemical_to_anatomy	end of	1	0	23821414	PMID:23821414; Original text:Children in the riluzole group experienced significantly more increases in their appetite and bodyweight than children in the placebo group by the end of the study.
increases	disease_to_anatomy	of the	1	0	23821414	PMID:23821414; Original text:Children in the riluzole group experienced significantly more increases in their appetite and bodyweight than children in the placebo group by the end of the study.
increases	disease_to_anatomy	end of	1	0	23821414	PMID:23821414; Original text:Children in the riluzole group experienced significantly more increases in their appetite and bodyweight than children in the placebo group by the end of the study.
3,4	chemical_to_anatomy	group (	1	0	30196397	PMID:30196397; Original text:Improvement in LSAS scores from baseline to the primary endpoint was significantly greater for 3,4-methylenedioxymethamphetamine group compared to the placebo group (P = 0.037), and placebo-subtracted Cohen's d effect size was very large (d = 1.4, CI - 0.074, 2.874).
3,4	chemical_to_anatomy	, and	1	0	30196397	PMID:30196397; Original text:Improvement in LSAS scores from baseline to the primary endpoint was significantly greater for 3,4-methylenedioxymethamphetamine group compared to the placebo group (P = 0.037), and placebo-subtracted Cohen's d effect size was very large (d = 1.4, CI - 0.074, 2.874).
3,4	chemical_to_anatomy	(p	1	0	30196397	PMID:30196397; Original text:Improvement in LSAS scores from baseline to the primary endpoint was significantly greater for 3,4-methylenedioxymethamphetamine group compared to the placebo group (P = 0.037), and placebo-subtracted Cohen's d effect size was very large (d = 1.4, CI - 0.074, 2.874).
, z	anatomy	points	1	0	24652601	PMID:24652601; Original text:0.22 to 1.29 points, Z = 2.75, P < 0.006, four studies, N = 105)
pulmonary hypertension	disease	spontaneous abortion	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
preterm birth	disease	spontaneous abortion	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease	spontaneous abortion	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
low birth weight	disease	spontaneous abortion	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
autism spectrum disorders	disease	spontaneous abortion	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
preterm birth	disease	pulmonary hypertension	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease	pulmonary hypertension	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
low birth weight	disease	pulmonary hypertension	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
autism spectrum disorders	disease	pulmonary hypertension	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease	preterm birth	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
low birth weight	disease	preterm birth	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
autism spectrum disorders	disease	preterm birth	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease	low birth weight	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease	autism spectrum disorders	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
autism spectrum disorders	disease	low birth weight	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
of the	anatomy	pulmonary	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
, and	anatomy	pulmonary	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
spontaneous abortion	disease_to_anatomy	pulmonary	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
spontaneous abortion	disease_to_anatomy	of the	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
spontaneous abortion	disease_to_anatomy	, and	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
pulmonary hypertension	disease_to_anatomy	pulmonary	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
pulmonary hypertension	disease_to_anatomy	of the	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
pulmonary hypertension	disease_to_anatomy	, and	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
preterm birth	disease_to_anatomy	pulmonary	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
preterm birth	disease_to_anatomy	of the	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
preterm birth	disease_to_anatomy	, and	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease_to_anatomy	pulmonary	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease_to_anatomy	of the	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
low birth weight	disease_to_anatomy	pulmonary	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
low birth weight	disease_to_anatomy	of the	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
low birth weight	disease_to_anatomy	, and	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
autism spectrum disorders	disease_to_anatomy	pulmonary	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
oxytocin	chemical_to_disease	psychiatric	1	0	26094200	"PMID:26094200; Original text:

It was brought to the authors' attention that there were several significant data analytic errors linked to the data entry and the software program that was used in the published meta-analysis comparing the effect of intranasal oxytocin versus placebo administration on psychiatric symptoms."
psychiatric	disease_to_mechanism	oxytocin	1	0	26094200	"PMID:26094200; Original text:

It was brought to the authors' attention that there were several significant data analytic errors linked to the data entry and the software program that was used in the published meta-analysis comparing the effect of intranasal oxytocin versus placebo administration on psychiatric symptoms."
pdd	disease_to_anatomy	, and	1	0	9442997	PMID:9442997; Original text:A significant effect of informant was found for the PDD group, and this effect was particularly pronounced when children with autism were considered separately.
pdd	disease_to_anatomy	group	1	0	9442997	PMID:9442997; Original text:A significant effect of informant was found for the PDD group, and this effect was particularly pronounced when children with autism were considered separately.
autism	disease	emotional and behavioral difficulties	1	0	28864836	PMID:28864836; Original text:Results showed that parents who attributed their child's autism to environmental factors, experienced emotional upset or confusion about autism, or perceived the condition to be pervasive or burdensome, were more likely to reported clinically significant emotional and behavioral difficulties.
autism	disease	emotional	1	0	28864836	PMID:28864836; Original text:Results showed that parents who attributed their child's autism to environmental factors, experienced emotional upset or confusion about autism, or perceived the condition to be pervasive or burdensome, were more likely to reported clinically significant emotional and behavioral difficulties.
emotional	disease	emotional and behavioral difficulties	1	0	28864836	PMID:28864836; Original text:Results showed that parents who attributed their child's autism to environmental factors, experienced emotional upset or confusion about autism, or perceived the condition to be pervasive or burdensome, were more likely to reported clinically significant emotional and behavioral difficulties.
pregnenolone	chemical_to_disease	irritability	1	0	32947424	PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
pregnenolone	chemical_to_disease	stereotypy	1	0	32947424	PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
pregnenolone	chemical_to_disease	hyperactivity	1	0	32947424	PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
pregnenolone	chemical_to_anatomy	of the	1	0	32947424	PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
pregnenolone	chemical_to_anatomy	, and	1	0	32947424	PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
autistic symptoms	disease_to_anatomy	group	1	0	23874533	PMID:23874533; Original text:The results show that the experimental group demonstrated significantly greater improvement in self-control than the control group, which concurs with the parental reports of reduced autistic symptoms and increased control of temper and behaviors.
vitamin d	chemical_to_anatomy	levels of	1	0	32966919	PMID:32966919; Original text:Serum levels of 25(25-hydroxyvitamin)D increased significantly in the vitamin D group (P = 0.001).
vitamin d	chemical_to_anatomy	group (	3	0	32966919|33383952|33383952	PMID:32966919; Original text:Serum levels of 25(25-hydroxyvitamin)D increased significantly in the vitamin D group (P = 0.001).|PMID:33383952; Original text:Meta-analysis of 24 case-control studies demonstrated that children and adolescents with disorder had significantly lower vitamin D concentration than that of the control group (mean difference (MD): -7.46 ng/mL, 95% confidence interval (95% confidence interval): -10.26; -4.66 ng/mL, p < 0.0001, I = 98%).|PMID:33383952; Original text:Furthermore, meta-analysis of maternal and neonatal vitamin D showed a trend of decreased early-life vitamin D concentration in the disorder group (MD: -3.15, 95% 95% confidence interval: -6.57; 0.26, p = 0.07, I = 99%).
vitamin d	chemical_to_anatomy	(p	1	0	32966919	PMID:32966919; Original text:Serum levels of 25(25-hydroxyvitamin)D increased significantly in the vitamin D group (P = 0.001).
gastrointestinal symptoms	disease	pervasive developmental disorder	1	0	11459079	PMID:11459079; Original text:We studied 9 Caucasian boys, 3.8-8.1 years old, with a DSM-IV diagnosis of a pervasive developmental disorder, living with their families, receiving no chronic medications, and without significant gastrointestinal symptoms.
gastrointestinal symptoms	disease_to_anatomy	, and	1	0	11459079	PMID:11459079; Original text:We studied 9 Caucasian boys, 3.8-8.1 years old, with a DSM-IV diagnosis of a pervasive developmental disorder, living with their families, receiving no chronic medications, and without significant gastrointestinal symptoms.
of the	anatomy	prefrontal cortex	1	0	34018333	PMID:34018333; Original text:Our results show that activation of the the ventromedial prefrontal cortex with anodal Transcranial direct current stimulation significantly improved mind in children with disorder compared with both, r-temporoparietal junction Transcranial direct current stimulation, and sham stimulation.
prefrontal cortex	anatomy	ventromedial prefrontal	2	0	34018333|34018333	PMID:34018333; Original text:Our results show that activation of the the ventromedial prefrontal cortex with anodal Transcranial direct current stimulation significantly improved mind in children with disorder compared with both, r-temporoparietal junction Transcranial direct current stimulation, and sham stimulation.|PMID:34018333; Original text:Specifically, precursors of mind (e.g., emotion recognition, perception, and imitation) and elementary mind skills (e.g., first-order mental state reasoning) were significantly improved by anodal the ventromedial prefrontal cortex Transcranial direct current stimulation.
prefrontal cortex	anatomy	ventromedial prefrontal cortex	2	0	34018333|34018333	PMID:34018333; Original text:Our results show that activation of the the ventromedial prefrontal cortex with anodal Transcranial direct current stimulation significantly improved mind in children with disorder compared with both, r-temporoparietal junction Transcranial direct current stimulation, and sham stimulation.|PMID:34018333; Original text:Specifically, precursors of mind (e.g., emotion recognition, perception, and imitation) and elementary mind skills (e.g., first-order mental state reasoning) were significantly improved by anodal the ventromedial prefrontal cortex Transcranial direct current stimulation.
of the	anatomy	ventromedial prefrontal	1	0	34018333	PMID:34018333; Original text:Our results show that activation of the the ventromedial prefrontal cortex with anodal Transcranial direct current stimulation significantly improved mind in children with disorder compared with both, r-temporoparietal junction Transcranial direct current stimulation, and sham stimulation.
of the	anatomy	ventromedial prefrontal cortex	1	0	34018333	PMID:34018333; Original text:Our results show that activation of the the ventromedial prefrontal cortex with anodal Transcranial direct current stimulation significantly improved mind in children with disorder compared with both, r-temporoparietal junction Transcranial direct current stimulation, and sham stimulation.
ventromedial prefrontal	anatomy	ventromedial prefrontal cortex	2	0	34018333|34018333	PMID:34018333; Original text:Our results show that activation of the the ventromedial prefrontal cortex with anodal Transcranial direct current stimulation significantly improved mind in children with disorder compared with both, r-temporoparietal junction Transcranial direct current stimulation, and sham stimulation.|PMID:34018333; Original text:Specifically, precursors of mind (e.g., emotion recognition, perception, and imitation) and elementary mind skills (e.g., first-order mental state reasoning) were significantly improved by anodal the ventromedial prefrontal cortex Transcranial direct current stimulation.
, and	anatomy	ventromedial prefrontal	2	0	34018333|34018333	PMID:34018333; Original text:Our results show that activation of the the ventromedial prefrontal cortex with anodal Transcranial direct current stimulation significantly improved mind in children with disorder compared with both, r-temporoparietal junction Transcranial direct current stimulation, and sham stimulation.|PMID:34018333; Original text:Specifically, precursors of mind (e.g., emotion recognition, perception, and imitation) and elementary mind skills (e.g., first-order mental state reasoning) were significantly improved by anodal the ventromedial prefrontal cortex Transcranial direct current stimulation.
, and	anatomy	ventromedial prefrontal cortex	2	0	34018333|34018333	PMID:34018333; Original text:Our results show that activation of the the ventromedial prefrontal cortex with anodal Transcranial direct current stimulation significantly improved mind in children with disorder compared with both, r-temporoparietal junction Transcranial direct current stimulation, and sham stimulation.|PMID:34018333; Original text:Specifically, precursors of mind (e.g., emotion recognition, perception, and imitation) and elementary mind skills (e.g., first-order mental state reasoning) were significantly improved by anodal the ventromedial prefrontal cortex Transcranial direct current stimulation.
, first	anatomy	prefrontal cortex	1	0	34018333	PMID:34018333; Original text:Specifically, precursors of mind (e.g., emotion recognition, perception, and imitation) and elementary mind skills (e.g., first-order mental state reasoning) were significantly improved by anodal the ventromedial prefrontal cortex Transcranial direct current stimulation.
, first	anatomy	ventromedial prefrontal	1	0	34018333	PMID:34018333; Original text:Specifically, precursors of mind (e.g., emotion recognition, perception, and imitation) and elementary mind skills (e.g., first-order mental state reasoning) were significantly improved by anodal the ventromedial prefrontal cortex Transcranial direct current stimulation.
, first	anatomy	ventromedial prefrontal cortex	1	0	34018333	PMID:34018333; Original text:Specifically, precursors of mind (e.g., emotion recognition, perception, and imitation) and elementary mind skills (e.g., first-order mental state reasoning) were significantly improved by anodal the ventromedial prefrontal cortex Transcranial direct current stimulation.
, and	anatomy	, first	1	0	34018333	PMID:34018333; Original text:Specifically, precursors of mind (e.g., emotion recognition, perception, and imitation) and elementary mind skills (e.g., first-order mental state reasoning) were significantly improved by anodal the ventromedial prefrontal cortex Transcranial direct current stimulation.
homocysteine	chemical_to_anatomy	peripheral blood	1	0	32763544	PMID:32763544; Original text:The pooled results showed that the peripheral blood homocysteine levels were significantly elevated in children with disorder when compared to healthy controls (Hedges's g = 0.56, 95% CI = 0.36 to 0.76, P < 0.001).
developmentally	disease	seizure	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
developmentally	disease	epileptic	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
developmentally	disease	epilepsy	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
epileptic	disease	seizure	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
epilepsy	disease	seizure	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
epilepsy	disease	epileptic	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
bacteria	bacteria_to_anatomy	of the	1	0	24441420	PMID:24441420; Original text:The most significant changes being introduced with the DSM-5 are highlighted, as well as some of the concerns that will be a focus of attention with respect to the potential impacts going forward.
of eye	anatomy	of the	1	0	19538990	PMID:19538990; Original text:An atypical pattern of eye contact behaviour is one of the most significant symptoms of Autism Spectrum Disorder (Autism Spectrum Disorder).
autism spectrum disorder	disease_to_anatomy	of eye	1	0	19538990	PMID:19538990; Original text:An atypical pattern of eye contact behaviour is one of the most significant symptoms of Autism Spectrum Disorder (Autism Spectrum Disorder).
region	anatomy	the brain	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
basal ganglia	anatomy	the brain	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
parietal	anatomy	the brain	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
the brain	anatomy	the lateral	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
ganglia	anatomy	the brain	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
temporal	anatomy	the brain	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
temporal lobe	anatomy	the brain	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
occipital lobe	anatomy	the brain	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
lobe	anatomy	the brain	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
basal ganglia	anatomy	region	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
parietal	anatomy	region	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
, and	anatomy	region	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
region	anatomy	the lateral	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
ganglia	anatomy	region	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
region	anatomy	temporal	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
region	anatomy	temporal lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
occipital lobe	anatomy	region	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
lobe	anatomy	region	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
basal ganglia	anatomy	parietal	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
, and	anatomy	basal ganglia	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
basal ganglia	anatomy	the lateral	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
basal ganglia	anatomy	ganglia	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
basal ganglia	anatomy	temporal	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
basal ganglia	anatomy	temporal lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
basal ganglia	anatomy	occipital lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
basal ganglia	anatomy	lobe	2	0	21692142|20969835	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.|PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
ganglia	anatomy	parietal	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
parietal	anatomy	temporal lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
occipital lobe	anatomy	parietal	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
lobe	anatomy	parietal	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
, and	anatomy	ganglia	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
, and	anatomy	temporal lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
, and	anatomy	occipital lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
, and	anatomy	lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
ganglia	anatomy	the lateral	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
temporal	anatomy	the lateral	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
temporal lobe	anatomy	the lateral	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
occipital lobe	anatomy	the lateral	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
lobe	anatomy	the lateral	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
ganglia	anatomy	temporal	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
ganglia	anatomy	temporal lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
ganglia	anatomy	occipital lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
ganglia	anatomy	lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
temporal	anatomy	temporal lobe	2	0	21692142|24374754	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.|PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
occipital lobe	anatomy	temporal	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
lobe	anatomy	temporal	2	0	21692142|24374754	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.|PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
occipital lobe	anatomy	temporal lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
lobe	anatomy	temporal lobe	2	0	21692142|24374754	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.|PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
lobe	anatomy	occipital lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
asd	disease_to_anatomy	region	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
asd	disease_to_anatomy	basal ganglia	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
asd	disease_to_anatomy	parietal	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
asd	disease_to_anatomy	the lateral	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
asd	disease_to_anatomy	ganglia	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
asd	disease_to_anatomy	temporal	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
asd	disease_to_anatomy	temporal lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
asd	disease_to_anatomy	occipital lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
asd	disease_to_anatomy	lobe	1	0	21692142	PMID:21692142; Original text:We found six significant clusters of convergence indicating disturbances in the brain structure of ASD patients, including the lateral occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate to the right parietal operculum.
copper	nutrient_to_disease	autistic	1	0	34049201	PMID:34049201; Original text:There were significant differences in the levels of copper (copper) in the hair and serum between autistic children and the control group.
copper	chemical_to_disease	autistic	1	0	34049201	PMID:34049201; Original text:There were significant differences in the levels of copper (copper) in the hair and serum between autistic children and the control group.
behavioral impairments	disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease	neurofunctional impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease	behavioral impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease	behavioral impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease	extended selective attention	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neurofunctional impairments	disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease	neurofunctional impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease	neurofunctional impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease	neurofunctional impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease	autism	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease	extended selective attention	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease	extended selective attention	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
of primary	anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
of primary	anatomy	of the	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
of primary	anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
of primary	anatomy	temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	anatomy	of the	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	anatomy	temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
of temporal	anatomy	of the	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
of temporal	anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
of temporal	anatomy	temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_disease	behavioral impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_disease	neurofunctional impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_disease	asociality	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_disease	extended selective attention	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_anatomy	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease_to_mechanism	oxytocin	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	disease_to_mechanism	oxytocin	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neurofunctional impairments	disease_to_mechanism	oxytocin	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease_to_mechanism	oxytocin	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease_to_mechanism	oxytocin	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease_to_anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease_to_anatomy	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease_to_anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease_to_anatomy	of the	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease_to_anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease_to_anatomy	temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	disease_to_anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	disease_to_anatomy	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	disease_to_anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	disease_to_anatomy	of the	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	disease_to_anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	disease_to_anatomy	temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neurofunctional impairments	disease_to_anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neurofunctional impairments	disease_to_anatomy	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neurofunctional impairments	disease_to_anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neurofunctional impairments	disease_to_anatomy	of the	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neurofunctional impairments	disease_to_anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neurofunctional impairments	disease_to_anatomy	temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease_to_anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease_to_anatomy	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease_to_anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease_to_anatomy	of the	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease_to_anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease_to_anatomy	temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease_to_anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease_to_anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease_to_anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease_to_anatomy	temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease_to_anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease_to_anatomy	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease_to_anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease_to_anatomy	of the	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease_to_anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease_to_anatomy	temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
dravet syndrome	disease	hunter syndrome	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
dravet syndrome	disease	motor delays	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
hunter syndrome	disease	motor delays	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
dravet syndrome	disease_to_mechanism	foxg1	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
hunter syndrome	disease_to_mechanism	foxg1	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
motor delays	disease_to_mechanism	foxg1	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
dravet syndrome	disease_to_anatomy	, a	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
dravet syndrome	disease_to_anatomy	of the	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
dravet syndrome	disease_to_anatomy	(p	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
dravet syndrome	disease_to_anatomy	, and	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
hunter syndrome	disease_to_anatomy	, a	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
hunter syndrome	disease_to_anatomy	of the	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
hunter syndrome	disease_to_anatomy	(p	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
hunter syndrome	disease_to_anatomy	, and	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
motor delays	disease_to_anatomy	, a	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
motor delays	disease_to_anatomy	of the	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
motor delays	disease_to_anatomy	(p	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
motor delays	disease_to_anatomy	, and	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
foxg1	mechanism_to_anatomy	, a	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
foxg1	mechanism_to_anatomy	of the	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
foxg1	mechanism_to_anatomy	(p	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
foxg1	mechanism_to_anatomy	, and	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
asd	disease	intellectual disability	1	0	28036350	PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.
developmental disorders	disease	intellectual disability	1	0	28036350	PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.
asd	disease	developmental disorders	1	0	28036350	PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.
intellectual disability	disease_to_anatomy	of the	1	0	28036350	PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.
developmental disorders	disease_to_anatomy	of the	1	0	28036350	PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.
, joint	anatomy	, motor	1	0	31703073	PMID:31703073; Original text:A significant improvement was noted in child distress (SMD = 0.55), communication (SMD = 0.23), expressive language (SMD = 0.47), joint engagement (SMD = 0.63), motor skills (SMD = 0.25), parental distress (SMD = 0.33) parental self-efficacy (SMD = 0.42) parent-child relationship (SMD = 0.67) repetitive behaviors (SMD = 0.33), self-regulation (SMD = 0.54), social skills (SMD = 0.53) symptom severity (SMD = 0.44) and visual reception (SMD = 0.29).
repetitive behaviors	disease_to_anatomy	, joint	1	0	31703073	PMID:31703073; Original text:A significant improvement was noted in child distress (SMD = 0.55), communication (SMD = 0.23), expressive language (SMD = 0.47), joint engagement (SMD = 0.63), motor skills (SMD = 0.25), parental distress (SMD = 0.33) parental self-efficacy (SMD = 0.42) parent-child relationship (SMD = 0.67) repetitive behaviors (SMD = 0.33), self-regulation (SMD = 0.54), social skills (SMD = 0.53) symptom severity (SMD = 0.44) and visual reception (SMD = 0.29).
repetitive behaviors	disease_to_anatomy	, motor	1	0	31703073	PMID:31703073; Original text:A significant improvement was noted in child distress (SMD = 0.55), communication (SMD = 0.23), expressive language (SMD = 0.47), joint engagement (SMD = 0.63), motor skills (SMD = 0.25), parental distress (SMD = 0.33) parental self-efficacy (SMD = 0.42) parent-child relationship (SMD = 0.67) repetitive behaviors (SMD = 0.33), self-regulation (SMD = 0.54), social skills (SMD = 0.53) symptom severity (SMD = 0.44) and visual reception (SMD = 0.29).
area	anatomy	cortex	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
cortex	anatomy	prefrontal cortex	2	0	24374754|22457638	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).|PMID:22457638; Original text:Genes regulating cell cycle also exhibited autism-specific number variations in DNA derived from prefrontal cortex, and these genes were significantly associated with autism in genome-wide association study datasets.
cortex	anatomy	temporal lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's	anatomy	cortex	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
's area	anatomy	cortex	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
cortex	anatomy	temporal	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's area	anatomy	cortex	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
cortex	anatomy	lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
area	anatomy	prefrontal cortex	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
area	anatomy	temporal lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
area	anatomy	broca's	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
's area	anatomy	area	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
area	anatomy	temporal	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
area	anatomy	broca's area	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
area	anatomy	lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
prefrontal cortex	anatomy	temporal lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's	anatomy	prefrontal cortex	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
's area	anatomy	prefrontal cortex	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's area	anatomy	prefrontal cortex	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
lobe	anatomy	prefrontal cortex	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's	anatomy	temporal lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
's area	anatomy	temporal lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's area	anatomy	temporal lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
's area	anatomy	broca's	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's	anatomy	temporal	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's	anatomy	broca's area	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's	anatomy	lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
's area	anatomy	temporal	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
's area	anatomy	broca's area	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
's area	anatomy	lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's area	anatomy	temporal	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
broca's area	anatomy	lobe	1	0	24374754	PMID:24374754; Original text:Specifically, significant differences in the ratios of regional cerebral blood flow and global cerebral blood flow before (Fb) and after (Fe) EA treatment in different lesions were observed (in the left prefrontal cortex, t=5.01, P<0.01; in the right prefrontal cortex, t=2.32, P<0.05; in the left temporal lobe, t=4.54, P<0.01; in the right temporal lobe, t=2.90, P<0.05; in the left Broca's area, t=5.82, P<0.01).
attention-deficit/hyperactivity disorder	disease	cerebral palsy	1	0	30446273	PMID:30446273; Original text:Assessing the occurrence of ASD and Attention-Deficit/Hyperactivity Disorder would improve the significant cost of healthcare, therapies, and overall daily living for families with children affected by Cerebral Palsy.
asd	disease	cerebral palsy	1	0	30446273	PMID:30446273; Original text:Assessing the occurrence of ASD and Attention-Deficit/Hyperactivity Disorder would improve the significant cost of healthcare, therapies, and overall daily living for families with children affected by Cerebral Palsy.
asd	disease	attention-deficit/hyperactivity disorder	1	0	30446273	PMID:30446273; Original text:Assessing the occurrence of ASD and Attention-Deficit/Hyperactivity Disorder would improve the significant cost of healthcare, therapies, and overall daily living for families with children affected by Cerebral Palsy.
cerebral palsy	disease_to_anatomy	, and	1	0	30446273	PMID:30446273; Original text:Assessing the occurrence of ASD and Attention-Deficit/Hyperactivity Disorder would improve the significant cost of healthcare, therapies, and overall daily living for families with children affected by Cerebral Palsy.
oxytocin	chemical_to_disease	fear	1	0	28467893	PMID:28467893; Original text:A single dose of intranasal oxytocin significantly improved the recognition of basic emotions, particularly fear, and increased the expression of positive emotions among the healthy individuals.
fear	disease_to_mechanism	oxytocin	1	0	28467893	PMID:28467893; Original text:A single dose of intranasal oxytocin significantly improved the recognition of basic emotions, particularly fear, and increased the expression of positive emotions among the healthy individuals.
fear	disease_to_anatomy	, and	1	0	28467893	PMID:28467893; Original text:A single dose of intranasal oxytocin significantly improved the recognition of basic emotions, particularly fear, and increased the expression of positive emotions among the healthy individuals.
asd	disease_to_mechanism	cntnap2 gene	1	0	26559825	PMID:26559825; Original text:Overall, including case-control, sibs, and meta-analysis, we could not detect any significant association with the CNTNAP2 gene and high functioning ASD.
cntnap2 gene	mechanism_to_anatomy	, and	1	0	26559825	PMID:26559825; Original text:Overall, including case-control, sibs, and meta-analysis, we could not detect any significant association with the CNTNAP2 gene and high functioning ASD.
asd	disease	neurodevelopmental disorders	1	0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
intellectual delays	disease	neurodevelopmental disorders	1	0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
asd	disease	intellectual delays	1	0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
neurodevelopmental disorders	disease_to_mechanism	cntnap2	1	0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
asd	disease_to_mechanism	cntnap2	1	0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
intellectual delays	disease_to_mechanism	cntnap2	1	0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
paracetamol	chemical_to_disease	patent ductus arteriosus	2	0	31985831|29624206	PMID:31985831; Original text:Two studies compared prophylactic administration of paracetamol for a the patent ductus arteriosus with placebo or no intervention in 80 infants.|PMID:29624206; Original text:Two studies compared prophylactic administration of paracetamol for a the patent ductus arteriosus with placebo or no intervention in 80 infants.
paracetamol	chemical_to_anatomy	ductus arteriosus	2	0	31985831|29624206	PMID:31985831; Original text:Two studies compared prophylactic administration of paracetamol for a the patent ductus arteriosus with placebo or no intervention in 80 infants.|PMID:29624206; Original text:Two studies compared prophylactic administration of paracetamol for a the patent ductus arteriosus with placebo or no intervention in 80 infants.
patent ductus arteriosus	disease_to_anatomy	ductus arteriosus	4	0	31985831|31985831|29624206|29624206	PMID:31985831; Original text:Two studies compared prophylactic administration of paracetamol for a the patent ductus arteriosus with placebo or no intervention in 80 infants.|PMID:31985831; Original text:There was no significant difference in the failure to close a the patent ductus arteriosus (typical typical risk ratio 0.96, 95% 95% confidence interval 0.55 to 1.65; I² = 11%; typical typical risk difference -0.01, 95% 95% confidence interval -0.09 to 0.08; I² = 17%) (low quality of evidence).|PMID:29624206; Original text:Two studies compared prophylactic administration of paracetamol for a the patent ductus arteriosus with placebo or no intervention in 80 infants.|PMID:29624206; Original text:There was no significant difference in the failure to close a the patent ductus arteriosus (typical typical risk ratio 0.96, 95% 95% confidence interval 0.55 to 1.65; I² = 11%; typical typical risk difference -0.01, 95% 95% confidence interval -0.09 to 0.08; I² = 17%) (low quality of evidence).
asperger's syndrome	disease	autistic disorders	1	0	9300193	PMID:9300193; Original text:Knowledge about the spectrum of autistic disorders, including Asperger's syndrome, has grown significantly.
glutathione	chemical_to_disease	autism spectrum	1	0	22129897	PMID:22129897; Original text:Recent evidence shows that subjects diagnosed with an autism spectrum disorder (disorder) have significantly lower levels of glutathione than typically developing children.
autism spectrum	disease_to_anatomy	levels of	1	0	22129897	PMID:22129897; Original text:Recent evidence shows that subjects diagnosed with an autism spectrum disorder (disorder) have significantly lower levels of glutathione than typically developing children.
cysteine	chemical	sulfate	1	0	22129897	PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
sulfate	chemical	taurine	1	0	22129897	PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
cysteine	chemical	taurine	1	0	22129897	PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
taurine	chemical_to_anatomy	, and	1	0	22129897	PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
cortex	anatomy	parietal cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
parietal cortex	anatomy	the cerebellum	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cerebellum	anatomy	parietal cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate cortex	anatomy	parietal cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate	anatomy	parietal cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
parietal	anatomy	parietal cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, a	anatomy	parietal cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, and	anatomy	parietal cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cingulate cortex	anatomy	parietal cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cortex	anatomy	the cerebellum	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cerebellum	anatomy	cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cortex	anatomy	parietal	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, a	anatomy	cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cerebellum	anatomy	the cerebellum	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate cortex	anatomy	the cerebellum	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate	anatomy	the cerebellum	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
parietal	anatomy	the cerebellum	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, a	anatomy	the cerebellum	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, and	anatomy	the cerebellum	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cingulate cortex	anatomy	the cerebellum	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cerebellum	anatomy	parietal	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, a	anatomy	cerebellum	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate cortex	anatomy	parietal	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, a	anatomy	anterior cingulate cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
anterior cingulate	anatomy	parietal	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, a	anatomy	anterior cingulate	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
cingulate cortex	anatomy	parietal	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
, a	anatomy	cingulate cortex	1	0	22426803	PMID:22426803; Original text:In addition, a significant decrease in NAA was evident across age categories in the parietal cortex, the cerebellum, and the anterior cingulate cortex.
major depressive disorder	disease	mdd	1	0	33130294	PMID:33130294; Original text:Two variants were significantly associated with ASD (rs9401458 and rs9401452) and one with major depressive disorder (MDD).
asd	disease	major depressive disorder	1	0	33130294	PMID:33130294; Original text:Two variants were significantly associated with ASD (rs9401458 and rs9401452) and one with major depressive disorder (MDD).
asd	disease	mdd	1	0	33130294	PMID:33130294; Original text:Two variants were significantly associated with ASD (rs9401458 and rs9401452) and one with major depressive disorder (MDD).
mental retardation	disease	schizophrenia	1	0	19736351	PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).
mental retardation	disease_to_anatomy	(p	1	0	19736351	PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).
schizophrenia	disease_to_anatomy	(p	1	0	19736351	PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).
dgcr6 genes	mechanism	prodh	1	0	19736351	PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
autism	disease_to_mechanism	dgcr6 genes	1	0	19736351	PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
autism	disease_to_mechanism	prodh	1	0	19736351	PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
dgcr6 genes	mechanism_to_anatomy	(p	1	0	19736351	PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
prodh	mechanism_to_anatomy	(p	1	0	19736351	PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
autistic spectrum disorder	disease	developmental regression	1	0	18956241	PMID:18956241; Original text:A significant proportion of children diagnosed with Autistic Spectrum Disorder experience a developmental regression characterized by a loss of previously-acquired skills.
behavioral abnormalities	disease	psychosis	1	0	796586	PMID:796586; Original text:Childhood psychosis is a group of disorders characterized by numerous behavioral abnormalities, the most significant of which may well be in the area of language.
area of	anatomy	group of	1	0	796586	PMID:796586; Original text:Childhood psychosis is a group of disorders characterized by numerous behavioral abnormalities, the most significant of which may well be in the area of language.
behavioral abnormalities	disease_to_anatomy	area of	1	0	796586	PMID:796586; Original text:Childhood psychosis is a group of disorders characterized by numerous behavioral abnormalities, the most significant of which may well be in the area of language.
behavioral abnormalities	disease_to_anatomy	group of	1	0	796586	PMID:796586; Original text:Childhood psychosis is a group of disorders characterized by numerous behavioral abnormalities, the most significant of which may well be in the area of language.
psychosis	disease_to_anatomy	area of	1	0	796586	PMID:796586; Original text:Childhood psychosis is a group of disorders characterized by numerous behavioral abnormalities, the most significant of which may well be in the area of language.
psychosis	disease_to_anatomy	group of	1	0	796586	PMID:796586; Original text:Childhood psychosis is a group of disorders characterized by numerous behavioral abnormalities, the most significant of which may well be in the area of language.
, and	anatomy	chromosome 11	1	0	23471985	PMID:23471985; Original text:The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample.
chromosome	anatomy	chromosome 11	1	0	23471985	PMID:23471985; Original text:The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample.
spon1 variant	mechanism_to_anatomy	chromosome 11	1	0	23471985	PMID:23471985; Original text:The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample.
spon1 variant	mechanism_to_anatomy	, and	1	0	23471985	PMID:23471985; Original text:The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample.
spon1 variant	mechanism_to_anatomy	chromosome	1	0	23471985	PMID:23471985; Original text:The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample.
, sex	anatomy	and body	1	0	25580916	PMID:25580916; Original text:Baseline characteristics including age, sex and body weight, as well as baseline scores in 5 subscales did not demonstrate statistically significant difference between the 2 groups.
blood	mechanism	vascular endothelial growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism	blood neurotrophin-3	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism	brain-derived neurotrophic factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism	nerve growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism	vascular endothelial growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism	vascular endothelial growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism	brain-derived neurotrophic factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism	nerve growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism	nerve growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
peripheral blood	anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
, nerve	anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
endothelial	anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
of brain	anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
, nerve	anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
endothelial	anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
levels of	anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
, nerve	anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
, nerve	anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
endothelial	anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
, nerve	anatomy	endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	vascular endothelial growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	vegf	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	blood neurotrophin-3	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	brain-derived neurotrophic factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	nerve growth factor	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_anatomy	endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism_to_anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism_to_anatomy	endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism	disease_to_anatomy	areas of	1	0	29726269	PMID:29726269; Original text:Between baseline and posttreatment, children showed significant gains in most areas of intellectual functioning and a significant decrease of autism symptom severity, but no change in adaptive behavior.
autism spectrum disorders	disease_to_anatomy	the brain	1	0	15749245	PMID:15749245; Original text:Autism spectrum disorders affect behaviors that emerge at ages when typically developing children become increasingly social and communicative, but many lines of evidence suggest that the underlying alterations in the brain occur long before the period when symptoms become obvious.
adhd	disease	asd	1	0	28000020	PMID:28000020; Original text:The aim of the present narrative review was to explore if structural brain imaging studies may shed light on key brain areas that are linked to both ASD and ADHD symptoms and undergo significant changes during development.
adhd	disease_to_anatomy	of the	1	0	28000020	PMID:28000020; Original text:The aim of the present narrative review was to explore if structural brain imaging studies may shed light on key brain areas that are linked to both ASD and ADHD symptoms and undergo significant changes during development.
pregnenolone	chemical_to_disease	abc)-irritability	1	0	24849255	PMID:24849255; Original text:Pregnenolone yielded a statistically significant improvement in the primary measure, Aberrant Behavior Checklist (ABC)-Irritability [from 17.4 ± 7.4 at baseline to 11.2 ± 7.0 at 12 weeks (p = 0.028)].
pregnenolone	chemical_to_anatomy	(p	1	0	24849255	PMID:24849255; Original text:Pregnenolone yielded a statistically significant improvement in the primary measure, Aberrant Behavior Checklist (ABC)-Irritability [from 17.4 ± 7.4 at baseline to 11.2 ± 7.0 at 12 weeks (p = 0.028)].
abc)-irritability	disease_to_anatomy	(p	1	0	24849255	PMID:24849255; Original text:Pregnenolone yielded a statistically significant improvement in the primary measure, Aberrant Behavior Checklist (ABC)-Irritability [from 17.4 ± 7.4 at baseline to 11.2 ± 7.0 at 12 weeks (p = 0.028)].
fra(x	disease	mental retardation	1	0	3052070	"PMID:3052070; Original text:We examined 31 studies which investigated the association of fra(X) syndrome with either inherited mental retardation or ""autism"" and found that the conclusion of those researchers could be significantly affected by sample size."
autism	disease	fra(x	1	0	3052070	"PMID:3052070; Original text:We examined 31 studies which investigated the association of fra(X) syndrome with either inherited mental retardation or ""autism"" and found that the conclusion of those researchers could be significantly affected by sample size."
desulfovibrio	bacteria_to_chemical	p-cresol sulfate	1	0	33087514	PMID:33087514; Original text:Although not statistically significant, p-cresol sulfate was relatively higher in the disorder group at baseline, and after Microbiota transfer therapy, the levels decreased and were similar to levels in typically developing (TD) controls.
desulfovibrio	bacteria_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Although not statistically significant, p-cresol sulfate was relatively higher in the disorder group at baseline, and after Microbiota transfer therapy, the levels decreased and were similar to levels in typically developing (TD) controls.
p-cresol sulfate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Although not statistically significant, p-cresol sulfate was relatively higher in the disorder group at baseline, and after Microbiota transfer therapy, the levels decreased and were similar to levels in typically developing (TD) controls.
heptanoate	chemical	leucylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
leucylglycine	chemical	methylsuccinate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
leucylglycine	chemical	valylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical	leucylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	leucylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	leucylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
leucylglycine	chemical	nicotinamide riboside	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	leucylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
leucylglycine	chemical	sarcosine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	methylsuccinate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	valylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	imp	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	heptanoate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	heptanoate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	nicotinamide riboside	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	iminodiacetate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	sarcosine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
methylsuccinate	chemical	valylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical	methylsuccinate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	methylsuccinate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	methylsuccinate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
methylsuccinate	chemical	nicotinamide riboside	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	methylsuccinate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
methylsuccinate	chemical	sarcosine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical	valylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	valylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	valylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
nicotinamide riboside	chemical	valylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	valylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
sarcosine	chemical	valylglycine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	imp	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	imp	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical	nicotinamide riboside	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	imp	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical	sarcosine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	galactonate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	nicotinamide riboside	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	iminodiacetate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	sarcosine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	nicotinamide riboside	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	iminodiacetate	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	sarcosine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	nicotinamide riboside	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
nicotinamide riboside	chemical	sarcosine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	sarcosine	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
leucylglycine	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
methylsuccinate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
valylglycine	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
nicotinamide riboside	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
sarcosine	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
autism	disease	neurobiological disorder	1	0	33087514	PMID:33087514; Original text:Despite the prevalence of autism and its extensive impact on our society, no U. S. Food and Drug Administration-approved treatment is available for this complex neurobiological disorder.
propranolol	chemical_to_disease	autism	1	0	21487259	PMID:21487259; Original text:Propranolol significantly improved performance on category fluency, but not letter fluency among autism participants.
disorders of cognitive development	disease_to_anatomy	large	1	0	23582872	PMID:23582872; Original text:It is clear that statistically significant large, highly recurrent copy number variants across disorders of cognitive development are highly enriched for biological processes related to the synapse.
sleep	disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron deficiency	disease	sleep	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	disease	sleep	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	sleep	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
restless	disease	sleep	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron deficiency	disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
restless	disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	disease	iron deficiency	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	iron deficiency	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron deficiency	disease	restless	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	iron	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	disease	restless	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	restless	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	chemical_to_disease	sleep	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	chemical_to_disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	chemical_to_disease	iron deficiency	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	chemical_to_disease	autism spectrum disorder	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	chemical_to_disease	restless	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
ferritin	mechanism	hemoglobin	1	0	17352947	PMID:17352947; Original text:Mean ferritin increased significantly (16 microg/L to 29 microg/L), as did mean corpuscular volume and hemoglobin, suggesting that low ferritin in this patient group resulted from insufficient iron intake.
iron	chemical_to_mechanism	hemoglobin	1	0	17352947	PMID:17352947; Original text:Mean ferritin increased significantly (16 microg/L to 29 microg/L), as did mean corpuscular volume and hemoglobin, suggesting that low ferritin in this patient group resulted from insufficient iron intake.
iron	chemical_to_mechanism	ferritin	1	0	17352947	PMID:17352947; Original text:Mean ferritin increased significantly (16 microg/L to 29 microg/L), as did mean corpuscular volume and hemoglobin, suggesting that low ferritin in this patient group resulted from insufficient iron intake.
attention	disease	behavioral difficulties	1	0	31665323	"PMID:31665323; Original text:However, children of ""overtreated"" mothers displayed significantly more attention-deficit/hyperactivity disorder symptoms and behavioral difficulties than those of normal-normal gestational thyroid function mothers."
autistic spectrum disorder	disease	depression	1	0	31947912	PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
attention deficit hyperactivity disorder	disease	depression	1	0	31947912	PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
anxiety	disease	autistic spectrum disorder	1	0	31947912	PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
autism	disease_to_anatomy	cortex	1	0	22457638	PMID:22457638; Original text:Genes regulating cell cycle also exhibited autism-specific number variations in DNA derived from prefrontal cortex, and these genes were significantly associated with autism in genome-wide association study datasets.
autism	disease_to_anatomy	prefrontal cortex	1	0	22457638	PMID:22457638; Original text:Genes regulating cell cycle also exhibited autism-specific number variations in DNA derived from prefrontal cortex, and these genes were significantly associated with autism in genome-wide association study datasets.
schaaf-yang syndrome	disease_to_mechanism	magel2	1	0	32702813	PMID:32702813; Original text:We highly suggest that the MAGEL2 gene should be added to gene-panels or gene-filters in next-generation sequencing-based diagnostics, which is of great significance for early diagnosis and early intervention of Schaaf-Yang syndrome patients.
dmsa	chemical	glutathione	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
, and	anatomy	platelet	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
dmsa	chemical_to_disease	inflammation	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
glutathione	chemical_to_disease	inflammation	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
dmsa	chemical_to_anatomy	, and	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
dmsa	chemical_to_anatomy	platelet	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
glutathione	chemical_to_anatomy	platelet	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
inflammation	disease_to_anatomy	platelet	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
folinic acid	chemical_to_anatomy	group (	1	0	32387472	PMID:32387472; Original text:The global ADOS score and social interaction and communication sub scores were significantly improved at week 12 compared to baseline in the folinic acid group (P = 0.003, P = 0.004 and P = 0.022, respectively), but not in the placebo group (P = 0.574, P = 0.780, P = 0.269, respectively).
folinic acid	chemical_to_anatomy	(p	1	0	32387472	PMID:32387472; Original text:The global ADOS score and social interaction and communication sub scores were significantly improved at week 12 compared to baseline in the folinic acid group (P = 0.003, P = 0.004 and P = 0.022, respectively), but not in the placebo group (P = 0.574, P = 0.780, P = 0.269, respectively).
of the	anatomy	precentral gyrus	1	0	15652870	PMID:15652870; Original text:In a separate analysis, dorsolateral and medial frontal regions were significantly enlarged in patients aged 2 to 5 years compared with control subjects of the same age, but the precentral gyrus and orbital cortex were not.
, dorsolateral	anatomy	precentral gyrus	1	0	15652870	PMID:15652870; Original text:In a separate analysis, dorsolateral and medial frontal regions were significantly enlarged in patients aged 2 to 5 years compared with control subjects of the same age, but the precentral gyrus and orbital cortex were not.
medial frontal	anatomy	precentral gyrus	1	0	15652870	PMID:15652870; Original text:In a separate analysis, dorsolateral and medial frontal regions were significantly enlarged in patients aged 2 to 5 years compared with control subjects of the same age, but the precentral gyrus and orbital cortex were not.
orbital cortex	anatomy	precentral gyrus	1	0	15652870	PMID:15652870; Original text:In a separate analysis, dorsolateral and medial frontal regions were significantly enlarged in patients aged 2 to 5 years compared with control subjects of the same age, but the precentral gyrus and orbital cortex were not.
, dorsolateral	anatomy	of the	1	0	15652870	PMID:15652870; Original text:In a separate analysis, dorsolateral and medial frontal regions were significantly enlarged in patients aged 2 to 5 years compared with control subjects of the same age, but the precentral gyrus and orbital cortex were not.
medial frontal	anatomy	of the	1	0	15652870	PMID:15652870; Original text:In a separate analysis, dorsolateral and medial frontal regions were significantly enlarged in patients aged 2 to 5 years compared with control subjects of the same age, but the precentral gyrus and orbital cortex were not.
of the	anatomy	orbital cortex	1	0	15652870	PMID:15652870; Original text:In a separate analysis, dorsolateral and medial frontal regions were significantly enlarged in patients aged 2 to 5 years compared with control subjects of the same age, but the precentral gyrus and orbital cortex were not.
, dorsolateral	anatomy	medial frontal	1	0	15652870	PMID:15652870; Original text:In a separate analysis, dorsolateral and medial frontal regions were significantly enlarged in patients aged 2 to 5 years compared with control subjects of the same age, but the precentral gyrus and orbital cortex were not.
, dorsolateral	anatomy	orbital cortex	1	0	15652870	PMID:15652870; Original text:In a separate analysis, dorsolateral and medial frontal regions were significantly enlarged in patients aged 2 to 5 years compared with control subjects of the same age, but the precentral gyrus and orbital cortex were not.
medial frontal	anatomy	orbital cortex	1	0	15652870	PMID:15652870; Original text:In a separate analysis, dorsolateral and medial frontal regions were significantly enlarged in patients aged 2 to 5 years compared with control subjects of the same age, but the precentral gyrus and orbital cortex were not.
intellectual	disease	intellectual disability	1	0	24246273	PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
field of	anatomy	levels of	1	0	24246273	PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
intellectual disability	disease_to_anatomy	field of	1	0	24246273	PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
intellectual disability	disease_to_anatomy	levels of	1	0	24246273	PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
intellectual	disease_to_anatomy	field of	1	0	24246273	PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
intellectual	disease_to_anatomy	, and	1	0	24246273	PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
intellectual	disease_to_anatomy	levels of	1	0	24246273	PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
phthalate	chemical_to_disease	spectrum disorders	1	0	27567353	PMID:27567353; Original text:Among the three case control studies, two of them showed a significant relation between exposure to phthalate and spectrum disorders and the last case control study had negative results.
overweight	disease	underweight	2	0	30470952|30470952	PMID:30470952; Original text:For maternal parental body mass index (13 studies), both maternal obesity [OR 1.41 (95% CI 1.19-1.67)] and maternal overweight [OR 1.16 (95% CI 1.05-1.27)] were significantly associated with disorder, while maternal underweight was not associated with disorder [OR 1.08 (95% CI 0.98-1.20)].|PMID:30470952; Original text:Relative to normal weight, maternal obesity and overweight were significantly associated with increased disorder risk, while maternal underweight was not associated with disorder.
obesity	disease	overweight	2	0	30470952|30470952	PMID:30470952; Original text:For maternal parental body mass index (13 studies), both maternal obesity [OR 1.41 (95% CI 1.19-1.67)] and maternal overweight [OR 1.16 (95% CI 1.05-1.27)] were significantly associated with disorder, while maternal underweight was not associated with disorder [OR 1.08 (95% CI 0.98-1.20)].|PMID:30470952; Original text:Relative to normal weight, maternal obesity and overweight were significantly associated with increased disorder risk, while maternal underweight was not associated with disorder.
obesity	disease	underweight	2	0	30470952|30470952	PMID:30470952; Original text:For maternal parental body mass index (13 studies), both maternal obesity [OR 1.41 (95% CI 1.19-1.67)] and maternal overweight [OR 1.16 (95% CI 1.05-1.27)] were significantly associated with disorder, while maternal underweight was not associated with disorder [OR 1.08 (95% CI 0.98-1.20)].|PMID:30470952; Original text:Relative to normal weight, maternal obesity and overweight were significantly associated with increased disorder risk, while maternal underweight was not associated with disorder.
overweight	disease_to_anatomy	risk	1	0	30470952	PMID:30470952; Original text:Relative to normal weight, maternal obesity and overweight were significantly associated with increased disorder risk, while maternal underweight was not associated with disorder.
underweight	disease_to_anatomy	risk	1	0	30470952	PMID:30470952; Original text:Relative to normal weight, maternal obesity and overweight were significantly associated with increased disorder risk, while maternal underweight was not associated with disorder.
obesity	disease_to_anatomy	risk	1	0	30470952	PMID:30470952; Original text:Relative to normal weight, maternal obesity and overweight were significantly associated with increased disorder risk, while maternal underweight was not associated with disorder.
alanine	chemical	glucose	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	mechanism	leptin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism	leptin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
hemoglobin a1c	mechanism	leptin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism	insulin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
hemoglobin a1c	mechanism	insulin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism	hemoglobin a1c	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
, and	anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
(p	anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
glucose	chemical_to_disease	insulin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_disease	insulin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
glucose	chemical_to_mechanism	leptin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
glucose	chemical_to_mechanism	insulin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
glucose	chemical_to_mechanism	alanine aminotransferase	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
glucose	chemical_to_mechanism	hemoglobin a1c	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_mechanism	leptin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_mechanism	insulin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_mechanism	alanine aminotransferase	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_mechanism	hemoglobin a1c	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
glucose	chemical_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
glucose	chemical_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	disease_to_mechanism	leptin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	disease_to_mechanism	insulin	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	disease_to_mechanism	alanine aminotransferase	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	disease_to_mechanism	hemoglobin a1c	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	disease_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	disease_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	disease_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
leptin	mechanism_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
leptin	mechanism_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
leptin	mechanism_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	mechanism_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	mechanism_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	mechanism_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
hemoglobin a1c	mechanism_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
hemoglobin a1c	mechanism_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
hemoglobin a1c	mechanism_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
asperger syndrome	disease	brain abnormalities	1	0	12585818	PMID:12585818; Original text:No consistent focal brain abnormalities for Asperger Syndrome were detected.
alzheimer disease	disease	autism	1	0	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
autism	disease	fragile x syndrome	1	0	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
alzheimer disease	disease	fragile x syndrome	1	0	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
autism	disease_to_mechanism	saβ precursor proteinα	1	0	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
alzheimer disease	disease_to_mechanism	saβ precursor proteinα	1	0	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
fragile x syndrome	disease_to_mechanism	saβ precursor proteinα	1	0	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
autistic	disease	intellectual disability	1	0	18565495	PMID:18565495; Original text:There was a strong discrepancy in relative risk (relative risk) according to IQ, with more autistic patients with intellectual disability having epilepsy (relative risk = .555; 95% confidence interval [CI]: .42-.73; p < .001).
plasma	mechanism	transferrin	1	0	22370992	PMID:22370992; Original text:There was a significant difference in the change in plasma transferrin levels and a trend toward a significant difference in the change in plasma superoxide dismutase levels between the 2 groups.
plasma	mechanism	plasma superoxide dismutase	1	0	22370992	PMID:22370992; Original text:There was a significant difference in the change in plasma transferrin levels and a trend toward a significant difference in the change in plasma superoxide dismutase levels between the 2 groups.
plasma superoxide dismutase	mechanism	transferrin	1	0	22370992	PMID:22370992; Original text:There was a significant difference in the change in plasma transferrin levels and a trend toward a significant difference in the change in plasma superoxide dismutase levels between the 2 groups.
superoxide	chemical_to_mechanism	plasma	1	0	22370992	PMID:22370992; Original text:There was a significant difference in the change in plasma transferrin levels and a trend toward a significant difference in the change in plasma superoxide dismutase levels between the 2 groups.
superoxide	chemical_to_mechanism	transferrin	1	0	22370992	PMID:22370992; Original text:There was a significant difference in the change in plasma transferrin levels and a trend toward a significant difference in the change in plasma superoxide dismutase levels between the 2 groups.
superoxide	chemical_to_mechanism	plasma superoxide dismutase	1	0	22370992	PMID:22370992; Original text:There was a significant difference in the change in plasma transferrin levels and a trend toward a significant difference in the change in plasma superoxide dismutase levels between the 2 groups.
memantine	chemical_to_disease	irritability	1	0	22999292	PMID:22999292; Original text:Difference between the two treatment arms was significant as the group that received memantine had greater reduction in Aberrant Behavior Checklist-Community subscale scores for irritability, stereotypic behaviour and hyperactivity.
memantine	chemical_to_disease	hyperactivity	1	0	22999292	PMID:22999292; Original text:Difference between the two treatment arms was significant as the group that received memantine had greater reduction in Aberrant Behavior Checklist-Community subscale scores for irritability, stereotypic behaviour and hyperactivity.
autism	disease	impairment in socialization and communication	1	0	22999292	PMID:22999292; Original text:Autism is a neurodevelopmental disorder that causes significant impairment in socialization and communication.
autism	disease	neurodevelopmental disorder	1	0	22999292	PMID:22999292; Original text:Autism is a neurodevelopmental disorder that causes significant impairment in socialization and communication.
impairment in socialization and communication	disease	neurodevelopmental disorder	1	0	22999292	PMID:22999292; Original text:Autism is a neurodevelopmental disorder that causes significant impairment in socialization and communication.
autism	disease	developmental delay	1	0	21851192	PMID:21851192; Original text:Recently published data from our lab observed that children with autism spent significantly less time in this state during a single night recording than did typically developing children and those with developmental delay without autism.
autism spectrum disorder	disease	behavioral and neuropsychiatric symptoms	1	0	28303420	PMID:28303420; Original text:In a retrospective, naturalistic review of 74 individuals aged 30 and older meeting DSM-5 criteria for Autism Spectrum Disorder, the point prevalence of behavioral and neuropsychiatric symptoms (behavioral and neuropsychiatric symptoms) declined significantly for 12 of 13 behavioral and neuropsychiatric symptoms over a mean of 25 years while many other features of Autism Spectrum Disorder remained stable.
(p	anatomy	3 of	1	0	16239862	PMID:16239862; Original text:Risperidone was superior to placebo in preventing relapse: this occurred in 3 of 12 patients continuing on risperidone versus 8 of 12 who switched to placebo (p = .049).
autism spectrum disorders	disease	fragile x syndrome	1	0	33170170	PMID:33170170; Original text:We selected 174 genes (64 X-linked and 110 autosomal) for an NGS panel in order to screen patients with Intellectual disability and/or autism spectrum disorders, after fragile X syndrome and significant Copy Number Variants have been excluded.
fragile x syndrome	disease	intellectual disability	1	0	33170170	PMID:33170170; Original text:We selected 174 genes (64 X-linked and 110 autosomal) for an NGS panel in order to screen patients with Intellectual disability and/or autism spectrum disorders, after fragile X syndrome and significant Copy Number Variants have been excluded.
autism spectrum disorders	disease	intellectual disability	1	0	33170170	PMID:33170170; Original text:We selected 174 genes (64 X-linked and 110 autosomal) for an NGS panel in order to screen patients with Intellectual disability and/or autism spectrum disorders, after fragile X syndrome and significant Copy Number Variants have been excluded.
, basal	anatomy	frontal lobe	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
, basal	anatomy	basal ganglia	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
, basal	anatomy	limbic system	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
, basal	anatomy	lobe	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
basal ganglia	anatomy	frontal lobe	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
frontal lobe	anatomy	limbic system	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
frontal lobe	anatomy	lobe	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
basal ganglia	anatomy	limbic system	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
limbic system	anatomy	lobe	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system	disease_to_anatomy	, basal	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system	disease_to_anatomy	frontal lobe	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system	disease_to_anatomy	basal ganglia	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system	disease_to_anatomy	limbic system	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system	disease_to_anatomy	lobe	1	0	20969835	PMID:20969835; Original text:We report evidence that brain anatomy and aging in people with disorder is significantly different as compared to controls-so that in adulthood they no longer have a significantly larger overall brain volume, but they do have anatomical and functional abnormalities in frontal lobe, basal ganglia and the limbic system.
venlafaxine	chemical_to_disease	irritability	1	0	26361994	PMID:26361994; Original text:Univariate analyses showed that the symptom of irritability improved in the entire sample (p = 0.023 after 2 weeks, p = 0.061 at study endpoint), although no difference was observed between the venlafaxine and placebo groups.
venlafaxine	chemical_to_anatomy	(p	1	0	26361994	PMID:26361994; Original text:Univariate analyses showed that the symptom of irritability improved in the entire sample (p = 0.023 after 2 weeks, p = 0.061 at study endpoint), although no difference was observed between the venlafaxine and placebo groups.
ammonia	chemical	clonazepam	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical	zuclopenthixol	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical	zuclopenthixol	2	0	26361994|26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.|PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
2	anatomy	28	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
2	anatomy	set of	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
2	anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
28	anatomy	set of	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
, and	anatomy	28	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
28	anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
, and	anatomy	set of	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
set of	anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
, and	anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical_to_disease	aggressive behaviors	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_disease	aggressive behaviors	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_disease	aggressive behaviors	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical_to_anatomy	2	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical_to_anatomy	28	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical_to_anatomy	set of	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical_to_anatomy	, and	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical_to_anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	2	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	28	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	set of	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	, and	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_anatomy	2	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_anatomy	28	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_anatomy	set of	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_anatomy	, and	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
aggressive behaviors	disease_to_anatomy	2	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
aggressive behaviors	disease_to_anatomy	28	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
aggressive behaviors	disease_to_anatomy	set of	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
aggressive behaviors	disease_to_anatomy	, and	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
aggressive behaviors	disease_to_anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical	venlafaxine	1	0	26361994	PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
venlafaxine	chemical	zuclopenthixol	1	0	26361994	PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
clonazepam	chemical_to_anatomy	group	1	0	26361994	PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
venlafaxine	chemical_to_anatomy	group	1	0	26361994	PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
zuclopenthixol	chemical_to_anatomy	group	1	0	26361994	PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
aripiprazole	chemical_to_disease	weight gain	1	0	31063671	PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
a	chemical_to_disease	weight gain	1	0	31063671	PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
aripiprazole	chemical_to_anatomy	end of	1	0	31063671	PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
a	chemical_to_anatomy	end of	1	0	31063671	PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
weight gain	disease_to_anatomy	of the	1	0	31063671	PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
weight gain	disease_to_anatomy	end of	1	0	31063671	PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
autism	disease_to_anatomy	site	1	0	25861158	PMID:25861158; Original text:tDCS also significantly increased at the stimulation site, and an increase in tDCS was significantly associated with improvements in the two domains of autism treatment evaluation checklist impacted by tDCS.
risperidone	chemical_to_anatomy	(primary	1	0	15492353	PMID:15492353; Original text:Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the the Aberrant Behavior Checklist (primary endpoint) compared with those who were taking placebo.
risperidone	chemical_to_disease	hyperactive	1	0	15492353	PMID:15492353; Original text:Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the the Aberrant Behavior Checklist; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom.
hyperactive	disease_to_anatomy	of the	1	0	15492353	PMID:15492353; Original text:Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the the Aberrant Behavior Checklist; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom.
hyperactive	disease_to_anatomy	, and	1	0	15492353	PMID:15492353; Original text:Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the the Aberrant Behavior Checklist; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom.
, and	anatomy	and 3	1	0	34617108	PMID:34617108; Original text:-0.41, 95% confidence interval (-0.41, 95% confidence interval): -0.68 to -0.15], and 3 studies reported improvements in cognition (standard mean difference = -0.46, 95% -0.41, 95% confidence interval: -0.91 to -0.01) following GFCF dietary intervention.
, and	anatomy	, and 3	1	0	34617108	PMID:34617108; Original text:-0.41, 95% confidence interval (-0.41, 95% confidence interval): -0.68 to -0.15], and 3 studies reported improvements in cognition (standard mean difference = -0.46, 95% -0.41, 95% confidence interval: -0.91 to -0.01) following GFCF dietary intervention.
, and 3	anatomy	and 3	1	0	34617108	PMID:34617108; Original text:-0.41, 95% confidence interval (-0.41, 95% confidence interval): -0.68 to -0.15], and 3 studies reported improvements in cognition (standard mean difference = -0.46, 95% -0.41, 95% confidence interval: -0.91 to -0.01) following GFCF dietary intervention.
en2 gene	mechanism	wnt2 gene	1	0	22522212	PMID:22522212; Original text:Furthermore, we detected an interaction effect on age of first phrase between a SNP rs2228946 in the WNT2 gene and another SNP rs6460013 in the EN2 gene (p = 0.0012).
en2 gene	mechanism_to_anatomy	(p	1	0	22522212	PMID:22522212; Original text:Furthermore, we detected an interaction effect on age of first phrase between a SNP rs2228946 in the WNT2 gene and another SNP rs6460013 in the EN2 gene (p = 0.0012).
wnt2 gene	mechanism_to_anatomy	(p	1	0	22522212	PMID:22522212; Original text:Furthermore, we detected an interaction effect on age of first phrase between a SNP rs2228946 in the WNT2 gene and another SNP rs6460013 in the EN2 gene (p = 0.0012).
, and	anatomy	, stress	1	0	34797272	PMID:34797272; Original text:Results revealed that all dimensions of job stress (perception of stress sources, stress manifestation, and total Teachers' Stress Inventory scores) reduced significantly at posttest and follow up assessments among the yoga group, compared to the a group-randomized waitlist control.
, stress	anatomy	group	1	0	34797272	PMID:34797272; Original text:Results revealed that all dimensions of job stress (perception of stress sources, stress manifestation, and total Teachers' Stress Inventory scores) reduced significantly at posttest and follow up assessments among the yoga group, compared to the a group-randomized waitlist control.
, and	anatomy	, facial	1	0	33376247	PMID:33376247; Original text:When combining the presence of magnetic resonance imaging findings, facial morphological variants, and genetic copy number variants, statistically significant relationships were found with disorder and attention-deficit hyperactivity disorder diagnoses (p = 0.0006 and p = 0.002, respectively).
(p	anatomy	, facial	1	0	33376247	PMID:33376247; Original text:When combining the presence of magnetic resonance imaging findings, facial morphological variants, and genetic copy number variants, statistically significant relationships were found with disorder and attention-deficit hyperactivity disorder diagnoses (p = 0.0006 and p = 0.002, respectively).
attention-deficit hyperactivity disorder	disease_to_anatomy	(p	1	0	33376247	PMID:33376247; Original text:When combining the presence of magnetic resonance imaging findings, facial morphological variants, and genetic copy number variants, statistically significant relationships were found with disorder and attention-deficit hyperactivity disorder diagnoses (p = 0.0006 and p = 0.002, respectively).
attention-deficit hyperactivity disorder	disease_to_anatomy	, facial	1	0	33376247	PMID:33376247; Original text:When combining the presence of magnetic resonance imaging findings, facial morphological variants, and genetic copy number variants, statistically significant relationships were found with disorder and attention-deficit hyperactivity disorder diagnoses (p = 0.0006 and p = 0.002, respectively).
of gut	anatomy	the brain	1	0	34455945	PMID:34455945; Original text:They present a complex and unknown etiology, which in most cases includes significant peripheral alterations outside the brain such as in the composition of gut microbiota.
hyperandrogenemia	disease_to_anatomy	, and	1	0	17187010	PMID:17187010; Original text:Significant improvements in sociability, cognitive awareness, behavior, and clinical symptoms/behaviors of hyperandrogenemia were also observed.
glutamine	chemical	n	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamate	chemical	n	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
n	chemical	oxytocin	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
n	chemical	naa	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamine	chemical	oxytocin	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamine	chemical	naa	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamate	chemical	oxytocin	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamate	chemical	naa	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
naa	chemical	oxytocin	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
n	chemical_to_mechanism	oxytocin	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamine	chemical_to_mechanism	oxytocin	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamate	chemical_to_mechanism	oxytocin	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
naa	chemical_to_mechanism	oxytocin	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
n	chemical_to_anatomy	medial prefrontal	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamine	chemical_to_anatomy	medial prefrontal	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamate	chemical_to_anatomy	medial prefrontal	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
naa	chemical_to_anatomy	medial prefrontal	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
